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I 
ABSTRACT 
Autoimmune inflammatory reactions occur in a number of disorders to a variety 
of self antigens but the precise cellular and molecular mechanisms resulting in 
pathology are largely unresolved.  In some instances T cell mediated reactions 
are thought to be the main contributors to disease mechanisms but it is 
becoming increasingly evident that B cells, and their cognate antibodies, play a 
significant and contributory role in disease pathogenesis.  Therefore 
establishing the occurrence of highly-specific B cell antigen-driven adaptive 
immune responses within autoimmune disorders would provide a valuable 
understanding into the roles of B cells within these disorders.   
 
The work of this study sought to determine the incidence of these B cell 
antigen-driven adaptive immune responses in the target tissues of the 
autoimmune disorders myositis and vasculitis, two autoimmune disorders 
characterised by a wide range of autoantibodies which have been implicated in 
the pathological mechanisms of these diseases.  This study aimed to test the 
hypothesis that infiltrating B cells within the target tissue of myositis and 
vasculitis patients were being stimulated by antigen present within the tissue 
resulting in clonal diversification and affinity maturation mechanisms which 
would contribute to the pathological mechanisms of these disorders.   
 
Initially the cellular phenotypes and organisations of the inflammatory infiltrating 
cell population were characterised by immunohistochemical techniques, with 
particular interest on the infiltrating B cell and plasma cell populations.  No 
typical ectopic germinal centre structures were observed in the target tissues 
from either disorder; cellular aggregations varied from loose aggregations to 
dense cellular follicles.  Both B cell and plasma cell phenotypes were included 
in these infiltrating populations in correlation with varying numbers of cells 
positive for helper, cytotoxic and regulatory T cell, follicular dendritic cell, 
macrophage and proliferating cell markers.  Double fluorescent labelling of B 
cells with the Ki67 proliferation marker indicated the possible expansion and 
clonal diversification of these cells within the target tissues.  To address the 
main objective of this study and the possible antigen-driven mechanisms and 
active participation of these infiltrating B cells within the target tissue of these 
II 
disorders, Ig gene repertoires, mutational characteristics, clonal diversification 
and affinity maturation were examined from infiltrating cells microdissected from 
areas of aggregation within the target tissues of both disorders. From the 
muscle infiltrating cells, Ig gene selections which were both patient and disease 
specific, mutational characteristics and oligoclonal expansion of B cells were 
observed establishing the involvement of muscle infiltrating B cells in the 
antigen-driven responses within inflamed muscle.  Alternatively in the inflamed 
skin of vasculitis patients very few Ig gene rearrangements could be identified 
and no clonally related sequences or oligoclonal expansion of B cells were 
observed despite mutational characteristics indicating that antigen-driven 
diversification had occurred within these cells.  Collectively the results indicate a 
role for B cells in the antigen-driven responses towards autoantigens within both 
disorders, either within an active antigen-driven response within the target 
tissue or at alternative sites resulting in cell migration into the target tissues.     
  
In the final part of this study recombinant antigens were used to identify antigen-
specific B and plasma cells within the inflammatory infiltrating cell population in 
some cases of myositis.  Pilot experiments were conducted to establish the 
sequence characteristics of Ig genes from these antigen-specific cells.  
 
Results of this study demonstrate the influence of B cell antigen-driven 
responses, either directly or indirectly, within the target tissues of myositis and 
vasculitis patients respectively, although the exact mechanisms leading to 
autoimmune reactions, and additional roles of B cells within these reactions, 
remain unresolved.  The work presented from this study provides a foundation 
for further work to fully ascertain the role of B cells and antibodies within the 
target tissues of autoimmune disorders and in characterising the disease-
associated antibodies, identifying stimulating antigens as well as assessing the 
effects of somatic hypermutation on the affinity and specificity of autoantigen 
specific antibodies.  Increased understanding of B cells in these disorders will 
ultimately assist in the diagnosis and management of these diseases. 
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Chapter 1 – General Introduction 
1.1 The Immune Response in Health and Autoimmunity 
The immune system is the body’s protection from infections and pathological 
agents and the damage they can cause by utilising a variety of cells and soluble 
factors.  After breaching the initial physical and chemical barriers of the body, 
the immune system mediates the body’s protection from invading pathogens 
using the innate and adaptive components of the immune system (1).  The 
innate immune system is the body’s immediate line of defence which occurs 
rapidly following infection with no specificity and limited memory. This 
component of the immune system is effective in defending against a large array 
of pathogens due to it’s recognition of common pathogenic structural features.  
Invariant pathogen recognition receptors (PRRs), which include Toll-like 
receptors (TLRs), on effector cells such as macrophages, neutrophils, 
eosinophils, basophils, mast cells and dendritic cells recognise simple and 
regular molecular structures and patterns, pathogen-associated molecular 
patterns (PAMPs) on invading pathogens.  The effector mechanisms of these 
cells, like phagocytosis, aim to eliminate and neutralise the invading pathogen.  
If these mechanisms fail, the adaptive immune responses are activated to 
enhance the protection generated by innate responses.  In contrast to the 
innate immune system, the responses of adaptive immunity are antigen specific 
and exhibit memory, providing enhanced protection against re-infection of the 
pathogen, but occur in a time-delayed manner in comparison to the innate 
responses.  Although these responses work by different mechanisms both can 
work in collaboration with each other through direct cell contacts and cytokine 
and chemokine interactions, ultimately shaping the nature of the immune 
response.  The adaptive immune responses are mediated through the effector 
mechanisms of B and T cells; each expresses a receptor of unique antigen 
specificity, B cell Receptor (BCR) and T cell Receptor (TCR) respectively, 
following the random recombination of receptor gene segments.  Selection and 
activation of these cells in the immune response can result in humoral and/or 
cell mediated immune responses.  Humoral immunity mechanisms respond to 
extracellular antigens and results in the production of antigen-specific 
antibodies produced by B cells which can aid the eradication of pathogens by 
neutralisation, opsonisation and complement activation (1).  Antigens bound to 
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the BCR of B cells are endocytosed, processed and presented on Major 
Histocompatibility Complex (MHC) class II molecules at the cell surface.  These 
B cells become activated following interactions with antigen-specific CD4+ T 
helper cells, which have previously been activated by antigen to differentiate 
into effector cells following antigen recognition and co-stimulation from antigen 
presenting cells (APCs) such as dendritic cells and macrophages, and 
recognise the antigens presented on the MHC class II molecules of B cells at 
the edges of lymphoid follicles in the periphery lymphoid organs.  CD4+ T helper 
cells activate B cells through a number of paired interactions at the cell surface.  
Key interactions include CD40 ligand (CD154) on T cells with CD40 on B cells.  
This interaction causes B cells to increase expression of co-stimulatory 
molecules, particularly of the B7 family (CD80/CD86), which interact with CD28 
expressed on T cells which provides important signals to sustain T cell growth 
and differentiation.  In addition to these interactions, CD4+ T helper cells also 
secrete cytokines upon activation.  T helper 1 cells secrete cytokine including 
IFN-γ and TNF-α while T helper 2 cells secrete cytokines including IL-4, 5, 10 
and 13.  These cytokines, in addition to other activation signals, can drive 
proliferation and differentiation of the cells as well as induce clonal expansion, 
isotype switching and synthesis and secretion of antibodies from B cells.  In 
some instances, with T independent antigens, antibody production can be 
induced in the absence of T helper cells as these antigens provide sufficient B 
cell stimulation in the absence of T cells.  Cell mediated mechanisms respond 
to antigens that are generated intracellularly, e.g. by virus infection, and 
presented on MHC molecules expressed on APCs (1).  CD8+ and CD4+ cells 
are activated to differentiate into effector cells in the T cell rich zones of the 
peripheral lymphoid organs.  In cell mediated immunity, CD4+ T helper cells 
recognise antigens presented on MHC class II molecules by APCs and become 
activated through similar cell surface interactions that have been previously 
described like the CD40L-CD40 and B7-CD28 interactions and activate 
phagocytes.  CD4+ T helper 1 cells participate in macrophage activation, the 
secretion of IFN-γ by the T cell along with the co-stimulation via the CD40 
ligand is sufficient to activate the macrophage and boost the antimicrobial 
mechanisms within the macrophages.  In addition to macrophage activation, the 
IFN-γ released by the T helper 1 cells can also be used to activate other cells 
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involved in cell mediated immunity such as CD8+ T cells and NK cells.  CD8+ T 
cells recognise pathogenic peptides presented by MHC class I molecules on 
APCs and are activated to release cytotoxic effector proteins such as perforins 
and granzymes, which induce cell death of the virus infected cell.  CD4+ T 
helper cells may also be required in the activation of CD8+ T cells.  In cases 
where sufficient co-stimulation is not provided by the APC, CD4+ T cells may be 
required to provide extra help in the activation and stimulation of CD8+ T cells 
through stimulation of the APC to upregulate the surface expression of B7 
molecules which can increase the co-stimulation to CD8+ T cells driving 
proliferation and differentiation of these cells in the cell mediated immune 
response.  Regardless of which mechanism is mediating the immune response, 
any infection and the responding immune mechanisms will initiate an 
inflammatory reaction in response to the invading pathogen.     
 
1.1.1 Inflammation 
Inflammation is a major component of the body’s defence mechanism and is a 
complex process initiated by physical, chemical, biological or immunological 
injury and the inflammatory response constitutes an important part in both the 
innate and adaptive immune responses (1).  Inflammation involves activation of 
resident tissue cells and recruitment of immune cells from the circulation in 
response to inflammatory mediators such as cytokines and chemokines 
resulting in tissue disruption, both structurally and functionally.   
 
The recruitment of B and T lymphocytes, and other inflammatory cells, to sites 
of inflammation is a multi-step process which includes tethering and rolling, 
activation, firm adhesion and transendothelial migration (TEM) of lymphocytes; 
a process which is mediated by chemokines and a number of adhesion 
molecules (Figure 1.1) (1-4).  Circulating lymphocytes tether and role along 
endothelium as a result of low-affinity interactions with the selectin adhesion 
molecules (L-, P- and E-selectin) which effectively slow down the flow of the 
circulating lymphocytes.  This brings lymphocytes into contact with the 
endothelial surface and allows them to sample the local environment.  
Activation molecules and stimulation of the cells leads to a firm adhesion to the 
endothelium while in the absence of stimuli the lymphocytes detach and remain 
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in the circulation.  The firm adhesion of stimulated cells is mediated by the up-
regulation of integrins which brings the adherent cell to arrest and allows 
progression to TEM.  TEM is a complex process and the exact mechanisms are 
unresolved but it is dependent on the integrin binding to endothelial cells and 
the activation of lymphocytes by chemokines.  TEM generally occurs through 
endothelial cell junctions, formed by the interactions of a number of adhesion 
molecules, including junctional adhesion molecules (JAMs) along increasing 
chemokine gradients. JAMs have been implicated in vascular inflammation as a 
result of redistribution to the apical surface to increase the adhesion of 
lymphocytes (5).  The final obstacle in the recruitment of lymphocytes is the 
basement membrane but the mechanisms of this are incompletely understood.  
Release of endothelial cells into the circulation as a result of necrosis has been 
observed, intensifying the pathology at the endothelial surface and exacerbating 
inflammatory reactions (6-9).  Resolution of inflammation aims to restore the 
injured tissue back to its normal state but in cases where the stimulating factors 
could not be removed, or by loss of regulation, chronic inflammation results in 
severe tissue damage and loss of function with progressing clinical symptoms.  
These chronic inflammatory reactions can occur due to defects in the body’s 
regulatory processes of tolerance which results in immune and inflammatory 
responses against self components of the body resulting in autoimmune 
responses.      
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Figure 1.1 The Multistep Model of Lymphocyte Extravasation 
 
Recruitment of lymphocytes to areas of inflammation occurs from a multistep process.  Initially 
interactions between lymphocytes and adhesion molecules (selectins) slow the rate of lymphocyte 
movement along the endothelial surface.  Chemokines (
 
) at the epithelial surface stimulate the 
lymphocyte and integrin binding halts the lymphocyte on the cell surface.  Lymphocytes then migrate 
through the epithelial cell layer by transendothelial migration towards a source of chemokine production.  
Unstimulated cells detach from the endothelial surface and remain in the circulation.  Chronic 
inflammation can result in endothelial cell necrosis causing them to detach from the basement 
membrane and enter the circulation.  Adapted from 1-4. 
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1.1.2 Tolerance Mechanisms in Controlling Autoimmunity 
Tolerance is the regulation of immune responses to antigens ensuring that 
immune responses to self-antigens are controlled and repressed while 
maintaining the capacity to exert an effective immune response against foreign 
antigens; essentially the discrimination between self- and non-self antigens.  
Tolerance is applied to cells with antigen-specific receptors, T and B cells, and 
is acquired following interaction of a self-antigen with an antigen-specific 
lymphocyte which results in signalling for cell inactivation.  Due to the process 
of the antigen receptor generation by random recombination of receptor gene 
fragments, the development of autoreactive cells is a normal consequence.  
Between 20 and 50% of TCRs and BCRs generated are thought to bind with 
dangerously high affinity to self antigens; the work of one group found that 75% 
of gene rearrangements in immature B cells were autoreactive (10-12).  Despite 
the generation of these autoreactive cells, tolerance mechanisms aim to 
regulate and arrest the development of these cells.   
 
Tolerance is induced at a number of stages along lymphocyte development and 
differentiation pathways.  To prevent immune responses towards self-antigens, 
developing T and B cells, with specificity towards self-antigens, undergo 
negative selection in early stages of development within the primary lymphoid 
organs, the thymus and bone marrow for T and B cells respectively, resulting in 
cell inactivation.  This process of cell inactivation is known as central tolerance 
but such reactions can also be carried out in the periphery with mature 
lymphocytes, which have either escaped central tolerance mechanisms or 
became self-reactive as a result of further receptor-gene diversification 
processes in the periphery, resulting in peripheral tolerance.  The lymphocyte 
tolerance mechanisms in these reactions can result in cell editing, deletion or 
inactivation (anergy) (1;11;12), but these mechanisms are not mutually 
exclusive and cells that were initially anergised may be deleted at a later stage.  
Upon detection of an autoreactive high affinity self antigen by BCR or TCR 
expressed on immature B cells or immature thymic T cells within the bone 
marrow and thymus respectively, the maturation of the cell is halted.  Within the 
bone marrow homing and activation receptors such as CD62L and B cell 
activating factor (BAFF) are poorly expressed or induced.  Conversely 
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recombination-activating gene 1 (RAG1) and RAG2 are continually expressed 
to allow the BCRs to be edited.  Receptor editing involves the further 
rearrangement of the antigen specific receptor to alter the antigen specificity of 
the cells allowing the rescue of these cells from inactivation.  For the antibody 
light (L) chains of B cells, upstream VL and downstream JL gene segments of 
the rearranged VLJL can recombine to form a new VLJL rearrangement (1).  In 
heavy (H) antibody chains of B cells, due to the process of V(D)J 
recombination, discussed further in section 1.4, all unused D segments are 
deleted.  For editing of the rearranged gene to occur, cleavage at cryptic 
recombination signal sequences (cRSS) located near the 3’ end of the VH gene 
results in formation of a double-stranded break.  Following cleavage, 
recombination with a new VH gene results in a new V(D)J rearrangement (13), 
reviewed (14).  The receptor editing processes of central tolerance can also 
occur within the periphery as receptor revision.  This peripheral tolerance 
mechanism, and its importance in tolerance, has been recently substantiated by 
the work of Wang and Diamond (15) reviewed (16).  This study demonstrated 
the re-expression of RAG proteins, essential components of recombination 
processes, in peripheral autoreactive B cells in germinal centre (GC) responses 
but also following activation of autoreactive B cells by soluble antigen outside of 
the GC environment.  This work follows previous studies which have identified 
RAG expressing B cells in the peripheral blood of lupus patients (17) and the 
synovial tissue of Rheumatoid Arthritis (RA) patients (18).  Within T cell 
populations TCRs can stimulate an editing process which downregulates TCRs 
and allows RAG expression to continue to allow the offending TCR α-chain to 
be replaced or diluted with a second α-chain that is less self-reactive.  If the 
receptor fails to edit sufficiently in both B and T cells, cell deletion occurs due to 
increased levels of BIM (BCL-2-interacting mediator of cell death) that inhibit the 
BCL-2 family of proteins which are essential for lymphocyte survival or activate 
death receptors such as Fas (11;12).  Both editing and deletion processes 
occur within developing T cells but deletion appears to be the dominant 
process.  Anergy is a process which leaves B and T cells in an unresponsive 
state and occurs when B and T cells recognise antigens without sufficient levels 
of co-stimulation, from helper T cells and APCs that are required for full cell 
activation.  Several mechanisms of anergy have been documented and include 
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the downregulation and decreased display of BCRs and TCRs on the cell 
surface, the blocked transfer of new antigen receptors from the endoplasmic 
reticulum as well as increased expression of inhibitory receptors such as CD5 
on both B and T cells and cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T cells 
which are increased on self reactive cells and inhibit cell activation (1;11;12;19-
21).  An additional mechanism is also thought to play a role in tolerance, clonal 
ignorance in which B and T cells that have failed to be edited or trigger deletion 
co-exist with antigen without being affected by it as the self-reactive cells are 
either not in contact with the stimulating antigen or they binds so weakly that 
there is insufficient signalling to activate the cell.  In the periphery, with large 
numbers of circulating B and T cells, self-reactive cells can fail to receive 
sufficient stimulation and activation factors such as BAFF and IL-7 for B cells 
and T cells respectively and are competitively deleted (22;23).  In addition to 
regulating self-reactive cells that have escaped the central tolerance 
mechanisms, peripheral tolerance mechanisms also need to regulate a second 
generation of self-reactive cells that are produced within GC reactions, a result 
of the additional receptor gene diversification mechanisms.  These cells 
potentially have an increased affinity for self antigens and have the potential to 
diversify into memory and long-lived plasma cells which would produce self-
reactive antibodies indefinitely.  GC reactions also have the potential to be a 
powerful stimulus for self-reactive cells in the production of autoantibodies by 
the presentation of self antigens within immune complexes.  Little is known 
about the tolerance mechanisms that normally deal with self-reactive cells 
participating in GC reactions but it has been demonstrated that self-reactive 
BCRs induce subtle differences in the cell’s responsiveness to chemokine 
gradients which excludes them from follicles and minimises the self-reactive 
cell’s participation in germinal centre reactions (12;24).  
 
Another aspect of tolerance is the role of regulatory T and B cells within 
peripheral tolerance.  In recent years vast arrays of studies have been 
conducted on regulatory T cells (Tregs) and their ability to suppress rather than 
activate immune responses.  These CD4+ differentiated T cells can arise during 
normal T cell development and are thought to make up approximately 5-10% of 
the CD4+ cell population but are committed to a regulatory fate in the thymus 
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after high-affinity binding to MHC molecules containing self peptides rather than 
being deleted or inactivated under the tolerance mechanisms described above 
(25).  Once released into the periphery as a mechanism of tolerance, the exact 
mechanisms of suppression by these cells are not fully established.  Studies 
have demonstrated that suppressive mechanisms include the regulation of 
responses by the IL-10 and TGF-β cytokines produced by these cells (26) and it 
has also been shown that they can affect the maturation and antigen-
presentation capacity of DCs (27).  Regulatory T cells have been classified as 
natural Tregs but adaptive Tregs have also been described which differentiate 
from a heterogeneous group of naïve CD4+ T cells in the periphery under the 
influence of particular environmental conditions to elicit suppressive effects on 
auto-reactive responses. 
 
Recently it has been shown that B cells may also have a suppressive and 
regulatory role in immune responses in addition to their role as positive 
regulators of immune responses.  Most of the evidence for regulatory B cells 
presently comes from studies in autoimmune mouse models, such as EAE 
where they prevent the development of disease as well as reduce the severity 
of disease once it has been established, but the existence of a Breg cell subset 
has yet to be confirmed in humans.  It is thought that these cells may suppress 
the activation and differentiation of T cells, disrupt the antigen-presenting 
function in DCs, promote autoantibody mediated clearance of apoptotic cells to 
reduce the autoantigenic load or induce the activity of Tregs (28;29).   Studies 
have established that Bregs mediate their effects through IL-10 but what 
remains unclear is if this regulatory mechanism is a general property of multiple 
B cells subsets or if it is unique to a specific suppressive subset of B cells 
(28;30;31).        
 
Although these mechanisms aim to remove and inactivate self-reactive T and B 
cells, and prevent the initiation of immune reactions towards self-antigens, not 
all of these cells are removed during these tolerance mechanisms under normal 
conditions.  Self-reactive responses may also occur as some antigens may be 
ignored by these mechanisms as they are below the critical threshold and are 
present at too low a concentration or some antigens may be present at 
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immunologically privileged sites that do not elicit a destructive immune 
response under normal conditions.  Disruption to the integrity of these tolerance 
mechanisms leads to the initiation of self-reactive responses within the body, 
resulting in specific B and T cell adaptive immune responses against self 
antigens leading to the development of autoimmune diseases.  
 
1.1.3 Breaking of Self-Tolerance and the Autoimmune Response 
A vast array of autoimmune disorders exists but the precise aetiology and 
initiating antigens of these responses is unknown in most cases.  Autoimmune 
disorders can be broadly classified , based on the tissue or organ involved, as 
organ-specific like Multiple Sclerosis (MS), Myasthenia Gravis (MG), Type 1 
Diabetes (T1D), Hashimoto’s Thyroiditis (HT) with responses to organ specific 
autoantigens and the formation of tissue specific autoantibodies or non-organ-
specific or systemic which includes Rheumatoid Arthritis (RA), Systemic Lupus 
Erythematosus (SLE), Inflammatory myopathies, such as Dermatomyositis 
(DM), Sjögrens Syndrome (SS) and various vasculitic disorders which affect 
multiple organs and generate autoantibodies that are not tissue specific, 
although not all autoimmune disorders can be classified according to these 
criteria (1).  The initiation of autoimmune responses occurs when there is 
disruption of tolerance mechanisms and activation of self-reactive cells as 
previously described, although self-reactive cells are part of the normal cell 
repertoire and activation of self-reactive cells, at a low level, is physiological and 
crucial to the normal immune function and does not always necessarily lead to 
the development of a pathological response to self-antigens.  Under normal 
conditions self-reactive cells help to shape and form the repertoire of mature 
lymphocytes.  Autoreactive cells are part of the normal cell repertoire but with 
autoimmune disorders occurring in approximately 5% of the population a 
number of other susceptibility factors must also play a role in autoimmune 
disorders (1).  Pathological autoimmune responses develop when a number of 
safe-guard and tolerance mechanisms are overcome or disrupted resulting in a 
sustained response towards self-antigen generating effector mechanisms that 
result in tissue damage.  A combination of factors such as genetic 
predisposition and exposure to environmental triggers are thought to initiate 
autoimmune responses in addition to alterations in tolerance mechanisms. 
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Firstly, age and gender may play a role in the initiation of autoimmune 
responses.  Autoantibodies are more prevalent in older people and certain 
autoimmune disorders have female or male bias.  DM and SLE are more 
commonly observed in females, with a 9:1 female:male bias observed in SLE, 
whereas Ankylosing Spondylitis (AS) affects more male than female patients 
(1;32;33).     
 
Genetic susceptibility factors can have various influences on the development 
of autoimmune disorders from a genetic predisposition from inherited MHC 
genes to polymorphisms of genes that are involved in maintenance of self-
tolerance and immune regulation such as regulatory proteins.  Many 
autoimmune disorders are heterogeneous with no one gene sufficient to initiate 
disease mechanisms.  The most common evidence of a genetic predisposition 
is the higher incidence of disease in monozygotic twins, with a lower but still 
increased incidence in dizygotic twins and family members in relation to an 
unrelated population.  Regardless of any other variables for the initiation of 
autoimmune reactions, predispositions of autoimmune disorders are associated 
with certain MHC alleles. MS and RA are associated with the DR2 and DR4 
alleles respectively while SLE, SS, MG and Inclusion Body Myositis (IBM) have 
an association with the DR3 allele (1;34).  Most autoimmune disorders have an 
association with MHC class II alleles but there are cases for a strong 
association with type I alleles, like B27 observed in over 90% of AS patients 
(35), reviewed (36).  These particular alleles may contribute to the development 
of autoimmune reactions through the presentation of self antigens, or mimics, 
driving positive selection of autoreactive cells; the presence or absence of the 
appropriate MHC determines whether a potential autoantigen is presented and 
the occurrence of a response to the antigen.  These alleles may only be 
expressed at low levels or have low affinity towards the antigen that would not 
drive a negative selection response but are present at a sufficient level and with 
sufficient affinity to drive positive selection.  It may also be the case that the 
antigens presented on these alleles may fail to stimulate the formation of 
regulatory T cells or they are inefficiently presented.  
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Polymorphisms in a number of other genes have also been associated with the 
development of autoimmune reactions.  Single-nucleotide polymorphisms 
(SNPs) have been observed in the CTLA-4 and PTPN22 genes (1;12;37;38).  
As previously mentioned CTLA-4 is an inhibitory receptor expressed on T cells.  
Lack of CTLA-4 has been shown to cause a large accumulation of self-reactive 
T cells in peripheral and nonlymphoid organs and causes disruption of both 
TCR-induced proliferation but also impairs the suppressive properties of Tregs.  
Defects in this gene caused by SNPs are associated with diseases such as T1D 
and Grave’s disease (19).  Similarly to CTLA-4, PTPN22, protein tyrosine 
phosphate nonreceptor type 22, is involved in suppression of T cell activation 
and SNPs within this gene are associated with T1D as well as RA and SLE 
(39;40).  Mutations within the AIRE (autoimmune regulator) gene, which 
promotes the thymic expression of peripheral tissue-restricted genes, have 
been found to be responsible for autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED) which leads to destruction of multiple 
endocrine tissues (1;12;37;38).  In addition to subtle mutational changes within 
genes, the deletion or overexpression of genes resulting in defects in cytokine 
production or signalling can also contribute to the pathogenesis of 
autoimmunity; overexpression of TNF-α is associated with arthritis and 
vasculitis while underexpression of the same cytokine is associated with SLE.  
Elevated BAFF levels have also been reported in a number of autoimmune 
disorders, including the inflammatory myopathies, in particular DM (41;42).         
 
As well as these genetic mechanisms, defects may also occur in other aspects 
of the immune response.  Defects in regulatory T cell functions have been 
described in SLE (43) and in MS patients where Treg populations are normal 
but their suppressive activity is defective (1;44).  Several autoimmune disorders 
have also been associated with apoptosis.  The process of programmed cell 
death is essential for the prevention of autoimmune reactions as this process is 
responsible for the removal of self-reactive cells and the downregulation of 
immune responses to self antigens.  Impaired generation or clearance of 
apoptotic cells and alterations in apoptosis machinery can reduce resistance to 
normal processes of cell death and expose cytoplasmic and nuclear 
components that are normally sheltered from the immune system.  Mutations 
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within Fas genes have been associated with autoimmune lymphoproliferative 
syndrome (ALPS), T1D and MS (1;38).  
 
Breakdowns in tolerance and the initiation of autoimmune reactions have also 
been associated with a number of infections that can initiate autoimmune 
reactions by a number of pathways.  For example, certain subsets of vasculitis 
have been associated with hepatitis B and C viruses as well as Staphylococcus 
aureus and parvovirus B19 infections (45), SLE has been associated with the 
Epstein-Barr virus (32;33) and Guillain-Barré syndrome is associated with 
Campylobacter jejuni infections (12;46;47).   Infectious agents may directly 
activate autoreactive cells by presenting antigens that are cross-reactive with 
self antigens in a process of molecular mimicry.  As a result, the immune 
response and resultant antibodies produced against the infectious agent are 
directed against self antigens.  The structures of the infections agent and the 
self antigen do not need to be identical as long as they are sufficiently similar to 
be recognised by the same antigen receptor or antibody.  Once self-reactive 
cells have been activated by these cross-reactive mechanisms, the effector 
functions of these cells can lead to tissue destruction.  This mechanism has 
been shown for Guillain-Barré syndrome where antibodies produced in 
response to C. jejuni infections are directed towards components of the 
peripheral nerves (12;46;47).  An infectious agent may not necessarily trigger a 
pathogenic autoimmune response directly; this may follow as a result of epitope 
spreading in the reaction.  Epitope spreading is the diversification of the epitope 
specificity and extension of the autoreactive response from the initial focused 
epitope to new epitopes and new autoantigens (37;38;48).  As a result of the 
immune response towards the initial infectious agent, previously hidden or 
cryptic epitopes of the autoantigen may be presented to the immune system, as 
well as a modified version of the initial epitope due to altered processing 
mechanisms, resulting in a cascade of autoreactive cells within the response 
and an extension of the self-reactive immune response to multiple epitopes.  
Epitope modification can also occur due to exposure to drugs or other chemical 
agents.  These may modify self-components and result in the formation of neo-
antigens which the immune system has never seen and therefore is not tolerant 
towards, eliciting an autoreactive immune response (1;37).  Drug associated 
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disorders been observed in a number of autoimmune disorders, including SLE 
patients following exposure to procainamide, as well as a number of other 
drugs, and in myositis patients as a result of statin therapy (32;33;49).      
 
The strong inflammatory response to infections may itself stimulate an 
autoreactive response as a result of non-specific activation of self reactive cells 
in a process known as bystander inflammation (37;38;48).  The response to 
infections may result in tissue damage or cell death which may cause release, 
and increase the presentation, of potential autoantigens that have previously 
been sequestered from the immune system which stimulate the activation of 
autoreactive cells.  The inflammatory mediators, such as cytokines, generated 
during the immune response could lead to the attraction, activation and 
expansion of autoreactive cells at sites of infection as well as stimulation of 
anergic cells which have previously been inactive, perpetuating the autoimmune 
response.  It has also been described that stimulatory ligands released by the 
invading infectious agent, such as CpG dinucleotides, may stimulate antibody 
production from autoreactive B cells, stimulating the autoimmune response 
(12;50).  These ligands are recognized by TLRs on B cells and partially 
substitute for T cell help promoting autoantibody production. 
 
The adaptive immune responses involved during autoimmunity are incapable of 
removing the offending antigen therefore the immune responses persists with a 
constant supply of antigen resulting in amplification of the response which 
manifests as tissue damage as a result of the effector mechanisms.  The 
effector mechanisms associated with autoimmune disorders are generally 
classified according to the scheme adopted for hypersensitivity reactions (1).  
Type I, IgE mediated, reactions do not seem to play a major role in autoimmune 
reactions but conversely Type II, autoantibody mediated, reactions are 
common.  Autoantibodies bind to the cell surface and either alone via Fc 
receptor opsonisation or with the help of complement damage cells.  This is 
observed in autoimmune hemolytic anaemia (AIHA) where IgG autoantibodies 
bind to red blood cells leading to rapid destruction of the cells.  In 
Goodpasture’s syndrome the IgG autoantibodies bind directly to cells in the 
tissue resulting in tissue damage.  Within this type of reaction, the antibodies 
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can bind and either interfere or enhance the functional activity of the cell.  In 
MG, the binding of autoantibodies to the acetylcholine receptor block the 
neuromuscular transmission from the receptor whereas in Grave’s disease the 
autoantibodies continually stimulate production of thyroid hormone.  Type III, 
immune complex (IC) mediated disorders result from circulation of ICs 
composed of soluble antigen and autoantibodies resulting in systemic 
manifestations.  ICs are normally cleared in healthy individuals but clearance 
may be defective or may be overwhelmed by the continuous supply of 
autoantigens in self-reactive responses.  ICs can mediate tissue damage by 
activation of complement or phagocytic cells through Fc receptors.  These types 
of effector mechanisms have been observed in autoimmune disorders such as 
various vasculitic disorders and SLE where ICs are deposited in blood vessels 
and kidneys respectively.  Finally Type IV, T cell mediated, mechanisms occur 
in disorders such as Type 1 diabetes and MS.  These autoreactive T cells not 
only play a helper role in autoimmune development but also have a direct, 
cytotoxic, role in tissue damage similar to the mechanisms during a normal 
immune response.  
 
As described above, autoimmune diseases are multifactoral and involve an 
extensive range of cells and effector mechanisms but B cells and their 
production of autoantibodies are frequently central to these mechanisms and 
autoimmune reactions.  Some disorders are thought to be directly dependent on 
the actions of B cells while in some disorders it is thought that B cells merely 
play an accessory role.  The full extent of B cell involvement and the precise 
role of these cells have not fully been established in a number of autoimmune 
diseases.  Given the potential for B cells in GC reactions to generate and 
diversify high-affinity self-reactive B cells, and the resultant autoantibodies, as 
well as the identification of GCs as tertiary lymphoid organ (TLO) formations at 
ectopic sites adjacent to autoantigen sources in a number of autoimmune 
disorders, reviewed (51), the production of tissue-specific and/or disease 
relevant autoantibodies and development of effector mechanisms in situ is an 
important component of the autoimmune response in a number of disorders.  
Previous studies have identified autoreactive B cells generated in ectopic GCs 
in a number of autoimmune disorders including MG (52), SS (53) and HT (54) 
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and most recently in RA (55), but they have not yet been identified in a number 
of other autoimmune disorders such as myositis and vasculitis.  Myositis, as 
well as vasculitis, discussed further in sections 1.2 and 1.3, are a series of 
systemic disorders with unknown aetiology that have been associated with 
aspects of the different genetic and environmental features discussed in this 
section that may disrupt self tolerance resulting in the formation of 
autoantibodies and leading to the initiation of autoimmune disease.  The work 
presented in this thesis examines the loss of B cell tolerance in these disorders 
to determine if B cells are being locally stimulated by self-antigen leading to the 
production of potentially self reactive high affinity autoantibodies. 
 
1.2 Myositis  
Inflammatory myopathies, or myositis, are inflammatory disorders of the muscle 
composed of 3 principal subsets, dermatomyositis (DM), polymyositis (PM) and 
Inclusion body myositis (IBM) (56-68).  Other forms of myositis have also been 
described and include giant cell myositis, eosinophilic myositis, granulomatous 
myositis, necrotizing myositis and drug-associated myositis, induced notably by 
HMG-CoA reductase inhibitors (statins) (49;56;69;70).  A diagram representing 
normal muscle architecture, in cross-section, is shown in Figure 1.2 and 
identifies the regions where inflammation and lymphocyte aggregation are 
observed within the 3 myositis subsets.  Each of the 3 principal disorders is 
characterised by moderate to severe muscle weakness and mononuclear 
inflammatory cell infiltrates (59). Patients with myositis present with varying 
degrees of muscle weakness which may develop over weeks to months as a 
result of muscle inflammation.  Diagnosis of myositis is based on the results of 
an electromyography, elevated muscle enzymes in serum (creatine kinase 
(CK)) by as much as 50 fold and a muscle biopsy to define histological 
changes.  Concentrations of CK usually parallel the disease activity but normal 
levels may be found in some DM and IBM patients; continuous elevated CK 
levels have been reported during active PM (58;71).  Inflammatory myopathies 
are systemic and often multi-organ illnesses, skin, heart, lungs, gastrointestinal 
tract and joints can all be affected in each disorder (56). Classification criteria 
for myositis was originally devised by Bohan and Peter (72;73) but this failed to 
distinguish between PM and IBM and the criteria has recently been revised 
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(58).  Each of the 3 inflammatory myopathies have been seen in connection 
with various autoimmune and connective tissue diseases as well as being 
associated with malignancies (58); malignancy is thought to be associated with  
up to 45 % of adult DM patients (71).  DM and PM have been reported in 4-16% 
of Systemic Lupus Erythematosus (SLE) cases with DM most commonly found, 
a retrospective study of myositis in SLE found that the muscle disease observed 
in SLE was similar, in a small sample size, to primary myositis disorders (61).  
The pathogenesis and mechanisms of cellular injury are still unresolved in 
myositis; possible mechanisms are summarized in Figure 1.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Dermatomyositis (DM) 
DM, found in both children and adults, is observed in women more than men 
and is the most common inflammatory myopathy (58;63).  DM is characterised 
by a heliotrope rash on the upper eyelids, face or upper trunk accompanying or 
more commonly preceding proximal muscle weakness (63;74;75).  Gottron rash 
is also observed in approximately 30% of DM patients; a raised rash or papules 
at the knuckles, prominent in metacarpophalangeal and interphalangeal joints 
(56;58;63;75). Inflammation is predominately perivascular and/or perimysial or 
in the interfascicular septae and around, rather than within, the muscle fascicles 
but can extend into the individual muscle fascicles along the endomysium at 
fascicle edges (Figure 1.2).  Perivascular atrophy is another characteristic within 
DM patients, a result of degeneration and phagocytosis of muscle fibres often in 
 
Muscle tissue consists of three dense 
layers of connective tissue.  The outermost 
layer, encircling the whole muscle is the 
epimysium.  The perimysium surrounds 
bundles, or fascicles, of individual muscle 
fibres.  Within the fascicle each individual 
muscle fibre is surrounded by the 
endomysium.   Muscles are well supplied 
with blood vessels and capillaries which are 
abundant within the endomysium 
surrounding each muscle fibre. 
 
In inflammatory myopathies various 
patterns of lymphocytic infiltration are 
observed.  In DM this pattern is largely 
perimysial/perivascular surrounding 
fascicles while in PM/IBM inflammatory 
infiltrates are largely endomysial and are 
found surrounding individual muscle fibres 
within fascicles.   
Epimysium 
Perimysium 
Endomysium 
Blood  
Vessel 
Muscle 
Fibre 
Fascicle 
Muscle 
Figure 1.2 Transverse-Sectional 
Representation of Skeletal Muscle Tissue. 
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groups at the periphery of the fascicle at perimysial locations (60). Lymphocyte 
infiltrations in DM have a higher than normal percentage of B and CD4+ cells 
compared to CD8+ cells (58-60;65).  The proximity of CD4+ cells to B cells and 
macrophages and the absence of lymphocytic invasion into muscle fibres 
suggest that DM is a humorally mediated immune response, possibly towards 
microvessels.  B cells observed within inflammatory myopathies are more 
commonly observed in muscle tissue from patients with DM compared to PM or 
IBM (65).  The immune process in DM is thought to be directed against 
microvascular antigens in a process mediated by the complement C5b-9 
membrane attack complex (MAC).  Complement deposits result in necrosis of 
the endothelial cells leading to muscle fibre destruction (58-60).  Complement 
activation occurs early in disease triggering the release of proinflammatory 
cytokines which upregulate VCAM-1 and ICAM-1 on endothelial cells and 
facilitates the transmigration of activated lymphoid cells to the perimysial and 
endomysial spaces (60).  
 
Different subsets of DM have been described in patients (75-77); patients with 
amyopathic DM (ADM) display the classical cutaneous features of DM for 
prolonged periods of time without clinical evidence of muscle weakness and 
with normal muscle enzymes.  Hypomyopathic DM (HDM) has also been 
described which is similar to ADM except that upon testing evidence of muscle 
inflammation is evident.  These distinctive subsets have also been observed 
within juvenile myositis (78).  DM is the most frequent inflammatory myopathy 
observed in children, approximately 85% of all juvenile inflammatory 
myopathies (78).  The peak onset age of juvenile DM is approximately 7 years 
although a broad distribution is observed throughout childhood. 25% of cases 
have onset prior to age 5, and is primarily observed within girls although a 
similar incidence has been reported between boys and girls (63;78).  Certain 
characteristics are observed in juvenile DM that are not frequent within the adult 
form of the disease; dystrophic calcification with calcium deposits in the skin, 
subcutaneous tissue or muscle are observed in 30% of patients (78).  For both 
the adult form of the disease and juvenile DM the same major immunogenetic 
risk factors haven been identified which include HLA DRB1*0301 and it’s linked 
allele DQA1*0501.  In addition to similar risk factors, similar protective factors 
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have been identified in European Americans, DQA1*0201, *0101 and *0102 
(78).  The similar risk and protective factors observed between juvenile DM and 
the adult form suggest common elements within the disorders.          
 
1.2.2 Polymyositis (PM) 
PM is generally observed after the second decade of life and is best defined as 
a subacute myopathy that evolves over weeks to months and presents with 
symmetrical weakness of the proximal muscles (58).  The actual onset of PM is 
hard to define as there are no early recognition signs such as the rash observed 
in DM.  As a stand-alone disorder PM is uncommon and is more commonly 
observed in conjunction with other autoimmune and connective tissue 
disorders.  PM is characterised by scattered necrotic and regenerating muscle 
fibres and endomysial inflammation with invasion and destruction of non-
necrotic muscle fibres (Figure 1.2) (65;66).  Inflammatory infiltrates mostly 
consist of CD8+ T cells and macrophages which invade MHC class I antigen 
expressing muscle fibres leading to fibre necrosis via the perforin pathway 
suggesting the immune reactions target muscle fibres (56;58-60;63;65;66).  
MHC class I expression, absent from normal muscle fibres but found 
widespread in inflammatory myopathies (79), is thought to be induced by 
cytokines secreted by activated T cells and macrophages.    The MHC class I 
(muscle) : CD8 complex (T cell) is characteristic of PM.  A proportion of the infiltrating 
cytotoxic CD8+ T cells have been shown to be clonally expanded and suggest 
an antigen-driven T cell response.  These cells have conserved amino acid 
sequences within the CDR3 region of the T cell receptor (TCR) while other 
infiltrating, non-invading cells are clonally diverse (59;65;67;80-84).  Pathology 
within PM is a result of these clonally expanded CD8+ T cells invading muscle 
fibres that express the MHC class I antigen which results in fibre necrosis via 
the perforin pathway (63).  Cytotoxic CD8+ T cells can release 3 cytotoxic 
proteins: perforin, granzyme and granulysin (65).  Perforin may cause a leak in 
the sarcolemmal surface through which granzymes could invade the muscle to 
initiate fibre necrosis (65).  This pathogenesis pathway has also been observed 
in perforin/granzyme expressing CD4+ lymphocytes, reviewed (65), although 
perforin was found to be randomly distributed in the cytoplasm of CD4+ cells in 
comparison to CD8+ cells where perforin is located towards the target muscle 
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fibre (85) .  The ER stress response pathway has also been proposed to result 
in muscle damage (86).  Nagaraju et al (86) demonstrated that the ER stress 
response pathway was highly activated in human myositis and that 
overexpression of MHC class I, observed in muscle fibres, induces the ER 
response.  
 
Immunohistochemical studies have demonstrated that few CD20+ B cells are 
present within PM muscle biopsies in contrast to T cells which would indicate 
that humoral mediated immune responses do not play a major role within PM 
(87;88).  Greenberg et al (89) examined the infiltration of CD138+ plasma cells 
in PM muscle biopsies.  In PM samples B cells displayed a mean density of 2.8 
cells / mm2, while CD138+ plasma cells displayed a mean density of 11.0 cells / 
mm2 which were predominately located in the endomysium.  The identification 
of plasma cells within PM biopsies was confirmed by sequence analysis of Ig V-
genes expressed by single plasma cells isolated by laser capture 
microdissection.  Although the occurrence of plasma cells was established the 
functional role of these cells in PM was unclear until a subsequent study (90) 
demonstrated that infiltrating plasma cells in PM were clonally related and 
undergoing an antigen-driven response. 
 
1.2.3 Inclusion Body Myositis (IBM) 
In male patients over the age of 50 IBM is the most frequent inflammatory 
myopathy with distinctive atrophy and weakness of wrist and finger flexors and 
quadriceps and can often be asymmetrical (34;56;59;60;63;71;91).  Although 
similar to PM, less frequent myofibre necrosis and increased invasion of non-
necrotic fibres by lymphocytic infiltrates have been observed in IBM (65;66).  
Other features of IBM include rimmed vacuoles and groups of atrophic fibres 
(68).   A strong association with HLA DR3 has been reported and is present in 
approximately 75% of cases (34).  CD8+ T cells are the dominant infiltrating cell 
which surround and invade MHC class I expressing muscle fibres, the 
characteristic MHC class I : CD8 complexes found within PM are also 
characteristic of IBM (59;60;63). Also the invading CD8+ T cells within IBM have 
been demonstrated to be clonally expanded while non-invading infiltrating CD8+ 
T cells were found to be clonally diverse (59;80;92-94). Amemiya et al (92) 
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demonstrated the clonal restriction of T cells within IBM and observed that 
these clonally related T cell sets persist over the course of the disease.  It was 
also noted that identical rearrangements were found at different muscle biopsy 
sites of the same patient as well as in different patients implying a continued 
response to the same antigens.  In addition to clonally expanded muscle 
infiltrating T cells within the muscle, evidence has demonstrated that these 
clones also recirculate into the blood (65;80;93) but this may also occur as a 
result of the same antigen being present at both sites leading, independently, to 
the expansion of T cells at both sites.  IBM differs in its clinical presentation as 
the hallmarks of IBM are usually atrophy and weakness of the quadriceps and 
the wrist and finger flexors, producing distal rather than proximal weakness 
(56;68).  In contrast to PM, IBM has a slowly progressing clinical course, over 
months to years and is unresponsive to treatment (34;60).  Pathology 
associated with IBM is thought to occur by the same CD8+ perforin/granzyme 
mechanism that is observed in PM but an additional pathological mechanism is 
thought to occur in IBM patients.  Granular deposits are found to be distributed 
around vacuoles along with amyloid deposits, first identified in 1991, within or 
next to vacuoles, suggesting that two concurrent pathological processes are 
occurring within IBM (34;59;63).      
 
As found within PM, infiltrating plasma cells were identified in biopsies taken 
from IBM patients (89).  CD138+ plasma cells displayed a mean density of 17.2 
cells / mm2 while B cells were observed at a mean density of 4.2 cells / mm2.  
These infiltrating plasma cells were also found to be clonally related within IBM 
samples (90) indicating that an antigen–driven response was also occurring 
within IBM and that T cells may not be the only cell mediating an antigen-
specific response within inflammatory myopathies and other autoimmune 
diseases.  
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1.2.4 Autoantibodies and Autoantigens in Myositis 
As with most autoimmune disorders different autoantibodies have been 
described within the myositis subsets DM and PM (95;96).  Classically 
autoantibodies are absent from IBM although they have been detected in a 
small number of cases (95;97).  The presence and diversity of these 
autoantibodies demonstrates the significance of B cell tolerance in the 
complexity of these disorders.  Myositis autoantibodies can either be classified 
as myositis-specific autoantibodies (MSAs), specific for the muscle disorder 
myositis not specific for muscle tissue, or myositis-associated autoantibodies 
(MAAs)  (95;96), Table 1.1.  Generally individual patients comprise of a single 
MSA but may also have one or more MAAs (95).  Most of these autoantibodies 
are directed to protein or ribonucleoprotein complexes involved in protein 
Figure 1.3 Possible Mechanisms of Pathology in Myositis 
 
 
A muscle lesion induces the overexpression of autoantigens, most notably from regenerating muscle fibres.  The 
released autoantigen may undergo conformational changes resulting in cleavage by granzyme B generating 
unique fragments that were still able to generate a high autoantibody titre response.  Alterations in autoantigens 
may promote apoptosis within muscle fibres.  Autoantigen fragments may exert chemotactic effects resulting in the 
influx of several cell types.  B cell and CD4+ T cells and may be stimulated to produce autoantibodies which could 
contribute to further pathology or CD8+ T cells may surround and invade muscle fibres via the Granzyme : perforin 
pathway resulting in muscle fibre necrosis and further autoantigen release.  Adapted from 95.   
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synthesis, translocation or elongation.  MAAs target antigens are primarily 
located in the nucleoplasm or nucleolus. 
 
                Table 1.1 Myositis-Specific Antigen (MSAs) and Myositis-Associated Antigens (MAAs)  
 
Casciola-Rosen et al (98) recently examined autoantigen expression in normal 
and myositis tissues and observed increased levels of autoantigens in myositis 
affected muscle, particularly in regenerating muscle cells, compared to the low 
levels in control muscle. Low autoantigen expression in normal muscle indicates 
that an immune response, directed against myositis antigens, is unlikely to be 
initiated in normal, unperturbed normal muscle.  Enhanced autoantigen 
expression was observed in muscle cells of an immature and regenerating 
phenotype.  Despite the emergence of autoantigens in diseased muscle, no site 
of initiation for the immune response was identified although it was 
hypothesised that forms of proinflammatory muscle injury may induce muscle 
regeneration which in turn induces autoantigen expression resulting in 
pathology.  The study suggests that damage focused on cells achieving repair 
produces a feed-forward loop mechanism where regenerating cells provide an 
ongoing antigen supply in the disease progression and therefore are targets for 
Myositis-Specific 
Autoantibodies (MSA) Target Antigen 
Myositis-Associated 
Autoantibodies (MAA) Target Antigen 
    
Anti-tRNA synthetases - Aminoacyl-tRNA synthetases – 
 
  
Anti-Jo-1 Histidyl-tRNA synthetase Anti-Ro60 Cellular Antigen Ro60/SSA 
 
Anti-PL7 Threonyl- tRNA synthetase Anti-Ro52 Cellular Antigen Ro52/SSA 
 
Anti-PL12 Alanyl-tRNA synthetase Anti-La Cellular Antigen La/SSB 
 
Anti-EJ Glycyl-tRNA synthetase Anti-RNP Ribonucleoprotein 
 
Anti-OJ Isoleucyl-tRNA synthetase Anti-Ku Heterodimer bound to 
protein kinase 
 
Anti-KS Asparaginyl-tRNA synthetase Anti-PM/Scl Nucleolar macromolecular 
complex 
Anti-JS Glutaminyl-tRNA synthetase   
    
Anti-tRNA His tRNA His   
Anti-tRNA Ala tRNA Ala   
    
Anti-Mi-2 Nuclear Helicase 
 
  
Anti-SRP Signal-Recognition Particle 
 
  
Anti-FER Elongation Factor 1α (eEF1α) 
 
  
Anti-KJ 30/34kDa Translocation Factor 
 
  
Anti-Wa 48kDa unknown peptide 
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attack in the autoimmune process.  This may account for the well defined but 
patchy histological changes of myositis next to apparently normal areas of 
muscle.  Previous studies by Casciola-Rosen et al (99) in SLE have 
demonstrated that the majority of autoantigens were effectively cleaved by 
granzyme B generating unique fragments that were still able to generate a high 
titre autoantibody response, illustrating the complexity of antigen-driven 
responses.    
 
1.2.4.1 Aminoacyl-tRNA synthetases (ARS) 
The most prevalent MSAs are directed against amino-acyl-tRNA-synthetases 
(ARS) (95;96;100).  These molecules are cytoplasmic enzymes which catalyse 
the ATP-dependent binding of tRNAs to the corresponding amino acid, forming 
an aminoacyl-tRNA, so that the amino acid can be incorporated into a growing 
polypeptide chain.  The presence of anti-ARS and its clinical manifestations has 
been termed antisynthetase syndrome (ASS) which consists of myositis (DM or 
PM), idiopathic interstitial lung disease (ILD), arthritis and Raynaud 
phenomenon (100;101).  ASS carries a severe prognosis with a threefold 
increase in mortality compared to myositis without these antibodies (95).  Anti-
ARS antibodies are found in 16-26% of patients with inflammatory myopathies 
but the precise roles of these antibodies are still unresolved (100).  The specific 
anti-ARS antibodies found in myositis patients are shown in Table 1.1.  These 
antibodies are not cross-reactive and occur independently of one another (102).  
Anti-Jo-1 antibodies are the most prevalent antibodies found in myositis 
patients; they are found in 20-30% of patients while the other anti-ARS 
antibodies are only present in 1-3% of patients (100;103;104).  The increased 
occurrence of anti-Jo-1 antibodies indicates that synthetases are not randomly 
targeted; targeting of these antibodies may be the result of increased 
expression or improved presentation (105).  Anti-ARS antibodies are mainly 
observed in DM and PM patients and are rarely observed in IBM patients and in 
a pattern similar to other MSAs; only one type anti-ARS antibody is ever 
observed in each myositis patients (95;104).  Anti-OJ and anti-KS antibodies 
have been shown to have a stronger association with ILD than with myositis 
and may distinguish a subtype of ASS (106), while anti-Jo-1 and anti-PL-12 has 
a strong association with ILD in patients with myositis (107;108).  Levine et al 
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(107) recently addressed whether alterations in histidyl-tRNA synthetase 
expression and/or conformation was observed in the lung of affected patients.  
A unique, granzyme B cleavable form of histidyl-tRNA synthetase was located 
in the lung.  The presence of this form in the lung and not within muscle focuses 
attention on the lung as the potential driving environment for immunity against 
histidyl-tRNA synthetase.  Muscle may become targeted at later stages upon 
injury to muscle when histidyl-tRNA synthetase antigen levels are increased 
(98).  ARSs can be classified into Class I and Class II synthetases based on 
overall structure, characteristic motifs and site of tRNA attachment (96;105).  
Most of the ARSs found in myositis patients, anti-Jo-1, -PL-7, -PL-12, -EJ and –
KS, belong with Class 2 synthetases but anti-OJ is a Class 1 synthetase that 
exists as part of a multi-enzyme synthetase complex (96;105).  Recent studies 
have identified two new anti-ARS antibodies, anti-phenylalanyl synthetase 
antibodies (anti-Zo) (109) and anti-tyrosyl antibodies (110).   
 
ARS molecules have been shown to possess chemoattractant properties and 
generate an ARS-specific autoimmune response in myositis and ILD 
(105;111;112).  Histidyl-tRNA synthetase and a 1-48 amino acid histidyl-tRNA 
synthetase peptide were chemotactic for human CD4+, CD8+ and IL-2 activated 
monocytes that express the CCR5 receptor but not for neutrophils or 
unstimulated monocytes that do not express CCR5 (111;112).  Asparaginyl-
tRNA synthetase was chemotactic for CCR3-expressing mononuclear cells.  
The chemoattractant properties of these proteins were only two to four folds 
higher over background levels and were not as efficacious as chemokines but 
were potent enough to induce migration in vitro.  Both proteins were also 
chemotactic for immature dendritic cells (iDC) which express both CCR5 and 
CCR3.  These findings suggest that the tRNA synthetases may participate in 
the initiation of an adaptive immune response which leads to the production of 
autoantibodies; by engaging receptors on iDCs the tRNA synthetases may be 
more likely to initiate T and B cell responses (111).  The chemotactic activity of 
the tRNA synthetases for iDCs may initiate a cascade of immune events, 
beginning with the antigen presentation to T lymphocytes and production of B 
lymphocyte stimulating cytokines that results in the production of autoantibodies 
in some patients (111).  These chemotactic effects were not observed for the 
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nonautoimmune synthetases aspartyl and lysyl-tRNA synthetases.  Other 
autoantigens, such as La and ssDNA, were also examined but failed to induce 
leukocyte migration (112).  The reasoning of targeting anti-ARSs or why some 
are targeted over others is largely unknown, as previously described it could 
result from differing expression, presentation or generation of unique fragments 
from granzyme B cleavage.  The similarities in structure may suggest that a 
common structural factor is involved but it has been shown that antibodies to 
different synthetases do not crossreact (96;102). 
 
Anti-Jo-1 antibodies are the most prevalent anti-ARS found in myositis patients 
and are a diagnostic marker for autoimmune myositis and a prognostic marker 
for disease severity (104;113;114).  Anti-Jo-1 antibodies were first described in 
1980 from the serum of a patient affected with PM (104).  Formation of these 
antibodies could be attributed to molecular mimicry from infectious agents, Jo-1 
shares structural homology with a protein, EC-RF4, from Epstein Barr virus and 
the RNA of picornavirus (95;115).  It has been suggested that autoantibodies 
result from interaction of the synthetase with a virus during viral replication 
which leads to the presentation of the synthetase to the immune system in 
association with the foreign viral protein resulting in a break in tolerance.  The 
major epitope of histidyl-tRNA synthetase, a 60 amino acid portion, is located at 
the amino terminus of the protein and is predicted to have a coiled-coil 
configuration (WHEP-TRS domain) and autoantibody binding affects the 
conformation of the N terminus (104;107;113).  Studies on mutant histidyl-tRNA 
synthetase, to establish the effects on reactivity with anti-Jo-1 antibodies, 
demonstrated that anti-Jo-1 antibodies recognise multiple conformation 
dependent and independent epitopes which may have occurred as a result of 
fragmented histidyl-tRNA synthetase released from inflamed muscle (104).  
Anti-Jo-1 antibodies have been identified in patients before the onset of myositis 
(116), similar to that observed in other autoimmune disorders such as SLE 
(117).  A patient’s anti-Jo-1 status may change from positive to negative during 
the course of disease (104) and has been found to correlate with disease 
activity (118).  The presence of anti-Jo-1 antibodies has been associated with 
the presence of anti-Ro52 antibodies and was first discovered in 1997 
(119;120) and was later confirmed in a subsequent study (102).  Rutjes et al 
26 
(120) found that 21% of the sera from myositis patients were reactive with Jo-1 
while 20% was reactive with Ro52.  Isolating anti-Jo-1 positive sera 
demonstrated a higher frequency of anti-Ro52 antibodies, 58%, a similar 
percentage to the 70% found in the study conducted by Frank et al (102).  It 
was established this was not due to cross-reactivity since no competition could 
be detected for recombinant Jo-1 protein and affinity-purified anti-Ro52 and 
anti-Jo-1 antibodies did not cross react with each other.  Anti-Ro52 antibodies 
were also shown to be associated with other antibodies (102;121); other anti-
tRNA-synthetases, anti-SRP and anti-PM-Scl but are rarely detected in patients 
with anti-Scl70 or anti-centromere antibodies (121). The co-existence of these 
antibodies has recently been considered to generate a programmed cytokine 
imbalance in PM and DM patients (122).  Hassan et al (122) demonstrated that 
female patients with anti-Jo-1 and anti-Ro52 antibodies had a higher TNF:IL-10 
ratio. Elevated TNF cytokine levels have been observed in DM and PM and 
have been implicated in associated pathological mechanisms.  IL-10 is also of 
interest in autoimmune diseases as it exerts anti-inflammatory properties in 
addition to stimulatory effects on B cells and autoantibody production.  This 
elevated ratio was not observed within male patients or within patients who had 
anti-ANA or anti-RNP antibodies.  Elevated ratios of these cytokines may 
contribute to the development or aggravation of chronic inflammation.  Reasons 
for the association of anti-Jo-1 antibodies and anti-Ro52 antibodies remains 
unclear as tRNA synthetases charge their nucleic acids in the cytoplasm and 
Ro52 occurs primarily in the nucleus (119;120) but the concordance of these 
two apparently unrelated ribonucleoproteins may provide a greater insight into 
the aetiology or pathogenesis of inflammatory myopathies (119).  
 
Recently Eloranta et al (123) demonstrated that immune complexes containing 
anti-Jo-1 or anti-Ro52/Ro60 autoantibodies may act as endogenous IFN-α 
inducers that activate IFN-α production from plasmacytoid dendritic cells 
(PDCs).  This may suggest that the type 1 IFN system may play a role in the 
disease mechanism of myositis although different mechanisms may occur in 
different myositis subsets.   
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1.2.4.2 Mi-2 
Anti-Mi-2 autoantibodies are classified as MSAs and were first identified in 1976 
in a 60 year old female DM patient (124).  These autoantibodies are directed to 
a nuclear macromolecule complex of eight peptides ranging from 34 to 240 
kDa.  The complete complex is involved in transcription (95;124).  Mi-2 
autoantibodies preferentially recognise the 240 kDa portion of this complex.  
Two different but highly homologous proteins, resembling the 240 kDa portion 
of the complex, were identified and were labelled Mi-2α and Mi-2β.  Both of 
these proteins are recognised by anti-Mi-2 antibodies (96;124).  These Mi-2α 
and Mi-2β components exert helicase and acetylase-deacetylase activities 
which regulate transcription factor binding to DNA (95).  Mi-2β is part of a 
complex known as NURD (nucleosome remodelling deacetylase) (95;96).  
Immunogenetic studies have shown a strong correlation of anti-Mi-2 antibodies 
with HLA-DR7 and there is evidence that a tryptophan residue at position 9 of 
the HLA-DRβ chain is a common epitope essential for Mi-2 antibody production 
(124).  Anti-Mi-2 antibodies have been identified in approximately 4-18% of 
patients with myositis, and are primarily observed in patients with DM 
(95;124;125).  Hengstman et al (100) report the autoantibody occurrence within 
DM as 13 – 21% (100) and it had been reported that more than 90% of anti-Mi-
2 positive patients had juvenile or adult-onset DM (95;124) and show a classic 
representation of DM (124).  As previously mentioned in section 1.2.1 subsets 
of DM have been described, a lower frequency of the Mi-2 antibody have 
occasionally been reported in the DM subset amyopathic DM (ADM) (124).   
Hengstman et al (100) report that these antibodies have only been seen in 2 
patients with PM and never in IBM.  Additional studies (126;127) have 
established the presence of anti-Mi-2 antibodies in the sera of PM and IBM 
patients.  Most studies examining anti-Mi-2 antibodies used the NM fragment of 
the Mi-2β autoantigen which is thought to contain the major antigenic epitope.  
A recent study used the four different fragments of the Mi-2β autoantigen, NT, 
NM, M and CT fragments, to characterise these autoantibodies in myositis 
patients (126;127).  Using these 4 fragments the presence of anti-Mi-2 
autoantibodies were found in a large number of PM and IBM patients and these 
antibodies did not appear to be a marker for a specific subset of myositis.  This 
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study was unable to confirm that these antibodies were specific for DM in 
contrast to previous investigations. 
 
1.2.4.3 Additional MSAs 
In addition to the presence of autoantibodies towards the cytoplasmic amino-
acyl-tRNA-synthetase enzymes, autoantibodies may also be directed towards 
the cognate tRNA, tRNA His and tRNA Ala. Anti- tRNA Ala is detected in the sera 
of most patients with anti-PL12 autoantibodies whereas tRNA His is present in 
approximately a third of patients with anti-Jo-1 (100). 
 
Another MSA found within myositis patients is the anti-SRP autoantibody, which 
is directed against components of the signal recognition particle (SRP) 
(95;100;128).  Antibodies target a cytoplasmic ribonucleoprotein composed of 
six peptides (SRP 9, 14, 19, 54, 68, 72) including a dominant 54 kDa peptide 
and of a small RNA molecule (7 SL RNA).  SRP recognises signal sequences in 
the N-termini of secretary proteins or membrane proteins to regulate the 
translocation of newly synthesized proteins across the endoplasmic reticulum 
(ER) membrane.   Anti-SRP antibodies are uncommon and are found in only 
5% of myositis patients, predominately PM although the antibodies have been 
observed in a small proportion of DM and IBM patients (95;100).  
Autoantibodies are most frequently directed against the SRP 54 protein, those 
directed solely towards the 7 SL RNA may be markers for a less severe disease 
(95).  Patients with anti-SRP antibodies generally have proximal muscle 
involvement and have been associated with cardiac involvement.  These 
antibodies are characteristic of necrotizing myopathies (128). 
 
As shown in Table 1.1, other MSAs have been identified which are directed to 
cytoplasmic antigens.  These antibodies are extremely rare and not readily 
detectable but characteristically resemble antisynthetase syndrome (95).  Anti-
FER autoantibodies are directed towards an elongation factor, while the target 
antigen for anti-KJ antibodies is a translocation factor.  Anti-Wa antibodies are 
directed towards a 48 kDa peptide with an unknown function. 
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1.2.4.4 MAAs 
As shown in Table 1.1 many MAAs have been described in myositis patients.  
Anti-Ro and anti-La antibodies have been detected in approximately 4 to 58% 
and 3 to 6% of myositis patients respectively (95) and have also been observed 
in SLE and SS patients.  These antibodies are generally associated with an 
anti-synthetase like syndrome in comparison to anti-SRP positive myositis.  A 
faint association of anti-Ro antibodies has been observed in myositis patients 
with anti-Mi-2 and anti-PM-Scl antibodies.  As described in section 1.2.4.1 it is 
generally anti-Ro52 antibodies that are observed within myositis patients, in 
conjunction with anti-Jo-1 antibodies. 
 
Anti-RNP proteins target the 70 kDa peptide of an 11 peptide containing 
complex.  This ribonucleoprotein protein also contains five small RNA’s.  These 
antibodies are also found in other disorders, such as SLE, SS and scleroderma 
but are found in 5-60% of myositis patients (95). 
 
Antibodies to the Ku antigen have been reported in 3-19% of myositis patients 
(95).  The Ku antigen is a heterodimer composed of one 70 kDa and one 80 
kDa peptide bound to a 350 kDa DNA-dependent protein kinase.  The overall 
function of this complex is unknown but is thought to be involved in DNA repair 
and VDJ recombination.  This autoantibody has also been observed within other 
conditions, such as scleroderma, SS and undifferentiated connective tissue 
disease (95).  
 
Anti-PM-Scl autoantibodies are observed in 5-25% of myositis patients and are 
directed against a nucleolar macromolecular complex composed of 11-16 
peptides (95).  This complex is an exosome whose exoribonucleases destroy 
RNA’s.  A 100 kDa peptide is the main target for these autoantibodies.  This 
antibody in myositis in conjunction with overlap syndromes such as scleroderma 
contributes to 43-88% of cases of myositis associated with the autoantibody. 
 
1.2.4.5 Novel Autoantigens 
Recently a number of novel autoantibodies have been identified within myositis 
patients.  Anti-56 kDa antibodies have been found in 60-86% of myositis 
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patients and are directed against a nuclear ribonuceloprotein complex (95;129).  
These antibodies are fairly specific for myositis but have also been described in 
other forms of connective tissue disease (95;129).   
 
Sato et al (130), reviewed (129;131), identified autoantibodies to a 140 kDa 
peptide, CADM-140, in Japanese patients with clinically amyopathic 
dermatomyositis.  CADM-140 antibodies were identified in 19% of DM patients; 
all of these patients were diagnosed with clinically amyopathic DM (C-ADM).  
These antibodies were found to be associated with rapidly progressive ILD. 
 
Another novel antibody was identified within myositis patients (132), reviewed 
(129;131), directed to a 155 kDa protein.  This antibody was identified in sera 
from children and adults with inflammatory myopathies and was found to 
precipitate with a 155 kDa protein along with a weaker 140 kDa protein on most 
samples.  This anti-p155 antibody was strongly associated with myositis, more 
frequently within DM (29.4%) compared to PM (4.2%); it was also observed in 
75% of cancer-associated DM patients (132).  Within juvenile DM patients this 
anti-p155 antibody appeared to be more common than other defined 
autoantibodies.  Although this antibody was largely found within myositis 
patients, it has been observed in one patient with SLE who demonstrated no 
signs of myositis. 
 
More recently Kraj et al (133) identified an anti-155/140 antibody which was 
highly specific for DM and reacted simultaneously with two proteins of 155 and 
140 kDa.  In this study anti-155/140 antibodies were found in 13% of DM 
patients, a frequency slightly lower than anti-EJ antibodies but were comparable 
or higher than other MSAs that were examined in the study, including anti-Jo-1, 
anti-OJ, anti-PL-7, anti-Mi-2, anti-SRP and anti-CADM140 antibodies.  As 
observed for other MSAs (95) the anti-155/140 antibody did not co-exist with 
other known MSAs.  In this study the anti-155/140 antibody was associated with 
internal malignancy and skin manifestations typical of DM but were not 
associated with ILD, indicating a high expression of 155/140 kDa antigens in 
cancer, skin and muscle but is absent or poorly expressed in the lung.  Kraj et al 
(133) deemed that this antibody was different to that identified by Sato et al 
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(130) and Targoff et al (132) as a result of immunodepletion studies and the 
ever presence of the 140 kDa precipitated protein which was not observed in 
every patient within the Targoff study (132).  
 
Autoantibodies towards the small ubiquitin-like modifier 1 (SUMO-1) activating 
enzyme A and B subunits, SAE1 and SAE2 respectively, have recently been 
identified in DM patients (134).  These proteins are involved in the 
posttranslational modification of specific proteins.  Although these antibodies 
were only observed in two patients both patients presented with similar clinical 
features, severe skin disease and interstitial pneumonia, suggesting that these 
autoantibodies may identify a further discrete subset of DM patients.   
 
1.2.5 Therapies in Myositis. 
Treatment of inflammatory myopathies can be complex, partly because the 
specific target antigens are unknown, therefore traditionally therapy has been 
based on non-selective immunosuppression or immunomodulation.  Improved 
muscle strength, normalised CK levels and remission or stabilisation are the 
primary goals in treatment of myositis disorders (135).  DM has been found to 
be the most treatable myopathy while responses in PM have also been 
favourable but responses have found to vary.  IBM is characteristically the most 
resistant myopathy to treatment (62;135;136).  Corticosteroids, mostly 
prednisolone, are the standard initial treatment for these disorders, particularly 
in DM and PM although a recent case has reported clinical improvements in 
IBM (137), and have been used successfully for the last three decades.  
However the frequent side effects associated with the treatment results in a 
reduction or termination of the therapy and a switch, or a combined, approach 
with steroid-sparing immunosuppressive agents like methotrexate, azathioprine, 
cyclosporine A, cyclophosphamide and mycophenolate mofetil which have 
effects on various aspects of the immune response (62;91;135;136).  Long-term 
use of steroid therapy may result in reappearance of muscle weakness without 
changes in CK levels, necrotizing myopathy, without a prominent infiltration of 
immune cells (71;91).  No standard choice, combination or dose of these 
therapies is used and is influenced by a number of factors including disease 
severity and other underlying medical conditions.  Intravenous immunoglobulin 
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therapy (IVIg) is also used in treatment strategies; the large range of antibodies 
from this therapy has a number of immunomodulatory effects in these disorders 
(135;138;139).  Favourable responses with this treatment are mostly observed 
in DM and PM patients with no significant improvements in IBM patients, 
although some studies report limited effects (135;138).  Recent, more selective, 
therapies include the use of monoclonal antibodies aimed at more selective 
targets including TNF-α blockers (Etanercept, Infliximab and Adalimumab), 
complement component C5 (Eculizumab) as well as other cytokines, 
costimulatory and cell adhesion molecules (135).  Another monoclonal antibody 
therapy being tested in inflammatory myopathies, which is relevant to the 
current study of this thesis, is Rituximab, a chimeric depleting antibody against 
the CD20 marker on B cells.  Studies have shown favourable outcomes in 
myositis, after successful studies in other autoimmune disorders such as RA 
and SLE (140-149), although relapses in some myositis patients did occur after 
the return of B cells and depletion of autoantibody titres have been found to 
vary (150-153).  The exact mechanism of this antibody is unknown but could 
involve depletion by either activation of complement, inducing cell-mediated 
lysis, by apoptosis, or increased sensitisation to cytotoxic agents and 
corticosteroids. Despite the mechanism of action the initial rationale for using 
the antibody in autoimmune disorders was to reduce the production of 
autoantibodies.  It is also postulated that other B cell functions may be affected 
during therapy, such as antigen presentation, costimulatory and regulatory 
functions.  Further studies are now underway with additional CD20 therapies, 
Ocrelizumab and Ofatumumab, a humanized CD20 monoclonal antibody as 
well as TRU-015, a single-chain polypeptide which binds to CD20.  Other 
therapies aimed at B cells in autoimmune disorders include Epratuzumab, an 
anti-CD22 antibody and various therapies at the B cell activating factor 
BAFF/BLyS (154;155).     
 
As well as treating inflammatory myopathies some therapeutic interventions, for 
other disorders, are known to cause or contribute to the pathogenesis of 
inflammatory myopathies.  Although the exact mechanisms leading to pathology 
are unresolved the use of statins as well as corticosteroids have been found to 
result in inflammatory myopathies (49;56;69;70;156). 
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1.3 Vasculitis 
Vasculitis is inflammation of blood vessel walls; this may occur as a primary 
process (primary vasculitis) or as a secondary feature of other diseases 
(secondary vasculitis) such as systemic autoimmune disease, inflammatory 
disease and connective tissue disease, which can include the inflammatory 
myopathies (157-162).  A number of classification systems have been proposed 
to classify the varying forms of vasculitis, from the American College of 
Rheumatology (159;163) in 1990 and the Chapel Hill Consensus Conference in 
1994 (164;165) reviewed (157-160;166).  Additional classification schemes 
have been proposed based on the dominant blood vessel involved, the 
inflammatory cell primarily mediating vascular damage, the distinction between 
primary and secondary vasculitis and the incorporation of pathophysiological 
markers (157;162).  Multiple pathogenic pathways are generally thought to 
mediate vasculitis disorders (33;157;158), many of which affect the skin 
resulting in cutaneous vasculitis due to the large vascular supply to the skin 
(167).  The trigger that initiates inflammation or determines the location of 
vascular inflammation is unknown.  The annual incidence of cutaneous 
vasculitis ranges from 39.6 to 59.8 per million (157) and can affect all ages.  
Cutaneous vasculitis is observed slightly less in men than women and is often 
seen in adults more often than children (157).  The mean age of onset is 47 
years in adults and 7 years among children (157).  Vasculitis can have a wide 
range of clinical and pathological manifestations due to its capacity to affect 
vessels of different sizes, although considerable overlap exists (Figure 1.4) 
(157-162). 
 
1.3.1 Large Vessel Disease (>150 µm) 
Two distinct disorders have been identified that primarily affect larger vessels, 
Giant cell arteritis and Takayasu’s arteritis.  Both disorders involve 
granulomatosus inflammation, containing activated and antigen-driven T cells 
and macrophages, of the aorta and its major branches but Giant cell arteritis is 
generally observed in patients older than 50 years whereas Takayasu’s arteritis 
commonly occurs in patients younger than 50 years old (168;169).   
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1.3.1.1 Kawasaki Disease (KD) 
KD is an arteritis which can affect large, medium and small vessels, as with 
other vasculitic disorders the cause is unknown (168).  It is primarily a childhood 
disorder and is associated with mucocutaneous lymph node syndrome.  
Infectious agents have been proposed as possible triggering agents for the 
disease in immature immune systems leading to the inability to clear certain 
pathogens.  Boys younger than 5 years are most commonly affected (168;170).  
Oligoclonal IgA producing plasma cells have been recently identified in KD 
which were critical pathological mediators (167;169;171). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Medium Vessel Disease (50-150 µm) 
1.3.2.1 Polyarteritis nodosa (PAN) 
PAN is a necrotizing inflammatory disease of medium or small arteries and is 
observed in 2 to 9 cases per million annually (168;170).  This vasculitic disorder 
is typically considered a medium vessel disorder although it is not restricted to 
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Microscopic polyangitis 
Figure 1.4 Classifications of Primary Vasculitis Disorders 
 
Classification of the vasculitic disorders is based on the Chapel Hill Consensus Conference on the 
Nomenclature of Systemic Vasculitis (164;165).  These disorders are classified, in part, based on the 
predominant vessel affected; however substantial overlap among different vasculitis disorders exists. 
Adapted from 159. 
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medium vessels and can be observed in smaller vessels.  PAN can occur as a 
systemic disorder but cutaneous PAN represents 10% of cases (161).  Patients, 
20-50%, normally present with cutaneous manifestations such as livedo 
reticularis, nodules, ulcerations and digital ischemia as well as symptoms like 
fever, fatigue, myalgias, arthralgias and weight loss (168).  GI tract, renal and 
myocardial involvement may occur within patients rendering the disease life 
threatening (168).   This disease affects men more commonly than women and 
can occur at any age, maximum at 40-60 years (172). PAN been associated 
with hepatitis B infections (5 to 10 %) and streptococcal infection in children 
(161;170).       
 
1.3.3 Small Vessel Disease (<50 µm)  
Small vessel vasculitis presents with purpura, papules, vesicles and urticarial 
lesions.  Although skin is the primary organ involved, involvement of the renal, 
musculoskeletal and gastrointestinal systems may occur depending on the 
disease (161).  These vascular diseases are commonly associated with 
connective tissue diseases such as SLE, RA and SS (159;167;172-174).  Small 
vessel vasculitis restricted to the skin, without systemic involvement, is 
classified as leukocytoclastic vasculitis.  Histopathologically leukocytoclastic 
vasculitis manifests as segmental infiltration and disruption of the vessel wall by 
neutrophils, which is usually accompanied by extravasation of erythrocytes and 
endothelial cell swelling (159;167;172).   
 
1.3.3.1 Henoch-Schonlein Purpura (HSP) 
HSP represents approximately 10% of all cutaneous vasculitis cases.  All cases 
demonstrate palpable purpura but is only the presenting sign in 50% of cases 
(168).  Arthritis, gastrointestinal manifestations and nephritis are also observed 
within this subtype of vasculitis but all may not be present in a given patient.  
HSP is more common in childhood, primarily in boys aged 4 to 8 years old and 
is the most common form of systemic vasculitis in children (172).  The incidence 
of HSP in children is approximately 14 cases per 100,000 per year (172).  
Diagnosis of HSP is conditional on the presence of IgA deposition within and 
around blood vessels (175), although these IgA deposits are not specific for 
HSP and are commonly found in other vasculitis disorders (175).  Medium sized 
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vessels are rarely involved in HSP (172) and the pathogenesis associated with 
small vessels may be related to abnormal glycosylation of IgA.  The precise 
mechanisms mediating pathology in HSP is unknown as is the significance of 
antiendothelial IgA antibodies, anticardiolipin antibodies and IgA antineutrophil 
cytoplasmic antibodies (ANCAs) which can all be detected in HSP. 
 
1.3.3.2 Cryoglobulinemic vasculitis 
Cryoglobulinemic vasculitis is associated with circulating, cold-precipitable 
antibodies, cryoglobulins.  Mixed cryoglobulins consist of monoclonal IgM or 
polyclonal IgM directed against IgG.  Cryoglobulin immune deposits affect small 
vessels, predominately in the skin and glomeruli (161;168).  Patients present 
with erythematosus and papules often triggered by cold exposure or prolonged 
standing (175).  In this type of vasculitis patients may also present with medium-
sized vessel disease. 
 
1.3.3.3 ANCA-associated Small Vessel Vasculitis 
Wegener’s granulomatosis (WG), Churg-Strauss syndrome (CSS) and 
Microscopic polyangitis (MPA) are 3 forms of small to medium vasculitis that are 
associated with ANCAs but lack deposits of immune complexes, therefore these 
syndromes are also described as pauci-immune syndromes (176;177). 
 
1.3.3.3.1 Wegener’s Granulomatosis (WG) 
WG is a multisystem necrotizing granulomatosus vasculitis involving the upper 
and lower respiratory tract and the kidneys.  Rapidly progressive renal disease 
can occur as a result of necrotising and crescentic glomerulonephritis (178).   
WG can occur at any age and affects both males and females.  Generally the 
incidence of WG is 5 to 10 per million annually and 80-97% of cases are 
observed within Caucasian populations (168;172).  Cutaneous manifestations 
like palpable purpura, oral ulcers, papulonecrotic lesions, subcutaneous 
nodules and ulcers develop in 46 to 66% of cases, parallel disease activity in 
other organs and are the presenting sign in approximately 10% of patients 
(168;175).  Renal disease, a necrotizing pauci-immune glomerulonephritis, 
develops in 80% of cases.  Cutaneous WG vasculitis is associated with active, 
rapidly progressive disease and higher frequency of renal and joint disease 
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compared to WG patients without cutaneous vasculitis (175).  Diagnosis of WG 
is based on clinical features, biopsy and the presence of ANCA, described 
further in section 1.3.4.  Up to 80% of WG patients are c-ANCA positive, while 
10-15% of WG patients are p-ANCA positive.  A small percentage of WG 
patients are ANCA negative, these patients tend to have a better prognosis 
(168;172). 
 
1.3.3.3.2 Churg-Strauss Syndrome (CSS) 
CSS, also known as allergic granulomatosus, is a rare necrotizing vasculitis 
which is usually associated with asthma and eosinophilia (168;175).  Clinically 
and pathologically this vasculitis disorder resembles PAN, MPA and WG but 
has distinct features, asthma and tissue eosinophilia, making it a separate entity 
(175).  CSS affects small to medium vessels and is reported to occur in 3 
people per million (168).  Vasculitis occurs as the final distinct phase during 
disease progression, after allergic rhinitis (asthma) and eosinophilic lung 
infiltration, but may occur up to 30 years after initial symptoms (168;172).  
Vasculitis affects the lungs and heart in addition to peripheral nerves and skin.  
Cutaneous manifestations are reported in 60 to 70% of cases and include not 
only erythematosus lesions but also ulcers, livedo reticularis and facial oedema 
(168).  Renal involvement is also observed within CSS but is less severe than 
that observed in WG.  Diagnosis of CSS is based on clinical presentations, skin, 
lung and kidney biopsies and blood eosinophilia.  For CSS the presence of 
ANCA is not a diagnostic property as it is in WG.  50% of CSS patients are 
ANCA negative; the remaining patients are equally positive for both subtypes of 
ANCAs (168), this suggests that CSS may exist as two distinct disease entities.         
 
1.3.3.3.3 Microscopic Polyangitis (MPA) 
MPA is a pauci-immune nongranulomatosus small and medium vessel 
vasculitis most often associated with progressive renal disease (168;175).  90% 
of patients have renal disease in the form of pauci-immune necrotising and 
crescentic vasculitis (178).  Although disease can occur within medium sized 
vessels in MPA, the disease is often restricted to small vessels (175).  Features 
of MPA are similar to that of WG except that upper respiratory tract involvement 
is rarely observed (168).  Palable purpura is found in 46% of patients at 
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presentation, nodular lesions are not found within MPA and presentation of this 
should direct diagnosis towards WG or CSS (168).  Skin disorders are observed 
in 65% or less of patients; in 15% of cases cutaneous disease is the presenting 
clinical feature (175).  Skin biopsies from MPA patients closely resemble 
leukocytoclastic vasculitis and HSP.  Distinction between disorders is 
established by the presence of p-ANCA within MPA and the absence of 
immunoglobulin and complement localisation to vessel walls (175).  p-ANCA 
levels correlate with disease activity (175). 
 
1.3.4 Anti-Neutrophilic Cytoplasmic Antibodies (ANCA) 
Anti-neutrophilic cytoplasmic antibodies (ANCA) are predominately IgG 
autoantibodies directed against antigenic targets of primary granules of 
neutrophils and monocyte lysosomes (178) and are implicated in the 
pathogenesis of ANCA-associated systemic vasculitides (AASV), necrotizing 
small vessel vasculitis with a paucity of immune complexes in conjunction with 
the presence of ANCAs (6;178).  Titres of these antibodies appear to precede 
clinical disease activity and rising levels of these antibodies during remission 
phases of the disease are indicative of relapses (179-181).  Indirect 
immunofluorescence established two patterns of staining with ANCAs; a diffuse 
cytoplasmic staining of neutrophils and monocytes, but not lymphocytes, (c-
ANCA) and a perinuclear staining (p-ANCA).  Two main target antigens were 
identified from these two ANCAs, c-ANCAs are generally directed against 
proteinase 3 (PR3), while p-ANCAs are directed against myeloperoxidase 
(MPO) (6;113;178;182).  PR3 is a 29-30 kDa serine protease consisting of 288 
amino acids (182).  The structure of PR3 shows considerable homology to 
neutrophil elastase.  Under inflammatory conditions PR3 is released 
extracellularly, together with other granule constituents and oxygen radicals 
which can degrade collagens, proteoglycans and other connective tissue 
constituents. PR3-cANCA recognise restricted epitopes on PR3 involving the 
catalytic site and interfere with the enzyme inactivation (182).  MPO is a 
covalently linked dimer with a molecular weight of 140 kDa localised in the 
azurophilic granules of neutrophils and lysosomes, making up almost 5% of the 
total protein content of the neutrophil.  MPO catalyses the formation of 
intracellular toxic products, such as hydrogen peroxide and oxygen radicals, 
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which are effective in killing phagocytosed bacteria and viruses.  ANCA-
associated vasculitic disorders are characterised by neutrophil infiltration.  Falk 
et al (183) demonstrated that neutrophils express PR3 and MPO on their 
surface when primed with low dose proinflammatory cytokines.  Neutrophils 
become fully activated when incubated with sera from PR3-ANCA and MPO-
ANCA positive patients and produce reactive oxygen species as well as release 
lytic enzymes including PR3 and elastase.  Ohlsson et al (184) demonstrated a 
strong increase, 10 fold, in mRNA levels for PR3 in monocytes from patients 
with AASV compared to both healthy controls and SLE disease controls.  These 
high mRNA levels do not necessarily indicate increased total PR3 protein 
levels.  Isolation of neutrophils from the bloodstream demonstrated that different 
individuals differ in their expression of membrane PR3 (mPR3) (185).  Most 
individuals contain a heterogeneous population of neutrophils with both positive 
and negative neutrophils for PR3 membrane expression, the proportion of these 
cells are stable and may be genetically determined (185). In WG or in other 
inflammatory conditions patients have an elevated proportion of mPR3-positive 
neutrophils (185;186). 
  
ANCAs have been implicated in the pathology of AASV.  A direct link between 
ANCA and the development of glomerulonephritis and vasculitis was 
demonstrated in an MPO knockout mouse model where passive transfer of 
mouse MPO was sufficient to induce the disorders in knockout mice (187), 
reviewed (6;157;178;185;188).  The pathogenic potential of these antibodies 
was confirmed by transfer of purified anti-MPO IgG into RAG2 knockout mice 
which developed focal necrotizing and crescentic glomerulonephritis with a 
paucity of glomerular Ig deposition in the absence of functional T or B 
lymphocytes, although renal lesions were not as widespread as positive control 
mice.  This may indicate that additional factors are required to enhance the 
inflammatory response.  A subsequent study demonstrated that mice depleted 
of neutrophils were completely protected from anti-MPO induced 
glomerulonephritis (185).  Additionally transfer of recombinant murine PR3 into 
PR3 and neutrophil knockout mice generated murine PR3-specifc polyclonal 
antibodies although antibody transfer into wild-type mice did not induce 
vasculitis (6;176;185;188).  An aggravated local immune response was 
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observed supporting PR3 mediated tissue damage.  Comparison of these MPO 
and PR3 mouse models may indicate that anti-MPO and anti-PR3 have 
different mechanisms of action.  In addition to mouse studies, a human study 
reported that a newborn child developed glomerulonephritis and pulmonary 
haemorrhage 48 hours after delivery from a mother with MPO-ANCA 
microscopic polyangitis (188).  MPO-ANCA IgG was found in the child’s blood 
concluding that transplacental transfer of MPO-ANCA IgG resulted in the 
glomerulonephritis and pulmonary haemorrhage.   
 
The mechanisms generating ANCAs are unresolved; Pendergraft et al (189), 
reviewed (159;178;185;188;190), suggested the generation of ANCAs may 
result from autoantigen complementarity.  In patients with inflammatory vascular 
disease the patients generated antibodies to the autoantigen, PR3, as well as 
antibodies to a peptide translated from the antisense, or complementary, DNA 
strand of PR3 (cPR3).   The study was based on the hypothesis that the antigen 
that initiates the sequence of events leading to autoimmunity is not an 
autoantigen, but rather the complementary, antisense, peptide or a mimic of this 
peptide.  This complementary peptide initiates the autoantibody production.  
Following this an anti-idiotype response occurs.  The resulting anti-idiotypes 
react with the antigen derived from the sense peptide and whose amino acid 
sequence is complementary to the sequence of the initiating, antisense, 
antigen.  This theory was confirmed in mouse models where mice immunised 
with a complementary human peptide, cPR3 whose structure mirrors that of 
PR3, produced antibodies against that peptide, cPR3, as well as to the peptides 
sense counterpart, PR3.  The structure of cPR3 mirrors that of PR3          
 
At least two separate signalling pathways are thought to be involved in the 
activation of neutrophils by ANCA (6;178;179).  The F(abs’)2 portion of ANCA 
IgG activates a G-protein coupled receptor pathway while the Fc portion of the 
antibody binds to the constitutively expressed FcγRIIa and FcγRIIIb receptors of 
the neutrophil, activating Syk kinase and protein kinase C-β and mediates 
calcium release.   
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1.3.5 Antiendothelial Cell Antibodies (AECA) 
Antibodies directed against endothelial cells (AECA) have been detected in the 
sera of patients with vasculitis (173), they have also been found in myositis with 
vascular injury resulting in myofibre damage (58).  AECAs are a heterogeneous 
group of antibodies directed against a variety of endothelial cell antigenic 
membrane proteins.  Endothelial cell dysfunction and persistent local 
inflammation is considered to be an early event which subsequently leads to the 
development and progression of vascular wall disorders, such as vasculitis (7), 
but may also play a significant role in other disorders like myositis.  The 
endothelium participates in homeostatic mechanisms including regulation of 
vascular tone and directing biological responses such as leukocyte trafficking to 
inflammatory sites, Figure 1.1, (7).   The mechanisms of AECA are thought to 
include complement or antibody dependent cellular cytotoxicity, induction of 
endothelial cell apoptosis and upregulation of adhesion molecules resulting in 
continued recruitment of leukocytes, but the exact role of AECAs in vasculitis is 
largely unresolved (176;191).  Certain forms of endothelial injury are associated 
with ANCA.  Endothelial cells may express, process and present ANCA 
antigens to cytotoxic T cells.  Previous studies have demonstrated that 
endothelial cells develop an activated phenotype in ANCA-associated vascular 
injury with enhanced expression of adhesion molecules, ICAM-1 & VCAM-1, 
that promote interaction with circulatory inflammatory cells (7).  An association 
of ANCA-associated vasculitis and endothelial cells had been proposed by 
Woywodt et al (6;8) who demonstrated that patients with ANCA-associated 
vasculitis have high numbers of circulating endothelial cells compared to 
controls.  It was also observed that these endothelial cells had undergone 
necrosis indicating that they detached from the basement membrane as a result 
of a direct, active and pathogenic mechanism but the exact role of this in 
vasculitis is unresolved.     
 
Stromal cells such as fibroblasts and smooth muscle (SM) cells can also 
produce biologically active proteins that act to regulate endothelial cell function 
(192), thus the interactions of stromal cells with endothelial cells at the sites of 
inflammation are likely to be important in the initiation and maintenance of the 
local inflammatory response and determination of site specificity.  Baiu et al 
42 
(193) studied the role and pathogenicity of anti-SM antibodies in vasculitis.  
Vasculitis was induced by adoptive transfer of SM-stimulated lymphocytes and 
the production of autoantibodies targeting blood vessels and the pathogenicity 
of these autoantibodies was established.  Results demonstrated the 
development of small vessel vasculitis in mice accompanied by the presence of 
pathogenic antibodies reactive with vascular smooth muscle as well as the 
persistence and expansion of activated, potentially pathogenic, B cells.  These 
results were confirmed as a result of serum transfer experiments.  The anti-SM 
antibodies were shown to recognise intracellular antigens which has also been 
observed in human patients (193) suggesting that other mechanisms resulting 
in damage to vascular cells need to occur first in order for B cells to be exposed 
to the intracellular antigen.  Other antibodies found in vasculitis patients, such 
as anti-Ro, La, DNA or RNP, may be associated with underlying disorders in 
these patients.    
 
1.3.6 Pathogenesis of Vasculitis 
The pathogenesis of vasculitis includes different immune mechanisms that 
cause leukocytes to adhere to endothelial cells, penetrate into vessel walls and 
release injurious products resulting in vessel wall injury.  Like the classification 
of vasculitis disorders, the mechanisms of pathogenesis have also been 
classified into 4 types (157;158;162).  The first major pathogenic mechanism in 
vasculitic syndromes is termed allergic vasculitis and is strongly associated with 
atopic disorders.  In vasculitic disorders such as urticarial vasculitis and CSS 
activated Th2 lymphocytes play a central role through their production of 
cytokines to mediate the accumulation of mast cells, basophils and eosinophils.  
Bridging of IgE receptors on these cells leads to the secretion of inflammatory 
and toxic mediators.  Antibody-mediated vasculitis is another major pathogenic 
mechanism, especially in ANCA-associated vasculitis as previously described.  
The third pathogenic mechanism in vasculitis is immune-complex vasculitis.  
Immune complexes are associated with cutaneous lesions of vasculitic 
disorders and are observed in HSP, cryoglobulinemic vasculitis, 
leukocytoclastic vasculitis and PAN.  80% of direct immunofluorescence 
examinations are positive for IC or complement deposition (157).  Deposition of 
IC results in complement activation and release of anaphylatoxins C3a and C5a 
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that recruit inflammatory cells, in particular neutrophils and mast cells which are 
necessary for the progression of IC-mediated vascular damage.  This process is 
also highly regulated by adhesion molecules.  T cell hypersensitivity vasculitis is 
the final classification of immunopathogenic mechanisms.  These mechanisms 
are largely seen in large vessel vasculitic disorders or granulomatous 
vasculitides but lack the IC deposition and ANCA association.  Although the 
immune mechanism of pathogenesis has been classified, more than one 
immune mechanism may be involved over the course of a single disease as 
well as the occurrence of overlap syndromes.         
 
1.3.7 Therapies in Vasculitis 
Therapeutic strategies within vasculitis disorders are similar to those described 
for myositis disorders in section 1.2.5.  Currently corticosteroid and 
immunosuppressive therapies, as previously described, are the foundation of 
treatments strategies but the regime and combination of treatments is 
dependent on a number of factors including vasculitis severity and underlying 
medical conditions (157;159).  Similarly to myopathies the exact pathogenic 
mechanisms and target antigens are still being defined, therefore treatments to 
date are non-selective but new selective therapies are being studied in different 
vasculitic disorders.  TNF-α treatments, Infliximab and Entanercept, have shown 
promise in some treatments while being disappointing in others and have also 
been related to the development of autoimmune processes (157;194-201).  
TNF-α could mediate the endothelial dysfunction in vasculitis therefore such 
targeted therapy could improve endothelial functions in these disorders.  B cell 
depletive therapy using Rituximab has also shown promising results in vasculitic 
disorders in a number of studies (148;157;159;177;202-206).  Depletion of B 
cells in the patients included in these studies were accompanied by partial or 
complete remission and decreased autoantibody levels with few side effects 
which further substantiates the role of B cells in such autoimmune disorders.  
Additional B cell therapies targeting CD20, CD22 and BAFF could also impact 
on these disorders (154;155).   
 
The aetiology of most autoimmune disorders is largely unknown, including 
myositis and vasculitis.  Many different factors have been implicated in the 
different cellular and molecular mechanisms associated with autoimmune 
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disorders, including the involvement of B cells, the central theme of this study.  
The participation and significance of B cells in these mechanisms are 
substantiated by the occurrence of autoantibodies and immune complexes 
within autoimmune disorders as well as the recent clinical improvements 
observed using B cell depletive therapies.       
 
1.4 B cells 
B cells, along with T cells, were first identified in 1960 (207) and participate in 
adaptive immune responses by mediating humoral immunity through the 
release of antigen specific antibodies.  B cells originate in the bone marrow from 
undifferentiated hematopoietic stem cells (HSC), which have the capacity to 
develop into all lymphohematopoietic lineages, and undergo a process of 
maturation from early lymphoid progenitors (ELP) to common lymphoid 
progenitors (CLP) by the increased expression of IL-7Rα (208).  CLPs are also 
the precursor cells for natural killer (NK) cells, dendritic cells (DCs) and T 
lymphocytes (208;209).  In B cell diversification CLPs then diversify through 
pro-B cell and pre-B cell maturation to an immature B cell stage leading to a 
mature B cell (Figure 1.5) (154;208-213).  Mature B cells them become 
activated by a relevant antigen and co-stimulatory factors and migrate to 
germinal centres to differentiate into memory cells and plasma cells which are 
all specific for the original antigen (154;208-213).  Plasma cells are antibody-
secreting cells which are no longer in cell cycle and generally reside within the 
bone marrow.  Within this phenotype of cells there are long-lived and short-lived 
plasma cells (209;213-216).  Prior to plasma cell differentiation activated B cells 
transition into activated cells, termed plasmablasts, which secrete antibodies 
but still remain in cell cycle.  Similarly to plasma cells these can be divided into 
short and long-lived categories.  The exact relationship between these cell 
types remains to be defined.  Memory cells can also be differentiated into 
antibody secreting cells by repeated antigenic challenge resulting in 
reactivation, rapid proliferation and mutation of memory B cells (209;213).  B 
cell generation depends on signalling through the c-kit, Flt3 and IL-7 receptors 
and development control is exerted by a network of key transcription factors that 
include PU.1, Ikaros, Bcl11a, E2A, EBF, Foxp1 and Pax5 (217-219); in the 
absence of these regulators B cell development is severely affected.  During the 
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life span of B cells they circulate between peripheral blood and tissue, on 
contact with antigen B cells undergo their final stages of development 
(207;208).   
 
 
 
 
 
 
 
 
1.4.1 B Cell Gene Repertoire Development 
During the course of B cell development various gene segments rearrange to 
establish the repertoire of the immunoglobulins (Ig) expressed on the B cell 
surface (Figure 1.5 & 1.6).  The Ig’s produced by B cells are composed of 2 
heavy polypeptide chains and 2 light polypeptide chains, kappa or lambda, 
made up by a combination of gene segments.  The germline variable (V) region 
of the IgH, heavy, chain are coded by the VH (variable), D (diversity) and JH 
(joining) gene segments located on chromosome 14 in humans (220-224).  The 
variable and joining gene segments for lambda light chains are located on 
chromosome 22 while the kappa gene segments are located on chromosome 2.   
7 VH families exist based on sequence homology of at least 80% (225-228), 
with approximately 51 functional gene segments.  Approximately 27 functional 
DH gene segments make up 7 DH families based on sequence homology, which 
range from 11 to 37 base pairs in length (229), while 6 JH genes are present 
within the genome.  Kappa and lambda have 7 and 10 different V gene families 
respectively with approximately 40 and 30 gene segments respectively (Table 
1.2).  5 kappa J gene segments are found in the kappa locus with a single 
Figure 1.5 Differentiation Pathway of B Cells 
  
The maturation of B cells occurs in two phases, antigen-independent in the bone marrow and antigen-dependent in 
the periphery.  Stem cells diversify into lymphoid progenitors which further differentiate into pro-B cells before pre-B 
cells are formed where a rearranged VDJ unit is expressed at the cell surface with a surrogate light chain.  Immature B 
cells are formed, still within the bone marrow, that express IgM which evolve into mature B cells expressing IgM and 
IgD.  The terminal differentiation steps occur within germinal centre reactions in secondary lymphoid organs where 
naïve B cells are activated to differentiate into memory B cells and plasma cells.  Markers in red signify where loss of 
transcription factors arrests B cell development; the grey arrow represents the transition of B cells from the bone 
marrow to the peripheral compartments. Adapted from 217.  
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constant kappa gene while four pairs of functional J lambda and constant genes 
are found within the lambda locus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene segments combine to form functional immunoglobulin genes in a 
recombination reaction termed V(D)J recombination (Figure 1.6) (1;220;230-
234).  These rearrangements are guided by conserved non-coding DNA 
sequences that are found adjacent to the points where recombination takes 
place.  These conserved sequences consist of a heptamer (5’CACAGTG3’) 
followed by a nonconserved region, spacer, which is either 12 or 23 nucleotides 
long (Figure 1.7A).    The conserved length of the spacer corresponds to one or 
two turns of the DNA double helix respectively.  This is then followed by a 
second conserved nonamer sequence (5’ACAAAAACC3’).  The heptamer-
spacer-nonamer combination is also known as the recombination signal 
sequences (RSSs).  Recombination of gene segments follows the 12/23 rule 
where only a gene segment flanked by a RSS with a 12 base pair (bp) spacer 
can be joined to one flanked by a 23 bp spacer RSS; DH gene segments can be 
Figure 1.6 A simplified Diagram of Gene Rearrangement Processes of Heavy (A) and Light (B) Chain 
Immunoglobulin Genes 
 
In the gene rearrangement process heavy chains are rearranged first (A).  Initially one of the D gene segments 
is translocated to one of the several J gene segments forming a DJ gene combination.  A V gene segment, 
with its own corresponding leader (L) sequence, is then translocated to the DJ segment to form a VDJ variable 
gene segment.  After completion of the heavy chain rearrangements light chain rearrangements are completed 
(B).  One of the V gene segments with its corresponding leader (L) sequence is translocated to a J gene 
segment creating a VJ gene segment encoding the complete light chain variable region.  The kappa chain is 
rearranged first, if this produces a non-functional rearrangement a lambda rearrangement then occurs.  A 
primary RNA transcript is then produced from the rearranged DNA.  Splicing then occurs to remove the 
intervening introns and bring together the VDJ/VJ segments with the constant (C) exons.  The kappa gene 
locus contains only one constant gene whereas each J segment of the lambda locus is associated with a 
different constant lambda region.  Adapted from 1. 
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joined to a JH gene segments and a VH gene segment to a DH gene segment 
but VH gene segments cannot be joined to JH gene segments as they are both 
flanked by 23 bp spacers whereas DH gene segments are flanked by 12 bp 
spacers.  The mechanisms of V(D)J recombination bring together a 12 bp 
spaced and a 23 spaced RSS (Figure 1.7B&C).  The DNA molecule is then 
broken in two places and rejoined in a different configuration.  The gene 
segments join to form a coding joint while the remainder of the DNA in a hairpin 
loop form a signal joint creating a circular piece of chromosomal DNA which is 
lost during cell division.  Rearrangement of immunoglobulin genes is a multistep 
enzymatic process and starts with the binding of products from the 
recombination-activating genes, RAG1 and RAG2, whose expression is unique 
to lymphoid cells, and high-mobility group proteins (HMG) to RSSs, following 
the 12/23 rule.  The endonuclease activity of the RAG protein complexes 
produces two single-strand DNA breaks just 5’ of the bound RSSs leaving a 
free 3’-OH group at the end of each coding segment.  This 3’-OH then 
hydrolyses the phospodiester bond on the complementary uncut strand forming 
double-strand breaks, which are held tightly in a complex by the RAG proteins.  
These form a hairpin by joining to the cut end of its complementary strand on 
the other side of the break.  The two RSSs are precisely joined by DNA ligase 
IV to form the signal joint.  To complete the rearrangement of the gene 
segments the DNA hairpin is nicked open by a single-stranded break by the 
RAG proteins, this can occur at various points along the hairpin creating 
sequence variability when the sequences join.  The DNA repair enzymes, DNA-
dependent protein kinase (DNA-PK) and the Ku heterodimer (Ku70:Ku80) 
modify the opened hairpins by removing nucleotides by exonuclease activity 
and adding non-templated (N) nucleotides by terminal deoxynucleotidyl 
transferase, TdT, or templated (P) nucleotides.  DNA ligase IV joins the 
processed ends to generate a continuous double-stranded DNA, reconstituting 
a chromosome which includes the rearranged gene.   
 
The majority of gene segments do not join in phase with the reading frame 
resulting in non-functional rearrangements.  Also inappropriate gene 
rearrangements, approximately 75%, produce recognition to self antigens 
resulting in apoptosis or anergy of cells at the pre-B stage.  These cells may be 
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rescued by receptor editing, a dominant mechanism in B cell tolerance.  
Secondary Ig gene rearrangements occur, which are RAG-mediated, altering 
the specificity of an autoreactive B cell at the immature B cell stage 
(233;235;236). 
 
VH1 VH2 VH3 VH4 VH5 VH6 VH7 VH Family 10 3 23 11 2 1 1 
DH1 DH2 DH3 DH4 DH5 DH6 DH7 DH Family 5 4 5 4 4 4 1 
JH1 JH2 JH3 JH4 JH5 JH6 JH Family 1 1 1 1 1  
Vκ1 Vκ2 Vκ3 Vκ4 Vκ5 Vκ6 Vκ Family 19 9 7 1 1 3 
Jκ1 Jκ2 Jκ3 Jκ4 Jκ5 Jκ Family 1 1 1 1 1 
Vλ1 Vλ2 Vλ3 Vλ4 Vλ5 Vλ6 Vλ7 Vλ8 Vλ9 Vλ10 Vλ Family 5 5 9 3 3 1 2 1 1 1 
Jλ1 Jλ2 Jλ3 Jλ7 Jλ Family 1 1 1 1 
          Vκ7, Jλ4, 5 and 6 are considered non-functional 
Table 1.2 Distribution of VH, Vκ and Vλ Functional Genes  
 
The assembly of different gene segments in V(D)J recombination and the 
random pairing of heavy and light chains provide the diverse gene repertoire of 
the B cell.  This diversity is further enhanced by exonuclease activity removing 
nucleotides and addition of up to 20 non-templated (N) or up to 4 templated (P) 
nucleotides, inverted repeats of V, D or J coding ends, at joining sequences 
within the CDR3 region generating the most diverse region of the Ig 
rearrangement (Figure 1.7C) (237;238).  Additional mechanisms are also 
employed to further increase diversity following exposure to antigen, somatic 
hypermutation leading to affinity maturation and receptor revision.  Receptor 
revision in the periphery, similar to that of receptor editing in the bone marrow, 
can also increase the diversity through secondary recombination of low affinity 
immunoglobulin genes to alter the specificity and affinity towards antigen 
(233;239;240). 
 
1.4.2 VH Repertoire from Healthy Individuals 
Studies have been conducted within normal, healthy individuals to establish the 
normal repertoire of immunoglobulin genes which allow the modifications to the 
repertoire to be established within autoimmune diseases (241-250).  Some of 
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these studies have demonstrated that the frequency of gene usage was similar 
to that of the germline complexity (241-243).  Guigou et al (245) first used in situ 
hybridization, on cDNA libraries from peripheral blood samples, using Ig DNA 
probes specific for VH1 to VH6 to analyse the expression pattern of VH families 
in the human adult repertoire of two healthy patients.  Results produced an 
expression gradient for VH genes; VH3 (52%) > VH4 (19%) > VH1 (11%) > VH5 
(10%) > VH6 (5%) > VH2 (3%).  This gradient of gene usage is comparable to 
the complexity of functional germline genes within each family although bias for 
activated B cells is possible.  Brezinschek et al (241;242)  in subsequent studies 
used single-cell PCR analysis on genomic DNA to analyse the heavy chain 
repertoire of human peripheral B cells.  In functional repertoires VH3 was used 
most frequently followed by VH4, VH1, VH5, VH2 and VH6, an ordering similar to 
the number of functional genes within each VH family.  This preferential use of 
VH3 gene segments was not found in non-functional repertoires.  Selection for 
particular individual VH germline genes was also reported.  VH3-23, VH4-59, 
VH4-39, VH3-07, VH3-30, VH1-18, VH3-30*03, VH3-34 and VH3-09 were over-
represented in these repertoires and were found to be expressed by more than 
50% of B cells.  A limitation of these studies was the low number of patients 
involved which may not fully represent the true diversity of the Ig repertoire.  
 
The most recent study examining the VH gene repertoire was conducted using 
nearly 6,500 functional human Ig heavy chain genes which aimed to represent 
the natural Ig diversity and was compared to 325 non-functional genes (251).  
This study involves a larger set of genes than was previously examined, 
including the previous studies by Brezinchek et al (241;242).  Clonally related 
gene duplicates and genes of autoimmune origin were filtered from the dataset 
of sequences isolated from the Genbank nucleotide database in addition to 
genes of perinatal origin, due to the known gene segments and CDR3 biases.  
The study established that functional gene rearrangements more closely 
resembled the genomic complexity compared to the non-functional gene 
rearrangements.  The data from functional genes support that of previous 
findings (241;242) that VH3 gene segments are used most frequently, followed 
in descending order by VH4, VH1, VH5, VH2, VH6 and VH7 which is also similar to 
the germline complexity.  Also in support of previous findings the gene segment 
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VH3-23 was most frequently used followed by the VH4-34 gene segment in this 
study.  Analysis of DH gene segments demonstrated a significant departure of 
the proportions within functional and non-functional from the germline 
complexity at both the family and individual gene segments usage level.  The 
functional repertoire of DH demonstrated that DH3 gene segments were most 
frequently used followed by DH2, DH6, DH1, DH5, DH4 and finally DH7.  Due to 
the difficulties in assigning DH gene segments in rearranged Ig genes, the 
normal repertoire of DH gene segments had not been extensively studied prior 
to this study.  The repertoire of JH gene segments was also found to correlate 
with previous studies with the JH4 gene segments most frequently used 
followed by JH6, JH5, JH3, JH1 and JH2.  As very few JH gene segments are 
present within the genome, the repertoires observed within the functional, as 
well as the non-functional, were found to differ significantly from the germline 
complexity.  In addition to the repertoires of the individual gene segments the 
study also examined D-J segments pairings.  Several pairings were found to 
occur statistically above expected values, including DH2-2 to JH6 and JH2, DH1-
14to JH1 and JH5, DH5-24 to JH4 and DH7-27 to JH3.  Overall it was observed 
that several 5’DH gene segments paired with increase frequency to the most 
3’JH gene segments (JH5 and 6) while with decreased frequency to closer 
chromosomal segments (JH1-4).  However, some 3’DH gene segments did show 
an increased frequency of pairings with the closest JH gene segments and a 
decreased frequency in pairing with the furthest JH5 and JH6 gene segments.  In 
addition to establishing the normal repertoire the study hypothesised that 
multiple D-J successive recombinations may occur before translocation of the 
VH gene, although very little evidence for this mechanism had been found.           
 
Conversely studies have been conducted in healthy individuals that 
demonstrate that the peripheral B cell repertoire differs from the gene frequency 
within the germline and biased expression of certain VH families have been 
observed in certain individuals (246-248;250).  Huang et al (246) demonstrated 
a selection for VH1 and VH5 gene segments with a selection against VH3 family 
genes in cDNA libraries from 2 patients.  Suzuki et al (250) assessed the 
contribution of individual VH3 and 4 gene segments to the human antibody 
repertoire.  Synthetic oligonucleotide probes, which were specific to individual 
51 
VH gene segments within rearranged genomic DNA, were used to assess 8 
individual VH3 and 9 individual VH4 gene segments in the PBL repertoire of two 
healthy patients.  Of the eight individual VH3 gene segments assessed the VH3-
23 and VH3-30 gene segments were rearranged more frequently than expected 
based on germline complexity which accounted for approximately 17% and 20% 
of VH3 gene rearrangements in both subjects respectively.  In both subjects the 
eight VH3 gene segments analysed accounted for over 50% of the VH 
rearrangements, an increase from the 16 to 30% predicted based on VH3 gene 
numbers.  VH4-34 was shown to be over-expressed in one of the subjects, 
accounting for more than 25% of the sequences isolated. This rearrangement 
with another two VH4 rearrangements, VH4-31 and VH4-4b, accounted for more 
than 50% of the VH4 rearrangements.  Conversely VH4-17, VH4-55 and VH4-28 
were rarely found.  The work of this study suggests that a limited number of VH 
gene segments dominate the VH repertoire but due to the polymorphic nature of 
these segments the dominance of individual VH gene segments will differ 
between individuals.  The repertoire was analysed after an 8 month intermission 
and little change in the VH repertoire was observed indicating that the utilization 
of these VH gene segments was a stable feature in the VH repertoire of this 
subject.  The over-representation of the VH4-34 gene was also noted in another 
study into the normal adult human peripheral blood B cell repertoire.  Kraj et al 
(247) established the representation of the VH4-34 gene in the repertoire of two 
healthy individuals.  VH family distribution was found not to significantly differ 
from expected values based on the germline complexity but in both the cDNA 
library and rearranged Ig DNA library VH4-34 gene segments were over-
represented relative to other VH4 gene segments accounting for 25 and 70% of 
DNA sequences in the two patients.  
 
Previous work on biased subsets of VH gene segments within peripheral 
repertoires led Kraj et al (248) to assess the human VH repertoire at different 
stages of B cell development.  The study compared the VH3 and VH4 gene 
representation of pre-B, immature B and preimmune mature B cells from two 
healthy individuals.  Within pre-B cells there was a large representation of VH4 
gene segments.  VH4-34 was the most prominent and accounted for over 20% 
of sequences in both patients.  VH4-59 was also highly prominent within VH 
52 
repertoires while VH4-31, VH4-4b and VH4-61 were very low within both 
repertoires.  For the VH3 repertoire a biased representation of certain VH3 gene 
segments, VH3-23 and VH3-30, was observed at the pre-B cell stage and this 
was carried through to mature B cell stages.  Other genes such as VH3-11 were 
highly prominent at early B cell stages but were rare in later B cells stages while 
VH3-20 were very infrequent in early B cell stages but this increased in the 
mature B cell population.  VH3-15 was shown to be highly frequent on immature 
B cells compared to pre-B cells but this was not observed at later stages of B 
cell development.  The authors suggest that bias within the VH repertoire is 
established at the earliest pre-B cells stage resulting from preferential 
rearrangement which may later be modified by VH gene-mediated mechanisms 
such as effective surrogate light chain pairing and ligand mediated selection. 
 
Many mechanisms for these reported bias gene usage repertoires have been 
proposed (247;252;253).  These mechanisms include chromosomal positions, 
accessibility to recombinase machinery, and the presence of gene-specific 
promoter or enhancer sequences in addition to a greater number of gene copies 
in the germline.  It has also been shown that preferential use of certain VH 
elements may result from cellular selection due to antigen binding.  Gu et al 
(254) established that the recruitment of newly generated B cells into the long-
lived peripheral B cell population is mediated through positive selection by 
internal and/or external ligands.  Despite these previous studies the most recent 
and comprehensive study (251) has illustrated that the Ig repertoire is similar to 
the germline complexity. 
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1.4.3 Somatic Hypermutation (SHM) 
The release of B cells into the periphery from the bone marrow allows B cells to 
recirculate through peripheral lymphoid tissues and to come into contact with 
their cognate antigens resulting in B cell activation.  Activated B cells can enter 
primary lymphoid follicles leading to the formation of germinal centres (GCs), 
also containing antigen-specific T cells.  Within GCs the B cells undergo two 
distinct immunoglobulin gene diversification processes; somatic hypermutation 
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Figure 1.7 A simplified diagram of the mechanisms of V(D)J recombination 
 
Figure 1.7A – Conserved heptamer (     ) and nonamer (     ) sequences flank the gene segments of the heavy and 
light chains.  These are separated by a spacer of either 12 base pairs or 23 base pairs.  In V(D)J recombination a 
12/23 rule is in place to ensure that only a gene segment flanked with a 12bp spacer can be joined with a 23bp 
spacer.  Heptamer – spacer – nonamer combinations are known as recombination signal sequences (RSSs) 
 
Figure 1.7B&C – Ig rearrangement is a multistep process, initially RAGs and HMG bind to RSSs (    ) and bring the 
regions together before causing single stranded DNA breaks resulting in hairpin structures at the ends of the Ig 
gene segments.  A number of proteins (DNA-PK, Ku) bind to the hairpins and the sequences are cleaved at random 
and additional bases are added by TdT to generate diverse ends.  DNA ligase IV ligates the gene segments forming 
a coding joint.  The cleaved DNA circularises forming a signal joint which is lost during cell division.  Adapted from 1. 
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(SHM) and class switch recombination (CSR), although SHM has been 
demonstrated to occur outside GCs in animal models that cannot develop GCs 
(255).  SHM introduces non-template point mutations in the variable region of Ig 
heavy and light chains, a process which underlies the process of affinity 
maturation, generating an immunoglobulin with an altered, higher or lower, 
affinity for its cognate antigen (256).  The full workings of SHM have yet to be 
established although some mechanisms have been elucidated.  Activation-
induced cytidine deaminase (AID) plays a significant role in SHM, as well as 
CSR.  AID is a B cell specific molecule that plays a central role in adaptive 
immunity by initiating SHM (257-261).  Although AID functions as a DNA 
mutator it is predominately located in the cytoplasm of B cells but nuclear 
localisation and export signals allows transfer between the nucleus and 
cytoplasm (261).  Mutations are confined to a 1 to 2 kilobase region in the 
rearranged immunoglobulin genes of which the variable region defined the 5’ 
boundary of the hypermutation region.  Mutations begin approximately 150 bp 
downstream of the transcription start site but the mutational frequency is not 
constant and decreases exponentially with increasing distance from the 
transcription start site (262).  Point mutations generally occur in SHM, although 
insertions and deletions are occasionally observed, at a rate of 1x10-3 mutations 
per base per generation (261;263).  Transition mutations (a pyrimidine (C or T) 
to pyrimidine base change or a purine (A or G) to purine base change) occur 
approximately twice as frequently as transversion mutations (a pyrimidine to 
purine base change and vice versa) and a high proportion of these arise in 
mutational hotspot motifs.  Mutations are often seen in conjunction with WRCY 
motifs (W=A/T, R=A/G and Y=C/T) or its complement RGYW (264).  AID 
initiates SHM by the deamination of C nucleotides, on single strand DNA, 
resulting in a U.G mismatch.  Following this DNA polymerases can insert an A 
nucleotide opposite the U nucleotide to generate C>T or G>A transition 
mutations following replication, the mismatch could be removed by the UNG 
(uracil-DNA glycosylase), base-excision repair  (BER) mechanism, to create an 
abasic site that can then be bypassed by error-prone polymerases (η or ζ) to 
give rise to both transition and transversion mutations or the mismatch can be 
targeted by the mismatch repair (MMR) to initiate an error-prone polymerase 
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mediated mutation process that introduces A-T and G-C mutations that are 
proximal but not located within hot spots. (257-259;262)    
 
1.4.4 Class Switching Recombination (CSR) 
Class switching recombination (CSR) is also initiated by AID, although the exact 
role of AID is unknown (257;261;265;266).  CSR is a process that changes the 
Cµ constant regions to another constant region (Cγ, Cα or Cε) to define the Fc 
mediated functions but allows the antibody to retain its specificity and affinity for 
antigen.  Tight regulation of CSR is required as abnormal levels of IgG, IgA or 
IgE favour the onset of autoimmune and allergic disorders such as SLE and 
asthma (265).  CSR results from DNA recombination between switch (S) region 
DNA segments located upstream of each C gene and deletion, circularisation, 
of the intervening DNA.  The choice of which S region serves as recipient for 
CSR is determined by which cytokines are released by the helper T cells that 
interact with the IgM-producing B cell (261).  Evidence suggests that once AID 
deaminates C to U in both the donor and recipient S region, the resulting 
mismatch recruits all the same enzymes that are recruited during SHM to create 
ssDNA breaks with CSR a result of DNA repair and germline transcription 
(257;261;265;266).  It has also been proposed that AID generates dsDNA 
breaks, generated by closely spaced single-strand breaks, with the recruited 
enzymes and additional enzymes are recruited to complete the process of CSR 
by nonhomologous end joining (261).  It has been recently demonstrated that 
AID is expressed in bone marrow pre-B cells and immature B cells initiated by 
the signalling through BCR and TLRs (266) providing an innate population of 
IgG and IgA expressing cells that could be involved in receptor editing of self-
reactive immature B cells.     
 
1.4.5 Germinal Centres  
GCs are composed of a network of B cells, FDC and CD4+ T cells whose 
interactions result in the B cell humoral immune response in secondary 
lymphoid tissues and the generation of antigen-specific antibodies.  The 
microenvironments of GCs are essential in the development of normal B cell 
immune responses as they provide an infrastructure that captures and stores 
antigen, drives B cell division and maturation, selects B cells with antigen 
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specific high affinity receptors and differentiates cells into memory B cells and 
Ig-secreting plasma cells.  GCs are derived from 1-3 B cells clones (267).  
Small recirculating follicular B cells are displaced to the outer edge of the 
network of FDCs to form the follicular mantle (268).  GCs first appear at day 4-5 
postimmunisation, achieve maximum cell numbers by day 10-11 and decline 
after about 3 weeks (269).   Antigen stimulated B cells within secondary 
lymphoid tissues migrate to the edges of B cell follicles where they interact with 
T helper cells and begin to form GCs (270).  Classically mature GC reactions 
are a two-stage process, firstly B cells form the GC dark zone and begin to 
proliferate, during proliferation B cells undergo somatic hypermutation to 
diversify the antibody variable region to produce variants with different affinities 
to the specified antigen (268;269;271-273).  Following this, B cells termed 
centroblasts convert to smaller, non-proliferating centrocytes with surface 
expression of mutated Igs and migrate to the GC light zone where they 
encounter a network of FDC, that present native antigen in the form of immune 
complexes, and CD4+ T cells, that provide helper signals to promote B cell 
proliferation and differentiation, and undergo intense selection.  Selection is 
based on competition for antigen; only those B cells with an increased affinity 
for antigen can undergo isotype switching and be selected to differentiate into 
memory B cells or plasma cells.  FDCs with successfully bound high affinity B 
cells switch off the apoptotic machinery of these high affinity B cells (273).  The 
majority of B cells die through apoptosis and are immediately taken up by 
germinal centre tingible-body macrophages as somatic mutations result in a 
lower affinity for the specified antigen or the B cells may even become reactive 
with self antigens.  Over the course of the GC reaction the light zone is 
continuously replenished by migration of GC B cells from the dark zone.  It is 
also thought that selected centrocytes can return to the dark zone for further 
rounds of division and somatic mutations giving rise to the cyclic re-entry model 
(268;274).  The organisation of light and dark germinal centre zones is 
mediated by CXCR4 and CXCR5.  Allen et al (275) demonstrated that CXCR4 
was essential for the segregation of dark and light zones, CXCR4 was more 
abundant on centroblasts rather than centrocytes and was required for 
centroblast localization in the dark zone where its ligand, SDF1/CXCL12, was 
more abundant in comparison to the light zone.  Conversely CXCR5 helped 
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direct CXCL13-positive cells to the light zone but this was not essential for 
segregation of zones.  The study proposed that centroblasts downregulate 
CXCR4 and differentiate into centrocytes and migrate towards the light zone 
while centrocytes upregulate CXCR4 to allow re-entry into the dark zone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent studies have used two-photon laser-scanning fluorescent microscopy to 
capture the movement and behaviour of B cells in germinal centres and present 
GC mechanisms which are in contrast to the previous GC mechanisms (276-
278), reviewed (274;279;280) (Figure 1.8).  Allen et al (276;279) tracked 
germinal centre B cells in mouse lymph nodes, in a perfusion chamber. Initially 
it was demonstrated that germinal centre B cells possessed highly dynamic 
Figure 1.8 Germinal Centre Organisation and Reactions 
 
Germinal Centre (GC) reactions occur within two distinct zones of the GC; the Light Zone (LZ) and the Dark Zone (DZ).  
The DZ is composed of GC B cells, a sparse network of stromal cells, GC T cells and tingible-body macrophages (TBM).  
The LZ is composed of GC B cells, a dense network of FDCs, GC T cells and TBMs.  GC B cells migrate within their 
respective compartments as well as moving between compartments by regulating CXCR4 levels.  Antigen is displayed on 
FDCs as immune complexes (IC).  GC B cells cycle within the DZ through cell proliferation and cell death.  Reducing 
CXCR4 levels cells from the DZ can migrate to the LZ where GC B cells rapidly move within the FDC network to be 
selected as high affinity GC B cells.  From the LZ, GC B cells either undergo apoptosis, exit the GC to differentiate into 
plasma cells or memory cells or they return to the LZ, a result of increasing CXCR4 levels.  Recent evidence had found 
that follicular B cells may enter GCs scanning the antigens present and may be recruited to an ongoing GC reaction if they 
have a higher affinity towards antigen. Adapted from 276. 
 
Classically GC mechanisms defined GC B cells as centroblasts and centrocytes within the DZ and LZ respectively.  
Centroblasts were thought to undergo a rapid process of proliferation and somatic mutation before differentiating into 
centrocytes within the LZ where selection of high affinity antigen B cells were selected.  The cycle of mutation and 
selection required to isolate high-affinity GC B cells led to the cyclic re-entry model where GC B cells migrate between 
zones between each phase of mutation and selection.    
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shapes, extending dendritic processes when they moved in contrast to the 
spherical phenotype characteristic of naïve B cells.  Tracking analysis indicated 
that GC B cells were highly motile, similar to that of follicular mantle B cells and 
in contrast to plasma cells which demonstrated little motility.  This motility was 
partially dependent on the chemokine CXCL13, expressed by FDCs.  The 
behaviour of B cells in the dark and light zones were examined and it was 
demonstrated that GC B cells stayed within the dark or light zone although 5-
8% travelled from one zone to another per hour.  Cell division and cell death 
were observed in both regions of the germinal centre, in contrast to the classic 
model of germinal centre reactions mentioned previously.  Schwickert et al 
(278) and Hauser et al (277) also tracked the movement of germinal centre B 
cells, but these were conducted in live mice that had received fluorescently 
labelled antigen specific B cells.  Similar to Allen et al (276) the studies 
demonstrated that GC B cells were highly motile and re-circulate within the dark 
and light zones but Schwickert (278) demonstrated that bi-directional movement 
between zones occurred but at a higher frequency of 26% per hour in contrast 
to 5-8% per hour described by Allen et al (276) and Hauser et al (277). 
Schwickert et al (278) also demonstrated that the contact between antigen 
bearing FDCs and antigen specific B cells was short lived, in the light zone, but 
frequent suggesting that B cells were crawling along FDCs scanning for 
antigen. This is in contrast to naïve B and T cells which stop moving when they 
initially encounter antigen.  The study also demonstrated that follicular B cells 
are frequent visitors to the GC compartment indicating that B cells may scan 
antigen trapped within the confines of germinal centres.  In addition to this it 
was found that high-affinity antigen-specific B cells can be recruited to an 
ongoing germinal centre reaction which would enhance competition and ensure 
that rare high-affinity B cells, not initially recruited into the germinal centre 
reaction, might gain the opportunity to participate within antibody responses.  
This is in contrast to lower-affinity B cells which could not easily colonise an 
established germinal centre.  This mechanism has recently been substantiated 
by Bende et al (281) who analysed the B cell composition of 48 GCs of reactive 
lymph nodes from 3 different donors and demonstrated that single, 
hypermutated B cell clones were found in multiple GCs, along with the offspring 
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from these clones.  These results indicated the repeat involvement of antigen-
experienced B cells within GC reactions.     
 
Allen et al (276) concluded that the rates of interchange between the two zones 
and the bi-directional movements were consistent with the cyclic re-entry model.  
Conversely Hauser et al (277) concluded that there was not sufficient migration 
between each cell division to substantiate the cyclic re-entry model and instead 
favoured the intrazonal model (Figure 1.9).  Within this model most cells stay 
resident in the dark or light zones and selection in each of the zones occurs 
independently.  In a more recent study statistical and functional modelling 
approaches were applied to the two-photon data to formulate a migration model 
which also incorporated chemokine receptor expression levels (282).  
Collectively these results demonstrate diverse germinal centre models which 
differ from the conventional and classic models.   
 
 
 
 
 
 
 
 
 
Analogs of germinal centre structures with comparable proliferation, mutation 
and apoptotic reactions, ectopic GCs, have been identified in non-lymphoid 
tissues in a variety of diseases, MG (52), SS (283), RA (284), HT (54) and 
breast cancer (285).  The biological functions of this lymphoid neogenesis have 
been implicated in the pathology of autoimmune diseases by the generation of 
autoantibodies from autoreactive B cells although the steps leading to auto-
antibody production remain elusive.  Abnormal GC reactions have been 
observed in SLE which are thought to play a central role in SLE pathogenesis 
(286).    
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Figure 1.9 Migration Models for Germinal 
Centre Reactions 
 
Previous findings on GC reactions implied that 
GC B cells which succeed in the selection 
process return to the dark zone for further 
division following a cyclic re-entry model (A).  
Recent studies have found that intra-zonal 
recirculation (B) may be the predominant mode 
of migration within GCs.  This model suggests 
that GC B cell migration is parallel to, rather 
than perpendicular to the DZ – LZ interface with 
infrequent exchanges between the zones.  
 
Solid arrows indicate strong movement of GC B 
cells, dashed arrows indicate a less prominent 
movement.  Blue arrows indicate cells exiting 
the GC.  Adapted from 277. 
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1.4.6 Role of B cells in Myositis and Vasculitis  
The autoimmune origin and the role of B cells remain uncertain in myositis and 
vasculitis.  The autoimmune origins of these disorders are supported by the 
disease’s association with other autoimmune diseases, production of 
autoantibodies, formation of immune complexes and the response of the 
disease to B cell depletive therapies.  In a recent study the role of B cells has 
been established in myositis where the study aimed to distinguish DM from PM 
by B cell activation (287). The study examined RP105, a leucine-rich repeat 
molecule, structurally similar to Toll-like receptors, located on the surface of B 
cells that was found to transmit an activation signal for B cell proliferation and 
resistance to apoptosis, this molecule is lost upon activation.  SLE patients were 
found to have increased numbers of RP105 negative cells in peripheral blood, a 
phenotype of B cells consistent with that of activated B cells or germinal centre 
B cells, therefore the study investigated if DM and PM could be distinguished 
from one another by establishing the surface expression of RP105 on 
circulating B cells in both myopathies.  The results showed a noticeably 
increased percentage of RP105 negative cells in DM compared to PM, 33.0% 
compared to 5.8%, suggesting the expansion of RP105 negative B cells is a 
hallmark of DM and indicating that B cells have a fundamental role in the 
pathogenesis of DM different from that of PM.  Recent studies indicate RP105 
regulates antigen-presenting functions and Treg development in a model of 
collagen-induced arthritis (288).  In vasculitis,  the work of Baiu et al (193) 
implicated a role for B cells in the pathophysiology of vasculitis as does the 
presence of immune-complex formations and many autoantibodies within 
vasculitic lesions.    
 
Pathogenic roles for B cells in both myositis (DM) and vasculitis are 
substantiated by the recent studies using the B cell depletive therapy, Rituximab 
(149-151).  Pilot studies indicated that Rituximab is an efficient treatment of DM 
as the resulting B cell depletion reduced DM symptoms (150-152).  
Improvements in muscle strength were observed as well as decreased levels of 
creatine kinase and a reduction in skin rashes but these symptoms reappeared 
during relapse associated with a return of circulating B cells.  Although 
preliminary, and from a small sample size, these results emphasise the role of B 
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cells in the pathogenesis of DM.  A recent study has also demonstrated the use 
of Rituximab in the treatment of 4 Juvenile DM patients, with and without 
myositis specific autoantibody (MSA) production (152).  Clinical improvement 
was observed in three of the patients while the fourth had progression of the 
disease indicating that B cells are not fully accountable for the pathogenesis 
associated with myositis.  Similar results have also been observed in Rituximab 
use in SLE and RA (149).  Additional studies have demonstrated remission as a 
result of the Rituximab treatment in ANCA-associated vasculitic 
(148;157;159;177;202-206).   
 
Collectively evidence from the studies described above substantiate a role for B 
cells in myositis and vasculitis but the exact mechanisms of B cells and their 
role in disease pathogenesis in these disorders remain unresolved.     
 
1.5 Hypothesis and Aim of Study 
The core objective of this study was to establish a role for B cells in the 
autoimmune disorders of myositis and vasculitis.  By assessing the VH antibody 
repertoire and clonal diversification of infiltrating B cells and plasma cells this 
study could examine the hypothesis that infiltrating lymphocytes within the 
muscle and vasculature were being locally stimulated by endogenous or 
exogenous antigens contributing to the pathological mechanisms of these 
disorders.  Therefore the following main aims of this study were addressed: 
 
• Identify infiltrating B cells and plasma cells within the inflammatory target 
tissue of myositis and vasculitis patients (Chapters 3 and 5). 
• Establish the Ig gene repertoires of these muscle and skin infiltrating B 
cells and determine if gene selections are occurring (Chapters 4 and 5). 
• Identify clonally related sets of sequences to indicate if B cell antigen-
driven responses occur in the target tissues of myositis and vasculitis 
patients (Chapters 4 and 5). 
• Identify and characterise infiltrating antigen specific cells and determine 
the Ig repertoire of these cells (Chapter 6). 
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Chapter 2 – Materials and Methods 
 
2.1 Materials 
All chemicals were supplied by Sigma-Aldrich (St. Louis, MO, USA) and Griener 
Bio-One (Kremsmuenster, Austria), Sarstedt (Numbrecht, Germany) and 
StarLab (UK) supplied the plasticware unless otherwise stated.   
 
2.2 Identification of Cellular Infiltrates in Myositis and Vasculitis Biopsies  
 
2.2.1 Patients and Samples 
Muscle and skin tissue biopsies were obtained from patients undergoing 
diagnostic biopsies for myositis or vasculitis, following informed consent.  
Ethical approval was obtained from North Glasgow Hospital Research Ethics 
Committee.  Samples, at time of biopsy, were embedded in Tissue-Tek OCT 
compound (Sakura Finetek, Torrance, CA) and snap-frozen in dry ice and 
ethanol and stored at -70°C.  Alternatively archiva l muscle biopsies from 
previous diagnostic procedures, conducted by Dr W Behan, were obtained from 
the Pathology Department, Western Infirmary, Glasgow.  Biopsies had been 
embedded in OCT and either stored in liquid nitrogen or at -70°C.  To obtain 
retrospective consent for these samples to be used for research purposes 
amendments to the original ethical approval were completed and the medical 
records department for each patient’s hospital was contacted to obtain 
information of the patients General Practitioner to allow the patient’s contact 
information to be sought.    
 
A total of 28 myositis patients, plus a control biopsy from a healthy patient, were 
selected from archival records.  Sample MYO1 had already been selected and 
gave consent for the study.  From the 28 patients selected 9 were deceased at 
the commencement of the study.  To allow these samples to be used within the 
study the patient details were blinded and the samples number selected to the 
investigator by Linda MacKinnon, Pathology Department, Western Infirmary, 
Glasgow.  From the 9 samples only 6 could be obtained from the archival 
stores, 3 could not be located or had been sent away.  Four patients could not 
be found within any medical records departments therefore consent could not 
be sought from the patients and there was no confirmation if the patient was 
living or deceased therefore the samples were not included in the study.  For 
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the remaining 15 patients, including the control patient, consent for the samples 
to be used in the study was requested.  From these requests consent was given 
by 13 patients.  From these, 10 of the samples could be obtained from archival 
stores, 3 could not be located or had been sent away.  For 2 patients, MYO5 
and MYO18, records indicated that each patient had 2 separate biopsies 
conducted. For patient MYO5 a further biopsy was conducted 3 years following 
a diagnostic biopsy and for patient MYO18 a second biopsy was conducted a 
year following the diagnostic biopsy.  For these patients both biopsies were 
sought but only the biopsies following the diagnostic procedure could be 
obtained, the diagnostic biopsies could not be located.  From the archival 
selection a total of 17 muscle samples from 16 different myositis patients and 1 
control patient (Table 2.1) were used within the study.  These samples, plus the 
sample from patient MYO1 who had already been included in the study, 
resulted in a total of 17 myositis biopsies being used within the study with the 
addition of a control sample.  A summary of the pathology reported in these 17 
myositis biopsies is shown in Table 2.2.  Each sample was examined using 
immunohistochemical techniques for the presence of B cells and plasma cells 
and those with evident cellular infiltrates were examined further.   
 
An additional muscle biopsy was obtained (MYO4) during the duration of the 
study but due to storage and transit conditions the sample was unable to be 
included in the study. 
 
8 skin biopsies were obtained during diagnostic procedures from the 
Dermatology Department, Royal Infirmary, Glasgow.  Only 3 of these biopsies 
could be used for the vasculitis study (Table 2.3).  Pathologists from the Royal 
Infirmary hospital reported no active vasculitis within 3 of the biopsies and 
problems with sample handling meant an additional 2 could not be included in 
the study.  The remaining 3 skin biopsies had active vasculitis confirmed by the 
Pathology Department, Royal Infirmary.  As previously mentioned, each sample 
was examined using immunohistochemical techniques for the presence of B 
cells and plasma cells and those with evident cellular infiltrates were examined 
further. 
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2.2.2 Tissue Sectioning 
Serial frozen sections (8 µm) were cut with a Shandon cryostat and were 
mounted on positively charged slides (Menzel Glaser, Germany or VWR, UK).  
Sections were air dried for at least 1 hour, fixed in acetone for 10 minutes and 
stored at -70°C with a desiccant.                                       
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History Other Features 
MYO1 DM F 40 0 142 NR 
ANA NR, ENA 
Negative, Jo-1 
Negative, Weakly 
Positive Anti-DNA 
(52U/ml, normal 
range <30U/ml) 
No Prednisolone at 
biopsy, other 
medication unknown 
No 
Significant 
Family 
History 
Recorded 
Skin Rash for 8 months prior to biopsy.  
6 week history of weakness in 
shoulder muscles prior to biopsy. 
MYO3 PM M 80 0 897 30 
ANA 1:2560, 
RNP/Sm Positive, 
Jo-1 Positive, RF 
and Centromere 
Negative 
Clopidogrel and 
NSAID (Name not 
apparent in notes) 
None 
Prostate Cancer (Previous Surgery, No 
medical treatment).  Died with 
pericarditis. 
MYO5 
PM (With 
Sjogren's 
Syndrome) 
F 40 3.5 years 1031 <6 
ANA 1:40 (2000) 
Pattern 
Homogenous       
ANA Negative 
(2001)                   
ENA Negative                        
RF 294 (2000) 
(Normal Range 1-15 
IU/ml) 
Prednisolone 2.5mg 
daily                 
IVIg every 8 weeks 
Brother - 
Reiter's 
Syndrome 
Cousin - 
SLE 
Diagnostic muscle biopsy conducted 
April 2000, CK 800 IU/ml. Patient also 
diagnosed with Sjogren's Syndrome 
(2000). Prednisolone started at 40mg 
daily, reduced to 2.5mg at second 
biopsy, October 2003.  IVIg therapy 
began September 2000 (2g/kg).  CK 
levels started to rise in January 2001 
and reached 650 IU/ml in October 
2001 despite steroid and IVIg therapy.  
Past Infection with EBV. 
MYO6 PM M 63 0 919 <6 
ANA Negative       
ENA Negative  
RF<22 
GTN & Tildiem 
(Angina)         
Nexium (GI Upsets) 
Co-proximal 
(Analgesia) 
No 
Significant 
Family 
History 
Recorded 
Muscular pains began around 2 years 
prior to biopsy, CK levels increased 
from 260 IU/ml (18 months prior to 
biopsy) to 967 IU/ml (10 months prior 
to biopsy) with normal CKMB.  
Previous statin therapy, discontinued 2 
years prior to biopsy. Past medical 
history includes hiatus hernia, 
duodenal ulcer, angina, paraumbilical 
hernia, sleep apnoea syndrome 
MYO7 PM M 50 0 8390 NR 
ANA Positive, ENA 
Negative, Jo-1 
Negative 
No Prednisolone at 
biopsy, other 
medication unknown 
No 
Significant 
Family 
History 
Recorded 
Pain and weakness noticed in shoulder 
and wrist a year prior to biopsy.  
Arthralgia 
Cont… 
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History Other Features 
MYO16 DM F 33 0 1076 7 
ANA Positive 
(1:5120) Pattern 
Nucleolar (probable 
Topoisomerase 1), 
ENA Positive, Anti-
DNA Negative 
Oral Contraceptive 
Pill, Diclofenac 
No 
Significant 
Family 
History 
Recorded 
Past medical history of postural 
hypotension, no drug therapy received.  
Two year history of polyarthralgia and 
onset of Raynaud’s disease just prior 
to biopsy. 
MYO17 
PM  
 
Diagnosis 
reported as 
IBM, 6 years 
following 
biopsy.             
F 66 0 2716 NR 
Scleroderma / 
Myositis Screen 
Negative, ANA 
Negative, ENA Ro 
Negative, ENA 
La/Sm/RNP 
Negative, RF<22 
No Prednisolone at 
biopsy and no 
record of any other 
therapy at time of 
biopsy.  Patient 
received a 7 day 
trial 40mg 
Prednisolone (8 
months prior to 
biopsy) for 
Dyspnoea. 
No 
Significant 
Family 
History 
Recorded 
Pathologist noted that the degree of 
inflammatory cell infiltrate within the 
biopsy was greater than normal.  IBM 
also suspected.   Exacerbation of 
myositis occurred 4 years post biopsy, 
despite therapy. Biopsy was reviewed 
6 years post biopsy, Diagnosis IBM.  
Past medical history includes 
Rheumatic Fever as a child, 
Cholecystectomy (1975), 
Hysterectomy (1981), Bowens Disease 
(1996), treated surgically, Asthma 
(1997).  Following diagnosis, 
prednisolone therapy initiated.  
Additional therapies included 
Azathioprine, IVIg and Methotrexate 
were used but stopped due to lack of 
effect, patient continued with 
Cyclosporin therapy. 
MYO19 PM F 62 0 
Elevated in 
a single 
occasion to 
400 but 
normal at 
time of 
biopsy 
NR 
ANA Positive 
(1:2560) Pattern 
Nucleolar, ENADNA 
Negative, ENA 
Negative 
Methotrexate 
15mg/week and oral 
corticosteroid (dose 
not specified) 
NR 
Past medical history includes 
seronegative inflammatory synovitis.  
Patient received corticosteroid injection 
following knee aspiration in July 2001.  
At this time recent medical history 
included excision of basal cell 
carcinoma at the right medial canthus.  
Previous to this past medical history 
includes appenicectomy (1957), 
anxiety and depression (1967-1969), 
Varicose vein injection (1972), hallux 
valgus repair (1986), hypertension 
(1992) and Potts fracture of left ankle 
(1996). 
Cont… 
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History Other Features 
MYO23 PM F 45 0 5829 46 
Jo-1 Positive, ANA, 
ENA, RF and 
Centromere 
Negative 
Steroid therapy for 1 
week which was 
stopped 2 weeks 
prior to biopsy.  
Thyroxine 
No 
Significant 
Family 
History 
Recorded 
5 week history of diffuse swelling of 
both lower limbs with weakness prior 
to biopsy.  Hyperthyroidism (partial 
resection) 
MYO24 PM F 59 0 6623 
No 
Record at 
Biopsy, 
Reported 
at 13, 6 
weeks 
after 
biopsy 
ANA negative   
Ro/La/Sm/RNP/Jo/ 
Scl70 Negative 
120mg 
Prednisolone (im) 
given 4 days prior to 
biopsy. 18 month 
treatment with 
statins, stopped a 
week prior to 
biopsy.  Losartan 
25mg, Metformin 
1.5gms, 
Bendrofluazide 
2.5mg, Glicazide 
160mg, Salbutamol. 
Previous treatment 
for pernicious 
anaemia. 
NR 
Past Medical History includes 
hypertension, asthma, Type II diabetes 
and pernicious anaemia.  Diagnosed 
with adenocarcinoma of endometrium 
(Grade II) April 2006.  Died May 2006, 
second day post op myocardial 
infarction. 
MYOC 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
PM M 66           
 (At Biopsy) - 2500-3000 NR NR 
Treatments at 
biopsy unknown.  
Previous statin and 
steroid therapy. 
No History 
of muscle 
disease 
Six month history of muscle weakness 
and cramping at time of biopsy.  Past 
medical history includes a long history 
of cardiac problems. 
 
 
 
 
 
Cont… 
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History Other Features 
MYOE 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
Chronic 
Inflammatory 
Myopathy 
(Pathology 
consistent with 
PM) 
F 49 0 NR 46 
Anti-DNA + (Feb 03, 
10 months prior to 
biopsy),                             
Anti-Mitochondrial 
Negative (Dec 02), 
Anti-Smooth Muscle 
Negative (Dec 02), 
Anti-Gastric Parietal 
Cell Negative (Dec 
02) 
Had been on 
Prednisolone 
(40mg) for four 
months prior to 
biopsy.  Stopped 
Steroid therapy for 
around 6 weeks 
resumed on 20mg, 
at time of biopsy 
patients was on 
10mg.  Other 
medications include 
thyroxine (50mg), 
Clarithromycin 
(500mg), Citalopram 
(40mg) and 
Viscotears. 
NR 
8 month history of symmetrical joint 
pain in shoulders, elbows, wrists, 
hands, knees and feet prior to biopsy. 
Past medical history includes Bell's 
palsy, pneumonia and hypothyroidism.  
Patient was admitted with acute 
bronchitis approximately 4 weeks prior 
to biopsy. 
MY025 
 F 37       Control Sample from Healthy Volunteer 
MYO2 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
Inflammatory 
Myopathy 
(Pathology 
consistent with 
PM) 
F 77 (At Biopsy) - 17203 173 Not Known 
Prednisolone 60mg 
(Just prior to biopsy) NR 
At time of biopsy patient had a recent 
myocardial infarct, cardiac arrest and 
then resuscitation.  At this time patient 
had obvious proximal weakness.  CK 
was previously normal. 
MYOA 
Inflammatory 
Myopathy 
(possible IBM) 
F 70 0 694 
50 
(A month 
prior to 
biopsy) 
ANA 1/2560, 
Anti-mitochondria, 
Anti-smooth muscle 
and 
Anti-gastric parietal 
cell.  Anti-SRP 
Negative, Anti-Jo-1 
NR 
Atenolol, 
Dihydrocodeine, 
oxytetracycline, 
Vioxx, Frusemide 
No 
Significant 
History 
Medical History includes Fibromyalgia, 
Pulmonary TB, Primary biliary 
Cirrhosis, Hypertension, OA knees and 
Pulmonary fibrosis.  Died cerebral 
haemorrhage 15/01/04 
 
 
Cont… 
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History Other Features 
MYOD DM F 75 0 >3000 NR 
ENA Negative, DNA 
<30U/ml, ANCA 
Negative, ANA NR 
No Prednisolone at 
biopsy, other 
medication unknown 
NR 
Four week history of weakness in arms 
and legs.  Heliotrope rash on hands. 
One year post biopsy a chest x-ray 
revealed a lung tumour (Right hand 
side at the hilum).  Diagnosis of DM 
associated with underlying lung 
tumour. 
MYO18 PM F 52 13 months 597 
NR (at 
time of 
biopsy) 
ANA 1:40, nucleolar 
RF Normal                                    
ENA Negative 
Prednisolone 15mg          
Co-Codamol  
Omeprazole 20mg  
Alendronate 70mg 
once weakly 
No 
Significant 
History 
Diagnostic Biopsy conducted January 
2001, CK 11226, CRP <5, 
Prednisolone started at 60mg daily, 
reduced to 15mg daily.  Second Biopsy 
conducted February 2002 
MYO21 PM M 64 0 783 36 
ANCA Positive 
(pANCA-MPO) 
RF Negative 
ANA Negative 
Prednisolone 60mg 
(Just prior to biopsy) 
Other medications 
include: Enalapril 
(10mg od), 
Isosorbide 
Mononitrate (60mg 
od), Sertraline 
(50mg od), 
Simvastatin (40mg 
od), Nicorandil 
(20mg), 
Montellukast (10mg 
od), Serertide 500, 
Salbutamol 
NR 
Marked Eosinophilia (10, normal range 
<0.4110^9/l).  
 No deterioration in chest symptoms. 
 
Medical History includes Polyarteritis 
nodosa (PAN) with cutaneous 
involvement, asthma and Ischaemic 
heart disease.  Myocardial Infarction 6 
years prior. 
Table 2.1 Myositis Patients 
 M, Male; F, Female; CK, Creatine Kinase; CRP, C-Reactive Protein; NR, No Record. 
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Inflammatory Infiltrate 
Sample Fibre Size Variation 
Necrotic Fibres 
(Undergoing 
Phagocytosis) 
Basophilic / 
Regenerating 
Fibres 
Internal 
Nuclei 
Perivascular 
Atrophy HLA 
/ Location 
Invasion 
of 
Fibres 
Presence of 
Vacuoles 
Presence of 
Inclusions Fibrosis 
MYO1 -    -   Perivascular -  - - 
MYO3    Occasional - - -  - - - - Minimal 
MYO5    Occasional     Surrounding Necrotic Fibres - - - - 
MYO6  Mild  () -     Surrounding Necrotic Fibres & Perimysial BV  - - - 
MYO7 -  ()    -  Perimysial - -  - 
MYO16  Mild  ()  Rare  Occasional  -  
Surrounding Necrotic 
Fibres - - - - 
MYO17     - -  
Endomysial, 
Surrounding Necrotic 
and Regenerating 
Fibres 
-  
( Reported 
2004, 6 years 
after biopsy) 
- 
MYO19 -  ()  Rare -    
Surrounding Necrotic 
Fibres & Perimysial BV. 
Not in Perifascicular 
region. 
- -  - 
MYO23    -    - - - - - 
MYO24     -   Surrounding Necrotic Fibres - -  - 
MYOC     -   Surrounding necrotic fibres in each fascicle  -   
MYOE -  ()  Mild - -   Surrounding Necrotic Fibres and BV - - -  
MYO2 -   - -   Endomysial   -  
MYOA   Occasional  Occasional     Surrounding Necrotic Fibres - - -  
MYOD   -  Mild  -  - -  Occasional - - 
MYO18   ()  - - -  - - - - - 
MYO21  Mild  ()  -    Endomysial - - - - 
Table 2.2 Myositis Pathological Summary 
- No record or discussion of feature in pathology report 
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Sample Diagnosis M/F Age at Diagnosis 
Disease 
Duration 
at Biopsy 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range <10 
Autoantibody Profile Therapies at time 
of Biopsy 
Family 
History Other Features 
VAS1 
Cutaneous 
Vasculitis (With 
Sjogren's 
Syndrome) 
F 59 8 months NR NR ANA 1:2560, speckled                   Ro & La Positive 
Beclomethasome 
and Salbutamol 
Ischaemic 
heart 
disease & 
Thyroid 
Disease 
Diagnostic Biopsy conducted 
in Jun 04 and found features of 
leukocytoclastic vasculitis.  In 
June 04, RF positive and 
atypical c-ANCA positive.  Past 
Medical history includes 
childhood chest infections, 
hyperthyroidsm and asthma. 
VAS6 
Leukocytoclastic 
Vasculitis of 
lower limbs and 
scalp 
M 43 0 NR 7 ANA Negative      ANCA negative 
Sulphasalazine 
500mg daily, 
Kenalog 40mg, 
Indocid, 
Imipramine, 
Diazepam, DF-118, 
Zantac 
Mother - 
Post-
traumatic 
epilepsy         
Father - 
Angina 
Background of Ankylosing 
Spondylitis 
VAS7 
Henoch-
Schonlein 
Purpura.       
Biopsy confirmed 
Leukocytoclastic 
Vasculitis 
M 49 0 NR 20 
ANA Negative          
RF Negative      
Atypical c-ANCA 
moderately positive 
(MPO and PR3 
negative) 
Mitochondrial Negative 
Smooth muscle 
Negative            
Gastric Parietal cell 
Negative                 
Liver kidney 
microsomal Negative           
Glomerular basement 
membrane Negative 
Spironalactone, 
Warfarin, Vitamin B 
Co Strong, 
Thiamine, Folate, 
Biprobase 
No 
Significant 
Family 
History 
Noted 
Polyarthralgia (Left Hand, 
Right Wrist, Both elbows, 
knees and ankles)                                        
IgA 9.9g/l (Normal Range 0.8-
4) IgG 21.5g/l (Normal Range 
6-16) IgM 6.7 (Normal Range 
0.5-2)  Positive E Coli Blood 
culture - May 05                                                     
Long History of excess alcohol.  
Past Medical History includes 
Liver Cirrhosis,Recurrent 
DVT's, Pleural Effusion, Folate 
Deficiency and Borderline 
Protein C Deficiency 
 
Table 2.3 Vasculitis Patients 
M, Male; F, Female; CK, Creatine Kinase; CRP, C-Reactive Protein; NR, No Record.
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2.2.3 Immunohistochemistry 
Slides from -70°C were thawed at room temperature f or 30 minutes in a staining 
vessel containing anhydrous silica gel.  To fix sections slides were transferred 
to acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP pen (Immedge Pen, Vector Laboratories, Burlingame, CA, USA) and 
allowed to dry for 5 minutes.  100 µl of 2% bovine serum albumin/ Tris-buffered 
saline (2%BSA/TBS) was added to each section to block for 30 minutes.  All 
incubations were carried out at room temperature in a humidified chamber.    
Blocking solution was poured off and 100 µl of 2% BSA/TBS containing mouse 
anti-human primary antibody (DAKO, Denmark) was added to each section 
(Table 2.4).  Negative control experiments were performed using antibodies 
with matched isotypes.  Sections were incubated for 1 hour. The primary 
antibody solution was poured off and sections were washed twice in TBS 
(Section 2.5) for 5 minutes.  Following washing 100 µl of 2% BSA/TBS 
containing 5 µl of rabbit anti-mouse IgG secondary antibody (DAKO) was added 
to each section and was incubated for 30 minutes.  After the secondary 
antibody was poured off and sections were washed twice in TBS for 5 minutes 
100 µl of 2% BSA/TBS containing 2 µl of alkaline phosphatase anti-alkaline 
phosphatase (APAAP) was added to each section and was incubated for 30 
minutes.  Sections were again washed twice in TBS for 5 minutes. 100 µl of 
substrate was then added to each section and allowed to develop for 20 
minutes.  Substrate solution contained 10 µl of 5% New Fuchsin in 2 M HCl, 25 
µl of 0.7 M sodium nitrite, 3.5 ml of Buffer E (0.05 M Tris, 0.9% NaCl, pH 9.7), 
1.25 ml of 0.2M 2-amino-2-methyl-1,3-propanediol (AMPD), 50 µl of 40 mg/ml 
levamisol, 30 µl of Naphthol AS-BI phosphate and 100 µl of 2M HCl.  Following 
substrate incubation sections were washed twice in TBS for 5 minutes and once 
in sterile distilled water for 5 minutes.   Sections were counter-stained with 
Mayer’s Haemotoxylin and washed in Scotts tap water substitute (Section 2.5) 
to allow proper colour development, except for sections with Ki67 staining. As 
this is a nuclear marker haemotoxylin staining would camouflage the signal.  
Sections were viewed using a Nikon (Melville, NY) Diaphot inverted microscope 
and images were taken using a JVC 3-CCD camera.  The analog signal from 
the camera was converted into a digital signal using an ADS Tech (Ireland) 
Pyro A/V link convertor and images were taken using Adobe Premier Elements 
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software.  Sections were stored in a wet chamber at 4°C for microdissection.  
Sections not used for microdissection were mounted using glycerol gelatine. 
 
Initially sections at intervals of between 40 to 80 µm were stained for CD20+ B 
cells and plasma cells to determine the presence of these cell phenotypes 
throughout the collection of serial sections obtained from the biopsy; n=3-7 
depending on tissue availability.  Serial sections surrounding areas of infiltrating 
B cells and/or plasma cells were then used to establish the infiltration of the 
other cell phenotypes.  Representative images of these cellular infiltrations are 
presented in this thesis.   Semi quantitative analysis of cellular infiltration of the 
various cell phenotypes was conducted, described further in Tables 3.1 and 5.1. 
Antibody 
Specificity Source Species Clone Isotype Dilution 
CD20 DAKOa Mouse Monoclonal L26 -IgG2a 1:50 
FDC DAKO Mouse Monoclonal CAN.42 -IgM 1:100 
Plasma Cell DAKO Mouse Monoclonal V538c -IgG1 1:200 
CD3 DAKO Mouse Monoclonal T3-4B5 -IgG1 1:100 
CD4 DAKO Mouse Monoclonal MT310 -IgG1 1:20 
CD8 DAKO Mouse Monoclonal Dk25 -IgG1 1:100 
Ki67 DAKO Mouse Monoclonal MIB-1 -IgG1 1:100 
FoxP3 AB CAMb Mouse Monoclonal 236A/E7 -IgG1 1:40 
CD68 
(Macrophage) DAKO 
Mouse 
Monoclonal EMB11 -IgG1 1:100 
-IgG1 Isotype 
Control DAKO 
Mouse 
Monoclonal DAK-G01 
 Same as 
primary 
antibody 
concentration 
-IgG2a 
Isotype 
Control 
(Anti-
Aflatoxin) 
Kind gift 
from Prof 
Stimpson, 
Strathclyde 
University, 
Glasgow 
  
 
1:50 
-IgM Isotype 
Control DAKO 
Mouse 
Monoclonal DAK-G08 
 1:100 
a – Denmark, b – Cambridge, UK 
Table 2.4 Primary Antibodies used in Immunohistochemistry 
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2.2.4 Immunofluorescence 
Double immunofluorescent staining on frozen serial sections was carried out 
using the Mouse on Mouse (M.O.M) Immunodetection Immunofluorescent Kit 
(Vector Laboratories, Burlingame, CA, USA) designed to fluorescently detect 
several mouse primary antibodies on the same tissue whether or not the tissue 
is of mouse origin.  Primary antibodies used for fluorescent staining were the 
same as those described in Table 2.4 of section 2.2.3, although some antibody 
concentrations were optimized for multiple immunofluorescent staining, Table 
2.5.   Frozen sections were thawed at room temperature for 30 minutes in a 
staining vessel containing anhydrous silica gel.  To fix sections slides were 
transferred to acetone for 10 minutes and then allowed to dry.  Sections were 
circled with a PAP pen (Vector Laboratories) and allowed to dry for 5 minutes.  
All incubations were carried out at room temperature in a humidified chamber.  
Sections were incubated for 15 minutes with avidin blocking solution (Vector 
Laboratories) and briefly washed in TBS before a 15 minute incubation with 
biotin blocking solution (Vector Laboratories).  They were then washed twice for 
2 minutes in TBS before a 5 minute incubation with a working solution of M.O.M 
diluent to allow all non-specific protein sites to be blocked. After a 5 minute 
incubation excess M.O.M diluent was removed and sections were incubated for 
30 minutes with the first primary antibody, Table 2.5, in M.O.M diluent.  Sections 
were again washed twice in TBS for 2 minutes.  A working solution of 
biotinylated Horse Anti-Mouse Ig reagent in M.O.M diluent was then applied to 
each section and incubated for 10 minutes followed by two washes in TBS for 2 
minutes.  A working solution of fluorescein avidin DCS was then applied to each 
section for 5 minutes before two 5 minute washes in TBS.  For staining of the 
second antigen sections were again blocked with avidin and biotin blocking 
solutions for 15 minutes to prevent the interaction of the second set of labelling 
reagents with the first set of labelling reagents.  Sections were washed twice for 
2 minutes in TBS before sections were incubated for 1 hour with a working 
solution of M.O.M mouse Ig blocking reagent.  After two 2 minute washes 
sections were again incubated with a working solution of M.O.M diluent for 5 
minutes to block any non-specific protein binding sites.  Excess M.O.M diluent 
was removed and sections were incubated for 30 minutes with M.O.M diluent 
containing the second primary antibody.  After two 2 minute washes in TBS 
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sections were incubated for 10 minutes with a working solution of Anti-Mouse Ig 
reagent in M.O.M diluent.  Following two 2 minute washes sections were 
incubated for 10 minutes with Texas Red Avidin DCS (20 µg/ml). After two final 
5 minute washes sections were mounted in VECTASHIELD hardset mounting 
medium (Vector Laboratories) and viewed using a Zeiss Axiovert S100 
microscope with a Zeiss Plan-NEOFLUAR 63x lens (Carl Zeiss Ltd., Welwyn 
Garden City, UK).  For each view, 5 images were taken at 0.5 micron intervals 
and Openlab software (Improvision) was used to deconvolve the images.  
 
Antibody 
Specificity Source Species Clone Isotype Dilution 
CD20 DAKOa Mouse Monoclonal L26 -IgG2a 1:100 
Plasma Cell DAKO Mouse Monoclonal V538c -IgG1 1:200 
CD3 DAKO Mouse Monoclonal T3-4B5 -IgG1 1:100 
CD4 DAKO Mouse Monoclonal MT310 -IgG1 1:100 
CD8 DAKO Mouse Monoclonal Dk25 -IgG1 1:100 
Ki67 DAKO Mouse Monoclonal MIB-1 -IgG1 1:100 
FoxP3 AB CAMb Mouse Monoclonal 236A/E7 -IgG1 1:20 
CD68 
(Macrophage) DAKO 
Mouse 
Monoclonal EMB11 -IgG1 1:100 
-IgG1 DAKO Mouse Monoclonal DAK-G01 
 Same as 
primary 
antibody 
concentration 
-IgG2a  
(Anti-
Aflatoxin) 
Kind gift 
from Prof. 
Stimpson, 
Strathclyde 
University, 
Glasgow 
  
 
1:100 
a – Denmark, b – Cambridge, UK 
Table 2.5 Primary Antibodies used in Immunofluorescence 
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2.3   VH-Gene Repertoire of Infiltrating B Cells in Myositis and Vasculitis 
Samples 
2.3.1 Microdissection and DNA preparation 
To establish the antibody repertoire of the B cells and/or plasma cells in the 
cellular infiltrates the stained areas resembling B cell and plasma cell 
aggregates were microdissected under a Nikon Diaphot inverted microscope 
(Melville, NY).  To avoid contamination a fresh lancet was used for each section 
excised and discarded if it came into contact with any other site.  DNA was 
released by proteinase K digestion using the QIAGEN DNA Micro Kit (QIAGEN, 
Sussex, UK) according to manufactures instructions.  Briefly, microdissected 
tissue was added to 180 µl Lysis Buffer ATL and 20 µl Proteinase K.  
Microdissected samples were incubated at 56°C for a pproximately 4 hours to 
allow lysis.  Following lysis 200 µl of Buffer AL containing 1 µg of carrier RNA 
was added to each sample and mixed by pulse vortexing for 15 seconds.  200 
µl of 100% ethanol was then added to each sample and after mixing thoroughly 
samples were incubated at room temperature for 5 minutes.  Lysates were then 
transferred to a QIAamp MinElute column and centrifuged at 8000 rpm for 1 
minute to allow binding of the DNA to the column membrane.  The DNA bound 
to the column was washed firstly with 500 µl of Buffer AW1 by centrifugation at 
8000 rpm for 1 minute and then 500 µl of Buffer AW2 by centrifugation at 8000 
rpm for 1 minute.  Columns were then centrifuged at 14, 000 rpm for 3 minutes 
to dry the membrane.  To elute the DNA 20 µl of PCR Grade Water (Roche, 
Mannheim, Germany) was added to each column and allowed to incubate for 5 
minutes at room temperature before a final centrifugation at 14, 000 rpm for 1 
minute to release the DNA from the membrane.  For extremely small areas that 
were microdissected, cell lysis occurred in a total volume of 25 µl Buffer 
ATL/Proteinase K containing 10 µl Proteinase K.  An additional 25 µl of Buffer 
ATL was added to each sample following a 3 hour incubation at 56°C.  50 µl of 
Buffer AL was then added to each sample which again contained 1 µg of carrier 
RNA.  After pulse-vortexing for 15 seconds samples were mixed with 50 µl 
100% ethanol and allowed to incubate at room temperature for 5 minutes.  The 
remainder of the protocol was as described above.  Alternatively excised tissue 
was digested in 30 µl of Proteinase K (0.7 mg/ml, Roche, Mannheim, Germany) 
at 50°C for 1 hour and the enzyme was inactivated a t 95°C for 10 minutes.  This 
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method was used for analysis of sample MYO1.  Samples were either stored at 
-20°C or used directly in nested PCR reactions.  
 
2.3.2 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
For positive control PCR and analysis of patient’s peripheral blood, PBMCs 
were isolated from blood samples containing the anticoagulant heparin using 
Lymphoprep (Axis Shield, Oslo, Norway), a sterile and endotoxin tested solution 
for the isolation of pure lymphocyte suspensions.  Lymphoprep results in 
aggregation of erythrocytes, increasing their sedimentation rate allowing them 
to be isolated after centrifugation, as leukocyte sedimentation is only slightly 
affected and can therefore be removed from the upper layer (Figure 2.1).  An 
equal volume (6 mls) of 0.9% NaCl was used to dilute the blood.  6 mls of the 
diluted blood was then layered over 3 mls of lymphoprep and centrifuged at 800 
x g for 20 minutes without brake, or 30 minutes without brake if the blood had 
been collected over a 2 hour time frame.  After centrifugation PBMCs form a 
distinct band at the sample/medium interface, also known as the buffy coat, and 
were removed using a glass Pasteur pipette.  The upper serum layer was 
removed and stored at -20°C after PBMCs were remove d.  The fraction of 
PBMCs was diluted in 10 mls 0.9% NaCl and centrifuged at 250 x g for 10 
minutes twice. The pellet was then resuspended in 200 µl PBS (Section 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood 
Lymphoprep 
Lymphocytes 
(Buffy Coat) 
Serum 
Erythrocytes 
800 x g 
Before 
Centrifugation 
After 
Centrifugation 
Figure 2.1 Removal of lymphocytes from peripheral blood 
 
To establish the repertoire of lymphocytes from peripheral blood samples, lymphocytes were 
separated with the use of Lymphoprep (Axis Shield, Norway).  Lymphoprep is a ready made, sterile, 
and endotoxin tested solution which allows the isolation of pure lymphocyte suspensions.  The mixing 
of blood with lymphoprep causes aggregation of the erythrocytes, increasing their sedimentation rate.  
The lymphoprep solution only slightly affects the sedimentation rates of lymphocytes and therefore 
after centrifugation the erythrocytes, with their increased sedimentation rate, collect at the base of 
tube while lymphocytes form a distinct band at the sample/medium interface allowing the lymphocyte 
suspension to be removed.  Adapted from Lymphoprep (Axis Shield, Norway) datasheet. 
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2.3.3 Lymphocyte Cryopreservation 
In cases where additional blood samples were taken from patients, lymphocytes 
were extracted as described in section 2.3.2 but were either resuspended in 1 
ml Foetal Bovine Serum (FBS) supplemented with 10% dimethyl sulfoxide 
(DMSO) or 1 ml 60% wash buffer (RPMI supplemented with 1% 
Penicillin/Streptomycin and 1% 200 mM L-Glutamine) supplemented with 30% 
Foetal Bovine Serum and 10% DMSO and transferred to a 1.5 ml cryovial 
(Starstedt, Numbrecht, Germany).  The lymphocytes were cooled at 
approximately 1°C a minute in a freezing container (Nalgene Nunc, Abingdon, 
UK) containing isopropanol to a final temperature of -80°C.  The lymphocytes 
were kept at -80°C for 24 hours before being transferred to liquid nitrogen for 
long-term storage.  The tissue culture medium and supplements were obtained 
from Invitrogen (Paisley, UK).   
 
2.3.4 Sera Isolation 
Blood collected from patients in the absence of any anticoagulant was stored at 
4°C for at least 30 minutes to allow the clot to re duce.  The blood clot was then 
removed and the remaining serum was centrifuged at 3000 rpm for 10 minutes 
to remove any remaining erythrocytes.  The serum supernatant was then 
removed and stored at -20°C. 
 
2.3.5 Genomic DNA Isolation 
PBMC DNA was extracted from the resuspended fraction after PBMC isolation, 
section 2.3.2, using a QIAamp DNA mini kit (QIAGEN, Sussex, UK), according 
to manufacturers instructions.  In summary, 20 µl of QIAGEN proteinase K was 
added to 200 µl of buffy coat sample.  200 µl of Buffer AL was then added to 
sample and mixed by pulse vortexing for 15 seconds.  Samples were then 
incubated for 10 minutes at 65°C to ensure maximum lysis.  200 µl of 100% 
ethanol was then added to the sample and mixed for 15 seconds by pulse 
vortexting.  The sample mixture was then added to the QIAamp spin column 
and columns were centrifuged at 8,000 rpm for 1 minute.  500 µl of Buffer AW1, 
wash buffer, was added to the column and the column was again centrifuged for 
1 minute at 8, 000 rpm.  500 µl of Buffer AW2, wash buffer, was then added to 
the column and the column was centrifuged for 1 minute at 13, 000 rpm.  
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Columns were then centrifuged at 13, 000 rpm for an additional 3 minutes to 
remove any residual Buffer AW2.  Columns were transferred to 1.5 ml 
microcentrifuge tubes and 200 µl Buffer AE was added and allowed to stand for 
1 minute before being centrifuged for 1 minute at 13, 000 rpm.  DNA 
concentration was measured as described in section 2.3.11 and DNA was 
stored at -20°C.  10 µl of DNA, for positive contro l purposes or for analysing a 
patient PBL, was used in each PCR reaction as described in Section 2.3.7.  
 
2.3.6 Primers 
Primers for nested PCR were synthesised by Operon Biotechnologies 
(Huntsville, AL, USA), Tables 2.7 and 2.8.  For use in PCR, primers were 
synthesised at 0.2 µmole, desalted and arrived lyophilized and were 
reconstituted in PCR grade H2O (Roche, Mannheim, Germany) to produce a 
stock concentration of 100 µM (100 pmol/µl).  Primer stock concentrations were 
stored at -20°C.  For use in PCR, working solutions  of a total combined 
concentration of 20 µM (20 pmol/µl) were prepared as per Table 2.6.  For 
primary PCR reactions all VH leader sequences were combined in one working 
solution but for secondary PCR reactions each set of VH family primers were 
combined to produce family specific working solutions to allow for family specific 
amplification.  All J family primers were also combined.  Working concentrations 
of primers were also stored at -20°C. 
 
Number of 
primers in 
working solution 
µl of each primer 
required for final 
concentration of 
20 µM 
µl of 50 mM Tris-
HCl pH 8.0 
µl of sterile PCR 
grade H20 
1 4 6 10 
2 2 6 10 
3 1.33 6 10 
4 1 6 10 
5 0.8 6 10 
11 1 27.5 37.5 
 
Table 2.6 Volumes for preparing primer working concentrations (20 µM) 
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2.3.7 Nested PCR 
Immunoglobulin genes from infiltrating B cells and plasma cells were amplified 
by a nested PCR system (Figure 2.2) that ensures that only rearranged Ig 
V-genes were amplified and has been used previously within the laboratory to 
successfully analyse the repertoire of Ig V-genes from B cell clusters and 
germinal centres in SS (283), MG (52), breast cancer (285) and SLE (289).  
Primers were designed to amplify all known functional, rearranged human VH 
genes and are shown in Tables 2.7 and 2.8.  To avoid contamination of 
samples and PCR reagents all procedures prior to primary PCR amplification 
were performed in a clean laboratory prior to where post amplification steps 
were carried out.  All PCR reactions were prepared in a Captair™Bio 
Biocap™RNA/DNA hood (Erlab, France).  Filter tips were also used in sample 
preparation to limit PCR contamination as well as the use of a Microman M10 
pipette with sterilised and disposable pipette capillaries and pistons in 
transferring DNA from primary to secondary PCR reactions.  Microman pipettes 
are equipped with a positive displacement mechanism that isolates the 
aspirated liquid from the body of the pipette with prevents the sample-to-sample 
contamination that can result from aerosols (290).  The disposable pistons and 
capillaries are the only feature to make contact with the aspirated liquids 
therefore protecting against contamination from one sample to another. 
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Figure 2.2 A simplified Diagram of Nested Polymerase Chain Reaction (PCR) 
 
 
The Polymerase Chain Reaction (PCR) was used to amplify a specific sequence of DNA 
using primers, each complementary to the DNA target sequence (    ).  Target DNA was 
amplified through a series of cycles of denaturation to separate target DNA, primer 
annealing to target DNA and polymerisation of the target DNA  For this series of cycles 
Mg2+, each deoxynucleoside triphosphate (dNTP), PCR buffer and the thermostable DNA 
polymerase, Taq, are required in addition to the template DNA.  To increase the specificity 
of immunoglobulin gene amplification a second round of PCR was carried out in a process 
of nested PCR.  In the second phase of cycles a new set of primers (    ) were used that 
anneal within the fragments produced in the first round of PCR.  The use of nested PCR 
increased the specificity by ensuring that only the target sequence was amplified from the 
mixture from the first round; as only the target sequence should contain both sets of primer-
binding sites. 
 
 
 
PRIMARY AMPLIFICATION 
DNA 
Template 
Denaturation and 
Primer Annealing 
Polymerisation 
SECONDARY AMPLIFICATION 
Amplification of 
Target Sequence 
Denaturation and 
Primer Annealing 
Polymerisation 
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2.3.7.1 Nested PCR – VH Chain Amplification 
For primary amplification 10 µl of DNA was amplified in a reaction volume of 50 
µl with 10 pmole of VH leader primer mixture, 10 pmole of universal JH primer, 
2.6 U DNA polymerase, 2.5 mM MgCl2 and 200 µM dNTP’s in conjunction with 
hot-start ampli-wax Gem 50 beads (Applied Biosystems, Foster City, CA).  The 
conditions used for 35 cycles were, after an initial 2 minute hot start, 94°C for 1 
minute, 50°C for 1 minute and 72°C for 2 minutes fo llowed by one cycle of 72°C 
for 15 minutes.  The reactions were conducted on a Trio-Thermoblock 
(Biometra, Tampa, FL) or Tprofessional Thermocycler (Biometra) using the 
Expand High Fidelity PCR System (Roche, Mannheim, Germany). The Expand 
High Fidelity PCR System contains a unique combination of thermostable Taq 
DNA polymerase and Tgo DNA polymerase, providing a thermostable DNA 
polymerase with proofreading activity to generate PCR products of high yield, 
fidelity and specificity.  For secondary amplification 2 µl of primary amplification 
product was used as a template in reactions similar to primary PCR reactions 
except 20 pmole of each VH family and JH primer mixes were used.  Conditions 
for 40 cycles were 94°C for 1 minute, after an init ial 2 minute hot start at 94°C, 
61°C for 1 minute for V H 1, 2 and 3 primers or 65°C for 1 minute for V H 4, 5 and 
6 primers and 72°C for 2 minutes followed by one cy cle of 72°C for 15 minutes.     
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   Primer Name                           Sequence 
 
VH Leader primers       HUVH1L              TCA CCA TGG ACT GGA CCT GGA G  
 HUVH1L.2              TCA CCA TGG ACT GGA TTT GGA GG  
 HUVH2L              ACC ATG GAT ATA CTT TGT TCC ACG  
 HUVH2L.2              ACC ATG GAC ACA CTT TGC TCC ACG  
 HUVH2L.3              ACC ATG GAC ACA CTT TGC TAC ACA  
 HUVH3L              ACC ATG GAG TTT GGG CTG AGC TG  
 HUVH3L.2              ACC ATG GAA CTT GGG CTC CGC TG  
 HUVH4L              AAG AAC ATG AAA CAC CTG TGG TTC  
 HUVH4L.2                  AAG AAC ATG AAG CAC CTG TGG TTT  
 HUVH5L              ATC ATG GGG TCA ACC GCC ATC CT  
 HUVH6L              ACA ATG TCT GTC TCC TTC CTC ATC  
 
 
Universal JH primer         HUJHUNI              CTC ACC TGA GGA GAC GGT GAC CGG  
 
 
Table 2.7 Leader Primer Sequences for primary amplification round in Nested PCR 
 
 
 
                           Primer Name    Sequence  
VH Family primers 
 
VH 1                             HUVH1.1                CAG GTG CAG CTG GTG CAG TCT GG  
 HUVH1.2 CAR ATG CAG CTG GTG CAG TCT GG  
 HUVH1.3 GAG GTC CAG CTG GTA CAG TCT GG  
 
VH 2 HUVH2 CAG ATC ACC TTG AAG GAG TCT GG  
 HUVH2.1 CAG GTC ACC TTG ARG GAG TCT GG 
  
VH 3 HUVH3.1 GAG GTG CAG CTG GTG GAG TCT GG  
 HUVH3.2 GAG GTG CAG CTG TTG GAG TCT GG  
 HUVH3.3 GAG GTG CAG CTG GTG GAG ACT GG  
 HUVH3.4 GAG GTG CAG CTG GTG GAG TCT CG 
 
VH 4 HUVH4 CAG GTG CAG CTG CAG GAG TCG GG  
 HUVH4.1 CAG CTG CAG CTG CAG GAG TCS GG  
 HUVH4.2 CAG GTG CAG CTA CAR CAG TGG GG  
 
VH 5/ VH 7 HUVH5/7 SAG GTG CAG CTG GTG CAR TCT GG  
 
VH 6 HUVH6.1 CAG GTA CAG CTG CAG CAG TCA GG  
 
JH primers HUJH1 TGA GGA GAC GGT GAC CAG GGT GC  
 HUJH3 TGA AGA GAC GGT GAC CAT TGT CCC  
 HUJH4 TGA GGA GAC GGT GAC CAG GGT TCC  
 HUJH6 TGA GGA GAC GGT GAC CGT GGT CC  
 
 
Table 2.8 Family Primer Sequences for secondary amplification round in Nested PCR 
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2.3.8 Agarose Gel Electrophoresis 
PCR products were separated through 1.5% electrophoresis grade Ultra Pure 
Agarose (Invitrogen, Paisley, UK) in TBE (Section 2.5) and visualised with 
ethidium bromide (0.5 µg/ml) under UV light.  Samples were diluted with 6X 
Blue-Orange Gel loading dye (Promega, Madison, WI, USA) and the size of 
products was determined using a 10 KB ladder (Bioline, London UK).  PCR 
products were visualised under UV light using KODAK Gel logic 200 and 
KODAK 1D Image Analysis software (KODAK, Rochester, NY, USA).  Products 
of approximately 350-400 base pairs were expected. 
 
2.3.9 Gel Extraction 
DNA (20 µl) to be extracted and purified was run on a 1.5% agarose gel 
(Section 2.5) and DNA fragments were excised with a sterile sharp scalpel.  To 
eliminate any cross contamination a fresh scalpel was used for each DNA 
sample.  DNA was extracted using the QIAquick Gel Extraction Kit (QIAGEN, 
Sussex, UK) according to manufactures instructions.  In summary, after the 
weight of the gel slice was determined, 3 volumes of Buffer QG was added to 1 
volume of gel (100 mg ~ 100 µl) and gel extracts were incubated at 50°C for 10 
minutes to allow the gel slice to completely dissolve.  To aid dissolution of the 
agarose gel slice samples were vortexed every 2-3 minutes.  After incubation 1 
gel volume of isopropanol was added to each sample and mixed.  Samples 
were then applied to the QIAquick column and centrifuged at 13, 000 rpm for 1 
minute to allow DNA to bind to the column membrane.  QIAquick columns 
contain uniquely-designed silica gel membranes which adsorb DNA in the 
presence of high salt concentrations and at approximately pH 7.5.  This 
uniquely-designed membrane allows the removal of unwanted primers and 
impurities.  0.5 ml Buffer QG was applied to each column and centrifuged for 1 
minute at 13, 000 rpm to remove all traces of agarose.  0.75 ml Buffer PE was 
then applied to the QIAquick column and allowed to stand for 5 minutes before 
a 1 minute centrifugation at 13, 000 rpm.  Buffer PE, containing ethanol, 
removes the high salt concentrations from the column to allow for DNA elution.  
Columns were then centrifuged for an additional minute to remove any residual 
ethanol from Buffer PE.  Columns were then transferred to 1.5 ml 
microcentrifuge tube and 30 µl of Buffer EB (10 mM Tris-Cl, pH 8.5) was added 
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to the membrane to elute DNA.  After a 1 minute incubation samples were 
centrifuged for 1 minute at 13, 000 rpm and eluted DNA was stored at -20°C.  
 
2.3.10 Cloning of Rearranged Immunoglobulin Genes 
The TA cloning kit Dual promoter with pCR®II vector (Invitrogen, Paisley, UK) 
provided a one-step cloning approach for the direct insertion of VH PCR 
products into a plasmid vector. Taq polymerase used in PCR reactions provided 
a nontemplate-dependent addition of a single deoxyadenosine (A) to the 3’ 
ends of each PCR product.  The linearized plasmid vector was supplied with 
additional single 3’ deoxythymidine (T) residues allowing effective ligation of 
PCR product with the plasmid vector.  The use of the TA cloning kit Dual 
promoter with pCR®II vector eliminates the use of PCR primers that contain 
restriction sites, eliminates any enzymatic modifications of the PCR product and 
allows transcription from either direction of the insert. 
 
2.3.10.1 Ligation into Dual Promoter pCR®II Vector 
Ligation efficiencies were optimised within a 10 µl ligation reaction to contain 6 
µl DNA, 2 µl pCR®II vector (25 ng/µl) (Figure 2.3), 1 µl 10X Ligation buffer and 
1 µl T4 DNA Ligase (4.0 Weiss units).  Ligation reactions were incubated 
overnight at 14°C using the Trio-Thermoblock (Biome tra, Tampa, FL) PCR 
machine. 
 
2.3.10.2  Transformation into One Shot TOP10F’ Chemically Competent E.                                      
coli 
2 µl of the ligation reaction was pipetted into one 50 µl vial of One shot TOP10F’ 
chemically competent cells (Invitrogen, Paisley, UK) and was mixed by gentle 
stirring.  Vials were incubated for 30 minutes on ice before being heat shocked 
at 42°C for 30 seconds.  250 µl of room temperature  S.O.C medium (Invitrogen) 
was added to each vial of competent cells and vials were shaken at 37°C for 1 
hour at 225 rpm in a shaking incubator.  LB plates (25 g/l Miller’s Lab Broth 
Base (Invitrogen) supplemented with 15 g/l agar (Oxoid, Basingstoke, UK) 
containing Kanamycin (Gibco) (50 µg/ml)) were equilibrated at 37° for 30 
minutes then 40 µl 100 mM IPTG (Roche, Mannheim, Germany) and 40 µl 40 
mg/ml X-Gal (Roche, Mannheim, Germany) were spread on each plate and 
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allowed to soak into plates.  Following the 1 hour incubation 50 µl and 200 µl of 
each transformation vial was plated onto LB plates and plates were incubated 
overnight at 37°C before being moved to 4°C to allo w proper colour 
development.  Alternatively 75 µl from each transformation vial was plated onto 
LB plates. 
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Figure 2.3  pCR®II Vector 
 
The TA cloning kit Dual promoter with pCR®II vector provided a one-step cloning approach for the 
direct insertion of VH PCR products into a plasmid vector.  The linearized plasmid vector was 
supplied with additional single 3’ deoxythymidine (T) residues allowing effective ligation of PCR 
product with the plasmid vector as Taq polymerase used in PCR reactions provides a 
nontemplate-dependent addition of a single deoxyadenosine (A) to the 3’ ends of each PCR 
product. 
 
The disruption of the lacZ gene by the PCR product allows for colour screening of colonies as 
vectors containing a PCR insert would not be able to transcribe the lacZ gene therefore the 
colonies would be white whereas empty colonies with no PCR insert would be blue as 
transcription could occur from the lacZ promoter.  lacZ encodes the enzyme β-galactosidase 
enzyme which can be induced by isopropyl-β-D-thiogalactopyranoside (IPTG) and utilizes the 
substrate 5-bromo-4-chloro-3-inodyl-β-D-galactopyranoside (X-gal) to yield a blue product. 
 
pCR®II vector also contains a number of primer annealing sites for sequencing of the PCR insert, 
M13F and M13R, as well as a number of restriction sites, i.e. EcoR1, to allow for the presence 
and size of inserts within each plasmid to be determined.  Restriction digestion of the pCR®II 
vector containing the appropriate insert produced digested fragments of approximately 400 base 
pairs.  Adapted from TA cloning kit Dual promoter with pCR®II vector User Guide (Invitrogen, 
Paisley, UK). 
 
88 
2.3.11 Nucleic Acid Concentration 
The concentration of nucleic acids was determined using a Beckman DU640 
spectrophotometer by measuring the absorbance of the sample at a wavelength 
of 260 nm.  The absorbance at 280 nm was also determined and the ratio of 
260 nm / 280 nm assesses the purity of the sample.  A range of 1.6 to 1.9 was 
expected for DNA samples, a lower value of ratio indicated protein 
contamination as protein absorbs more strongly at 280 nm. To determine the 
nucleic acid concentration (µg/ml) the absorbance at 260 nm was multiplied by 
50 and then by the dilution factor.  
 
2.3.12 Sequencing and Analysis of Rearranged VH Genes 
 
2.3.12.1 Analysis of Transformants 
2.3.12.1.1 Overnight Cultures 
For analysis of positive clones single white colonies were picked from LB plates 
and were grown overnight in 3 mls LB broth (25 g/l, Invitrogen, Paisley, UK) 
supplemented with 50 µg/ml kanamycin (Gibco). Cultures were incubated and 
shaken at 37°C at 225 rpm.  After an overnight incu bation glycerol stocks were 
produced from each culture for long-term storage.  1 ml glycerol stocks were 
produced containing 15% sterile glycerol and stored at -80°C.  Plasmid DNA 
was purified using QIAprep Miniprep kit (QIAGEN, Sussex, UK), as described in 
section 2.3.12.1.2, from the remaining culture after bacterial cells were 
harvested after a 10 minute centrifugation at 13, 000 rpm.  
2.3.12.1.2 Plasmid DNA Extraction (Miniprep) 
Plasmid DNA was isolated using QIAprep Miniprep kit (QIAGEN, Sussex, UK), 
a system based on alkaline lysis of bacterial cells which utilises a unique silica-
gel membrane system. After harvesting and resuspension of bacterial cells in 
Buffer P1 (50 mM Tris-Cl, pH8.0, 10 mM EDTA, 100 µg/ml RNase A), the cells 
were lysed in Buffer P2 (200 mM NaOH, 1%SDS (w/v)) by gently inversion of 
microcentrifuge tube.  The lysate was then neutralised by the addition of Buffer 
N3 (acidic potassium acetate) and gently mixed until the solution became 
cloudy.  Samples were then centrifuged for 10 minutes at 13, 000 rpm resulting 
in a compact white pellet. The remaining supernatants were applied to the 
QIAprep spin columns and centrifuged for 1 minute at 14, 000 rpm.  The 
columns were washed with 0.5 ml Buffer PB and centrifuged again for 1 minute 
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at 13, 000 rpm.  After addition of 0.75 ml Buffer PE columns were left to stand 
for 3 minutes before a 1 minute centrifugation at 13, 000 rpm.  Columns were 
then centrifuged for an additional minute at 13, 000 rpm to remove residual 
wash buffer.  Columns were then transferred to 1.5 ml microcentrifuge tubes 
and 50 µl of filter sterile distilled water was added to each column to elute the 
plasmid DNA from the column.  After a 1 minute incubation columns were 
centrifuged for 1 minute at 13, 000 rpm and eluted DNA was stored at -20°C. 
 
2.3.12.1.3 EcoR1 Restriction Digestion of Plasmid DNA 
 To check the presence and size of inserts within each plasmid EcoR1 
restriction digest (G↓AATTC) was conducted on each plasmid after purification.  
In a 10 µl reaction 5 µl of each purified plasmid was mixed with 3 µl water and 1 
µl reaction buffer and 1 µl EcoR1 Restriction enzyme (10 U/µl) (Invitrogen, 
Paisley, UK).  Reactions were incubated at 37°C for  1 hour.  The presence of 
an insert was determined by agarose gel electrophoresis, as described in 
Section 2.3.8.  1.5% agarose gel was used and inserts approximately 400 bp 
were expected. 
 
2.3.12.1.4 Measurement of DNA Concentration 
A DNA concentration for each purified plasmid was calculated as described in 
section 2.3.11. 
 
2.3.12.2 Sequencing 
DNA sequencing was performed by The Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer.  200-300 ng of each plasmid DNA sample 
was sent for each sequencing reaction and plasmids were sequenced from the 
M13F and M13R regions of the plasmid using primers, Table 2.9, supplied by 
The Sequencing Service, Dundee.  The Sequencing Service also included a gc 
melt within the sequencing reactions to ensure efficient sequencing. 
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    Primer Name                      Sequence 
    Sequencing  M13F GTAAAACGACGGCCAGTG 
    Primers M13R GGAAACAGCTATGACCATG 
 
   
Table 2.9 Primers used for sequencing of pCR®II plasmid 
 
 
 
2.3.12.3 Sequence Analysis 
Sequence results, text files and electropherograms, obtained from The 
Sequencing Service, Dundee were checked and analysed using Chromas Lite 
software (Technelysium Pty Ltd, Australia).  The text file sequence was checked 
against the electropherogram for each sequence to ensure no anomalies had 
occurred during reading of the sequence.  The corresponding human germline 
genes were identified by searching the IMGT database using the JOINSOLVER 
software (http://joinsolver.niams.nih.gov) for the best matching genes in a Kabat 
data format (291).  JOINSOLVER was specifically developed to analyze the 
CDR3 region of the immunoglobulin genes, a region fundamental in identifying 
clonally related sequences, and to provide a more accurate assessment of D 
segments.  JOINSOLVER initially searches for D germline sequences.  The 
human D germline gene database employed includes all D gene segments from 
the IMGT database in addition to the reverse and DIR germline genes.  
JOINSOLVER identifies codon 93 as the beginning of CDR3 by searching for 
the conserved motif sequence TAT TAC TGT which comprises codons 90 to 92 
of the VH gene.  If this conserved motif is not found the search is reinitiated with 
an allowance for one base change, if this fails homologies to the germline 
genes are used to find the most likely start of the CDR3 region.  Once the VH 
end of the CDR3 had been identified, the JH border of the CDR3 was 
determined using the conserved motif C TGG GG at the 3’ end of the CDR3 
region.  Once the CDR3 region has been established VH, JH and D gene 
assignment was conducted.  The VH and JH regions are scored with an 
alignment score, a score of +5 is assigned for a nucleotide match with a score 
of -4 for a mismatch between the unknown sequence and germline sequence. 
Following VH and JH assignment, the D segment assignment is conducted using 
a consecutive nucleotide matching system.  Matches to the D segment are 
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scored and sorted based on the VH-JH distance, the distance in nucleotides 
between the end of the VH segment and the beginning of the JH segment.  A 
Monte Carlo simulation was used to establish the minimal D segment match 
length required to assign a D segment (Table 2.10), this was found to depend 
on the VH-JH distance.  These minimal match lengths were used in conjunction 
with the VH-JH distance of the sequence to determine if the highest scored D 
segment could be statistically assigned to the immunoglobulin rearrangement 
with a 95% probability that the match was not from random chance.  In some 
instances a mismatch was found within the D segment, disrupting the 
consecutive match length.  To allow a higher percentage of D genes to be 
assigned statistically advice was sought and followed according to the criteria 
kindly provided by Dr Gary Sims, a contributor to the development of the 
JOINSOLVER software (Figure 2.4).     JOINSOLVER also conducts junction 
analysis at the VD and DJ junctions to assign P nucleotides, inverted repeats at 
germline encoded ends and N nucleotides, nontemplated junctional additions.   
 
Assignment of VH, D and JH gene segments and mutational numbers were also 
analysed for all sequences using IMGT/V-QUEST software 
(http://imgt.cines.fr)(292;293) with a search for insertions and deletions.  Any 
deviations from JOINSOLVER assignments were noted.  IMGT, the 
international ImMunoGeneTics information system® was created in 1989 by the 
Laboratoire d’ImmunoGénétique Moléculaire (LIGM) (Université Montpellier II 
and CNRS) at Montpellier, France.  It is a high-quality integrated knowledge 
resource specialising in immunoglobulins (IG), T cell receptors (TR) and major 
histocompatibility complex’s (MHC) and deals with all the IG and TR nucleotide 
sequences published in the DDBJ, EMBL and GenBank databases.  IMGT/V-
QUEST (V-QUEry and STandardization) is an integrated on-line software 
programme which analyses IG and TR rearranged nucleotide sequences.  
IMGT/V-QUEST first identifies the locus to which the sequence belongs and 
then identifies the V, D and J genes and alleles by best alignment score of the 
input sequence with the IMGT reference directory.  The programme first aligns 
the V-region, then the J-region and finally the D-region.  The junction of these 
sequences, CDR3, encompasses the sequence between the V-region 
conserved cysteine (2nd- CYS) at position 104 and the J-region conserved 
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tryptophan (J-TRP) at position 118 found within the Trp-Gly-X-Gly conserved 
motif.  IMGT/JunctionAnalysis, an integrated system in IMGT/V-QUEST 
performs analysis of the V-D-J junction. 
 
VH-JH Distance 
(bp) 
Minimal D Segment Match Length 
Required (bp) at a stringency of 0.05 
(To allow a 95% probability that the match was not 
from random chance) 
8 8 
9-11 8 
12-23 9 
24-27 9 
28-75 10 
76-79 10 
 
Table 2.10 Assignment of D gene segments based on VH-JH distance and D segment match 
length 
 
For each sequence the VH-JH distance is calculated using the JOINSOLVER software, in order 
to assign the best matching D gene segment with a 95% probability the associated number of 
minimal match lengths must be observed within the D segment sequence. 
 
 
 
 
 
 
 
 
 
Figure 2.4 Additional Criteria for assignment of D gene segments 
 
Figure 2.4 demonstrates supplementary criteria used in the statistical assignment of D gene 
segments in immunoglobulin rearrangements found within myositis and vasculitis samples, 
kindly provided by Dr Gary Sims, a contributor to the development of the JOINSOLVER 
software.  These criteria describe the additional match length required when a mismatch 
disrupts the consecutive match length observed within the segment to allow a D gene 
assignment with a 95% probability that the match was not from random chance. 
 
The VH, D, JH gene usage distribution of functional gene rearrangements was 
analysed by determining the percentage usage of each gene family within 
infiltrating B cells and/or plasma cells of myositis and vasculitis samples. These 
gene distributions were compared to the baseline germline complexity and to 
published normal distributions from studies conducted by Volpe and Kepler 
(251).  The number of single point mutations within each variable gene segment 
of functional gene rearrangements were also analysed and given as a 
For each mismatch in a sequence add 2 to the minimal D segment match length. 
 
eg. if the consecutive match required is 8. (x=match; o=mismatch) 
oxxxxxxxo 7 match = not significant 
oxxxxxxxxo 8 match = significant 
oxxxxxoxxxo 8/9 match = not significant 
oxxxxxxoxxxo 9/10 match = not significant 
oxxxxxxxoxxxo 10/11 match = significant 
oxxxxxoxxoxxxxxo 12/14 match = significant 
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percentage of the total number of sequences.  Base differences within the first 
24 bases of sequence were disregarded as this part of the sequence binds the 
5’ VH primer.  In addition to mutational numbers, the location of mutations were 
analysed between Framework regions (FR) and Complementary Determining 
Regions (CDR).  The number of mutations in each segment was expressed as 
a percentage of the total length of the segment to correct for the longer lengths 
observed within the framework regions.  The approximate base positions of 
each region is summarised in Figure 2.5.  As well as analysing the location of 
mutations within variable gene segments the types of mutation were also 
analysed.  The numbers of mutations resulting in an amino acid change 
(replacement, R, mutation) were calculated in VH gene segments along with the 
number of silent, S, mutations where a nucleotide change does not result in an 
amino acid change within the sequence. Each mutation within the sequence 
was handled independently on a base-by-base method (Figure 2.6) rather than 
a codon-by-codon method.  This corresponds to the method used by the 
JOINSOLVER software for calculating R and S mutational numbers; confirmed 
in consultation with Dr Nancy Longo and Dr Daniel Russ (National Institute of 
Health, Bethesda, MD, USA), two authors of the JOINSOVLER software (291).  
Statistical analysis of these R and S mutational numbers for antigen-driven 
selection was conducted according to Hershberg et al (294) and the 
corresponding computer programme (http://clip.med.yale.edu/selection) which 
demonstrates an improved method for detecting selection by mutational 
analysis of Ig V region sequences.  The software uses a focused binomial test 
which accounts for known biases of somatic hypermutation at two levels, the 
impact of local sequence context on mutability and the transition bias, in order 
to establish positive or negative mutational selections within the sequence with 
high specificity and increased sensitivity. Use of this software required the VH 
gene segments of the immunoglobulin sequences obtained from The 
Sequencing Service to be converted to a FASTA format with the IMGT unique 
format including gaps.  These sequences were initially analysed using IMGT/V-
QUEST software (292;293) to confirm the VH gene segment assignment and 
were aligned with the corresponding germline gene.  Both sequences were 
entered into the software with the germline gene following the input query 
sequence and the CDR regions were selected manually to correspond to Kabat 
94 
nomenclature.  The software calculated the number of R and S mutations within 
FR and CDR1 and 2 regions independently as well as testing for positive and 
negative selections for each of these mutations in both the FR and CDRs.  The 
use of this software also allowed the number of independent mutations and 
selection to be analysed in sets of clonally related sequences.  All sequences 
were entered into the software with the germline VH sequence following the 
clonally related sequences.  CDR3 lengths in addition to P and N nucleotides 
and exonuclease activity at the VD and DJ junctions were also calculated and 
expressed as a mean value ± SEM.  For assignment of P and N nucleotides 
these values were checked for each sequence as the criteria for handling 
mismatches within the D segment, as previously described, resulted in a 
change to the P and N nucleotide numbers.  Clonally related sequences were 
identified on the basis of identical VDJ gene rearrangements, CDR3 regions 
and junctional sequences.  Genealogical trees were constructed by analysis of 
shared and unshared mutations within these sequences.  In some instances the 
best matching and highest scoring VH gene alignment for clonally related sets 
were not always assigned, some alternative and lower scoring sequence 
matches were used to correlate with clonally related sequence sets where the 
same CDR3, junctional rearrangements and common mutational patterns as the 
other isolated sequences were found, the clonally related gene was generally 
found to be the 4-6th best matching gene segment.   
 
The text file sequence and gene alignments for all sequences are given in 
Appendix 1. 
  
2.3.12.3.1 PCR Error Rate 
The number of base changes regarded as significant was based on the PCR 
error rate for the polymerase, previously calculated (52), as less than one base 
per 4 VH genes. 
 
 
 
 
 
 
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Calculation of Replacement (R) and Silent (S) mutations on a base-by-base 
method 
 
Figure 2.6 demonstrates the criteria used to assign each point mutation as Replacement (R) or 
Silent (S) with the VH segment of rearrangements.  For this study each mutation is taken 
independently on a base-by-base method, in this example this concluded with 1 R and 1 S 
mutation within the codon.  If the assignment of R and S mutations had been on a codon-by-
codon basis this would only represent 1 R mutation. 
VH D JH 
CDR1 CDR2 CDR3 
31 35 56 65 93 102 
Vκ Jκ 
CDR1 CDR2 CDR3 
24 34 50 56 89 97 
Vλ Jλ 
CDR1 CDR2 CDR3 
24 34 50 56 89 97 
A 
B 
C 
Figure 2.5 A simplified Diagram of Immunoglobulin Gene Segments for Sequence Analysis 
 
Figure 2.5 demonstrates the different gene segments that form the rearranged VH (A), Vλ (B) and 
Vκ (C) genes. Within these rearrangements there are areas of variability known as 
Complementarity Determining Regions (CDR) which are flanked by less variable Framework 
Regions (FR).  Figures represent approximate codon locations of CDRs.  CDRs constitute the 
antigen binding site with CDR3 being the most hypervariable as it is generated by the 
recombination of different gene segments, VDJ in heavy chains and VJ in light chains.   
 
For sequence analysis the number and type of mutations within variable gene segments, FR and 
CDRs were compared.  Base differences within the first 24 bases of sequence were disregarded 
as this part of the sequence binds the 5’ VH primer.  CDR3 was not incorporated into mutational 
analysis due to the difficulty in distinguishing point mutations and junctional variation as a result of 
gene recombination. Clonally related sequences were identified on the basis of identical VDJ 
gene rearrangements, CDR3 regions and junctional sequences. 
 
 
Sequence mutation 
 
 GGA->GAC  (Gly->Asp) 
 
Base-by-base method 
 
GGA -> GAA - mutation in the 2nd base (Gly->Glu) 1 R 
GGA -> GGC - mutation in the 3rd base (Gly -> Gly) 1 S 
 
Codon-by-codon method would only generate 1 R mutation  
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2.3.13 Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism 4 (GraphPad 
Software Inc., San Diego CA, USA) and after consultation with Dr Tony 
Speekenbrink (Statistics Analyses Advisor to the Clinical Microbiology 
Department, University of Glasgow).  P values less than 0.05 were deemed 
significant.  All p values are given in Appendix 2. 
   
The distribution of VH, DH and JH family usage, as well as individual VH and DH 
gene usage, was compared to published normal PBL values (251) and the 
germline complexity using Pearson’s Chi square analysis to determine a 
statistical selection for or against particular gene families, or individual genes, 
expressed on infiltrating cells from the muscle or skin.  Absolute values 
obtained for each VH, DH and JH family, as well as individual genes, were used 
to construct contingency tables in the GraphPad software for each VH, DH and 
JH family and tested for selection against the values of the corresponding family 
in the normal PBL and the germline complexity.    
 
CDR3 lengths, P and N nucleotides and exonuclease activity were analysed in 
functional and non-functional sequences using a two-tailed unpaired t-test.  The 
One-way analysis of variance test was used in conjunction with Tukey-Kramer 
multiple comparison post test to determine any statistical difference between 
mean CDR3 lengths in mutated sequences.  These statistical tests allowed any 
statistical difference in the mean CDR3 lengths of the 4 different mutational 
groups (0-2, 3-10, 11-20 and 20+) to be established as well as correcting for 
multiple comparisons within the same data set, this eliminates the Type 1 errors 
that occur when statistical tests are used repeatedly. 
 
Statistical analysis of R and S mutations was conducted as described 
previously in section 2.3.12.3.  Briefly a focused binomial test was used to 
calculate the parameters of the null model of mutation and test for positive and 
negative selection in the CDR and FW separately.  P values less than 0.05 
were deemed significant.    
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2.4 Identification of Antigens Driving the Immune Response in Myositis    
Patients 
2.4.1  Protein Biotinylation 
50 µg of recombinant proteins to be biotinylated, Table 2.11, were mixed and 
incubated for 2 hours with 5 µl of 1 mg/ml Biotin (Long Arm)  N 
hydroxysuccinimide ester – water soluble (NHS) (Vector Laboratories), 
dissolved in 100 mM bicarbonate buffer pH 8.5 or 1X PBS.  After 2 hours the 
biotinylation reaction was stopped by the addition of 1 ml 10% glycine in H20.  
To remove excess biotin, samples were dialyzed against 100 mM bicarbonate 
buffer pH 8.5 or 1X PBS using 0.5 ml-3 ml Slide-A-Lyzer Dialysis cassettes 
(Pierce, Rockford, IL, USA).  Initially cassette membranes were rehydrated in 
dialysis buffer for 30 seconds to increase the flexibility of the membrane.  
Cassettes were checked for leaks by injecting sterile distilled water into the 
cassette immediately prior to the addition of the sample.  After removal of the 
distilled water samples were injected into cassettes using a syringe filled with 
the sample and an 18-gauge 1-inch beveled needle.  Excess air was removed 
from the cassette to allow maximal sample solution contact with the dialysis 
buffer.  Dialysis was carried out at 4°C and dialys is buffer was changed after 3 
hours, then after overnight followed by a further 2 hour incubation in dialysis 
buffer.  To remove samples syringes with an 18-gauge 1-inch beveled needle 
were filled with air at least equal in volume to the sample.  The air was then 
discharged into the cassette to allow the membranes of the cassette to 
separate.  The cassette was then rotated to allow the biotinylated sample to be 
drawn back into the syringe.  Biotinylated proteins were aliquoted and stored at 
-20°C.  BSA was also biotinylated by the above proc edure to use as a control in 
experiments. 
 
2.4.2 Dot Blot 
To verify biotinylation of recombinant proteins an aliquot of the protein was 
serially diluted 1:10 until a final dilution of 1:100, 000.  10 µl neat biotinylated 
protein (50 µg/ml) and each serial dilution were spotted onto Hybond™-N nylon 
membrane (Amersham Life Sciences, Buckinghamshire, England).  Proteins 
were allowed to soak into the membrane before the membrane was blocked 
with 1X Casein in TBS/Tween (Section 2.5) for 30 minutes.  The membrane 
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was washed twice for 10 minutes each in TBS/Tween then for 10 minutes in 
TBS.  The membrane was then incubated with 5 ml ABComplex AP reagent 
(Vector Laboratories) for 30 minutes.  The reagent consists of 5 ml TBS with 2 
drops of Reagent A, Avidin DH, and 2 drops of Reagent B, biotinylated alkaline 
phosphatase H.  The reagent was mixed 30 minutes prior to use and allowed to 
stand at room temperature.  Membrane was washed twice for 10 minutes each 
in TBS/Tween then for 10 minutes in TBS before incubating with 5 ml Alkaline 
phosphatase substrate as described in section 2.2.3 and 2.5 or 5 ml of Vector 
Blue Alkaline Phophatase Substrate III (Vector Laboratories).  A working 
solution of Vector Blue substrate consisting of 5 mls 100  mM Tris-HCl pH 8.2, 2 
drops Reagent 1, 2 drops Reagent 2 and 2 drop of Reagent 3 was prepared 
immediately prior to use and membrane was incubated for 20 minutes of until 
colour development.  Membranes were then washed 3 times in TBS for 10 
minutes.  All incubations were carried out at room temperature.  Non-
biotinylated BSA was used as a negative control. 
 
RECOMBINANT PROTEIN SOURCE 
Jo-1 
A kind gift from Prof. Paul Plotz, National 
Institute of Health, Bethesda, MD, USA 
Calf Thymus DNA Sigma (St. Louis, MO, USA) 
Sm/RNP The Binding Site (UK) 
Scl-70 The Binding Site (UK) 
 
Table 2.11 Recombinant Proteins for biotinylation to identify antigen specific cells 
 
2.4.3 Antigen Specific Staining 
Slides from -70°C were thawed at room temperature f or 30 minutes in a staining 
vessel containing anhydrous silica gel.  To fix sections slides were transferred 
to acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP pen (Immedge Pen, Vector Laboratories) and allowed to dry for 5 minutes.  
They were then incubated for 15 minutes with avidin blocking solution (Vector 
Laboratories) and briefly washed in TBS before a 15 minute incubation with 
biotin blocking solution (Vector Laboratories).  Sections were then washed twice 
for 5 minutes in TBS.  100 µl of 1X Casein (Vector Laboratories) was added to 
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each section to block for 15 minutes.  Blocking solution was poured off and 100 
µl of 20 µg/ml biotinylated recombinant protein was added to sections, with 
appropriate negative controls, and incubated for 1 hour.  The sections were 
then washed 3 times in TBS for 5 minutes and then incubated with 100 µl of 
ABComplex AP Reagent (Vector laboratories) solution for 30 minutes.  The 
reagent consists of 5 mls TBS with 2 drops of Reagent A, Avidin DH, and 2 
drops of Reagent B, biotinylated alkaline phosphatase H.  Reagent was mixed 
30 minutes prior to use and allowed to stand at room temperature.  Sections 
were washed 3 times in TBS for 5 minutes then incubated with 5 mls Alkaline 
phosphatase substrate as described in section 2.2.3 and 2.5.  Following 
substrate incubation sections were washed twice in TBS for 5 minutes and once 
in sterile distilled water for 5 minutes.  All incubations were carried out at room 
temperature in a humidified chamber.  Biotinylated BSA as a negative control 
on myositis sections and biotinylated antigen was also used on tonsil sections 
as a negative control. 
 
2.4.4 Double Immunofluorescent Antigen Specific Staining 
Double Immunofluorescent immunohistochemistry for antigen specific cells was 
performed as described in section 2.2.4 using 2 µg/ml recombinant protein 
(Table 2.11).  Use of the biotinylated recombinant proteins eliminated the need 
for using M.O.M biotinylated Anti-Mouse Ig reagent therefore this step was 
eliminated where appropriate before the appropriate detecting solution was 
applied to each section.  Biotinylated BSA was used on sample sections as a 
negative control. 
 
2.4.5 Laser Capture Microdissection 
Laser capture microdissection (LCM) was performed using a PixCell® IIe Laser 
Capture Microdissection System (Arcturus Bioscience Inc, Mountain View, CA) 
to direct the low-powered infrared laser through the CapSure® HS (Arcturus) 
caps to melt the film onto the cell of interest (Figure 2.7A).  CapSure® HS caps 
are coated with a special thermoplastic film which melts onto the surface of the 
target cell when pulsed with the infrared light from the laser.  This film also 
absorbs the laser radiation ensuring that any infrared radiation that does 
penetrate the polymer does not create or catalyse any chemical alterations to 
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the DNA/RNA of the sample ensuring its integrity for further downstream 
applications.  CapSure® HS caps contain a 12 µm discontinuous circular ridge 
that sits on the surface of the tissue ensuring the cap is elevated above the 
sample microdissection (Figure 2.7B). This ensures that the only part of the film 
that comes into contact with the sample is that which has been melted by the 
laser onto the cell of interest.  The ExtracSure Extraction device is placed on 
the caps after capture of the cells of interest and seals around the perimeter of 
the cap surface and covers the circular ridge that was in contact with the 
sample during LCM.  Extraction buffer can then be safely added to ExtracSure 
device to allow extraction of DNA (Figure 2.7C-A).  For RNA extraction the 
ExtracSure device was not required.  100 µl of lysis buffer is placed in a 0.5 ml 
microcentrifuge tube and inverted to allow cell lysis (Figure 2.7C-B). Taken 
from PixCell® IIe Laser Capture Microdissection System User Guide, Arcturus 
Bioscience Inc, Mountain View, CA.  
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Figure 2.7 A simplified diagram of Laser Capture Microscopy (LCM) 
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Figure 2.7 A simplified diagram of Laser Capture Microscopy (LCM) 
 
Laser capture microdissection (LCM) to isolate single cells was performed using a PixCell® IIe 
Laser Capture Microdissection System (Arcturus Bioscience Inc, Mountain View, CA). A low-
powered infrared laser is passed through CapSure® HS caps (Figure 2.7A) over the cell which 
is to be dissected.  CapSure® HS caps are coated with a special thermoplastic film which melts 
onto the surface of the target cell when pulsed with the infrared light from the laser (Figure 
2.7B).  For extraction of genomic DNA the ExtracSure Extraction device is placed on the caps 
after capture of the cells of interest and seals around the perimeter of the cap surface and filled 
with DNA extraction buffer (Figure 2.7C-A).  The ExtracSure Extraction device is not required 
for RNA isolation (Figure 2.7C-B); alternatively 100 µl of lysis buffer is placed in a 0.5 ml 
microcentrifuge tube and inverted to allow cell lysis.  Adapted from (295) and PixCell® IIe Laser 
Capture Microdissection System User Guide, Arcturus Bioscience Inc, Mountain View, CA. 
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2.4.5.1 Immunohistochemistry for LCM 
Immunohistochemical staining for LCM was performed as described in section 
2.2.3, although incubation times were reduced and antibody concentrations 
were increased. This was to ensure efficient transfer and quality of nucleic acid 
obtained during microdissection.   Sections were also dehydrated as moisture 
present within the sample can impede transfer efficiency.  Briefly, slides from -
70°C were thawed at room temperature for 15 minutes  in a staining vessel 
containing anhydrous silica gel.  To fix sections slides were transferred to 
acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP pen (Immedge Pen, Vector Laboratories) and allowed to dry for 5 minutes.  
Sections were rehydrated in TBS for 30 seconds.  100 µl of 2% BSA/TBS was 
added to each section to block for 15 minutes.  Blocking solution was poured off 
and 100 µl of 2% BSA/TBS containing mouse anti-human primary antibody 
(DAKO) was added to each section (Table 2.12) and incubated for 15 minutes.  
Negative control experiments were performed using antibodies with matched 
isotypes.  The primary antibody solution was poured off and sections were 
washed twice in TBS for 30 seconds.  Following washing 100 µl of 2% 
BSA/TBS containing 10 µl of rabbit anti-mouse IgG secondary antibody (DAKO) 
was added to each section and was incubated for 10 minutes.  After secondary 
antibody was poured off and sections were washed twice in TBS for 30 seconds 
100 µl of 2% BSA/TBS containing 4 µl of alkaline phosphatase anti- alkaline 
phosphatase (APAAP) was added to each section and was incubated for 10 
minutes.  Sections were again washed twice in TBS for 30 seconds. 100 µl of 
substrate solution, as per section 2.2.3 and 2.5, was then added to each section 
and allowed to develop for 20 minutes.  Following substrate incubation sections 
were washed twice in TBS for 5 minutes and once in sterile distilled water for 1 
minute.  Sections were counter-stained with Mayer’s Haemotoxylin and washed 
in Scotts tap water substitute to allow proper colour development.  All 
incubations were carried out at room temperature in a humidified chamber.  For 
laser microdissection sections were dehydrated in 75% ethanol for 1 minute, 
followed by 95% ethanol for 1 minute and then 100% ethanol for 1 minute.  
Finally sections were incubated for 5 minutes with Histoclear (National 
Diagnostics).  They were then allowed to air dry, under a fume hood, and stored 
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desiccated.  For antigen-specific cells staining was carried out as described in 
section 2.4.3. 
 
 
Antibody 
Specificity Source Species Clone Isotype Dilution 
CD20 DAKO Mouse Monoclonal L26 -IgG2a 1:25 
Plasma Cell DAKO Mouse Monoclonal V538c -IgG1 1:100 
-IgG1 Isotype 
Control DAKO 
Mouse 
Monoclonal DAK-G01  1:100 
-IgG2a 
Isotype 
Control 
(Anti-
Aflatoxin) 
Kind gift 
from Prof 
Stimpson, 
Strathclyde 
University, 
Glasgow 
   1:25 
 
Table 2.12 Primary Antibodies used for staining LCM sections 
 
2.4.5.2 Laser Microdissection 
Microdissection for single cells was performed using a spot size of 7.5 µM, 
power of 70 mV and 1 ms duration.   Cells were transferred to CapSure® HS 
caps. 
 
2.4.5.3 RNA Purification 
Isolation of RNA from microdissected single cells was performed using 
Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, CA. USA).    The nanoprep 
RNA purification method utilizes a guanidine thiocyanate lysis buffer which acts 
as a strong protein denaturant to allow cell lysis and prevention of RNA 
degradation by ribonucleases (RNases).  After transfer to the nano-spin cup, 
RNA is bound to the silica-based fibre matrix and RNA sample is treated with 
DNase to remove contaminating DNA and several washes removes DNase and 
other proteins resulting in RNA suitable for cDNA synthesis.   Briefly, 0.7 µl β-
Mercaptoethanol (14.2 M) was added to 100 µl lysis buffer for each sample in a 
0.5 ml Eppendorf.  The CapSure® cap containing laser-captured cell is snapped 
onto each microcentrifuge tube.  Each tube was inverted and vortexed for 30 
seconds to allow cell lysis.  100 µl of 70% ethanol was then added to each 
sample and mixed by pulse vortexing.  The entire lysate was then transferred to 
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an RNA-binding nano-spin cap and centrifuged for 60 seconds at 12,000 g.  
After discarding the filtrate 300 µl of 1x Low-Salt Wash Buffer was added to 
each cap and centrifuged at 12, 000 g for 60 seconds.  After removal of the 
filtrate the cap was centrifuged for 2 minutes to dry out the fibre matrix.  Each 
sample was then incubated with 15 µl DNase solution (2.5 µl reconstituted 
RNase-Free DNase 1 with 12.5 µl DNase Digestion Buffer) at 37°C for 15 
minutes.  300 µl 1x High-Salt Wash Buffer was then added to each sample and 
centrifuged for 60 seconds at 12, 000 g.  This was repeated twice with 300 µl 
Low-Salt Wash Buffer before a 3 minute centrifugation to dry out the fibre 
matrix.  10 µl Elution Buffer was then added to each sample and incubated for 2 
minutes at room temperature.  Total RNA was eluted after centrifugation at 
12,000 g for 5 minutes. 
 
2.4.5.4 cDNA Synthesis 
cDNA synthesis was performed using the AffinityScript Multiple Temperature 
cDNA synthesis Kit (Stratagene, La Jolla, CA. USA).  First strand cDNA 
synthesis reaction was performed using the total RNA sample from section 
2.4.5.3; 5.7 µl RNase-free water was added to the purified RNA before 1 µl of 
constant region gene specific primers (100 ng/µl) were added.  The reaction 
was incubated at 65°C for 5 minutes.  Constant regi on primers were 
synthesised by Operon Biotechnologies (Huntsville, AL, USA) and were as 
previously described by Wang and Stollar (296) (Table 2.13).  After 5 minutes 
reactions were allowed to cool to room temperature to allow primers to anneal 
to RNA.  Once cooled to room temperature 2 µl of 10x AffinityScript RT buffer 
was added to each reaction followed, in order, by 0.8 µl dNTP mix (25 mM 
each), 0.5 µl RNase Block Ribonuclease Inhibitor (40 U/µl) and 1 µl of 
AffinityScript Multiple Temperature Reverse Transcriptase.  Reactions were 
incubated for 60 minutes at 42°C. Reactions were st opped by incubating for 15 
minutes at 70°C.  cDNA synthesis reactions were sto red on ice for subsequent 
PCR reactions. 
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    Primer Name                      Sequence 
    Constant Region  HuCmu GCAGGAGACGAGGGGGA 
    Primers HuCgamma AGGGYGCCAGGGGGAA 
 HuCkappa AACAGAGGCAGTTCCAGA 
 HuClambda TGTGGCCTTGTTGGCTTG 
 
                               Table 2.13 Constant Region Primers for cDNA synthesis 
 
 
2.4.5.5 VH Nested PCR on single cells 
 
VH amplification from cDNA isolated from single infiltrating cells was carried out 
as previously described in section 2.3.7.  PCR products were visualised as 
described in section 2.3.8 and extraction and cloning were performed as 
described in sections 2.3.9, 2.3.10 and 2.3.12. 
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2.5 Buffers 
 
Tris-Buffered Saline 
(TBS) 
20 mM Tris Base 
137 mM NaCl 
2.7 mM KCl 
pH 7.4 
TBS/Tween 20 mM Tris Base 
137 mM NaCl 
2.7 mM KCl 
pH 7.4 
0.1% Tween 20 
Phosphate Buffered 
Saline (PBS) 
137 mM NaCl 
10 mM phosphate 
2.7 mM KCl 
Buffer E 0.05 M Tris Base 
0.9% NaCl 
pH 9.7 
Alkaline Phosphate 
Substrate for 
Immunohistochemistry 
10 µl of 5% New Fuchsin in 2 M HCl 
25 µl of 0.7 M sodium nitrite 
3.5 mls of Buffer E 
1.25 mls of 0.2 M 2-amino-2-methyl-1,3-propanediol 
(AMPD) 
50 µl of 40 mg/ml levamisol 
30 µl of Naphthol AS-BI phosphate 
100 µl of 2 M HCl 
 
Scotts Tap Water 
Substitute 
0.35% NaHCO3 
0.2% MgSO4 
 
 
Complete RPMI RPMI Medium 
1% Penicillin/Streptomycin 
1% 200mM L-Glutamine) 
30% Foetal Bovine Serum 
 
+10% DMSO for Lymphocyte Cryopreservation 
 
TBE Electrophoresis 
Buffer 
 
45 mM Tris base 
45 mM Boric Acid 
1 mM EDTA 
Agarose Gel 1.5% electrophoresis grade Ultra Pure Agarose 
(Invitrogen) 
1 x TBE 
0.5 µg/ml Ethidium Bromide 
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Chapter 3 - Phenotypic Characterisation of Cellular Infiltrates in Myositis 
Patients 
3.1 Introduction 
As discussed in Chapter 1 the presence and phenotypes of cellular infiltrates 
have previously been studied in myositis (87-89;297;298).  The roles, 
interactions, degree of infiltration and organisation of these cells have yet to be 
fully understood in these autoimmune disorders.  Including myositis, a variety of 
different cellular phenotypes have been identified in different autoimmune 
inflammatory reactions, these include B cells, either in their B cell state or in 
their differentiated plasma cell state.  These cells have been implicated in the 
pathogenesis of autoimmune disorders but their precise role in contributing to 
autoimmune pathology is largely unknown.   
 
To investigate the role of B cells in myositis and examine the Ig gene repertoire 
and clonal diversification of infiltrating cells the occurrence of these B cells and 
plasma cells within the target tissues of these disorders was initially determined.  
Therefore immunohistochemical studies were conducted to address the central 
aim of this chapter; 
 
• Establish the occurrence and organisation of CD20+ B cells and plasma 
cells within the infiltrating cellular population of the muscle. 
• Identify proliferating Ki67+ B cells within the muscle to indicate the 
possible expansion and clonal diversification of these cells within the 
muscle.  
• Determine the degree of infiltration, organisation and proliferation of 
additional cell phenotypes (T cells (CD3, CD4, CD8), macrophages 
(CD68), Follicular dendritic cells (FDC), proliferating cells (Ki67) and 
regulatory T cell (FoxP3)) within muscle samples. 
 
The work described in this chapter demonstrates that a large variety of cellular 
phenotypes was present within inflammatory reactions in myositis and are 
summarised in Table 3.1. 
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Sample Diagnosis Germinal Centre 
Formation 
Cellular 
Aggregation CD20 
Plasma 
Cell FDC CD3 CD4 CD8 FoxP3 CD68 Ki67 -IgG1 -IgG2a -IgM 
MYO1 DM - +++ ++ ++ - ++ ++ + ++ ++ ++ - - - 
MYO3 PM - +++ + ++ + ++ +++ + - ++ + - - - 
MYO5 PM - - + ++ + ++ ++ ++ - ++ + - - - 
MYO6 PM - ++ + + - ++ + + - ++ + - - - 
MYO7 PM - ++ + ++ - + +++ + - +++ + - - - 
MYO16 DM - +++ +++ ++ - ++ ++ + - +++ + - - - 
MYO17 PM/IBM - ++ + ++ + +++ ++ + + ++ + - - - 
MYO19 PM - ++ + ++ - ++ ++ + - ++ + - - - 
MYO23 PM - + + ++ + + ++ + - ++ + - - - 
MYO24 PM - ++ 
- (+ IF 
only) +++ - ++ ++ + + ++ + - - - 
MYOC  PM - + + ++ - ++ +++ ++ - ++ + - - - 
MYOE Myopathy 
(PM) 
- + + ++ - ++ ++ ++ - ++ ++ - - - 
MYO25 Control - N/A - - - - - - - + - - - - 
 
MYO2 Myopathy (PM) - + - -               - -   
MYOA Myopathy (IBM) - N/A - -               - -   
MYOD DM - N/A - -               - -   
MYO18 PM - - - -               - -   
MYO21 PM - + - -               - -   
Table 3.1 Immunohistochemistry Summary Table from Myositis Samples 
  
Table 3.1 provides a summary overview of the immunohistochemistry profiles observed from each sample for each myositis patient.  The table summarises the infiltration 
of each cell phenotype observed throughout the entire biopsy (n=3-7 sections for each cell phenotype depending on tissue availability) and is not based solely on the 
representative images presented in Figures 3.1, 3.5, 3.7, 3.9, 3.11, 3.13, 3.15, 3.17, 3.19, 3.21, 3.23, 3.25, 3.27 and 3.28.  Comparisons were made between cell 
phenotypes in the same patient and not between different patients.  For germinal centre formation, – represents the absence of these structures within the muscle 
sections.  The extent of cellular aggregation of infiltrating cells was established for each sample and was based on semi quantitative observations; - represents no cellular 
aggregation with a widespread scattering of lymphocytes throughout the muscle section; +, ++, +++ represents an increasing degree of aggregation of lymphocytes 
respectively observed within the muscle sections.  N/A was applied to samples where no or very little infiltration was present.  Immunohistochemistry summary profiles 
were based on semi-quantitative observations of cellular infiltration; - indicates where cell phenotypes were absent from the infiltrating population while +, ++, +++ 
represent increasing numbers of cell phenotypes respectively within the muscle infiltrating population.  Areas highlighted in yellow indicate where proliferating cell 
phenotypes were observed from fluorescent double immunohistochemistry (IF) experiments, these experiments were not included in the semi quantitative analysis and 
were used solely to establish the population of proliferating cells.  Areas in grey indicate where cell phenotypes were not tested for.          
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3.2 Characterisation of Cellular Infiltrates in Inflammatory Myopathies 
3.2.1 Sample MYO1 
Six extensive regions of cellular infiltration were observed through serial 
sections of sample MYO1 with additional scattered infiltration throughout the 
section between the muscle fibres.  No characteristic germinal centre structures 
were observed; areas of infiltration appeared as loose aggregates of cells 
situated between muscle fibres, mainly in perimysial and/or perifascicular 
regions of the muscle.  In region 1 (Figure 3.1), as well as other regions of 
infiltration,  CD20+ (A), CD3+ (D), CD4+ (E), CD8+ (F) and Ki67+ (G) cells were 
identified with plasma cell staining (C) mostly concentrated in the six regions but 
were also identified lightly scattered throughout the section in endomysial 
locations.  Very few FDCs (B) appeared to be present within the infiltrating cell 
population.  In addition, a large infiltration of CD68+ (H) cells was observed as 
well as an infiltration of FoxP3+ cells (I) throughout sections examined.  These 
cell markers were observed in each of the areas of cell aggregation as well as 
additional scattered staining throughout the muscle section.  Staining sections 
with the appropriate negative controls (J-L) identified virtually no staining in the 
regions identified by the other cellular stains although small amounts were 
observed throughout the section.  A large proportion of B cells, CD4+ cells and 
plasma cells were observed which may suggest a humoral, ectopic germinal 
centre response was occurring within the sample but no germinal centre 
structures or FDCs were observed.  Although CD8 staining was observed cell 
numbers appeared reduced in comparison to other cell types.   
 
Double staining experiments to characterise the nature of proliferating cells 
within sample MYO1 showed that the majority of proliferating cells were CD3+ 
(B) or CD4+ (C) cells (Figure 3.2).  There was the presence of an occasional 
proliferating CD20+ cell throughout the MYO1 sections.  Figure 3.3 (A & B) 
shows that FoxP3+ cells are included in the population of proliferating cells.  
Negative control experiments with the antibody isotype controls showed no non-
specific staining within sections (Figure 3.4). 
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Figure 3.1 Immunohistochemistry of serial muscle sections of sample MYO1 
 
A representative example of serial muscle sections from sample MYO1 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control (L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the muscle section.  Images A – I: 400X; Images J-L: 100X 
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Figure 3.2 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1  
 
A representative example of serial muscle sections from sample MYO1 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
FoxP3 
FoxP3 
Ki67 
Ki67 
FoxP3 Ki67 
 
FoxP3 Ki67 
 
A 
B 
Figure 3.3 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1 with Anti-FoxP3 
 
A representative example of serial muscle sections from sample MYO1 stained for FoxP3 
(A&B) and visualised by Fluorescein Avidin D before all sections were stained with Ki67 and 
visualised by Texas Red Avidin D.  This allowed any FoxP3 proliferating cells within the 
myositis sample to be identified.  Images were taken at 630X (A) and 1000X (B). Scale Bar 
(A) represents 15 µm, no Scale Bar was calibrated at 1000X.  Arrows identify proliferating 
cells within the sections. 
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Figure 3.4 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1 with negative control isotype antibodies  
 
A representative example of serial muscle sections from sample MYO1 stained with –IgG2a 
isotype control (A) or –IgG1 isotype control (B) and visualised by Fluorescein Avidin D 
before all sections were stained with –IgG1 isotype control and visualised by Texas Red 
Avidin D.  This allowed any non-specific staining within the myositis sample to be identified.  
Images were taken at 630X.  Scale Bar represents 15 µm.   
114 
3.2.2 Sample MYO3 
 
Immunohistochemical staining of sample MYO3 produced a different pattern of 
staining in comparison to sample MYO1 (Figure 3.5).  Two distinct regions of 
infiltration at endomysial locations were observed with varied degrees of cellular 
infiltration in addition to scattered staining throughout the section.  Staining for 
CD20+ (A) cells and FDCs (B) produced a very diffuse pattern of staining but 
there appeared to be a low infiltration of these cell classes present within the 
sample.  A large infiltration of plasma cells (C) was observed throughout the 
section.  These were aggregated in the regions of distinct infiltration but plasma 
cells were also observed scattered throughout the entire section. A large 
proportion of cells appeared to be CD3+ (D) and CD4+ (E) cells, in some 
instances the occurrence of CD4+ cells appeared to be greater than that of 
CD3+ cells.  CD8+ (F) cells were present within sample MYO3 but these 
appeared to be reduced in comparison to the numbers of CD3+ and CD4+ cells.  
A large infiltration of CD68+ (H) cells was also present within the sample; in 
addition to being aggregated in dense areas of infiltration, these cells were also 
scattered throughout the whole section.  Proliferating cells were observed within 
the sample using the Ki67 proliferation marker (G), as with the other cell 
markers staining was observed within the cellular aggregates as well as 
throughout the whole section.  No FoxP3+ (I) cells were evident within sample 
MYO3.  Staining of section with negative control isotype antibodies showed no 
non-specific staining (J-L). 
 
Identification of Ki67+ cells by double staining experiments showed the 
presence of CD3+ (B) and CD8+ (D) proliferating cells throughout the section at 
the areas of cellular aggregation (Figure 3.6).  Figure 3.6 represents a small 
area of the whole section but these proliferating cells were observed in other 
areas of cellular aggregation.  No other type of proliferating cell was observed 
within the sections stained.  Negative control staining produced no non-specific 
staining.  
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Figure 3.5 Immunohistochemistry of serial muscle sections of Sample MYO3. 
 
A representative example of serial muscle sections from sample MYO3 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.6 Double Immunohistochemical staining of serial muscle sections of sample 
MYO3 
 
A representative example of serial muscle sections from sample MYO3 stained for CD20 (A), 
CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all sections 
were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the type of 
proliferating cells within the myositis sample to be identified.  Images were taken at 630X; Scale 
Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.3 Sample MYO5  
Analysis of cellular infiltrates within sample MYO5 produced a largely 
endomysial pattern of staining, characterisation of cellular phenotypes was 
similar to that of sample MYO3 (Figure 3.7).  There was very little evidence of 
CD20+ (A) cells and FDCs (B) within the sample.  A large proportion of 
infiltrating cells were plasma cells (C) or CD3+ (D), CD4+ (E) and CD8+ (F) cells.  
As seen in MYO3 a large infiltrate of CD68+ (H) cells was observed.  Ki67+ (G) 
cells were present within the myositis biopsy but no FoxP3+ (I) cells were 
evident throughout the sections examined.  Negative control experiments were 
clear with no non-specific staining (J-L).  In contrast to sample MYO3 cells were 
not formed in loose aggregates with additional scattered staining throughout the 
section. In sample MYO5 there was a large endomysial infiltrate of cells 
throughout the entire section which did not appear to aggregate at any 
particular region within the muscle biopsy. 
 
Proliferating CD3+ (B), CD8+ (D) and CD68+ (E) cells were observed within the 
sample (Figure 3.8).  No proliferating CD20+ cells were observed within the 
sections examined but proliferating cells were found to be located next to 
CD20+ cells (Figure 3.8A).  Negative control staining produced no non-specific 
staining. 
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Figure 3.7 Immunohistochemistry of serial muscle sections of Sample MYO5. 
 
A representative example of serial muscle sections from sample MYO5 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control (L) and visualised by APAAP and New Fuschin substrate to establish 
cellular infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.8 Double Immunohistochemical staining of serial muscle sections of sample 
MYO5 
 
A representative example of serial muscle sections from sample MYO5 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.4 Sample MYO6 
In sample MYO6 there was no extensive region of cellular infiltration.  Cells 
present within the sample appear to surround the muscle fibres in an 
endomysial pattern (Figure 3.9).  Immunohistochemistry experiments produced 
largely diffuse areas of staining but some of the cells stained were identified as 
CD20+ (A) cells in addition to CD3+ (D), CD4+ (E) and CD8+ (F) cells.  No 
staining was observed for FDCs (B) but plasma cells (C) were evident amongst 
the infiltrating cells.  No proliferating cells (G) were evident within this area of 
aggregation in sample MYO6; a few proliferating cells were observed in other 
areas of infiltration.  There was a large infiltration of CD68+ (H) cells within the 
sample.  FoxP3+ (I) cells were not present. Negative control isotype antibodies 
produced no non-specific staining (J-L). 
 
Although few proliferating cells were present within sample MYO6, those that 
were present appeared to be CD68+ cells (Figure 3.10E).  No other proliferating 
cell type was observed in the serial sections analysed of sample MYO6.  As 
with the previous staining experiments no non-specific staining was present. 
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Figure 3.9 Immunohistochemistry of serial muscle sections of Sample MYO6. 
 
A representative example of serial muscle sections from sample MYO6 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.10 Double Immunohistochemical staining of serial muscle sections of sample 
MYO6  
 
A representative example of serial muscle sections from sample MYO6 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.5 Sample MYO7 
 
Immunohistochemical staining of sample MYO7 (Figure 3.11) demonstrated 
that infiltrating cells were present throughout the entire section, between muscle 
fibres, but did appear to form approximately three regions of aggregation, 
although some of these areas appeared to be damaged during section cutting.  
Within the cellular infiltrates very few CD20+ (A) cells or FDCs (B) were present.  
A large proportion of the cells were identified as plasma cells (C) or CD4+ (E) 
cells.  The number of cells observed using the CD4 marker appeared to be 
greater than that observed for both CD3+ (D) and CD8+ (F) cells, as observed in 
sample MYO3.  There was a large infiltrate of CD68+ (H) cells present within 
sample MYO7.  Very few Ki67+ (G) cells were present with no evidence of 
FoxP3+ (I) cells.  Negative control experiments were clear from non-specific 
staining (J-L).   
 
Double staining experiments showed that the proliferating cells present within 
the muscle sample were CD3+ (B), CD8+ (D) and CD68+ (E) cells (Figure 3.12).  
Occasionally a proliferating CD4+ (C) cell was observed throughout the section.  
Negative control staining was clear. 
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Figure 3.11 Immunohistochemistry of serial muscle sections of Sample MYO7. 
 
A representative example of serial muscle sections from sample MYO7 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.12 Double Immunohistochemical staining of serial muscle sections of sample 
MYO7  
 
A representative example of serial muscle sections from sample MYO7 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.6 Sample MYO16 
 
Within sample MYO16 three main regions of perimysial/perifascicular cellular 
infiltration were observed with additional scattered infiltration (Figure 3.13).  
Although infiltrates were largely focused at the fascicle edges, a number of 
individual muscle fibres at one area of aggregation were surrounded by 
infiltrating cells.  One of the main regions of cellular infiltration displayed 
considerable CD20+ (A), CD3+ (D), CD4+ (E) cells and plasma cell (C) 
infiltrates, as well as Ki67+ (G) cells with reduced cellular CD8+ (F) staining in 
comparison to other cell types.  The CD20+ cells formed a very dense follicle of 
cells situated between muscle fibres.  In other regions the infiltrating CD20+ 
cells were more loosely aggregated.  A large infiltration of CD68+ (H) cells was 
also present within sample MYO16.  These cells types were evident within the 
regions of aggregation but were also dispersed throughout the entire section.  
No FoxP3+ (I) cells or FDCs (B) were present within the infiltrating population.  
This pattern of infiltration was observed in the other regions of cellular 
aggregation but there was a reduction in the presence of CD20+ cells in the 
other regions compared to that observed in the region mentioned above.  
Negative control stains with appropriate isotype controls produced no non-
specific staining (J-L).  
 
Identification of the proliferating cells by double staining identified the Ki67+ cells 
as CD3+ (B), CD4+ (C), CD8+ (D) and CD68+ (E) cells (Figure 3.14).  No 
proliferating CD20+ (A) cells were observed in serial sections of the sample 
although the large areas of aggregation observed within immunohistochemistry 
experiments, Figure 3.13, could not be located in the later sections used for the 
immunofluorescence experiments.  As previously described no non-specific 
staining was observed within the sample. 
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Figure 3.13 Immunohistochemistry of serial muscle sections of Sample MYO16. 
 
A representative example of serial muscle sections from sample MYO16 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), IgG1 
Negative control (H), IgG2a Negative control (I), IgM Negative control (J) and visualised 
by APAAP to establish cellular infiltrates within the muscle section.  Images A – J 400X 
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Figure 3.14 Double Immunohistochemical staining of serial muscle sections of sample 
MYO16  
 
A representative example of serial muscle sections from sample MYO16 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.7 Sample MYO17 
 
Identification of cellular infiltrates within sample MYO17 showed many small 
areas of aggregation as well as scattered areas of cellular infiltration throughout 
the section at endomysial locations.  One extensive area of cellular infiltration 
between muscle fibres was observed within sample MYO17 (Figure 3.15). 
CD3+ (D), CD4+ (E) cells and plasma cells (C) dominated the cellular infiltrate 
with positive but reduced numbers of CD8+ (F) cells.  Very few CD20+ (A) cells 
or FDCs (B) were observed within the sample in comparison to CD3+, CD4+ and 
plasma cell staining.  Proliferating Ki67+ (G) cells were present within the 
sample as well as a large infiltrate of CD68+ (H) cells.  FoxP3+ (I) staining 
showed the presence of an occasional positive cell.  Some light diffuse staining 
was observed with the negative control isotype antibodies but the staining for 
cell markers are clearly specific due to the differences in staining intensity (J-L). 
 
Proliferating cells were shown to include CD20+ (A), CD3+ (B), CD4+ (C), CD8+ 
(D) and CD68+ (E) cells (Figure 3.16).  Negative control experiments with the 
antibody isotype controls showed no non-specific staining within sections.   
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Figure 3.15 Immunohistochemistry of serial muscle sections of Sample MYO17. 
 
A representative example of serial muscle sections from sample MYO17 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.16 Double Immunohistochemical staining of serial muscle sections of sample 
MYO17  
 
A representative example of serial muscle sections from sample MYO17 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.8 Sample MYO19 
 
Numerous small areas of endomysial infiltration were observed within sample 
MYO19 which appeared to vary in cell density, with additional scattered staining 
throughout the sample.  As demonstrated in Figure 3.17 all the regions 
displayed positive staining for CD20 (A), CD3 (D), CD4 (E), CD8 (F), Ki67 (G) 
cell markers and plasma cells (C).  As previously observed in some other 
myositis samples no staining was observed for FDCs (B) and CD8 staining was 
reduced in comparison to other cell types.  A large infiltration of CD68+ (H) cells 
but no FoxP3+ (I) cells were observed throughout sections examined for this 
sample.  Staining sections with the appropriate negative controls (J-L) identified 
virtually no staining in the regions identified by the other cellular stains. 
 
Double staining identified the proliferating cells within the muscle as a collection 
of CD20+ (A), CD3+ (B), CD4+ (C) and CD8+ (D) cells (Figure 3.18).  No 
proliferating CD68+ (E) cells were observed throughout the sample.  Negative 
control experiments were clear of non-specific staining. 
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Figure 3.17 Immunohistochemistry of serial muscle sections of Sample MYO19. 
 
A representative example of serial muscle sections from sample MYO19 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.18 Double Immunohistochemical staining of serial muscle sections of sample 
MYO19  
 
A representative example of serial muscle sections from sample MYO19 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.9 Sample MYO23 
 
For sample MYO23 no dense region of cellular infiltration was observed and 
infiltrating cells appeared to be in very small numbers throughout the entire 
section between muscle fibres in endomysial locations (Figure 3.19).  Of the 
cells that were present a large proportion were identified as plasma cells (C), 
CD4+ (E) and CD68+ (H) cells.  Some of the infiltrating cells were identified as 
CD20+ (A), CD3+ (D) and CD8+ (F) cells as well as FDCs (B).  Some of the 
infiltrating cells were proliferating with the presence of Ki67+ (G) cells. No 
FoxP3+ (I) cells were found within the section.  The use of negative control 
isotype antibodies produced no non-specific staining (J-L). 
 
Double immunohistochemical experiments demonstrated that proliferating cells 
within sample MYO23 were CD3+ (B), CD8+ (D) or CD68+ (E) cells (Figure 
3.20).  Negative control experiments were clear of non-specific staining.      
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Figure 3.19 Immunohistochemistry of serial muscle sections of Sample MYO23. 
 
A representative example of serial muscle sections from sample MYO23 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.20 Double Immunohistochemical staining of serial muscle sections of sample 
MYO23  
 
A representative example of serial muscle sections from sample MYO23 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.10 Sample MYO24 
 
For sample MYO24 plasma cells (C) and CD68+ (H) cells dominated the 
population of infiltrating cells (Figure 3.21).  Diffuse staining was observed for 
CD20+ cells (A) and FDCs (B) with no clear representation of these cells being 
present within sample MYO24, although CD20+ cells were later identified in 
immunofluorescent experiments (Figure 3.22).  CD3+ (D) and CD4+ (E) cells 
were evident within the sample.  These cells formed a few small areas of 
cellular aggregation but additional cells were dispersed through the whole 
section between the muscle fibres.  CD8+ (F) cells were also present within the 
sample but the staining was reduced in comparison to that of CD3 and CD4 cell 
markers.  Ki67+ (G) cells were present within the sample with also the 
occasional FoxP3+ (I) cell.  All negative control staining experiments were clear 
of non-specific staining (J-L). 
 
Identification of the proliferating cells within sample MYO24 by double staining 
showed that some of the infiltrating CD20+ (A) and CD4+ (C) cells were 
proliferating within sample MYO24 (Figure 3.22).  Negative control experiments 
with the antibody isotype controls showed no non-specific staining within 
sections 
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Figure 3.21 Immunohistochemistry of serial muscle sections of Sample MYO24. 
 
A representative example of serial muscle sections from sample MYO24 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.22 Double Immunohistochemical staining of serial muscle sections of sample 
MYO24  
 
A representative example of serial muscle sections from sample MYO24 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.11 Sample MYOC 
 
MYOC cellular infiltration was observed throughout the entire section, in an 
endomysial pattern, with small areas of aggregation (Figure 3.23).  No FDCs 
(B) were observed within the section and there was very little staining observed 
for CD20+ (A) cells.  CD3+ (D) and CD8+ (F) cells were found within the muscle 
as well as CD4+ (E) cells but the staining of CD4+ cells was greater than that 
observed for the CD3 cell marker, similar to that observed in other samples.  
Also present within sample MYOC were CD68+ (H) and a small number of Ki67+ 
(G) cells.  For sample MYOC no FoxP3+ (I) staining was observed within the 
section.  Negative control experiments produced no non-specific within the 
section (J-L). 
 
Very few proliferating Ki67+ cells were evident within sample MYOC, the 
phenotype of those that were present could not be identified from the sections 
examined (Figure 3.24).  Negative control experiments produced no non-
specific staining. 
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Figure 3.23 Immunohistochemistry of serial muscle sections of Sample MYOC. 
 
A representative example of serial muscle sections from sample MYOC stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.24 Double Immunohistochemical staining of serial muscle sections of sample 
MYOC  
 
A representative example of serial muscle sections from sample MYOC stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.12 Sample MYOE 
 
Immunohistochemical staining within sample MYOE showed that there were 
small numbers of CD20+ (A) cells within the cellular infiltrate of the sample 
(Figure 3.25).  Cells infiltrating the sample were quite diffuse with small areas of 
aggregation which were distributed between the muscle fibres. As with previous 
myositis samples no FDCs (B) were present within the infiltrating population of 
cells but plasma cells (C), CD3+ (D), CD4+ (E), CD8+ (F), Ki67+ (G), and CD68+ 
(H) cells were present.  Comparing the CD4+ staining with CD3+ staining 
showed that again there was a slightly greater infiltration of CD4+ cells in 
comparison to that of CD3+ cells.  FoxP3+ (I) infiltrating cells were not found 
within the sample.  Non-specific staining was not observed by the use of isotype 
negative control antibodies (J-L). 
 
Double staining experiments identified that some of the proliferating cells were 
CD20+ (A) cells but a large proportion of the proliferating cells were of other cell 
phenotypes (Figure 3.26).  CD3+ (B), CD4+ (C) and CD68+ (E) proliferating 
cells were identified within sample MYOE as were a few CD8+ (D) proliferating 
cells.  Negative control experiments were clear of non-specific staining.  The 
large cluster of CD20+ cells observed by immunofluorescent staining 
experiments could not be found in the remaining serial sections of sample 
MYOE to allow for possible microdissection.  
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Figure 3.25 Immunohistochemistry of serial muscle sections of Sample MYOE. 
 
A representative example of serial muscle sections from sample MYOE stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
 
146 
 
 
 
 
 
CD3 
CD20 
CD20 
CD4 
CD8 
CD68 
Ki67 
Ki67 
Ki67 
Ki67 
Ki67 
Ki67 
CD20 Ki67 
 
CD20 Ki67 
 
CD3 Ki67 
 
CD4 Ki67 
 
CD8 Ki67 
 
CD68 Ki67 
 
A 
B 
C 
D 
E 
F 
Figure 3.26 Double Immunohistochemical staining of serial muscle sections of sample 
MYOE  
 
A representative example of serial muscle sections from sample MYOE stained for CD20 (A-B), 
CD3 (C), CD4 (D), CD8 (E), CD68 (F) and visualised by Fluorescein Avidin D before all sections 
were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the type of proliferating 
cells within the myositis sample to be identified.  Images were taken at 630X; Scale Bar represents 
15 µm.  Arrows identify proliferating cells within the sections. 
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3.2.13 Sample MYO25 
 
Sample MYO25 was obtained from a healthy volunteer and was used as a 
control to identify any infiltrating cells within normal muscle.  As shown in 
Figure 3.27 no cell marker was identified within the normal muscle sections 
apart from the presence of some CD68+ cells (H).  As very few cell types were 
identified within sample MYO25 and with no Ki67+ (G) cells found within the 
control section no double staining experiments were conducted. 
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Figure 3.27 Immunohistochemistry of serial muscle sections of Sample MYO25. 
 
A representative example of serial muscle sections from sample MYO25 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H) 
denoted by circle, FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), 
IgM Negative control (L) and visualised by APAAP and New Fuschin substrate to 
establish cellular infiltrates within the muscle section.  Images A – L: 40X 
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3.2.14 Samples MYO2, MYOA, MYOD, MYO18 and MYO21 
 
From the 17 myositis samples included in this study 5 samples did not contain a 
sufficient cellular infiltrate in serial sections that warranted further experiments 
(Figure 3.28).  As the central aim of the work described in this chapter was to 
identify B cells and plasma cells to allow Ig gene repertoires and clonal 
diversification to be established, no further immunohistochemical analysis was 
conducted on these samples after the use of the CD20 and plasma cell markers 
revealed that these cell phenotypes were absent from the inflammatory 
infiltrating population.  For sample MYO2 a large cellular infiltrate was observed 
in the muscle sections although this was very widespread between the muscle 
fibres in an endomysial pattern with no definite areas of aggregation observed.  
No B cells or plasma cells were clearly evident in the infiltrating population, a 
very light diffuse staining was observed while using the CD20 marker but this 
was non-specific and the same diffuse staining was also evident using in the 
negative control experiments.  This may be the result of tissue damage that was 
observed in the sections as a result of tissue sectioning.  Cellular infiltrates were 
also observed in samples MYO18 and MYO21, the degree of infiltration in these 
samples was substantially reduced in comparison to sample MYO2 but areas of 
cellular aggregation were observed.  As previously mentioned no CD20+ or 
plasma cells were evident within these samples. Use of additional cellular 
markers on these samples would have characterised the cellular phenotypes of 
the infiltrating population in these samples but as the aim of the study and 
central objective of this chapter was to identify B cells and plasma cells these 
experiments were not concluded.  The identification of a cellular infiltrate within 
sample MYO18 is in contrast to the biopsy pathology report (Table 2.2) which 
indicated that no inflammatory infiltrate was observed.  An inflammatory infiltrate 
was absent from the sections analysed for samples MYOA and MYOD, 
therefore no CD20+ or plasma cells were found within these samples.  The 
absence of an inflammatory infiltrate in sample MYOA was again in contrast to 
that reported within the biopsy pathology report which did report the presence of 
cells infiltrating the muscle biopsy.  As with MYO18, the sections used in the 
analysis of MYOA were obtained from a different depth of muscle tissue 
compared to that used in the initial pathological assessment and may therefore 
account for the differences observed.    
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Figure 3.28 Immunohistochemistry of serial muscle sections of samples MYO2, 
MYOA, MYOD, MYO18 and MYO21 
 
A representative example of serial muscle sections from the above samples stained for 
CD20, IgG2a Negative control, Plasma cells and IgG1 Negative control and visualised by 
APAAP and New Fuschin substrate to establish cellular infiltrates within the muscle 
section.  From consecutive staining experiments from these serial sections no CD20+ or 
plasma cells were observed within these sections, therefore no further analysis was 
conducted.  Images at 400X. 
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3.3 Discussion 
Identification and characterisation of B cells and plasma cells within the muscle 
infiltrating inflammatory population of cells was the main objective of the work 
presented in this chapter, this would allow further experiments to establish the 
Ig gene rearrangements expressed on muscle infiltrating B cells and plasma 
cells and determine if these cells were being locally stimulated within the 
muscle by assessing the somatic hypermutation and clonal diversification 
mechanisms.  As well as these initial experiments to identify B cells, additional 
cell markers and double immunohistochemical experiments were conducted to 
identify and characterise follicular dendritic cells, macrophages, various T cell 
subsets and proliferating cells.  The results of this chapter demonstrate that 
CD20+ B cells and plasma cells were a substantial part of the muscle infiltrating 
population but that the infiltration of these cells as well as the other cell 
phenotypes identified was different between patients and myositis subsets. 
 
Characterisation of inflammatory infiltrates in different myositis subsets have 
previously been established (87-89;297;298) with continuous studies facilitating 
the classification of muscle infiltrating populations to improve the understanding 
in the role of these cells within the disease mechanisms of the inflammatory 
myopathies.  The current study supports the traditional observations as well as 
implicating additional roles for newly classified cells subsets, based on recent 
studies, of cellular infiltrates within inflammatory myopathies.  Identification of 
proliferating cell phenotypes within the muscle disorders may also indicate the 
active participation of these cells in the pathogenesis of these disorders. 
 
Unlike other studies investigating ectopic germinal centre type responses and 
the stimulation of B cells within the target tissues of various autoimmune 
disorders, such as MG (52), SS (283) and RA (284), no characteristic germinal 
centre type structures were observed within this study.  Previous studies in 
muscle have not reported these structures and infiltrates, as previously 
described in Chapter 1, localise between or around muscle fibres either at 
perivascular, perimysial or endomysial sites depending on the myositis subset.  
Cellular infiltrates within this study were found to either form dense follicles of 
cells or loose aggregations, either perimysial or endomysial depending on the 
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myositis subset, with no distinct structure or pattern and additional scattered 
staining throughout the entire sample. 
 
In the current study B cells were found to constitute a significant component of 
the inflammatory infiltrate in all samples examined, regardless of the myositis 
subset.  These cells were either in their CD20+ B cells state or differentiated 
plasma cell state and some of the CD20+ B cells were found to be proliferating 
within the muscle.  The heaviest infiltration of CD20+ B cells were found in 
samples MYO1 and MYO16 corresponding to the diagnosis of these patients 
(Table 2.1).  Both patients had a diagnosis of DM where larger populations of B 
cells are generally found in comparison to PM and IBM, as previously described 
in Chapter 1.  Although at smaller and limited populations, CD20+ B cell 
populations were observed in the majority of the patients who were diagnosed 
as PM and/or IBM.  In 4 of these patients proliferating CD20+ B cells were also 
observed which may indicate their active participation in an immune response.  
 
In addition to these correlations plasma cells were evident within all samples of 
this study in varying degrees, regardless of the myositis diagnosis implicating a 
role for these variant B cell derived cells within these disorders.  These results 
concur with recent studies further characterising inflammatory infiltrates within 
the myositis subsets as well as microarray studies which identified Ig 
transcripts, only transcribed in B cells and their progeny, in IBM and PM 
(89;299;300).  Although B cells were identified in DM biopsies in earlier studies 
with very few present in PM and IBM (87;88), plasma cells were not identified in 
these studies for either myositis subset.  The presence of plasma cells within 
inflammatory infiltrates was only recently studied in PM and IBM.  Greenberg et 
al (89) identified few or no B cells within the infiltrating cell repertoire of 
inflammatory myopathies but did demonstrate the presence of CD138+ plasma 
cells in the IBM and PM samples, confirmed by sequence analysis of Ig V-
genes expressed by single laser dissected cells.  These studies show that in 
IBM and PM plasma cells outnumber B cells by a factor of 4.  A greater 
infiltration of plasma cells was observed within IBM samples in comparison to 
PM samples.  It was also calculated that IBM had a mean of 0.84 times as 
many B cells and 4.3 times as many plasma cells compared to untreated 
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patients with DM.  The numbers of CD138+ plasma cells were also found to be 
smaller than the number of CD3+ T cells.  Recent studies have demonstrated 
the occurrence of autoantibodies in IBM reactive to a muscle constituent 
suggesting the involvement of a humoral immune response (97).  The role of 
these plasma cells in this humoral immune response remains unclear.  Despite 
implicating the participation of plasma cells in inflammatory myopathies the 
study did not show if plasma cell antibody production was a primary effector 
mechanism for muscle damage, any antigen specificity of the response and 
where the maturation of B cells into these plasma cells occurs.  A question 
therefore remains on the role of these matured B cells within inflammatory 
myopathies.  As plasma cells traditionally reside and secrete antibodies from 
the bone marrow (1) the presence of these cells within inflamed muscle may 
suggest an active pathological mechanism in these disorders, but why these 
cells locate to the inflamed muscle remains unresolved.  Further studies would 
establish if non-specific infiltration of these cells occurs due to the formation of a 
suitable niche as a result of the inflammatory reaction, if antigen-specific cells, 
plasmablasts, are recruited and mature within the inflamed muscle or if 
complete ectopic germinal centre type responses occur within the muscle 
resulting in selection, diversification and maturation of B cells within the muscle. 
 
The main objective of this study was to establish if B cell antigen-driven 
responses were occurring within inflamed muscle, reactions similar to germinal 
centre responses characterised by Ig gene selection, SHM and clonal 
diversification.  For such reactions a population of FDCs would be expected 
similar to that observed in other studies of ectopic germinal centre responses 
(52;283;284) in order for antigen presentation and activation of high affinity B 
cells.  Very few FDCs were identified within the samples of the current study; 
immunohistochemical analysis only identified these cells in 4 myositis patients 
within the study and demonstrated no distinct relationship with other cell types.  
These patients were diagnosed within PM or IBM and not DM where B cells are 
traditionally thought to play a greater role compared to PM and IBM.  These 
findings may implicate that additional cell phenotypes substitute and take over 
the antigen presenting role of FDCs in muscle inflammatory reactions or may 
suggest that antigen-driven, germinal centre responses may not be occurring 
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within the target tissue of these myositis disorders although somatic mutation 
and activation of autoreactive B cells has been found to occur outwith the 
germinal centre response (301). 
 
While the main intention of the work presented in this chapter was the 
identification of B cells and plasma cells in the muscle, additional cell 
phenotypes were also studied to examine the complexity of the immune 
response.  Within myositis subsets CD8+ cells are largely found in IBM and PM, 
demonstrating an endomysial pattern of infiltration while CD4+ cells are 
generally characteristic of DM and display a perivascular/perimysial pattern of 
infiltration (87;88).  In this study CD3+, CD4+ and CD8+ cells, some proliferating 
(Ki67+), were found in all autoimmune disorders studied and generally 
correlated with previous studies.  CD4+ cells are known to function through 
molecular mechanisms during contact with antigen presenting cells, in particular 
activation and maturation of B cells and production of cytokines while the 
function of CD8+, cytotoxic, cells is largely undefined.  These cells induce cell 
death, which is largely absent from muscle biopsies (302), through Fas, perforin 
and granzyme mechanisms.  Perforin has been implicated in the pathogenesis 
of myositis with an increased expression in DM and PM compared to controls 
(85).  In this study an additional subset of infiltrating T cells was examined, 
FoxP3+ regulatory T cells (Tregs).  The exact mechanisms of these cells are 
unknown but they are believed to play a pivotal role in controlling immune 
responses, maintenance of T cell homeostasis and controlling organ-specific 
autoimmune disorders.  This T cell subset has not been extensively studied in 
inflammatory myopathies and the results of this chapter demonstrate that they 
are largely absent from the muscle infiltrating population.  A considerable 
infiltration of these cells was only evident in 1 myositis specimen (MYO1, Figure 
3.1) while a limited population were evident in 1 other patient (MYO24, Figure 
3.21).  Studies have occurred within other systems and have suggested that 
regulatory T cells may affect the maturation and antigen presentation capacity 
of DCs (27) and have also been shown to be defective in SLE patients (43).  A 
novel type of regulatory T cells, CD4+ CD57+ FoxP3-, has recently been 
reported in germinal centres of human tonsil tissues (303) and found to 
enhance the survival of GC B cells and have suppressive effects on 
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conventional CD4+ CD57- T cells; an 80% reduction in cellular proliferation was 
observed.  This collection of results established the dual role of CD4+ CD57+ T 
cells in promoting germinal centre B cell responses while suppressing 
conventional T cell responses.  The presence or absence of regulatory T cells 
from inflammatory populations in muscle may play a role in the mechanisms in 
the muscle but additional studies would be required.     
 
Although exact figures of cellular infiltrations were not calculated, some samples 
appeared to have greater staining for CD3+ and CD4+ cells in comparison to 
CD8+ staining, regardless of the diagnosis.  This is in contrast to previous 
studies where a larger population of CD8+ cells were observed in PM and IBM 
(87;88).  In some cases CD4+ cells were more abundant than CD3+ cells which 
is clearly illustrated for samples MYO3 (Figure 3.5), MYO7 (Figure 3.11) and 
MYOC (Figure 3.23).  This correlates with other studies investigating cellular 
infiltrates in autoimmune inflammatory reactions (297).  These studies have 
demonstrated that these CD4+ cells may not all be the predicted CD4+ T helper 
cells and may in fact be plasmacytoid dendritic cells (PDCs) which may be an 
important component in the myositis pathological mechanisms.  While 
conventional or myeloid DCs are potent antigen-presenting cells and assist the 
adaptive immune response, PDCs play an important role in the innate immune 
response and are capable of producing interferon-α/β in quantities 200-1000 
fold greater than other cell types which stimulates production of intracellular 
proteins capable of providing defence against pathogens (298).  Greenberg et 
al (297) identified and studied CD123+ BDCA-2+ IFN-α+ PDCs in DM muscle 
specimens and implicated these cells to the pathophysiology of DM.  These cell 
types were abundant in 10 of 14 DM patients and were also present in muscle 
sections that lacked inflammatory cells with standard hematoxylin and eosin 
stains in routine clinical histopathological studies.  These immunohistochemical 
results demonstrate that infiltrating PDCs are characteristic of DM.  An 
upregulation of 86% of interferon-α and –β inducible genes was also observed 
in DM patients compared to 15% in other inflammatory myopathies in addition 
to the identification of MxA, an interferon-α/β-inducible protein in DM patients.  
These interferon signatures have recently been observed in peripheral blood 
samples of DM patients (304;305) and were also observed in PM patients in 
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one study (305).  Qualitative analysis of 14 DM patients showed that 13 of these 
patients produced greater expression of CD4 compared to CD3.  The study 
showed that there were approximately 5.3 times more CD4+ cells than CD3+ 
cells, suggesting that PDCs account for at least 30-90% of CD4+ cells and they 
outnumber CD4+ T cells by at least a factor of 2.  More recent studies (306;307) 
identified these cells within the skin of DM patients.  Wenzel et al (306) used 
anti-CD123 monoclonal antibodies and MxA to analyse the PDC infiltrating DM 
skin lesions and established that there was a significant increase of MxA 
expression in the epidermis and in the inflammatory infiltrate.  CD123+ cells, 
with plasmacytoid morphology, were found to heavily infiltrate the DM skin 
lesions compared to low levels observed in normal samples.  McNiff et al (307) 
also identified PDCs within skin lesions of DM patients and established that this 
pattern was distinct from that observed in lupus erythematosus.  Recently DCs 
have been identified in IBM, in addition to DM and PM (298), as well as in 
Juvenile DM (308).  Greenberg et al (298) identified BDCA-1 positive cells 
(myeloid DCs) in IBM and PM specimens, widely distributed as well as loose 
aggregations of cells.  Loose aggregations of cells were typically endomysial, 
which surrounded or invaded myofibres.  Very few PDCs (BDCA-2 positive) 
were observed in these cell aggregations, myeloid DC numbers were 3 fold 
higher than that of PDCs.  Similar numbers of myeloid and plasmacytoid cells 
were observed in perivascular and perimysial locations.  Conversely in DM PDC 
numbers were 16 fold and 3 fold higher than myeloid DCs in endomysial and 
perivascular sites respectively.  The precise role of DCs in inflammatory 
myopathies and other disorders has yet to be fully established.  Myeloid DCs 
are generally believed to return to lymph nodes where they present antigen and 
activate, or suppress, helper T cells.  PDCs are thought to have an 
immunomodulation role but have also been shown to act as antigen presenting 
cells (309) and have been shown to be critical for the generation of plasma cells 
and antibody responses (310), which may play a significant role in the 
pathophysiology of inflammatory myopathies.  
 
The PDCs from Greenberg et al (297;298) were characterised as CD4+, CD68+, 
CD123+ and BDCA-2+ but CD68 was used as a cellular marker for infiltrating 
macrophages within this study therefore no definitive distinction can be made 
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between the two cellular phenotypes in this study.  Further clarification of these 
cells types, with the use of additional cell markers, would be required to fully 
establish and evaluate the impact of both cell phenotypes on inflammatory 
myopathies.  Double immunohistochemical studies within the current study 
demonstrated the presence of proliferating CD68+ cells in some myositis 
patients, suggesting an active participation in the immune response.  Previous 
studies (311) have found increased numbers of proliferating alveolar 
macrophages were observed in DM, PM patients as well as in systemic 
sclerosis patients compared to healthy volunteers.  Recently macrophages in 
the lesion areas of atherosclerosis and RA patients have been found to express 
granzyme B, a cytotoxic protein thought to contribute to muscle pathology 
commonly found in CD8+ T cells (312).  A recent study has also demonstrated 
that human B cells can transfer BCR-targeted antigen to human macrophages 
and that the macrophages were able to capture B cell-derived membrane 
and/or intact intracellular proteins along with the antigen by a mechanism other 
that phagocytosis which is mediated by SR-A, class A scavenger receptors 
(313).  The study postulates that this transfer of antigen from specific B cells to 
other APCs results in a more focused immune response and may indicate a 
possible immune mechanism within inflamed muscle.   
  
Although characterisation of the muscle infiltrating populations provides 
valuable insights into inflamed muscle immune reactions, the effects of therapy 
on the inflammatory infiltrates needs to be considered.  Under ideal conditions 
muscle specimens would be obtained from patients who had not received 
immunomodulatory therapy but as shown in Table 2.1 various patients were 
receiving various therapies at the time of biopsy which may alter the infiltration 
of inflammatory cells in muscle or the degree of muscle pathology observed 
within the specimens.  As described in Chapter 1 statin therapy has been found 
to contribute to muscle pathology (49;69;70), although the mechanism of this 
has not been determined.  Patients MYO24 and MYOC were both receiving 
statin therapy which may impact on the degree of muscle damage as well as 
the degree of cellular infiltration.  The degree of muscle damage observed in 
sample MYO24 was found to exceed the damage observed by statin therapy, 
as observed by the reporting pathologist.  Within the same report the non-
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conspicuous infiltrate observed in this sample was attributed to the steroid 
therapy, 120 mg prednisolone intra-muscular injection.  Corticosteroid therapy 
suppresses both cell-mediated and humoral immunity.  In humoral immunity 
corticosteroids have been shown to reduce Ig concentrations (314;315) as well 
as influence the function of various cell phenotypes including PDCs and T cells 
(316).  The use of steroid therapy could reduce or alter the cellular infiltrates 
observed within muscle inflammation and alter the true heterogeneity of the 
immune reactions.  In this study 8 patients (MYO 5, 19, 23, 24, C, E, 2, 18) 
were receiving steroid therapy at the time of biopsy.  Despite the influence of 
therapy significant inflammatory infiltrates, in particular B cells and plasma cells 
were observed in a number of these samples (MYO5, 19, 23, C, E).  Other 
immunosuppressive therapies, such as methotrexate, may also disguise the 
true heterogeneity of the response.  Underlying medical conditions and family 
history may also play a role in the results presented in this chapter.  3 of these 
patients (MYO3, 24, D – Table 2.1) had underlying carcinomas while patient 
MYO19 was treated for inflammatory synovitis.  Patient MYO5 also had a 
background of Sjögrens syndrome and a strong family history of autoimmune 
disease which may come into play while assessing the mechanism of the 
muscle inflammation observed within such patients.  A final consideration would 
be the area selected for biopsy, due to the large area affected by the 
inflammation and the small specimen obtained for diagnosis and these studies, 
considerable difference may be observed between different muscle sites.      
  
To summarise, the work presented in this chapter demonstrates that B cells and 
their differentiated counterpart’s plasma cells are substantial within the 
infiltrating inflammatory population of myositis disorders.  The characterisation 
of proliferating B cells may indicate the active participation of these cells in the 
muscle response.  B cells and plasma cells were identified in association with a 
number of additional cell phenotypes, illustrating the complexity of immune 
reactions within muscle.  The identification of B cells and plasma cells within 
these samples allowed further work to be conducted to determine if B cells play 
an active role in antigen-driven responses within the inflamed muscle.     
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Chapter 4 - VH-Gene Repertoire and Clonal Diversification of Muscle 
Infiltrating B Cells in Myositis 
4.1 Introduction 
As previously discussed in Chapter 1, the role of B cells and plasma cells, and 
the antibodies they produce, in the autoimmune disease of myositis is still 
unresolved although B cells have been thought to contribute to the pathological 
immune response at these sites of inflammation.  The work conducted in 
Chapter 3, in addition to previously published work, classified the phenotypes of 
infiltrating cells in the inflammatory reactions of myositis of which B cells, and 
their differentiated counter-parts plasma cells, were prominent.  Despite the 
presence of these cells within the inflammatory infiltrate no characteristic 
germinal centre formations, the typical sites of somatic hypermutation and 
clonal diversification, were observed at these ectopic sites.  What remains 
unclear is the role of these B cells and plasma cells within the inflammatory 
infiltrate; therefore the work of this chapter aims to establish a role for these 
cells within myositis samples.  To determine if infiltrating lymphocytes were 
being stimulated locally to respond to an endogenous antigen resulting in tissue 
damage, areas of significant B cell and plasma cell infiltration established in 
Chapter 3 were microdissected from tissue sections.  The rearranged Ig gene 
amplification from the DNA of these cells was used to address the following key 
aims of the chapter; 
 
• Establish the Ig gene repertoire of infiltrating B cells and plasma cells to 
determine if positive, or negative, gene selection was occurring within 
infiltrating cells. 
• Analyse VH gene point mutations (number, location and category) to 
establish if clonally related B cells, with shared VDJ and CDR3 
sequences, are present within the muscle inflammatory infiltrate 
undergoing an antigen-driven B cell response. 
 
For the results of this chapter the patients were studied individually in addition 
to collective myositis analysis.     
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4.2 VH Repertoire and Sequence Analysis in Myositis 
4.2.1 Sample MYO1 
4.2.1.1 VH Gene Repertoire of Infiltrating B Cells from MYO1 
B cell aggregates from frozen sections from sample MYO1 were microdissected 
and the Ig rearrangements were amplified by nested PCR (Figure 4.1), cloned 
and sequenced.  Over 150 sequences were analysed from the 6 different 
regions of cellular infiltration observed and the best matching germline genes 
were identified (Table 4.1).  The gene usage distribution of functional gene 
rearrangements was analysed from 57 sequences as multiple copies of genes 
arose within the same regions of cellular infiltration (Figure 4.2).  Using 
absolute values in Chi square analysis, significant selections were observed for 
VH2 and VH3 genes against the normal control values (Figure 4.2A). No other 
selections were observed against normal control values or the germline 
composition.  Despite the selection for VH2 and VH3 genes, the VH gene 
distribution followed the distribution pattern of that described in the normal 
control data, VH3>VH4>VH1>VH2>VH5>VH6>VH7 (251).  DH gene assignments 
were conducted as described in section 2.3.12.3, V-J lengths and consecutive 
D match lengths are shown in Table 4.1.  DH genes could be assigned to 66.7% 
of the sequences isolated from sample MYO1.  Comparing the distribution of 
these genes to both the normal control values and the germline composition 
demonstrated that there was no selection for or against any DH gene families 
(Figure 4.2B).  Selections against JH1 and JH2 genes were observed within the 
sequences (Figure 4.2C), but these were only significant against the germline 
composition.  Analysis of the JH gene usage compared to normal control values 
revealed no positive or negative JH gene selections within the infiltrating 
repertoire.    
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Before Microdissection After Microdissection 
A 
B 
C 
400 bp 
400 bp 
VH1 VH2 VH3 
VH4 VH5 VH6 
_ 
MYO 
1 + 
_ 
MYO 
1 + 
_ 
MYO 
1 + 
Figure 4.1 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO1 
 
Six areas of B cell and plasma cell infiltration were microdissected from sample MYO1.  
Figure 4.1A and B demonstrates the microdissection of 2 regions of cellular infiltration.  
Images were taken at 400X.  DNA released from these microdissections was amplified 
using a Nested PCR system (Figure 4.1C), as previously described in Chapter 2.  – 
indicates negative control PCR reactions where DNA was substituted with water while + 
indicates positive control PCR reactions using peripheral blood mononuclear cells isolated 
from peripheral blood of a healthy individual.  Results show amplification of all 6 VH families. 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches)  
1 1-46*01 3-10*01 5*02 1 1 ARSVWFRELLEVQNWFDP 33 18(+1) 
 3-07*01 No D gene Assignment 6*02 1 12 AREGKEGYGMDV 12 10(+3) 
 3-23*01 5-12*01 3*02 1 0 AKGGGYDWGDDAFDI 24 12 
 3-30*04 4-17*01 3*02 1 11 AKDFGYDYGDYLYDAFDI 34 16 
 3-43*01 3-10*01 5*02 (1) 1 AKDPYSGSYYATGST 28 22 
 3-48*01 3-22*01 3*02 (1) 0 ARGSMVL**WDLI 27 12 
 3-66*01 No D gene Assignment 6*02 1 0 ARERALYYYGMDV 10 5 
 4-39*01 No D gene Assignment 4*02 1 0 ARHGLSEPYQQPPGYRFDY 40 12(+3) 
 4-59*01 3-22*01 5*02 (1) 0 ARA*TYYYDSSGYYSTTGST 38 29 
 4-59*01 6-13*01 6*02 1 2 ARHGKKQQLTRNYYYGMDV 28 11 
 5-51*03 No D gene Assignment 6*02 1 27 VRHAPYYFYGMDV 22 5 
         
2 3-09*01 6-13*01 4*02 (1) 0 AKDIPF*GIAAAGTLPPPGTS*L 53 20 
 3-33*01 3-22*01 4*02 4 10, 11, 11, 12 AREFYDTSGYWEDC 33 19(+1) 
 4-59*01 1-1*01 5*02 1 0 ARVLYNWNGGFGRFDP 30 13 
         
3 3-30*04 No D gene Assignment 3*02 (1) 29 AIDRLAG* 17 7 
 3-30*04 No D gene Assignment 4*02 4 11, 12, 12, 14 ARDRRGGWEGYFDY 21 6 
 3-30*04 No D gene Assignment 4*02 (1) 13 ARDRGGGMGGLL*L 22 8 
 3-30*04 No D gene Assignment 6*01 1 11 ARDR 3 6 
 3-30*04 No D gene Assignment 6*01 1 11 ARDRRGG 13 6 
         
4 2-05*01 No D gene Assignment 2*01 1 0 AHSRARLEGYFDL 17 6 
 3-07*02 6-19*01 6*02 2 12, 13 ARDLGSSGWHVNPEMFYYHAMDV 54 13 
 4-04*02 No D gene Assignment 4*02 1 19 ARGQLGNFDS 22 8 
 4-31*03 3-22*01 5*01 1 8 ARGNYDMTSDS 20 9 
 5-a*01 4-23*01 5*01 1 10 ARHGADYGGNPEGFDS 31 15 
         
5 1-46*01 1-26*01 4*02 1 0 ARTRIVGATRSIDY 32 18 
 1-69*04 1-26*01 4*03 1 0 ARTRIVGATRSIDY 32 18 
 1-69*04 3-16*02 4*02 1 0 ARDVWEIFGSGSYPYFDY 34 10 
 1-69*09 3-16*02 4*02 1 0 ARDVWEIFGSGSYPYFDY 34 10 
 2-05*10 1-1*01 5*02 2 20, 21 AHRLGGYSWNDGWFDP 31 14(+1) 
 2-05*01 No D gene Assignment 6*02 2 7, 8 ARREFSWGMDV 17 7 
 3-15*01 3-10*01 4*02 4 11, 12, 13, 13 TTDTRPRLGEFFYFWVGYFDP 54 10 
 3-23*01 No D gene Assignment 6*02 2 33, 44 VKNSGSGKPYYYAMDV 37 7 
 3-30*03 6-19*01 4*02 2 0, 1 AFSDNSGYHN 25 11(+1) 
 3-30*04 3-3*01 4*02 2 0, 1 ARDVHDFWSGYHFDY 26 19 
 3-48*02 2-21*01 3*02 1 0 ARDYPDCGGDCSPYDAFDI 33 18 
 3-66*01 2-21*01 3*02 2 26, 31 ARDYPDCGGDCSPYDAFDI 33 18 
        
 
Cont… 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
6 1-08*01 2-8*02 6*02 1 0 ARGRYCTGGVCYRDASYYYYGMDV 42 27 
 1-18*01 No D gene Assignment 6*02 1 15 ARTQTPDLYAIFGHYYGMDV 40 10(+1) 
 2-05*01 3-3*01 4*02 (1) 12 AHILAYYDFCSA*SPLLALT 54 15 
 3-11*03 4-17*01 6*02 2 0, 1 ARDKPYGDSRNNWYYYYYGMDV 33 11 
 3-23*01 1-26*01 4*02 1 0 AKDEGWVVGATKAPFDY 33 15 
 3-30*03 6-19*01 4*02 1 0 AKLGSYNSGRDY 25 11 (+1) 
 3-49*03 2-2*01 4*02 1 17 TRGNHLYCSSHSCYWDS 48 21(+4) 
 4-b*02 No D gene Assignment 5*02 1 14 ARDDLPIRFDP 16 5 
 4-04*02 No D gene Assignment 4*02 1 5 ARVTTGFFFDY 18 7 
 4-59*01 5-12*01 5*02 1 17 ARQGTVGSAYSGSDP 35 14(+1) 
 4-59*01 6-19*01 6*02 1 5 ARRRGGWYSSGHRGNYGMDV 37 14 
 
 
 
 
 
 
In addition to determining the gene assignments using the JOINSOLVER 
software, the IMGT/V-QUEST algorithm was also used to verify the gene 
assignments for this sample as well as all other samples in the study.  For the 
majority of sequences the gene assignments matched the JOINSOLVER 
software but in some cases IMGT/V-QUEST determined a different match for 
part of the gene rearrangement or detected deletions or insertions within the 
sequence altering the gene assignment (Appendix 1).  In cases where 
JOINSOLVER was unable to assign a D gene with statistical significance the 
region was also examined using the IMGT/V-QUEST software but no additional 
D gene assignments could be made with confidence.  In contrast to 
JOINSOLVER, IMGT/V-QUEST failed to find a rearrangement for the sequence 
in region 3 using VH3-30*04 (CDR3-ARDRRGG) and was only able to identify 
the same VH gene segment.  Also in region 3 with another Ig using the VH3-
30*04 (CDR3-ARDR) IMGT/V-QUEST categorised this sequence as non-
functional and was not able to identify any D gene segments.  In region 5 for the 
Ig using the VH1-69*09 DH3-16*01 JH4*02 rearrangement IMGT/V-QUEST 
assigned the D gene as 3-10*01 which was the 2nd highest matching score in 
Table 4.1 Heavy chain genes identified from myositis sample MYO1 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from regions 1 to 6 within the MYO1 myositis section.  The total 
number of sequences isolated is given in the 5th column of the table; non-functional rearrangements 
indicated in brackets.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were 
only counted once.  CDR3 amino acid sequences were also identified using the JOINSOLVER 
software; * indicates the presence of a stop codon within the CDR3. V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of 
the DH genes as described in section 2.3.12.3.    
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JOINSOLVER but DH3-16*01 had a higher consecutive match.  If mismatches 
were incorporated into the analysis of the DH3-10*01 gene it would have a D 
consecutive match length of 14 with 1 mismatch which may therefore indicate 
that the DH3-10*01 gene should be assigned although no mismatch analysis 
had to be conducted on the DH3-16*01 gene for it to be statistically assigned.  
The DH3-16*01 gene was not identified in the top 5 matched using the IMGT/V-
QUEST software.  Also IMGT/V-QUEST assigned the JH segment as 2P*01 but 
also suggested the gene segments of 6*01 and 6*02, these genes were found 
to be outwith the 6 best matching genes in JOINSOLVER with the 6*01 and 
6*02 genes generating negative alignment scores.  The 4*02 gene segment 
identified by JOINSOLVER was the 4th best matching gene in IMGT/V-QUEST.  
For the Ig rearrangement VH3-15*01 DH3-10*01 JH4*02 in region 5 both 
JOINSOLVER and IMGT/V-QUEST identified two JH genes that could possibly 
be assigned to the rearrangement, 4*02 and 5*02.  In JOINSOLVER and 
IMGT/V-QUEST the 4*02 gene had a score of 195 while the 5*02 gene had a 
score of 192.  Although the 5*02 gene had a greater number of consecutive 
matches both sequences exhibited a higher number of germline matches 
therefore either gene could be assigned, mismatches could be interpreted as 
mutations.  Insertions and deletions were detected in Ig rearrangement VH3-
23*01 DH3-10*01 JH6*02 with 44 mutations.  Once these had been resolved the 
gene rearrangement was revealed to be non-functional in IMGT/V-QUEST with 
the same gene assignments but with 34 mutations. 33 of these mutations were 
common between this sequence and the other sequence with the same gene 
rearrangement shown in Table 4.1 but an additional silent mutation was 
observed in codon 88 at the 3rd nucleotide position.  A deletion was also 
detected in the CDR2 for both sequences with the VH3-66*01 DH2-21*01 JH3*02 
in region 5.  Once the deletions had been restored the Ig rearrangement 
obtained was VH3-48*02 DH2-21*01 JH3*02 in both the JOINSOLVER and 
IMGT/V-QUEST software although IMGT/V-QUEST also determined the JH 
segment may also be assigned as JH6*02 which exhibited a higher consecutive 
match in IMGT/V-QUEST.   These sequences contained 1 and 11 mutations 
with no common mutations between the sequences.  
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Figure 4.2 VH Gene Family Usage of MYO 1 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal control values; * represent a significant difference from the germline (p<0.05).  
 
A 
B 
C 
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4.2.1.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO1 
Numbers of mutations within the VH gene segment of the functional gene 
rearrangements were analysed (Figure 4.3A).  Results demonstrate that 
approximately 30 to 40% of sequences are virtually non-mutated with only 0 to 
2 mutations within the VH segment of the gene rearrangement while a further 30 
to 40% contains 11 to 20 mutations within the VH segment.  Sequences 
containing 3 to 10 and over 20 mutations were found in approximately 10% of 
the infiltrating cells respectively.  In addition to mutational numbers, the location 
of mutations was analysed between Framework regions (FR) and 
Complementarity Determining Regions (CDR) regions (Figure 4.3B).  The 
number of mutations in each segment was expressed as a percentage of the 
total length of the segment.  Results demonstrate a higher percentage of 
mutations within CDR regions compared to framework regions for rearranged 
genes.  A higher percentage of mutations were observed in CDR1 compared to 
CDR2. 
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The type of mutations, replacement and silent, in the VH gene segment of the 
immunoglobulin gene were also analysed (Table 4.2), according to the revised 
method by Hershberg et al (294) described in section 2.3.12.3.  This updated 
A 
B 
Figure 4.3 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO1 
 
Figure 4.3A - The number of mutations 
within functional rearranged genes were 
analysed collectively from all 6 regions of 
cellular infiltration.  Base differences 
within the first 24 bases of sequence 
were disregarded as this part of the 
sequence binds the 5’ VH primer.  Graph 
demonstrates sequences within cellular 
infiltrates show a diverse distribution of 
mutational numbers. 
 
 Figure 4.3B - The locations of mutations 
observed within functional rearranged 
genes were categorised as being within 
FR or CDR regions.  The numbers of 
mutations within these regions were 
expressed as a percentage of the entire 
length of the region to correct for the 
longer lengths observed within the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR regions compared to framework 
regions. 
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analysis determined if positive or negative mutational selections were occurring 
within each sequence of the infiltrating repertoire.  A significant selection was 
only observed in 8 of the sequences from all 6 regions.  The only sequence 
which demonstrated selection in the CDRs was a non-functional rearrangement 
in region 3; results revealed a negative selection within the CDR.  All remaining 
sequences with a significant selection also demonstrated negative selection but 
in these sequences the negative selection was observed in the framework 
regions of the sequences. 
 
4.2.1.3 CDR3 Analysis 
Analysis of the VDJ junctional area within the sequences demonstrated that the 
mean amino acid CDR3 length within functional sequences was 15.3 ± 0.5 
(ranging from 4 to 24 amino acids) which was not significant against the non-
functional repertoire (ranging from 8 to 23 amino acids) (Table 4.3).  The CDR3 
length was also analysed in relation to the number of VH mutations observed 
within the sequence (Figure 4.4). The average CDR3 length was calculated for 
sequences in particular mutational ranges, as previous studies have shown a 
reduced CDR3 length in highly mutated sequences (238).  For this sample no 
significant changes in the CDR3 length were observed for the different 
mutational groups.  The numbers of P and N nucleotides at the VD and DJ 
junctions were also analysed (Table 4.3), from the sequences isolated in this 
sample no significant difference in these nucleotides was observed between the 
functional and non-functional sequences.  There was also no significant 
difference in the numbers of P and N nucleotides between the VD region of the 
junction and the DJ region.  Exonuclease activity at the 3’ of the VH gene 
segment was shown to be significantly lower from the 5’DH and 5’JH 
exonuclease activity in the functional repertoire.  No significant differences in 
exonuclease activity between the functional and non-functional repertoires were 
observed at any point of the junction. 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1 1-46*01 3-10*01 5*02 1 1 0 0 0.47626 -0.52374 0 1 0.674002 -0.326 
 3-07*01 No D gene Assignment 6*02 1 12 4 2 0.44397 0.988952 3 3 0.670119 -0.1031 
 3-23*01 5-12*01 3*02 1 0 - - - - - - - - 
 3-30*04 4-17*01 3*02 1 11 6 0 0.47645 0.141781 3 2 0.672622 -0.7284 
 3-43*01 3-10*01 5*02 (1) 1 0 0 0.45644 0 1 0 0.678704 0.6787 
 3-48*01 3-22*01 3*02 (1) 0 - - - - - - - - 
 3-66*01 No D gene Assignment 6*02 1 0 - - - - - - - - 
 4-39*01 No D gene Assignment 4*02 1 0 - - - - - - - - 
 4-59*01 3-22*01 5*02 (1) 0 - - - - - - - - 
 4-59*01 6-13*01 6*02 1 2 0 0 0.44001 -0.31358 0 2 0.656452 -0.118 
 5-51*03 No D gene Assignment 6*02 1 27 6 2 0.43118 -0.66779 11 8 0.700775 -0.0924 
 
        
 
   
 
2 3-09*01 6-13*01 4*02 (1) 0 - - - - - - - - 
 3-33*01 3-22*01 4*02 4 10 3 1 0.46759 -0.6274 2 4 0.673935 -0.0473 
 
    11 3 1 0.46759 -0.44768 2 5 0.673935 -0.0198 
 
    11 3 1 0.46759 -0.6274 3 4 0.673935 -0.0982 
 
    12 3 1 0.46759 -0.44768 3 5 0.673935 -0.0453 
 4-59*01 1-1*01 5*02 1 0 - - - - - - - - 
 
        
 
   
 
3 3-30*04 No D gene Assignment 3*02 (1) 29 2 3 0.47645 -0.02004 16 8 0.672622 -0.3824 
 3-30*04 No D gene Assignment 4*02 4 11 2 3 0.47645 -0.34645 4 2 0.672622 -0.1747 
 
    12 3 3 0.47645 -0.59353 4 2 0.672622 -0.1747 
 
    12 2 3 0.47645 -0.22438 4 3 0.672622 -0.0883 
 
    14 3 3 0.47645 -0.59353 6 2 0.672622 -0.3876 
Cont… 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
 3-30*04 No D gene Assignment 4*02 (1) 13 2 3 0.47645 -0.34645 6 2 0.672622 -0.3876 
 3-30*04 No D gene Assignment 6*01 1 11 2 3 0.47645 -0.34645 4 2 0.672622 -0.1747 
 3-30*04 No D gene Assignment 6*01 1 11 2 3 0.47645 -0.34645 4 2 0.672622 -0.1747 
 
        
 
   
 
4 2-05*01 No D gene Assignment 2*01 1 0 - - - - - - - - 
 3-07*02 6-19*01 6*02 2 12 6 2 0.44221 0.338457 2 2 0.668099 -0.1162 
 
    13 6 2 0.44221 0.338457 3 2 0.668099 -0.2156 
 4-04*02 No D gene Assignment 4*02 1 19 6 2 0.43349 0.8366 6 5 0.665093 -0.1415 
 4-31*03 3-22*01 5*01 1 8 3 0 0.43271 0.253968 4 1 0.653402 0.55407 
 5-a*01 4-23*01 5*01 1 10 1 2 0.45272 -0.1871 4 3 0.702728 -0.1197 
 
        
 
   
 
5 1-46*01 1-26*01 4*02 1 0 - - - - - - - - 
 1-69*04 1-26*01 4*03 1 0 - - - - - - - - 
 1-69*04 3-16*02 4*02 1 0 - - - - - - - - 
 1-69*09 3-16*02 4*02 1 0 - - - - - - - - 
 2-05*10 1-1*01 5*02 2 20 2 2 0.44387 -0.08592 9 7 0.6816 -0.1155 
 
    21 2 3 0.44387 -0.05531 9 7 0.6816 -0.0652 
 2-05*01 No D gene Assignment 6*02 2 7 4 1 0.44837 0.320677 1 1 0.681376 -0.2722 
 
    8 5 1 0.44837 0.185831 1 1 0.681376 -0.2722 
 3-15*01 3-10*01 4*02 4 11 5 1 0.43976 0.320397 4 2 0.659501 -0.6303 
 
    12 5 1 0.43976 0.320397 4 2 0.659501 -0.6303 
 
    13 5 1 0.43976 0.320397 5 2 0.659501 -0.8228 
 
    13 5 2 0.43976 0.505038 4 2 0.659501 -0.369 
 3-23*01 No D gene Assignment 6*02 2 33 9 6 0.45266 -0.45643 9 9 0.650002 -0.0071 
 
    44 9 6 0.45266 -0.28386 18 11 0.650002 -0.1018 
Cont… 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
 3-30*03 6-19*01 4*02 2 0 - - - - - - - - 
 
    1 0 1 0.46606 -0.53394 0 0 0.674321 -0.3257 
 3-30*04 3-3*01 4*02 2 0 - - - - - - - - 
 
    1 0 1 0.476452 
-
0.523548 
0 0 0.672622 
-
0.327378 
 3-48*02 2-21*01 3*02 1 0 - - - - - - - - 
 3-66*01 2-21*01 3*02 2 26 12 4 0.46522 0.340486 5 5 0.668169 -0.0208 
 
    31 15 3 0.46522 0.185352 6 7 0.668169 -0.0193 
 
        
 
   
 
6 1-08*01 2-8*02 6*02 1 0 - - - - - - - - 
 1-18*01 No D gene Assignment 6*02 1 15 6 2 0.47674 0.279322 6 1 0.688086 -0.8666 
 2-05*01 3-3*01 4*02 (1) 12 3 2 0.44837 0.807761 6 1 0.681376 -0.8999 
 3-11*01 4-17*01 6*02 2 0 - - - - - - - - 
 
    1 1 0 0.47238 0.472384 0 0 0.664488 0 
 3-23*01 1-26*01 4*02 1 0 - - - - - - - - 
 3-30*03 6-19*01 4*02 1 0 - - - - - - - - 
 3-49*01 2-2*01 4*02 1 17 5 2 0.44618 0.529547 8 2 0.663604 1.00709 
 4-b*02 No D gene Assignment 5*02 1 14 3 0 0.42687 0.474147 9 2 0.653301 0.26984 
 4-04*02 No D gene Assignment 4*02 1 5 1 0 0.44897 -0.74359 2 2 0.659438 -0.5379 
 4-59*01 5-12*01 5*02 1 17 4 3 0.44001 -0.18652 2 8 0.656452 -0.0003 
 4-59*01 6-19*01 6*02 1 5 1 1 0.44001 -0.50574 1 2 0.656452 -0.1343 
 
Table 4.2 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO1 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and the corresponding computer 
programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive or negative mutational selections within the sequence 
with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent 
mutations within the CDR respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while 
p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal 
test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of 
mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection.
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Functional 15.3 ± 0.5 CDR3 Length Non-Functional 16.1 ± 1.9 
 VD Junction DJ Junction 
Functional 0.6 ± 0.1 0.4 ± 0.1 P Nucleotide Non-Functional 1.4 ± 0.7 0.4 ± 0.4 
Functional 8.7 ± 0.8 7.7 ± 0.9 N Nucleotide Non-Functional 6 ± 1.5 10.2 ± 4.1 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.2 ± 0.2 5.6 ± 0.8 θ 4.7 ± 0.5 4.9 ± 0.6θ Exonuclease 
Activity Non-Functional 2 ± 0.7 2.2 ± 1.2 6.2 ± 2.9 4.6 ± 1.6 
 
Table 4.3 CDR3 and Junctional Analysis in Sample MYO1 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO1.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.  Θ represents a significant difference from 3’VH. 
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4.2.1.4 Clonal Diversification in MYO1  
 
Two clonally related sequences were identified in region 5 of sample MYO1 
(Figure 4.5A&B).  These sequences shared the same VDJ gene segments, the 
same CDR3 amino acid sequence, the same junctional sequences and also 
contained 14 common replacement mutations and 8 common silent mutations.  
Analysis of the common and independent mutations (Table 4.4) of these two 
clonally related sequences demonstrated that there was a significant negative 
Figure 4.4 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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selection within the framework regions of these sequences.  A positive selection 
was occurring within the CDRs but this was not significant.  As previously 
described, IMGT/V-QUEST detected deletions within these sequences, which not 
only changed the VH gene assignment but also the number of point mutations.  
Taking the sequence alignments and changes suggested by IMGT/V-QUEST 
indicates that these sequences would not be clonally related.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Germline3-66*01      GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC 
CloneA               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTTAGAGTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
                      
                         CDR1 
Germline3-66*01      TCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGATTCACTTTCACTAAGGCCTGGATGAACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
                      
                    ↓ AGT  CDR2 
Germline3-66*01      CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCA  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTACCATATACTACGCA  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTACCATATACTACGCA  
                      
 
Germline3-66*01      GACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTT  
CloneA               GACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTG  
CloneB               GACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTG  
                    
                           CDR3 
Germline3-66*01      CAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTACTGTGCGAGAGA 
CloneB               CAAATGAACAGCCTGAGAGACGAGGACACGACTGTGTATTACTGTGCGAGAGA 
 
 
 
 
 
 
 
 
3 (1) 
14 (8) 
A B 
7 (2) 
VH3-66*01 
Figure 4.5 Clonal Proliferation in Sample MYO1 
 
2 B cell sequences isolated from sample MYO1 demonstrated somatic hypermutation and clonal proliferation 
(A&B).  Figure A - The letters in the circles refer to individual sequences isolated from each B cell clone.  
Numbers indicate the minimum number of mutations required between each sequence with bracketed figures 
representing additional silent mutations.  The dashed circle represents a hypothetical intermediate whose 
sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the clonally 
related sequences were aligned using ClustalW software to highlight the common and independent mutations.  
CDR regions are highlighted in yellow, replacement mutations in blue and silent mutations in purple.  The 
sequence in red above the alignment within the CDR2 regions indicated the deletion detected by the IMGT/V-
QUEST software. 
A 
B 
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Table 4.4 Analysis of Replacement and Silent Mutations and Positive and Negative Selection 
in Clonally Related B Cells in Sample MYO1 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described in section 2.3.12.3 
and Table 4.2.  For clonally related sequences mutations shared across the sequences are only 
counted once and p values are calculated for the clone as a single entity. R-CDR/FW and S-
CDR/FW represent the number of replacement and silent mutations in the CDR and FW 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the 
mutations in the sequence except R mutations within the FW while pFW represents the probability 
of having a R mutation in the FW given all the mutations in the sequence except R mutations within 
the CDR and p-CDR/FW represent the p-value of the focused binominal test on the CDR and FW 
respectively.  A negative sign indicates negative selection.  p-values <0.05 are highlighted in yellow 
and were deemed significant. 
 
 
 
As shown in Table 4.1 a number of sequences demonstrated different mutational 
patterns but shared common gene segment usage and CDR3 and junctional 
sequences; these were not deemed to be clonally related as the rate of base 
changes fell within the PCR error rate of one base per 4 VH genes (52).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
17 4 0.46522 0.139067 7 7 0.668169 -0.0177 
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4.2.2 Sample MYO3 
4.2.2.1 VH Gene Repertoire of Infiltrating B Cells  
For sample MYO3 one large area of infiltrating cells was microdissected and 
amplification of VH1-6 families was carried out by nested PCR (Figure 4.6).  From 
the extensive region of infiltration in sample MYO3 sequence results produced 17 
functional sequences (Table 4.5) which showed a selection for VH1 gene 
segments, approximately 60% of the sequences isolated belonged to the VH1 
family, which was significant against both normal control values and the germline 
complexity (Figure 4.7A).  Figure 4.7A demonstrates an apparent reduced 
selection for VH3 and VH4 gene segments but this reduction was not significant 
against normal control values or the germline complexity when the absolute values 
were used in the Chi square analysis.  No gene segments were observed within 
the infiltrating repertoire for VH2, VH5, VH6 and VH7 families, similarly this was not 
significant against both sets of control values.  DH genes could be assigned to 
41.2% of the genes from the infiltrating repertoire.  The repertoire of these genes 
almost mirrors the distribution of the normal control values and the germline 
complexity (Figure 4.7B); no significant selections were observed within the genes 
isolated from the muscle sections from sample MYO3 except for the selection of 
DH3 genes which were significant against the germline complexity but were not 
significant against the normal control values.  For JH family segments a selection 
for JH5 gene segments was observed which was significant against normal control 
values but not the germline complexity (Figure 4.7C).  No other significant 
selections were observed for any other JH gene family within cellular infiltrates of 
MYO3.  
 
Comparing the V, D and J gene assignments from the JOINSOLVER software to 
that from the IMGT/V-QUEST produced no discrepancies between the two 
softwares.  
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Before Microdissection After Microdissection 
A 
B 
400 bp 
400 bp 
VH1 VH2 VH3 
VH4 VH5 VH6 
_ 
MYO 
3 + 
Figure 4.6 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO3 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYO3.  
Figure 4.6A demonstrates the microdissection of the region of cellular infiltration.  Images 
were taken at 200X.  DNA released from these microdissections was amplified using a 
Nested PCR system (Figure 4.6B), as described in Chapter 2.  – indicates negative control 
PCR reactions where DNA was substituted with water while + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual.  Results show amplification of all 6 VH families. 
_ 
MYO 
3 + 
_ 
MYO 
3 + 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01 3-22*01 4*02 2 0 ASGDSSGYTLDY 23 14 
    2 ASGDSSGYTLDY 23 14 
1-46*01 No D gene Assignment 5*02 2 10 AARVPVDSVMSSDH 39 6 
    11 AARVPVDSVMSSDH   
1-69*01 5-24*01 4*02 1 14 ARDTRRDVYNSGYDY 36 17 (+1) 
1-69*02 No D gene Assignment 5*02 1 23 AARVPVDSVMSSDH 39 6 
1-69*04 No D gene Assignment 4*02 1 10 ARDSVGGTGY 18 6 
1-69*09 No D gene Assignment 4*02 1 22 AARIASGDSSYFDY 27 8 
1-69*09 No D gene Assignment 5*02 1 24 AARVPVDSVMSSDH 39 6 
1-69*09 No D gene Assignment 4*02 1 25 ANGAAGYYDD 24 5 
3-07*02 2-15*01 6*03 1 15 ARKTGRGGSRPWYNRYYYMDV 39 11 
3-11*03 No D gene Assignment 6*02 1 1 ARDLSMVYYYYGMDV 14 5 
3-30*03 No D gene Assignment 4*02 1 18 AKEEEVRSSAPPVFDY 35 8 
3-49*03 No D gene Assignment 5*02 1 19 CRYYPSWFDP 30 7 
4-34*12 3-10*01 6*02 1 12 ARGPRNYYRTGRRERDFYYYYGMDV 44 17 (+2) 
4-39*01 1-26*01 4*02 1 5 ARRKARVGASQAFDY 29 11 
4-59*01 3-22*01 2*01 1 12 ARTPYYYDSTGYYYPLVGFDL 47 30(+1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 Heavy chain genes identified from myositis sample MYO3 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO3 myositis section.  The total number of sequences 
isolated is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    
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Figure 4.7 VH Gene Family Usage of MYO3 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
 
A 
B 
C 
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4.2.2.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO3 
Over 50% of the sequences isolated from sample MYO3 were highly mutated with 
mutational numbers over 11 per sequence (Figure 4.8A), which may indicate the 
infiltration of memory cells.  Just fewer than 20% of sequences were virtually non-
mutated with only 0 to 2 per sequence indicating the presence of a naïve 
population of cells with the remainder of sequences containing between 3 and 10 
mutations throughout the VH segment of the gene rearrangement.  Examining the 
percentage of mutations within framework and CDR regions demonstrates, like the 
previous sample, that there were a higher percentage of mutations within CDR 
regions of gene sequences, with the highest percentage of these mutations found 
within the CDR1 region (Figure 4.8B). 
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Analysis of replacement and silent ratios in the VH region were analysed as 
previously described.   From 17 sequences significant selections were only found 
within 2 of the sequences; positive selection within the CDR was observed within 1 
of the sequences while negative selection in the FW was observed within the other 
sequence (Table 4.6).  All other positive and negative selections within the CDR 
and regions were not significant.   
Figure 4.8 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO3 
 
Figure 4.8A - The number of mutations 
within functional rearranged genes were 
analysed in sample MYO3.  Base 
differences within the first 24 bases of 
sequence were disregarded as this part 
of the sequence binds the 5’ VH primer.  
Graph demonstrates sequences within 
cellular infiltrates show a diverse 
distribution of mutational numbers. 
 
 Figure 4.8B - The locations of mutations 
observed within functional rearranged 
genes were categorised as being within 
FR or CDR regions.  The numbers of 
mutations within these regions were 
expressed as a percentage of the entire 
length of the region to correct for the 
longer lengths observed within the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR regions compared to framework 
regions. 
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Table 4.6 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO3 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and the corresponding computer 
programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive or negative mutational selections within the sequence 
with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent 
mutations within the CDR respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while 
p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal 
test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of 
mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-03*01 3-22*01 4*02 2 0 - - - - - - - - 
    2 0 0 0.47127 0 2 0 0.70269 0.49377 
1-46*01 No D gene Assignment 5*02 2 10 0 0 0.47626 -0.0752 6 4 0.674 -0.6191 
    11 1 0 0.47626 -0.1539 5 5 0.674 -0.2677 
1-69*01 5-24*01 4*02 1 14 7 1 0.44858 0.05775 5 1 0.67095 0.85185 
1-69*02 No D gene Assignment 5*02 1 23 9 1 0.46421 0.599 6 7 0.67462 -0.065 
1-69*04 No D gene Assignment 4*02 1 10 8 1 0.46613 0.01279 1 0 0.67556 -0.6489 
1-69*09 No D gene Assignment 4*02 1 22 6 4 0.4646 -0.6319 7 5 0.67435 -0.0566 
1-69*09 No D gene Assignment 5*02 1 24 10 1 0.4646 0.45103 6 7 0.67435 -0.0654 
1-69*09 No D gene Assignment 4*02 1 25 8 3 0.4646 0.95751 8 6 0.67435 -0.089 
3-07*02 2-15*01 6*03 1 15 2 2 0.44221 -0.2033 6 5 0.6681 -0.1353 
3-11*03 No D gene Assignment 6*02 1 1 0 0 0.47238 -0.5276 0 1 0.66449 -0.3355 
3-30*03 No D gene Assignment 4*02 1 18 9 2 0.46606 0.31422 3 4 0.67432 -0.0451 
3-49*03 No D gene Assignment 5*02 1 19 9 2 0.44618 0.08515 6 2 0.6636 -0.6685 
4-34*12 3-10*01 6*02 1 12 3 0 0.41289 0.92298 5 4 0.65315 -0.5497 
4-39*01 1-26*01 4*02 1 5 0 0 0.42497 -0.1901 2 3 0.66224 -0.264 
4-59*01 3-22*01 2*01 1 12 2 1 0.44001 -0.3081 4 5 0.65645 -0.1109 
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4.2.2.3 CDR3 Analysis 
Analysis of the CDR3 in these sequences could only be conducted within the 
functional repertoire as no non-functional sequences were isolated (Table 4.7).  
For these sequences the mean amino acid CDR3 length was 14.8 ± 1 (ranging 
from 10 to 25 amino acids).  The mean CDR3 lengths were also compared 
between the different mutational groups but no significant differences in the CDR3 
length was observed (Figure 4.9).  Comparison of the P and N nucleotides at the 
VD and DJ junctions were not significant but a significant increase in exonuclease 
activity was observed at the 5’ of the JH gene segment compared to the 
exonuclease activity observed a the 3’ end of the VH gene.  No further significant 
differences were observed. 
Functional 14.8 ± 1 CDR3 Length Non-Functional N/A 
 VD Junction DJ Junction 
Functional 0.9 ± 0.4 0.4 ± 0.2 P Nucleotide Non-Functional N/A N/A 
Functional 6.9 ± 1.1 9.4 ± 1.7 N Nucleotide Non-Functional N/A N/A 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.9 ± 0.5 5.1 ± 1.7 5.8 ± 1.4 6.1 ± 0.7θ Exonuclease 
Activity Non-Functional N/A N/A N/A N/A 
Table 4.7 CDR3 and Junctional Analysis in Sample MYO3 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO3.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.  Instances where no non-functional sequences were identified and values could not be 
calculated were recorded as non applicable (N/A).  Θ represents a significant difference from 3’VH. 
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Figure 4.9 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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4.2.2.4 Clonal Diversification in MYO3  
Two clonally related sequences from sample MYO3 were observed (Figure 4.10).  
In addition the common VDJ gene segments, CDR3 composition and junctional 
sequences, these clonally related sequences shared 4 replacement mutations and 
3 silent mutations.  No other clonally related sequences were observed within 
sample MYO3.  Analysis of the R and S mutations (Table 4.8) showed that there 
was no significant selection observed within the CDR and FW regions although a 
non-significant negative selection was observed in both regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Germline1-46*01      CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT  
CloneA               CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT  
CloneB               CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCGTCGGTGAAGGTT  
                      
                          CDR1 
Germline1-46*01      TCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
CloneA               TCCTGCAAGGCGTCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
CloneB               TCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
                      
                             CDR2 
Germline1-46*01      CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTAC  
CloneA               CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTAC  
CloneB               CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAGGCTAC  
                      
 
Germline1-46*01      GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTAC  
CloneA               GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGCCTAC  
CloneB               GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTAC  
                     
            CDR3 
Germline1-46*01      ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA               ATGCAGCTGAGCAGCCTGAGTCAGGAGGACACGGCCATATATTATTGTGCAGCCAG  
CloneB               ATGGAGCTGAGCAGCCTGAGTCAGGAGGACACGGCCATATATTATTGTGCAGCCAG  
 
 
 
 
 
 
 
VH1-46*01 
4(3) 
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Figure 4.10 Clonal Proliferation in Sample MYO3 
 
Two B cell sequences isolated from sample MYO3 demonstrated somatic hypermutation and clonal 
proliferation (A&B).  Figure A - The letters in the circles refer to individual sequences isolated from each B cell 
clone.  Numbers indicate the minimum number of mutations required between each sequence with bracketed 
figures representing additional silent mutations.  The dashed circle represents a hypothetical intermediate 
whose sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the 
clonally related sequences were aligned using ClustalW software to highlight the common and independent 
mutations.  CDR regions are highlighted in yellow, replacement mutations in blue and silent mutations in 
purple. 
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R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1 0 0.47626 -0.0904 7 6 0.674 -0.3167 
 
Table 4.8 Analysis of Replacement and Silent Mutations and Positive and Negative Selection 
in Clonally Related B Cells in Sample MYO3 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally related 
sequences mutations shared across the sequences are only counted once and p values are 
calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number of 
replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
183 
4.2.3 Sample MYO5 
4.2.3.1 VH Gene Repertoire of Infiltrating B Cells  
Biopsy material from patient MYO5 used in this study was a second biopsy 
conducted 3 years after the initial diagnostic biopsy due to a flare up of myositis.  
As described in Chapter 3 no well-defined areas of infiltration were observed within 
sections, cellular infiltration was observed throughout the entire sample.  
Consequently the whole section was used to establish the gene repertoire used by 
infiltrating B and plasma cells (Figure 4.11).  22 functional gene rearrangements 
were used to establish the gene usage distribution (Table 4.9), multiple copies of 
the same gene were isolated from the repertoire but these were only counted as 
one. A selection against VH1 gene segments and a selection for VH5 gene 
segments were observed significant against both normal control values and the 
germline complexity (Figure 4.12A). A difference of approximately 20% was 
observed for each family respectively.  No other gene family displayed significant 
differences between the two sets of control data.  DH genes could be identified in 
40.9% of the sequences isolated from the inflammatory infiltrate in sample MYO5.  
The distribution mirrored the normal control distribution as well as the germline 
complexity and no significant selections were observed for any DH gene family 
(Figure 4.12B).  Similarly no selection was observed for any of the JH gene family 
segments and the repertoire of the inflammatory infiltrate mirrored the gene 
distribution of normal control values and the germline complexity (Figure 4.12C).   
 
From the sequences isolated from the inflammatory infiltrate in sample MYO5 no 
discrepancies in gene assignment was observed between the JOINSOLVER and 
IMGT/V-QUEST software’s. 
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Figure 4.11 Amplification of VH-gene rearrangements from Sample MYO5 
 
As no distinct aggregation of infiltrating cells was observed within sample MYO5 and 
infiltrating cells were observed throughout the whole section, the whole section was used to 
obtain DNA.  DNA released from the section was amplified using a Nested PCR system, as 
described in Chapter 2. PCR reactions were conducted for DNA isolated from the muscle 
sections (Figure 4.11A) in addition to DNA isolated from PBL (Figure 4.11B).  – indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive control PCR reactions using peripheral blood mononuclear cells isolated from 
peripheral blood of a healthy individual.  Results show amplification of all 6 VH families for 
both types of DNA tested. 
A 
B 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
2-70*04 No D gene Assignment 5*02 1 14 SRTYLTNGYDP 26 6 
3-30*04 1-7*01 4*02 2 4, 5 ARGGGYNWTYRVSGYCDS 46 14(+1) 
3-30*04 3-22*01 4*02 1 13 ARDITYSDDDTGGYYYPI 43 25 (+4) 
3-30*04 5-12*01 6*02 2 16, 19 ARGVGGSSGYDLPWYSSYGMDV 43 17(+2) 
3-30*09 No D gene Assignment 6*02 1 21 ARDRYSHAYYSGVDV 29 9 
3-30*09 No D gene Assignment 6*02 1 21 ARDRYSHAYYSGMDV 28 8 
3-53*01 3-22*01 4*02 2 18, 18 ARDHDANSYYYEGSAY 42 10 
3-72*01 No D gene Assignment 5*02 1 17 ARDLNGLGRN 21 8 
3-73*02 No D gene Assignment 4*02 1 26 TRWAPKTGGLDY 30 7 
4-34*01 No D gene Assignment 4*02 3 25, 27, 28 ARCLMGNYLH 22 6 
4-59*01 No D gene Assignment 4*02 1 10 AKGGGDTALLFGN 35 6 
5-51*01 No D gene Assignment 3*02 4 
12, 25, 31, 
32 ARAKCSAGQCRLPEAFDM 51 8 
5-51*01 6-19*01 4*02 2 4, 5 ARQGRSSGWYWSDFDY 31 16 
Table 4.9 Heavy chain genes identified from myositis sample MYO5 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO5 myositis section.  The total number of sequences 
isolated is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    
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Figure 4.12 VH Gene Family Usage of MYO5 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
 
A 
B 
C 
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4.2.3.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO5 
Mutational numbers within functional rearrangements demonstrated that a highly 
mutated population was present within sample MYO5 which may represent a 
memory cell population, approximately 75% of cells isolated from the muscle 
contained over 11 mutations (Figure 4.13A).  There was a very low presence of 
naïve cells within the muscle with no sequences being isolated with 0 to 2 
mutations, all remaining sequences had between 3 and 10 mutations per 
sequence.  Analysis of mutation locations demonstrated a higher percentage of 
mutations within CDR regions in comparison to framework regions (Figure 4.13B), 
a higher percentage of mutations was observed within CDR1 regions.  
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Based on the replacement and silent mutations within the sequences (Table 4.10) 
selection was observed in 5 of the 22 sequences isolated from sample MYO5.  
Two of these sequences demonstrated positive selection within the CDR while the 
remaining 3 sequences demonstrated negative selection in the FW regions.  In the 
other 17 sequences positive and negative selection were observed in both the 
CDR and FW region but these selections were not significant. 
A 
B 
Figure 4.13 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO5 
 
Figure 4.13A - The number of mutations 
within functional rearranged genes were 
analysed in sample MYO5.  Base 
differences within the first 24 bases of 
sequence were disregarded as this part of 
the sequence binds the 5’ VH primer. Graph 
demonstrates sequences within cellular 
infiltrates of sample MYO5 do not contain 
any naïve cells and that the population 
within sample MYO5 are highly mutated.  
 
Figure 4.13B - The locations of mutations 
observed within functional rearranged 
genes were categorised as being within FR 
or CDR regions.  The numbers of 
mutations within these regions were 
expressed as a percentage of the entire 
length of the region to correct for the longer 
lengths observed within the framework 
regions.  Graph demonstrates a higher 
percentage of mutations within CDR 
regions compared to framework regions. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
2-70*04 No D gene Assignment 5*02 1 14 8 1 0.46004 0.03713 4 1 0.67539 -0.9339 
3-30*04 1-7*01 4*02 2 4 3 0 0.47645 0.32957 0 1 0.67262 -0.3274 
    5 3 0 0.47645 0.61536 0 2 0.67262 -0.1072 
3-30*04 3-22*01 4*02 1 13 5 0 0.47645 0.23822 6 2 0.67262 0.68795 
3-30*04 5-12*01 6*02 2 16 6 2 0.47645 0.4565 6 2 0.67262 -0.6256 
    19 6 2 0.47645 0.87298 7 4 0.67262 -0.3219 
3-30*09 No D gene Assignment 6*02 1 21 12 3 0.47758 0.06524 4 2 0.67244 -0.1751 
3-30*09 No D gene Assignment 6*02 1 21 12 3 0.47758 0.06524 4 2 0.67244 -0.1751 
3-53*01 3-22*01 4*02 2 18 8 3 0.45711 0.08369 7 0 0.65885 0.81907 
    18 8 3 0.45711 0.16134 6 1 0.65885 -0.6915 
3-72*01 No D gene Assignment 5*02 1 17 3 3 0.45531 -0.3487 7 4 0.65729 -0.2354 
3-73*02 No D gene Assignment 4*02 1 26 14 1 0.47416 0.04699 6 5 0.66265 -0.2564 
4-34*01 No D gene Assignment 4*02 3 25 6 1 0.42123 0.76861 12 6 0.65376 -0.8267 
    27 7 2 0.42123 -0.7963 9 9 0.65376 -0.0672 
    28 7 2 0.42123 -0.6576 9 10 0.65376 -0.0385 
4-59*01 No D gene Assignment 4*02 1 10 3 0 0.44001 0.51005 5 2 0.65645 0.79209 
5-51*01 No D gene Assignment 3*02 4 12 1 1 0.43137 -0.2215 6 4 0.70065 -0.2864 
    25 5 5 0.43137 -0.4626 10 5 0.70065 -0.0642 
    31 7 6 0.43137 -0.4775 11 7 0.70065 -0.0148 
    32 7 6 0.43137 -0.4775 12 7 0.70065 -0.023 
5-51*01 6-19*01 4*02 2 4 1 1 0.43137 0.86274 2 0 0.70065 -0.8712 
    5 1 1 0.43137 0.86274 3 0 0.70065 0.89384 
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Table 4.10 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO5 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.3.3 CDR3 Analysis 
As no non-functional sequences were identified in the infiltrating repertoire in 
sample MYO5 no comparisons could be made between these sequences and the 
functional sequences of the cells infiltrating the muscle.  The mean amino acid 
CDR3 length was calculated at 15.5 ± 0.8 (ranging from 10 to 22 amino acids) 
(Table 4.11).  As demonstrated in Figure 4.13A no non-mutated sequences were 
found within the infiltrating repertoire therefore the mean CDR3 length could only 
be examined for the 3 different ranges of highly mutated sequences (Figure 4.14).  
Using the Tukey-Kramer multiple comparison test no significant difference in the 
CDR3 length was observed between the different mutational groups.  Like the 
previous samples no significant differences were observed for the P and N 
nucleotides at the VD and DJ junctions but in similarity to the other myositis 
samples a significant difference was observed for the exonuclease activity between 
the two junctional areas with a significant increase in exonuclease at the 5’ end of 
the JH gene segments and the 5’DH region compared to the 3’VH region (Table 
4.11).  There is also a significant difference in the DJ junction between the genes 
with an increased exonuclease activity at the 5’JH compared to the 3’ DH.   
 
Functional 15.5 ± 0.8 CDR3 Length Non-Functional N/A 
 VD Junction DJ Junction 
Functional 0.3 ± 0.2 0.2 ± 0.1 P Nucleotide Non-Functional N/A N/A 
Functional 8.2 ± 1.3 9.6 ± 0.5 N Nucleotide Non-Functional N/A N/A 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 0.2 ± 0.1 6.3 ± 2.8θ 0.9 ± 0.6 6.2 ± 1.4 θЖ Exonuclease 
Activity Non-Functional N/A N/A N/A N/A 
 
Table 4.11 CDR3 and Junctional Analysis in Sample MYO5 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO5.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.  Instances where no non-functional sequences were identified and values could not be 
calculated were recorded as non applicable (N/A).  Θ represents a significant difference from 3’VH 
while Ж represents a significant difference from 3’ DH. 
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4.2.3.4 Clonal Diversification in MYO5  
Four clonally related sets of genes were observed from sample MYO5 (Figure 
4.15A-H).  These clonally related sets of genes utilise VH gene segments from VH 
families 3, 4 and 5 and indicate a B cell antigen-driven response.  The use of 
varying VH families may also indicate an antigen-driven response to different 
antigens.  Each set of clonally related sequences share the same VDJ gene 
rearrangement, CDR3 and junctional composition as well as common replacement 
and silent mutations.  For clonal tree A clonal variants A and E share 1 
replacement mutation between them but do not share the other R and S mutations 
indicated within the genealogical tree indicating that they are formed during 
different clonal lineages.   The only sets of clonally related sequences which 
demonstrated a significant selection was the clonally related sequences from 
Figure 4.15A (Table 4.12); a significant negative selection was observed within the 
framework region when all the mutations from the clone were analysed as a single 
entity.  Despite the individual sequence of clone D from Figure 4.15D exhibiting 
negative selection in the framework regions when analysed individually this was no 
longer significant when the other mutations of the clone were taken into 
consideration.  
 
 
Figure 4.14 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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E 
Germline5-51*01      GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneA               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneB               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneC&D             GAGGTGCAGCTGGTGCAGTCTGGAGTAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneE               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
                    
                           CDR1 
Germline5-51*01      TCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
CloneA               TCCTGTAAGGCTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
CloneB               TCCTGTAAGGGTTCTGGATATAGTTTTCCCAACTTTTGGATCGGCTGGGTGCGCCAGCTG  
CloneC&D             TCCTGTAAGGGTTCTGGATATAGTTTTCCCAACTTTTGGATCGGCTGGGTGCGCCAGCTG  
CloneE               TCCTGTAAGGCTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
                      
                             CDR2 
Germline5-51*01      CCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATAC  
CloneA               CCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATAGTAGATAC  
CloneB               CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
CloneC&D             CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
CloneE               CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
                    
 
Germline5-51*01      AGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTAC  
CloneA               AGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneB               AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneC&D             AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneE               AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
                      
             CDR3 
Germline5-51*01      CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACA  
CloneA               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneB               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneC&D             CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneE               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
 
 
F 
Germline3-30*04      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneA               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneB               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
                      
                          CDR1 
Germline3-30*04      TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGGTTCATCTTCAGTAACTTTGCTATGCACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTATGCTATGCACTGGGTCCGCCAGGCT  
                      
                             CDR2   
Germline3-30*04      CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAC  
CloneA               CCAGGCAAAGGGCTGGAGTGGGTGGCAGTTATATCGTATGCTGGAACTAATAAAGACTAC  
CloneB               CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCGTATGCTGGAACTAATAAAGACTAC  
                      
 
Germline3-30*04      GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneA               GCAGACTCCGTTAAGGACCGATTCACCATCTCGAGAGACAATTCCAAGAACACGCTGTAT  
CloneB               GCAGACTCCGTTAAGGACCGATTCACCATCTCGAGAGACAATTCCAAGAACACGCTGTAT  
                      
            CDR3 
Germline3-30*04      CTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CTGGAAATGAACAACCTGAGACTTGAAGACACGGCTTTGTTTTACTGTGCGAGAGG  
CloneB               CTGGAAATGAACAACCTGAGACTTGAAGACACGGCTTTGTTTTACTGTGCGAGAGG  
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G 
Germline3-53*01      GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTC  
CloneA               GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGCGACTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
                      
                          CDR1 
Germline3-53*01      TCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTACAGCCTCTGGGTTCACCGTCAGGAATTACTACATGAACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGGTTCACCGTCAGGAATTACTACATGAACTGGGTCCGCCAGGCT  
                     
                              CDR2 
Germline3-53*01      CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCA  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATTATGATGGTAACACAGACTATGCA  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATTATGATGGTAACACAGACTATGCA  
                   
 
Germline3-53*01      GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTT  
CloneA               GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACGTTCCCAAGAACACGGTGTATCTT  
CloneB               GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACGTTCCCAAGAACACGGTGTATCTT  
                     
                            CDR3 
Germline3-53*01      CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA               CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCTAGAGA  
CloneB               CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCTAGAGA  
 
H 
Germline4-34*01      CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneA               CAGGTGCAGCTACAGCAGTGGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneB&C             CAGGTGCAGCTACAGCAGTGGGGCGCTGGGCTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneD               CAGGTGCAGCTACAGCAGTGGGGCGCTGGGCTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
                      
                          CDR1 
Germline4-34*01      ACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCC  
CloneA               ATCTGCACTGTCTCTGGTGGCTCCTTCAGTGGTTACTACTGGAACTGGATCCGGCAGCCC  
CloneB&C             ACGTGCACTGTCCATGGTGGGTCGTTCAGTGGATTCTTCTGGAGCTGGATTCGCCAGCCC  
CloneD               ACGTGCACTGTCCATGGTGGGTCGTTCAGTGGATTCTTCTGGAGCTGGATTCGCCAGCCC  
                     
                             CDR2 
Germline4-34*01      CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTACAAC  
CloneA               CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
CloneB&C             CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
CloneD               CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
                     
 
Germline4-34*01      CCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTG  
CloneA               CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
CloneB&C             CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
CloneD               CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
                      
                            CDR3 
Germline4-34*01      AAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGG  
CloneA               AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGTGCGAGATG  
CloneB&C             AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGTGCGAGATG  
CloneD               AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGCGCGAGATG  
                   
 
 
 
 
 
 
 
 
Figure 4.15 Clonal Proliferation in Sample MYO5 
 
4 sets of sequences were isolated from sample MYO5 demonstrated somatic hypermutation and clonal 
proliferation (A-H).  Figure A-D - The letters in the circles refer to individual sequences isolated from each B 
cell clone.  Numbers indicate the minimum number of mutations required between each sequence with 
bracketed figures representing additional silent mutations.  The dashed circle represents a hypothetical 
intermediate whose sequence was not found amongst the isolated sequences.  Figure E-H - The DNA 
sequences of the clonally related sequences were aligned using ClustalW software to highlight the common 
and independent mutations.  CDR regions are highlighted in yellow, replacement mutations in blue and silent 
mutations in purple. 
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VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
5-51*01 No D gene Assignment 3*02 9 7 0.44751 -0.6002 12 7 0.69597 -0.0142 
3-30*04 5-12*01 6*02 7 2 0.47645 0.66553 7 4 0.67262 -0.3219 
3-53*01 3-22*01 4*02 8 3 0.45711 0.16134 8 1 0.65885 0.97999 
4-34*01 No D gene Assignment 4*02 8 2 0.42123 -0.5993 13 12 0.65376 -0.0699 
 
Table 4.12 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO5 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally related 
sequences mutations shared across the sequences are only counted once and p values are 
calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number of 
replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
4.2.3.5 VH Repertoire from Myositis PBL 
A blood sample was obtained from patient MYO5 allowing the gene repertoire 
within the blood to be determined (Figure 4.11); although this was taken 3 years 
after the second biopsy was conducted.  Approximately 50 sequences have been 
isolated from the PBL repertoire (Table 4.13).  Within the PBL a selection for gene 
segments VH1 and 2 was observed which were significant against the published 
normal control values but were not significant against the germline complexity 
(Figure 4.16A).  A selection against VH4 segments was observed within the 
patient’s blood sample which was significantly decreased in comparison to 
published normal control values and the selection was also significant against the 
germline complexity.  The DH gene repertoire was assessed from the 41.9% of 
sequences where a D gene could statistically be assigned (Figure 4.16B).  As 
shown in Figure 4.16B this gene repertoire almost mirrors that of the normal control 
repertoire as well as the germline complexity, the only significant difference 
observed was a selection for the DH3 gene segments but this was only significant 
against the germline complexity and not the normal control values.  Analysis of the 
JH gene repertoire demonstrated a selection for JH2 and JH4 gene segments which 
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were used significantly higher in the MYO5 PBL repertoire compared to the normal 
control values (Figure 4.16C).  A selection against the use of JH1 and JH6 gene 
segments was also observed within the PBL repertoire.  For JH6 this decline was 
significant against normal control values but not the germline complexity whereas 
the decline in JH1 family usage was only significant against the germline complexity 
and not the normal control repertoire.   
 
For some sequences isolated from the PBL from patient MYO5 anomalies were 
detected between the JOINSOLVER and IMGT/V-QUEST software.  For the VH1-
69*01 DH5-12*01 JH5*02 gene rearrangement IMGT/V-QUEST identified a different 
highest DH gene match and assigned DH3-22*01 to the rearrangement.  In 
JOINSOLVER this gene was the 3rd best matching gene with only 8 consecutive 
nucleotides compared to the 9 observed for the DH5-12*01 gene which were 
sufficient to assign the DH gene statistically.  Using the IMGT/V-QUEST software 
the DH5-12*01 gene was the 2nd best matching gene and had a match score of 25 
compared to 69 for the DH3-22*01 gene.  For the non-functional gene 
rearrangement using the VH2-26*01 gene with 30 mutations, IMGT/V-QUEST 
assigned a different DH gene segment to this rearrangement.  Instead of assigning 
the DH2-21*02 gene a DH2-15*01 gene was assigned, this was found to be the 3rd 
best matching DH gene segment using JOINSOLVER.  Another difference was also 
observed with another non-functional gene, IMGT/V-QUEST failed to find a 
rearrangement for the VH3-23*01 JH1*01 identified using JOINSOLVER and was 
only able to identify the VH segment of the rearrangement.  IMGT/V-QUEST was 
also able to detect a deletion within the functional VH3-66*01 DH6-19*01 JH5*02 
rearrangement with 56 mutations.  This single codon deletion was observed within 
the CDR2.  When this deletion had been restored into the rearrangement both 
JOINSOLVER and IMGT/V-QUEST aligned the sequence to a VH3-21*01 DH6-
19*01 JH5*02 rearrangement with a total of 44 mutations, junctional sequences 
were common between both alignments. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01 No D gene Assignment 4*02 1 0 ARIHQEGPDY 17 8 
1-03*01 No D gene Assignment 3*02 1 19 ARAGHTVPNNAFDI 23 6 
1-18*01 2-21*02 3*02 1 17 ARDNVVVTVTTAFDI 24 14 
1-46*01 2-21*02 4*02 (1) 46 AECGGDCLYFD* 33 15 
1-46*01 3-22*01 2*01 1 2 ARVWNYYDSSGYYVGYFDL 36 26 
1-46*01 No D gene Assignment 5*02 1 31 ARGGGYGYIWFDP 19 6 
1-69*01 3-22*01 4*01 1 10 ARAYYSDSSGYGPFDN 39 24(+1) 
1-69*01 3-3*02 2*01 1 1 ARTEWLLSSYWYFDL 21 14 
1-69*01 3-3*02 6*02 2 37, 38 ARSSPFQNFWSALSYREAFYYAMDV 60 12 
1-69*01 3-9*01 4*02 1 19 ARCSTHYDDLSGYNMAYYFDY 43 20(+3) 
1-69*01 No D gene Assignment 1*01 (1) 25 ARDYRPKTSS 13 5 
1-69*01 5-12*01 5*02 1 21 ARNFYDNSGYNWFDP 24 9 
1-69*01 No D gene Assignment 6*02 1 25 ARAQFSYVAYIYYFYAMDV 40 8 
1-69*06 No D gene Assignment 3*02 1 33 ARGRGNNSEGFDI 31 6 
1-69*06 No D gene Assignment 5*02 1 10 ARDERYIGEVMTTNWFDP 31 7 
1-69*06 2-8*01 4*02 1 0 ARAPQGRKNCTNGVCYTGGT 49 25 
2-05*01 No D gene Assignment 4*02 1 2 AHRSNGPLFDY 20 6 
2-26*01 2-15*01 6*02 (1) 0 ARTDIVVVVAANPPSLLTTVWT 44 23 
2-26*01 2-21*02 5*02 (1) 30 TRTTESWWWLLRDDRGST(cc) 48 15(+1) 
2-26*01 No D gene Assignment 4*02 2 0, 1 ARIPELDRWYLFDY 23 8 
2-26*01 No D gene Assignment 5*02 2 19, 20 ARINREGWIGLG 30 6 
3-07*02 No D gene Assignment 4*02 1 0 ARDWWLDNY 17 7 
3-21*01 2-2*01 3*02 1 30 ARDGLPAARDI 22 11 
3-21*01 No D gene Assignment 5*02 1 30 ARGVGMPGNPVFRFDP 32 5 
3-21*01 No D gene Assignment 3*02 1 0 ARDDSTSPGSAFDI 21 8 
3-21*01 6-19*01 5*02 1 21 ARGVAMAGTRVCTFDP 36 12(+1) 
3-23*01 No D gene Assignment 1*01 (1) 15 ARWRGIS(cg) 21 5 
3-23*01 3-10*01 2*01 1 0 AKNPNMVRDLRGVWYFDL 33 11 
3-23*01 4-17*01 2*01 1 1 AKDSGVDYGAHGGLWYFDL 34 10 
3-30*04 No D gene Assignment 3*01 2 23, 26 ARESVPNCGAGTCHPRDRAFDV 45 9 
3-30*04 3-3*01 4*02 1 30 AREEGRQNTDFWSGYVFDC 54 17 
3-30*04 3-3*02 2*01 1 1 ARTEWLLSSYWYFDL 21 14 
3-48*01 No D gene Assignment 4*02 1 21 ARAGFFEPHFDF 33 
7 
Cont… 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-66*01 6-19*01 5*02 1 56 TRGLAVAGTGVLCFDP 39 11 
3-73*01 No D gene Assignment 4*02 1 23 ARPSAAYTSTWPGDY 45 7 
4-34*01 4-17*01 5*02 1 4 ARGGYGDYLKWFDP 22 12 
4-34*01 No D gene Assignment 6*02 1 13 ARALGF 11 6 
5-51*01 No D gene Assignment 4*02 1 35 AAFDTHAGARFLY 33 7 
5-51*01 No D gene Assignment 4*02 1 22 TRLDTDAGAKFEY 36 7 
5-51*01 No D gene Assignment 3*02 1 15 ARHSMYTFPDDALDK 37 6 
5-51*01 5-24*01 4*02 1 0 ARQDSRDGYNPFDY 25 17 
6-01*01 No D gene Assignment 4*02 2 0, 7 ARGGAGEDFDY 15 7 
6-01*01 No D gene Assignment 5*02 1 23 ARGFLKLGFDP 28 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 4.13 Heavy chain genes identified from the PBL sample of myositis patient MYO5 PBL 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO5 PBL sample.  The total number of sequences isolated 
is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino acid sequences were also identified using the JOINSOLVER software; * indicates the 
presence of a stop codon within the CDR3. V-J lengths and consecutive D match lengths (bp) were 
also identified using the JOINSOLVER software and allowed assignment of the DH genes as 
described in section 2.3.12.3.    
199 
 
VH GENE DISTRIBUTION 
 § 
VH1 VH2 VH3 VH4 VH5 VH6 VH7
0
20
40
60
80
100
Normal
Germline
Observed
 § 
*
 § 
VH Family
%
 
o
f F
u
n
ct
io
n
al
 
G
en
es
 
DH GENE DISTRIBUTION 
DH1 DH2 DH3 DH4 DH5 DH6 DH7
0
20
40
60
80
100
Normal
Germline
Observed
*
DH Family
%
 
o
f F
u
n
ct
io
n
al
 
G
en
es
 
 
JH GENE DISTRIBUTION 
JH1 JH2 JH3 JH4 JH5 JH6
0
20
40
60
80
100
Normal
Germline
Observed
 § 
 § 
 § 
*
JH Family
%
 
o
f F
u
n
ct
io
n
al
 
G
en
es
 
Figure 4.16 VH Gene Family Usage of MYO5 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal PBL values; 
* represent a significant difference from the germline (p<0.05).  
A 
B 
C 
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4.2.3.6 Mutational Analysis of B Cell Ig Sequences Isolated from PBL 
Mutational numbers within rearranged genes demonstrated a variety of mutational 
numbers within PBL sequences (Figure 4.17A).  Over 40% of sequences were 
highly mutated with over 21 mutations within VH gene segments.  Over 30% of 
cells were from a naïve population with between 0 and 2 mutations.  The 
remainder of sequences contain between 3 and 20 mutations.  Mutational 
distribution (Figure 4.17B) percentages within framework and CDR regions show 
that there were a higher percentage of mutations within CDR regions compared to 
framework regions.  Comparing mutational distributions between CDR regions 
show that there were a higher percentage of mutations within CDR1. 
   
      
0-2 3-10 11-20 21+
0
10
20
30
40
50
Number of Mutations
%
 
o
f S
eq
u
en
ce
s
 
   
Framework CDR1 CDR2
0
5
10
15
Nu
m
be
r 
o
f M
u
ta
tio
n
s
 
(%
 
o
f L
e
n
gt
h)
 
 
Analysis of the R and S mutations from Ig sequences isolated from the PBL (Table 
4.14) demonstrated negative selection within the framework regions of 10 of the 
sequences.  Positive selection in the CDR was observed in 3 of the sequences 
while 1 sequence demonstrated negative selection within the CDR.  This sequence 
also exhibited negative selection in the FW regions.  
 
A 
B 
Figure 4.17 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO5 PBL 
 
Figure 4.17A - The number of mutations 
within functional rearranged genes were 
analysed in the PBL sample of MYO5.  
Base differences within the first 24 bases 
of sequence were disregarded as this 
part of the sequence binds the 5’ VH 
primer.  Graph demonstrates sequences 
within cellular infiltrates show a diverse 
distribution of mutational numbers. 
 
 Figure 4.17B - The locations of 
mutations observed within functional 
rearranged genes were categorised as 
being within FR or CDR regions.  The 
numbers of mutations within these 
regions were expressed as a percentage 
of the entire length of the region to 
correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared 
to framework regions. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-03*01 No D gene Assignment 4*02 1 0 - - - - - - - - 
1-03*01 No D gene Assignment 3*02 1 19 6 1 0.47127 0.63617 8 4 0.70269 -0.4975 
1-18*01 2-21*02 3*02 1 17 7 0 0.47674 0.31052 6 4 0.68809 -0.5539 
1-46*01 2-21*02 4*02 (1) 46 11 2 0.47626 -0.7247 21 12 0.674 -0.3563 
1-46*01 3-22*01 2*01 1 2 0 0 0.47626 -0.5237 1 1 0.674 -0.652 
1-46*01 No D gene Assignment 5*02 1 31 9 5 0.47626 -0.672 10 7 0.674 -0.037 
1-69*01 3-22*01 4*01 1 10 4 2 0.44858 -0.9895 1 3 0.67095 -0.0181 
1-69*01 3-3*02 2*01 1 1 0 0 0.44858 -0.5514 0 1 0.67095 -0.3291 
1-69*01 3-3*02 6*02 2 37 11 1 0.44858 0.77525 14 11 0.67095 -0.1641 
    38 10 2 0.44858 -0.7636 14 12 0.67095 -0.0644 
1-69*01 3-9*01 4*02 1 19 9 2 0.44858 0.15835 5 3 0.67095 -0.2767 
1-69*01 No D gene Assignment 1*01 (1) 25 10 2 0.44858 0.1692 9 4 0.67095 -0.5608 
1-69*01 5-12*01 5*02 1 21 7 4 0.44858 0.88572 6 4 0.67095 -0.0695 
1-69*01 No D gene Assignment 6*02 1 25 11 1 0.44858 0.26589 6 7 0.67095 -0.0695 
1-69*06 No D gene Assignment 3*02 1 33 7 4 0.44956 -0.492 14 8 0.67148 -0.1623 
1-69*06 No D gene Assignment 5*02 1 10 2 1 0.44956 -0.8508 5 2 0.67148 -0.7688 
1-69*06 2-8*01 4*02 1 0 - - - - - - - - 
2-05*01 No D gene Assignment 4*02 1 2 1 0 0.44387 0.44387 1 0 0.6816 0.6816 
2-26*01 2-15*01 6*02 (1) 0 - - - - - - - - 
2-26*01 2-21*02 5*02 (1) 30 10 4 0.46263 0.44118 12 4 0.68432 -0.4245 
2-26*01 No D gene Assignment 4*02 2 0 - - - - - - - - 
    1 0 0 0 - 1 0 0.74726 0.74726 
Cont… 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
2-26*01 No D gene Assignment 5*02 2 19 9 1 0.46263 0.1913 5 4 0.68432 -0.2384 
    20 9 1 0.46263 0.30178 5 5 0.68432 -0.126 
3-07*02 No D gene Assignment 4*02 1 0 - - - - - - - - 
3-21*01 2-2*01 3*02 1 30 12 5 0.5135 0.93998 7 6 0.65938 -0.0219 
3-21*01 No D gene Assignment 5*02 1 30 10 3 0.5135 -0.5886 8 9 0.65938 -0.0202 
3-21*01 No D gene Assignment 3*02 1 0 - - - - - - - - 
3-21*01 6-19*01 5*02 1 21 7 6 0.49658 -0.6483 5 3 0.66123 -0.0241 
3-23*01 No D gene Assignment 1*01 (1) 15 6 1 0.45266 0.22144 6 2 0.65 0.94618 
3-23*01 3-10*01 2*01 1 0 - - - - - - - - 
3-23*01 4-17*01 2*01 1 1 0 0 0.45265 - 1 0 0.65000 0.65000 
3-30*04 No D gene Assignment 3*01 2 23 10 1 0.47645 0.03902 10 2 0.67262 0.48789 
    26 6 1 0.47645 -0.5693 11 8 0.67262 -0.2576 
3-30*04 3-3*01 4*02 1 30 11 3 0.47645 0.98399 7 9 0.67262 -0.0079 
3-30*04 3-3*02 2*01 1 1 0 0 0.47645 -0.5235 0 1 0.67262 -0.3274 
3-48*01 No D gene Assignment 4*02 1 21 5 3 0.51637 -0.1685 6 7 0.6621 -0.0222 
3-66*01 6-19*01 5*02 1 56 17 7 0.46522 -0.9478 19 13 0.66817 -0.0209 
3-73*01 No D gene Assignment 4*02 1 23 3 4 0.47416 -0.0347 8 8 0.66265 -0.0186 
4-34*01 4-17*01 5*02 1 4 0 0 0.42123 -0.5788 3 1 0.65376 0.75232 
4-34*01 No D gene Assignment 6*02 1 13 3 0 0.42123 -0.8171 5 5 0.65376 -0.3309 
5-51*01 No D gene Assignment 4*02 1 35 14 3 0.43137 0.0339 14 4 0.70065 -0.7216 
5-51*01 No D gene Assignment 4*02 1 22 8 1 0.43137 0.00717 13 0 0.70065 
0.05484 
Cont… 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
5-51*01 No D gene Assignment 3*02 1 15 2 2 0.43137 -0.4749 8 3 0.70065 -0.5078 
5-51*01 5-24*01 4*02 1 0 - - - - - - - - 
6-01*01 No D gene Assignment 4*02 2 0 - - - - - - - - 
    7 5 0 0.47248 0.09678 1 1 0.65538 -0.6893 
6-01*01 No D gene Assignment 5*02 1 23 9 2 0.47248 0.81772 5 7 0.65538 -0.0272 
 
 
 
Table 4.14 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO5 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while P-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.3.7 CDR3 Analysis 
No significant changes were observed in the CDR3 length between the 
functional and non-functional populations (Table 4.15) as well as between the 
different mutational groups within the functional population (Figure 4.18).  
Similarly no significant differences were observed for the P and N nucleotide 
additions between the two populations or between the two different junctional 
regions within each population.  As seen within the Ig sequences of the myositis 
infiltrating repertoire a significant difference was observed for the exonuclease 
activity.  A significant increase in this activity was observed at the 5’ end of the 
DH and JH gene in comparison to the 3’VH gene in the functional population.  A 
significant change was also observed at the 3’VH gene junction between the 
functional and non-functional populations.  A significant increase in exonuclease 
activity was observed in the non-functional sequences at the 3’VH region 
compared to the functional sequences.  This increase in exonuclease activity 
may have resulted in a frameshift resulting in a non-functional rearrangement.   
 
Functional 15.2 ± 6 CDR3 Length Non-Functional 13.8 ± 2.7 
 VD Junction DJ Junction 
Functional 1.0 ± 0.2 0.8 ± 0.2 P Nucleotide Non-Functional 0.3 ± 0.3 0 
Functional 7.8 ± 1.5 7.9 ± 1.4 N Nucleotide Non-Functional 4.7 ± 2.2 12 ± 5.1 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.6 ± 0.3* 5.1 ± 0.9θ 5.8 ± 1.0 4.9 ± 0.7 θ Exonuclease 
Activity Non-Functional 3.7 ± 0.7 5.3 ± 1.8 5.3 ± 0.7 7.3 ± 3.3 
 
Table 4.15 CDR3 and Junctional Analysis in Sample MYO5 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all PBL immunoglobulin sequences from 
sample MYO5.  Results are given as the Mean ± SEM.  * indicates a significant difference 
between functional and non-functional sequences established using an unpaired t test.   Θ 
represents a significant difference from 3’VH. 
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No clonally related sets of genes were isolated from the PBL population but as 
the sequences isolated represent only a small fraction of the overall PBL 
population the presence of clones within the isolated sequences was not 
anticipated.  In cases where multiple genes were isolated from the PBL 
repertoire which shared VDJ gene assignments and junctional sequences these 
sequences only differed or shared 1 mutation and were therefore not deemed 
clonally related.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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4.2.3.8 Comparison of Myositis Muscle VH Repertoire with Myositis PBL 
Repertoire 
Comparing the infiltrating cell repertoire from the muscle to that of the published 
repertoire of normal control values demonstrated selections for and against 
certain gene segments (Figure 4.12).  As a blood sample was obtained from 
this patient the VH gene repertoire of the muscle infiltrating B cells was also 
compared to the patients own PBL repertoire (Figure 4.19).  Although this is 
from a small percentage of the whole PBL repertoire, and a larger number of 
sequences would be required for a more accurate comparison, it does 
demonstrate a selection for and against gene families.  For VH gene family 
segments there was a selection against VH1 in the muscle repertoire in 
comparison with the PBL repertoire as there was a significant increase of these 
gene families evident within the PBL (Figure 4.19A).  No other selections were 
significant for the VH gene families despite the appearance of selection for VH3, 
VH4 and VH5 family genes; these were not significant when the absolute values 
were used in Chi square analysis although a p-value of 0.0574 (Appendix 2) 
was observed for VH5 family genes which may represent a significant selection 
for these genes segments if a larger population of sequences had been isolated 
from each sample.  DH1 gene segments were significantly selected for within 
the muscle repertoire and this selection for DH1 was not observed within the 
PBL repertoire (Figure 4.19B).  No significant changes in the JH repertoire was 
observed between the muscle and PBL Ig populations (Figure 4.19C).   
 
A larger number of sequences from the PBL repertoire is required to provide a 
more accurate representation of entire PBL repertoire and to fully determine if 
the selections for and against gene segments are in fact present between 
muscle and PBL repertoires.  In addition to comparing the VH repertoires 
between the muscle infiltrating population and the PBL population, comparing 
the individual gene rearrangements used in each population demonstrated that 
no similar gene rearrangements were found in both the muscle and blood B cell 
populations. 
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Figure 4.19 VH Gene Family Usage of MYO5 muscle and PBL 
VH gene family usage.  Distribution of functional genes from infiltrating cells within the muscle 
were compared to the patients own PBL repertoire.  * represent a significant difference from 
myositis PBL values (p<0.05).  
 
 
 
 
 
 
A 
B 
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4.2.4 Sample MYO6 
Areas of cellular infiltration within sample MYO6 were microdissected and the 
DNA released was amplified for all 6 VH families by nested PCR (Figure 4.20).  
Despite the presence of B cells and plasma cells within the infiltrating 
population only 1 sequence could be found within various regions of the sample 
(Table 4.16A).  This sequence utilised the VH3-72*01 gene segment, in addition 
to the JH4*02 gene segment; no D gene assignment could be statistically 
assigned.  The isolated sequence contained 15 mutations, with the higher 
percentage of these mutations being present within the CDR2 region.  Analysis 
of the R and S mutations indicates a negative selection in the FW regions of this 
sequence (Table 4.16B), negative selection was also found within the CDR but 
this was not significant.  Analysis of the junctional region of this sequence could 
not be completed as no DH gene could be statistically assigned.  No changes in 
gene assignments were observed using the IMGT/V-QUEST software. 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection After Microdissection 
A 
Figure 4.20 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO6 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYO6.  Figure 
4.20A demonstrates the microdissection of the region of cellular infiltration.  Images were taken 
at 400X.  DNA released from these microdissections was amplified using a Nested PCR system 
(Figure 4.20B), as described in Chapter 2.  – indicates negative control PCR reactions where 
DNA was substituted with water while + indicates positive control PCR reactions using 
peripheral blood mononuclear cells isolated from peripheral blood of a healthy individual.  
Results show amplification for VH1, 2, 3, 5 and 6 families. 
400 bp 
400 bp 
VH1 VH2 VH3 
VH4 VH5 VH6 
_ 
MYO 
6 + 
_ 
MYO 
6 + 
_ 
MYO 
6 + 
B 
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Mutational Distribution  
(% of length) VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3  
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-72*01 No D gene Assignment 4*02 1 15 ARVVEGVVSRDVLDY 15 3.6 0 8.3 30 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3 2 0.45531 -0.2424 4 6 0.65729 -0.0271 
Table 4.16 A&B Sequence Analysis from Sample MYO6 
 
Table 4.16A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYO6 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.16B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.5 Sample MYO7 
Areas of cellular infiltration microdissected from MYO7 (Figure 4.21) produced 
only 2 different functional gene rearrangements (Table 4.17A).  Both 
sequences isolated were from the VH3 gene family, VH3-66*01 and VH3-74*01.  
DH3-3*01 was the only D gene that could be statistically assigned in the VH3-
66*01 rearrangement along with the JH5*02 gene segment while the other gene 
rearrangement utilised the JH6*02 segment.  No changes were observed using 
IMGT/V-QUEST.  The VH3-74*01 was non-mutated but the other functional 
gene contained 9 VH mutations, with the higher percentage of these mutations 
present within the CDR2 region. Analysis of R and S mutations demonstrated 
no significant selection was present in either the CDR or FW regions (Table 
4.17B).  As no D gene could be assigned to the VH3-74*01 rearrangement no 
junctional analysis could be conducted.  Analysis in the VH3-66*01 
rearrangement found that 0 and 1 P nucleotides and 1 and 9 N nucleotides 
were present at the VD and DJ junctions respectively.  Exonuclease activity was 
calculated to have removed 2, 1, 9 and 4 nucleotides from the 3’ VH, 5’DH, 3’DH 
and 5’JH regions of the junction respectively. 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection After Microdissection 
A 
Figure 4.21 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO7 
The region of B cell and plasma cell infiltration was microdissected from sample MYO7.  Figure 
4.21A demonstrates the microdissection of the region of cellular infiltration.  Images were taken 
at 400X.  DNA released from these microdissections was amplified using a Nested PCR system 
(Figure 4.21B), as described in Chapter 2.  – indicates negative control PCR reactions where 
DNA was substituted with water while + indicates positive control PCR reactions using 
peripheral blood mononuclear cells isolated from peripheral blood of a healthy individual.  
Results show amplification for VH1, 3, 4 and 5 families. 
B 
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Mutational Distribution 
 (% of length) VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-66*01 3-3*01 5*02 1 9 ARILRSLEWSTGGWFDP 17 2.3 0 7.8 32 20 (+1) 
3-74*01 No D gene Assignment 6*02 1 0 ARGELVKRADYYYGMDV 17 0 0 0 22 8 
 
 
VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-66*01 3-3*01 5*02 3 1 0.46522 0.87 3 2 0.66817 -0.4153 
3-74*01 No D gene Assignment 6*02 - - - - - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.17 A&B Sequence Analysis from Sample MYO7 
 
Table 4.17A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYO7 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.17B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.6 Sample MYO16 
 
4.2.6.1 VH Repertoire of Infiltrating B Cells 
As shown in Figure 4.22, two significant areas of infiltration within sample MYO16 
were microdissected and the DNA released from these areas was amplified in a 
nested PCR protocol for VH amplification.  The sequences isolated from these 
areas, as well as a third area of infiltration, are shown in Table 4.18.  To establish 
the gene repertoire within sample MYO16, and to allow comparisons with normal 
control values and the baseline germline complexity, the sequence data from all 
regions was combined. From 36 functional gene rearrangements there was a 
significant selection for VH3 family gene segments against both the normal control 
values and the germline complexity (Figure 4.23A).  No significant differences 
were observed for the other VH gene families against either set of the control 
values.  In this sample DH gene assignments could be completed in 47.2% of the 
sequences. From this repertoire a selection for DH6 genes was observed which 
was significant against both the normal control values and germline complexity 
(Figure 4.23B), no other selection was observed.  A positive selection for JH3 gene 
segments was observed within JH family members (Figure 4.23C).  This selection 
was significant against normal control values but not against the germline 
complexity.  Other selections observed within the infiltrating muscle repertoire in 
sample MYO16 was a decreased selection for the JH1 and JH2 genes but these 
were only significant against the germline complexity and not the normal control 
values.  
 
The discrepancies observed between JOINSOLVER and IMGT/V-QUEST for these 
sequences was observed for the VH3-15*01 JH6*03 gene rearrangement with 1 
mutation from region 5, IMGT/V-QUEST also suggest the 2P*01, 4*03 and 4*01 JH 
gene assignment (Appendix 1).  These three genes were the only genes that 
IMGT/V-QUEST could assign and they were not found to be within the best 5 
matches using the JOINSOLVER software.  For the VH3-11*01 JH6*03 gene 
rearrangements in region 6 with 11 and 13 mutations the best matching VH 
germline gene in both JOINSOLVER and IMGT/V-QUEST was VH3-48*01, with 
fewer mutations, which resulted in an increased score of 1389 compared to 1326 in 
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JOINSOLVER and 1372 compared to 1309 in IMGT/V-QUEST.  In these instances 
the VH3-11*01 gene was shown to be the 4th and 6th best matching gene but as 
these genes were rearranged with the same D and J gene segments in addition to 
the same CDR3 and junctional sequence composition as the other VH3-11*01 gene 
rearrangements these sequences were considered to be assigned the VH3-11*01 
gene segment instead of the VH3-48*01 gene segment.  
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection After Microdissection 
A 
B 
C 
Figure 4.22 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO16 
 
Three regions of B cell infiltration were microdissected from sample MYO16.  Figure 4.22A 
and B demonstrates the microdissection of 2 regions of cellular infiltration.  Images were 
taken at 400X.  DNA released from these microdissections was amplified using a Nested 
PCR system (Figure 4.22C), as described in Chapter 2.  – indicates negative control PCR 
reactions where DNA was substituted with water while + indicates positive control PCR 
reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual.  Results show amplification of all 6 VH families. 
400 bp 
400 bp 
VH1 VH2 VH3 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1 3-09*01 6-6*01 4*02 5 0, 1, 1, 1, 1 AKDIGGQLVLGGVHYFDY 32 11 
 4-59*01 6-13*01 4*02 2 0, 2 ARVIAAAGKAAAYFDY 28 14 
 4-59*03 6-13*01 4*02 1 1 ARVIAAAGKAAAYFDY 32 14 
      
   
5 1-46*01 No D gene Assignment 4*03 (1) 2 SRVIPGFPLDRFD 41 7 
 1-46*01 6-6*01 4*02 1 1 ARGGYSSSSGDY 28 15 
 3-07*01 No D gene Assignment 3*02 10 
24, 32, 32, 
33, 33, 33, 
33, 33, 33, 
34 
SRVIPGFPLDRFDI 33 7 
 3-07*01 3-3*01 4*03 1 1 ARVGYYDFWGGWGFDY 31 22(+1) 
 3-15*01 3-3*01 4*02 1 13 ARVGYYDFWSGWGFDY 38 23 
 3-15*01 No D gene Assignment 6*03 1 1 TTDLGELPYYYYYMDV 16 8 
 3-15*01 No D gene Assignment 6*03 1 2 TTDLGELPYYYYMDV 16 6 
 4-34*01 3-10*01 5*02 1 0 ARVSKITMVRGVIIKRGWFDP 43 27(+1) 
         
6 1-18*01 3-9*01 4*02 1 0 ARVRYDGILTGYDDY 34 15 
 3-11*01 No D gene Assignment 6*03 6 
0, 1, 3, 3, 
11, 13 AREYGRSLWLTQYYYYMDV 28 9 
 3-48*01 2-21*01 6*03 2 0,1 AREVVVVIATPLSDYYYMDV 32 18 
 3-48*01 No D gene Assignment 6*03 1 1 AREYGRSLWLTQYYYYMDV 28 9 
 3-48*03 4-4*01 4*02 1 6 ARGFFPNYSNYGNLLGS 44 12 
 4-61*01 6-13*01 6*03 1 2 ARETSPGYSSSWYGSYYYYYMDV 36 21 
 
 
 
 
 
 
 
 
 
 
 
Table 4.18 Heavy chain genes identified from myositis sample MYO16 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO16 myositis section.  The total number of sequences 
isolated is given in the 5th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    
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Figure 4.23 VH Gene Family Usage of MYO16 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
 
A 
B 
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4.2.6.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO16 
Results of mutational numbers within functional rearrangements show that over 
60% of sequences isolated from sample MYO16 were essentially non-mutated (0-2 
mutations) while over 20% of sequences were highly mutated,  containing over 21 
mutations (Figure 4.24A).  The remainder of the sequences contain between 3 
and 20 mutations.  Results suggest the presence of a largely naïve population, 
possibly due to a recent migration from the PBL, as well as the presence of a 
number of highly mutated, possibly memory cells.  As seen with previous samples 
there were a higher percentage of mutations within CDR regions (Figure 4.24B) in 
comparison to framework regions.  There were a similar percentage of mutations 
between CDR1 and CDR2 regions. 
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Negative selection was observed in the FW regions of two of the isolated 
sequences; both of these sequences share the same VDJ gene rearrangement 
and junctional composition.  Negative selection in the FW was also observed in a 
3rd sequence in sample MYO16 but in contrast to the other 2 sequences a negative 
selection was also observed in the CDR of this sequence.  All other sequences 
demonstrated both positive and negative selection within the CDR and FW regions 
but these were not statistically significant. 
Figure 4.24 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO16 
 
Figure 4.24A - The number of mutations 
within functional rearranged genes were 
analysed collectively from all 3 regions of 
cellular infiltration within sample MYO16.  
Base differences within the first 24 bases of 
sequence were disregarded as this part of the 
sequence binds the 5’ VH primer. Graph 
demonstrates sequences within cellular 
infiltrates were primarily from a naïve 
population of infiltrating cells with some highly 
mutated sequences also present. 
 
Figure 4.24B - The locations of mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.  The numbers of mutations within 
these regions were expressed as a 
percentage of the entire length of the region 
to correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared to 
framework regions. 
A 
B 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1 3-09*01 6-6*01 4*02 5 0 - - - - - - - - 
 
    1 0 0 0.46314 -0.53685 0 1 0.67146 -0.3285 
 
    1 0 0 0.46314 -0.53685 0 1 0.67146 -0.3285 
 
    1 0 0 0.46314 - 1 0 0.67146 -0.6714 
 
    1 0 0 0.46314 - 1 0 0.67146 -0.6714 
 4-59*01 6-13*01 4*02 2 0 - - - - - - - - 
 
    2 1 0 0.44001 0.44001 1 0 0.65645 0.65645 
 4-59*03 6-13*01 4*02 1 1 0 0 0.44024 - 1 0 0.65722 0.65722 
      
   
 
   
 
5 1-46*01 No D gene Assignment 4*03 (1) 2 0 0 0.47626 -0.5237 1 1 0.674 -0.652 
 1-46*01 6-6*01 4*02 1 1 0 0 0.47626 0 1 0 0.674 0.674 
 3-07*01 No D gene Assignment 3*02 10 24 11 2 0.44397 0.16557 6 5 0.67012 -0.1312 
 
    32 14 2 0.44397 0.17902 8 8 0.67012 -0.0537 
 
    32 14 2 0.44397 0.12036 9 7 0.67012 -0.1422 
 
    33 14 3 0.44397 0.3412 7 9 0.67012 -0.0084 
 
    33 14 2 0.44397 0.17902 9 8 0.67012 -0.0829 
 
    33 14 2 0.44397 0.17902 9 8 0.67012 -0.0829 
 
    33 14 2 0.44397 0.17902 9 8 0.67012 -0.0829 
 
    33 15 2 0.44397 0.12446 8 8 0.67012 -0.0537 
 
    33 14 2 0.44397 0.17902 9 8 0.67012 -0.0829 
 
    34 14 2 0.44397 0.25277 9 9 0.67012 -0.0468 
 3-07*01 3-3*01 4*03 1 0 - - - - - - - - 
 
    1 0 0 0.44397 0 1 0 0.67012 0.67012 
 3-15*01 3-3*01 4*02 1 13 0 0 0.43976 -0.0097 5 8 0.6595 -0.0496 
 3-15*01 No D gene Assignment 6*03 1 1 0 0 0.43976 -0.5602 0 1 0.6595 -0.3404 
 3-15*01 No D gene Assignment 6*03 1 2 2 0 0.43976 0.19339 0 0 0.6595 0 
 4-34*01 3-10*01 5*02 1 0 - - - - - - - - 
Cont… 
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Region VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
6 1-18*01 3-9*01 4*02 1 0 - - - - - - - - 
 3-11*01 No D gene Assignment 6*03 6 0 - - - - - - - - 
 
    1 0 0 0.48848 - 1 0 0.66592 0.66592 
 
    3 0 0 0.48848 -0.2617 1 2 0.66592 -0.2975 
 
    3 0 0 0.48848 -0.5115 2 1 0.66592 1.03506 
 
    11 6 1 0.48848 0.31078 2 2 0.66592 -0.2566 
 
    13 6 1 0.48848 0.71789 2 4 0.66592 -0.0526 
 3-48*01 2-21*01 6*03 2 0 - - - - - - - - 
 
    1 0 0 0.51636 - 1 0 0.6621 0.6621 
 3-48*01 No D gene Assignment 6*03 1 1 0 0 0.49992 -0.5001 0 1 0.66392 -0.3361 
 3-48*03 4-41*01 4*02 1 6 4 1 0.49491 0.43894 0 1 0.66764 -0.1105 
 4-61*01 6-13*01 6*03 1 2 1 0 0.4489 0.4489 1 0 0.65022 0.65022 
 
Table 4.19 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO16 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.6.3 CDR3 Analysis 
The muscle infiltrating population of B cells in this sample only produced 1 non-
functional rearrangement, as a result the unpaired t-test could not be used to 
determine if a significant difference occurs between the CDR3 lengths and 
junctional sequences of these sequences; the unpaired t-test requires more 
than 1 value in the non-functional group.  As shown in Table 4.20 the mean 
CDR3 length of functional sequences was 16.7 ± 0.4 amino acids (ranging from 
12 to 23 amino acids), while the non-functional gene had a CDR3 length of 13 
amino acids.  Analysis of the CDR3 lengths in correlation with the VH mutations 
of the sequences demonstrated a significant decrease in the CDR3 length in 
highly mutated, 21+, sequences (Figure 4.25).  This significant decrease in 
CDR3 length was observed for all 3 previous mutational groups.  The different 
sequence features of the junctional regions were also analysed.  In the 
functional population of sequences a significant difference was observed for the 
removal of nucleotides by exonuclease activity between the VD and DJ 
junctional regions but not for the addition of P or N nucleotides in the junctions.  
As only 1 non-functional sequence was isolated in this sample a statistical 
comparison between functional and non-functional sequences could be 
conducted.  Within the functional population a significant increase of 
exonuclease activity at the 5’DH and 5’JH regions of the junction was observed 
compared to the 3’VH region.        
 
Functional 16.7 ± 0.4 CDR3 Length Non-Functional 13 
 VD Junction DJ Junction 
Functional 0.4 ± 0.2 0.6 ± 0.2 P Nucleotide Non-Functional N/A N/A 
Functional 6.2 ± 0.9 8.9 ± 1.1 N Nucleotide Non-Functional N/A N/A 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.1 ± 0.4 4.3 ± 0.7θ 2.7 ± 0.7 4 ± 0.6 θ Exonuclease 
Activity Non-Functional N/A N/A N/A N/A 
  
 Table 4.20 CDR3 and Junctional Analysis in Sample MYO16 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all immunoglobulin sequences from 
sample MYO16.  Results are given as the Mean ± SEM, statistical significance was established 
using an unpaired t-test.  Θ represents a significant difference from 3’VH. 
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4.2.6.4 Clonal Diversification in MYO16  
Within sample MYO16 two clonally related sets of sequences were discovered 
(Figure 4.26). This provides evidence of B cell clonal proliferation and mutation 
within cellular infiltrates of muscle inflammation.  These clones contained VH3 
family gene segments, VH3-07*01 and VH3-11*01, within the functional gene 
rearrangements. These clones were isolated from different regions of the 
muscle section; there was no evidence from the sequences isolated to suggest 
that clonally related B cells were migrating between different cellular aggregates 
suggesting that clones were generated independently in different cell clusters.  
In the clonal genealogical tree in Figure 4.26A 1 silent mutation was observed in 
the clonal branch consisting of clones C-J but this silent mutation was also 
observed in clone L.  As clones C-J did not contain the additional replacement 
mutation found in clones K and L this would suggest that the mutations were 
formed during different and branch mutational lineages.    
 
 
 
 
 
 
 
Figure 4.25 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
significant changes in CDR3 length for 
sequences containing over 20 mutations.  
This reduction in CDR3 length was 
significant against sequences containing 
0-2 mutations (*), 3-10 mutations (**) and 
11-20 mutations (***). p-values <0.05 
were deemed significant. * was 
calculated at <0.001. 
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A VH3-07*01 
A 
B 
17(7) 
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B VH 3-11*01  
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C 
Germline3-07*01      GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC 
CloneA               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACTC  
CloneC_D_E           GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneF               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCCGAGACTC  
CloneG               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTCGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneH               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneI               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneJ               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneK               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneL               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGGCTC  
                      
              CDR1 
Germline3-07*01      TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCT  
CloneC_D_E           TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneF               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneG               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneH               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneI               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneJ               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT 
CloneK               TCCTGTGCACCCCCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneL               TCCTGTGCACCCCCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
                      
        CDR2 
Germline3-07*01      CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTAT  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneC_D_E           CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneF               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneG               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneH               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneI               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneJ               CCAGGGAAGGGGCTGCAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneK               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneL               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
                      
 
Germline3-07*01      GTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTAT  
CloneA               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneB               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneC_D_E           CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneF               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneG               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneH               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneI               CTGCAGTCTGCGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneJ               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneK               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneL               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
                       
         CDR3 
Germline3-07*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneB               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneC_D_E           CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneF               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneG               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneH               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGCCTATTACTGTTCGAGGGT  
CloneI               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneJ               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneK               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneL               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
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Germline3-11*01      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTC  
CloneA-D             CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTC  
CloneE               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCCGAGACTC  
CloneF               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTC 
CloneG               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC 
CloneH               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneI               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
                      
              CDR1 
Germline3-11*01      TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneA-D             TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneE               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneF               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT 
CloneG               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneH               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
CloneI               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
                      
        CDR2 
Germline3-11*01      CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneA-D             CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneE               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneF               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneG               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneH               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTAC  
CloneI               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTAC  
                    
 
Germline3-11*01      GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneA-D             GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneE               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneF               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneG               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneH               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneI               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTAT  
                      
            CDR3 
Germline3-11*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA-D             CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneE               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneF               CTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneG               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneH               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneI               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Clonal Proliferation in Sample MYO16 
 
Two sets of sequences were isolated from sample MYO16 demonstrated somatic hypermutation and clonal 
proliferation (A-D).  Figure A&B - The letters in the circles refer to individual sequences isolated from each B 
cell clone.  Numbers indicate the minimum number of mutations required between each sequence with 
bracketed figures representing additional silent mutations.  The dashed circle represents a hypothetical 
intermediate whose sequence was not found amongst the isolated sequences.  Figure C&D - The DNA 
sequences of the clonally related sequences were aligned using ClustalW software to highlight the common 
and independent mutations.  CDR regions are highlighted in yellow, replacement mutations in blue and silent 
mutations in purple. 
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Analysis of the replacement and silent mutations of these clones indicates that 
positive selection occurs within the CDR while negative selection occurs in the 
FW regions of the sequences (Table 4.21).  These selections were only 
significant for the VH3-07*01 clone for negative selections in the framework 
regions; no other selection was statistically significant.  This negative selection 
was also observed in two of the individual sequences of this clone when the 
sequences were analysed independently (Table 4.19). 
 
VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-07*01 No D gene Assignment 3*02 18 3 0.44397 0.24823 14 12 0.67012 -0.0397 
3-11*01 No D gene Assignment 6*03 6 1 0.41326 0.39307 4 4 0.69174 -0.1382 
 
Table 4.21 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO16 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection was conducted as per Hershberg et al (294) as previously described.  For clonally 
related sequences mutations shared across the sequences are only counted once and p values 
are calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number 
of replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A 
negative sign indicates negative selection.  p-values <0.05 were deemed significant. 
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4.2.7 Sample MYO17 
From sample MYO17 only two functional sequences were isolated from multiple 
microdissections and DNA amplification (Figure 4.27).  Table 4.22A details the 
characteristics of the two different isolated sequences.  VH3-30*03 and VH6-
01*01 gene segments were used in these sequences along with JH4*02 and 
JH5*02 respectively.  A DH gene, DH3-9*01, could only be assigned to the VH3-
30*03 gene rearrangement; the consecutive D match length was not sufficient 
in the VH6*01 gene rearrangement for a gene to be statistically assigned.  Both 
VH3 and VH6 genes isolated from this sample were mutated, as shown in Table 
4.22; they contained 12 and 5 mutations respectively.  Examination of these 
mutations demonstrated that they were congregated mostly within CDR regions 
of the sequence.  For the VH3 gene these were mostly within the CDR1 region 
of the sequence while, conversely for the VH6 gene, mutations were solely 
located within the CDR2 region of the sequence.  Negative selection was 
observed in both the CDR and FW regions of both sequences (Table 4.22B) 
after analysis of the R and S mutations but these selections were not 
statistically significant.  Analysis of the junctional characteristics from the VH3-
30*03 gene rearrangement where a statistical DH match could be made 
revealed that no P nucleotides were present at with the VD or DJ junctions for 
either sequence.  The number of N nucleotides assigned was 7 and 9 at the VD 
and DJ regions respectively while the mean exonuclease activity at the 3’VH, 
5’DH, 3’DH and 5’JH region was 4, 0, 9 and 5 respectively.  
 
The gene assignments using the JOINSOLVER software match those of the 
IMGT/V-QUEST software for both sequences isolated from sample MYO17. 
 
 
 
 
 
 
 
 
 
226 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection After Microdissection 
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Figure 4.27 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO17 
 
Regions of B cell and plasma cell infiltration were microdissected from sample MYO17.  
Figure 4.27A and B demonstrates the microdissection of 2 regions of cellular infiltration.  
Images were taken at 400X.  DNA released from these microdissections was amplified 
using a Nested PCR system (Figure 4.27C), as described in Chapter 2.  – indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive control PCR reactions using peripheral blood mononuclear cells isolated from 
peripheral blood of a healthy individual. Results show amplification of VH 3, 4, 5 and 6 
families. 
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Mutational Distribution 
 (% of length) VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-30*03 3-9*01 4*02 1 12 ATGAYYDILSGARPFDY 17 3.2 13.3 5.6 38 20(+2) 
6-01*01 No D gene Assignment 5*02 1 5 VRSPLKQWLEP 11 1.8 0 1.8 29 6 
 
VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-30*03 3-9*01 4*02 4 1 0.46606 -0.908 3 4 0.67432 -0.0977 
6-01*01 No D gene Assignment 5*02 0 1 0.47248 -0.1468 2 2 0.65538 -0.278 
 
 
 
 
 
 
 
 
 
 
A 
B 
Table 4.22 A&B Sequence Analysis from Sample MYO17 
 
Table 4.22A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYO17 myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.22B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted by Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.8 Sample MYO19 
As described in Chapter 3 both CD20+ cells and plasma cells were identified 
within sample MYO19.  Despite the microdissection and DNA amplification 
(Figure 4.28) of various areas of infiltration within sample MYO19 only 1 
functional rearranged sequence could be isolated (Table 4.23A).  This gene 
used the 3-21*01 VH gene segment along with DH3-22*01 and JH3*02 in this 
functional rearrangement.  As described in Table 4.14 the sequence isolated 
from sample MYO19 only contained 4 mutations throughout the entire 
sequence.  These mutations were solely within framework regions of the 
sequence with CDR regions remaining non-mutated. Based on these mutations 
negative selection was observed within both the CDR and FW regions but these 
were not significant selections (Table 4.23B).  Only 1 P nucleotide was present 
in this rearrangement at the DJ region of the junction.  14 and 15 N nucleotides 
were present at the VD and DJ junctions respectively while 2, 6, 13 and 4 
nucleotides were removed respectively from the 3’VH, 5’DH, 3’DH and 5’JH 
region. 
 
No changes in gene assignment were observed for this sequence using the 
IMGT/V-QUEST software. 
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Figure 4.28 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO19 
 
Regions of B cell and plasma cell infiltration were microdissected from sample MYO19.  
Figure 4.28 A and B demonstrates the microdissection of 2 regions of cellular infiltration.  
Images were taken at 400X.  DNA released from these microdissections was amplified 
using a Nested PCR system (Figure 4.28C), as described in Chapter 2.  – indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive control PCR reactions using peripheral blood mononuclear cells isolated from 
peripheral blood of a healthy individual. Results show amplification of VH 3,4 and 6 families. 
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Mutational Distribution  
(% of length) VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-21*01 3-22*01 3*02 1 4 ARPLSTPYDSRSASAAAFDI 20 1.8 0 0 42 12 
 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
0 0 0.5135 -0.1151 1 3 0.65938 -0.1312 
 
 
 
 
 
 
 
 
 
 
Table 4.23 A&B Sequence Analysis from Sample MYO19 
 
Table 4.23A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYO19 myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.23B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.9 Sample MYO23 
4.2.9.1 VH Repertoire of Infiltrating B Cells 
Due to the low numbers of infiltrating cells within sample MYO23 and with no 
distinctive region of cellular aggregation it was not possible to obtain information 
from specific areas of the MYO23 sample.  As a result the gene repertoire of the 
whole section was determined after nested PCR reactions amplified the VH 
rearrangements from infiltrating cells (Figure 4.29).  A total of 9 different functional 
genes were isolated from the infiltrating population which consisted of 4 different 
gene rearrangements with different mutational patterns (Table 4.24).  Despite the 
small number of genes identified the repertoire of these genes was compared to 
both sets of control values (Figure 4.30), except for the DH genes as there was not 
enough DH genes (4) identified to allow a statistical comparison to be conducted.  
For VH genes only VH3 and VH4 gene segments were used within these 
rearrangements which resulted in a significant selection for the VH3 gene segments 
which was significant against both the normal control values and the germline 
complexity.  A significant selection for JH2 and JH5 genes was observed which was 
only significant against normal control values and not the germline complexity 
when the absolute values were used in the Chi square analysis. A selection 
against JH4 gene segments was also observed which again was only significant 
against the normal control values and not the germline complexity.  As only a small 
number of sequences could be isolated from the muscle section these selections 
may not be representative of the entire population within the whole area of 
inflammation.     
 
For all sequences isolated from sample MYO23 the gene assignments by 
JOINSOLVER matched those of IMGT/V-QUEST.  The only change to gene 
assignments arose in the VH3-33*01 JH5*02 sequence with 18 mutations.  This 
gene sequence was the 4th best matching gene for this sequence in both 
JOINSOLVER and IMGT/V-QUEST.  The difference between these sequences 
was a score of 10 using JOINSOLVER and a score of 9 using IMGT/V-QUEST, 
which represented 1 base difference.  The 4th best matching gene was used as this 
gene shared CDR3, junctional and JH compositions with other sequences.  
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-07*01 6-19*01 2*01 3 5, 6, 7 ARGYTSGWYSANWYFDL 27 19(+2) 
3-33*01 No D gene Assignment 5*02 4 8, 9(X2), 18 AKDSNRARPGWFDP 25 6 
3-33*03 6-19*01 2*01 1 9 ARGYTSGWYSATWYFDL 28 19(+2) 
4-04*07 No D gene Assignment 2*01 1 10 ARVDSRRQVWSPNWYFDL 34 6 
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Figure 4.29 Amplification of VH-gene rearrangements from Sample MYO23 
 
As no distinct area of aggregation from infiltrating cells was observed within sample MYO23 
and infiltrating cells were observed throughout the whole section, the whole section was 
used to obtain DNA.  DNA released from the section was amplified using a Nested PCR 
system, as described in Chapter 2.  – indicates negative control PCR reactions where DNA 
was substituted with water while + indicates positive control PCR reactions using peripheral 
blood mononuclear cells isolated from peripheral blood of a healthy individual. Results show 
amplification of all 6 VH families. 
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Table 4.24 Heavy chain genes identified from myositis sample MYO23 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO23 myositis section.  The total number of sequences 
isolated is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    
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Figure 4.30 VH Gene Family Usage of MYO23 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
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4.2.9.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO23 
Examining the number of mutations within functional rearrangements (Figure 
4.31A) showed that the majority of sequences contained between 3 to 10 
mutations while a small percentage, approximately 10% contained between 11 and 
20 mutations.  Sequences with 0 to 2 mutations or over 21 mutations were not 
found within the infiltrating repertoire.  Analysis of mutational location (Figure 
4.31B) demonstrated that there were a higher percentage of mutations within CDR 
regions of the gene in comparison to framework regions.  Between CDR regions 
CDR1 possessed a higher percentage of mutations in comparison to CDR2. 
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From these mutations positive and negative selections were observed in both the 
CDR and FW regions, the only significant selections were found in the gene 
rearrangements using the VH3-33*01 and VH3-33*03 gene segments (Table 4.25).  
These selections were shown to be negative within the framework regions of the 
sequences. 
 
A 
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Figure 4.31 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in MYO23 
 
Figure 4.31A - The number of mutations 
within functional rearranged genes were 
analysed collectively from the whole sample 
of cellular infiltration within sample MYO23.  
Base differences within the first 24 bases of 
sequence were disregarded as this part of the 
sequence binds the 5’ VH primer.  Graph 
demonstrates sequences within cellular 
infiltrates are not from a naïve population 
but rather a highly mutated population. 
 
Figure 4.31B - The locations of mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.  The numbers of mutations within 
these regions were expressed as a 
percentage of the entire length of the region 
to correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared to 
framework regions. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-07*01 6-19*01 2*01 3 5 2 0 0.44397 0.50381 2 1 0.67012 -0.9537 
    6 3 0 0.44397 0.27233 2 1 0.67012 -0.9537 
    7 2 0 0.44397 0.50381 4 1 0.67012 0.60288 
3-33*01 No D gene Assignment 5*02 4 8 2 2 0.46759 -0.2431 0 4 0.67394 -0.0012 
    9 2 2 0.46759 -0.2431 1 4 0.67394 -0.0065 
    9 2 2 0.46759 -0.2431 1 4 0.67394 -0.0065 
    18 6 2 0.46759 -0.7825 4 6 0.67394 -0.0195 
3-33*03 6-19*01 2*01 1 9 2 2 0.46654 -0.3726 2 3 0.67113 -0.0491 
4-04*07 No D gene Assignment 2*01 1 10 5 1 0.43938 0.31935 2 2 0.65629 -0.2761 
 
Table 4.25 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO23 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.9.3 CDR3 Analysis 
The mean amino acid CDR3 length from these sequences is shown in Table 
4.26.  No non-functional sequences were isolated from the infiltrating repertoire 
and therefore the CDR3 lengths in the two populations could not be compared.  
Previous analysis with the CDR3 lengths in this study has examined the CDR3 
lengths in different mutational groups.  As shown in Figure 4.31A all the 
mutations from these sequences fell into only 2 of the mutational groups which 
did not allow the statistical multiple comparison test to be conducted as 3 or 
more groups are required for the comparison.  Analysis of the P and N 
nucleotides as well as the exonuclease activity can only be conducted on gene 
rearrangements where a D gene has been assigned.  As this was the case for 
only 4 sequences which exhibited the same junctional composition no statistical 
comparisons could be conducted but the number of the different nucleotides are 
shown in Table 4.26. 
 
Functional 15.7 ± 0.6 CDR3 Length Non-Functional N/A 
 VD Junction DJ Junction 
Functional 0 0 P Nucleotide Non-Functional N/A N/A 
Functional 0 7.3 ± 0.3 N Nucleotide Non-Functional N/A N/A 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 2 ± 0 0 0 2.3 ± 0.3 Exonuclease 
Activity Non-Functional N/A N/A N/A N/A 
 
Table 4.26 CDR3 and Junctional Analysis in Sample MYO23 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all immunoglobulin sequences from 
sample MYO23.  Results are given as the Mean ± SEM, statistical significance was established 
using an unpaired t-test.  Instances where no non-functional sequences were identified and 
values could not be calculated were recorded as non applicable (N/A).   
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4.2.9.4 Clonal Diversification in MYO23  
Despite the low numbers of isolated sequences from sample MYO23, four 
clonally related sequences were found within the infiltrating repertoire (Figure 
4.32).  These sequences shared the same VDJ gene rearrangement as well as 
common junctional areas.  In these clonally related sequences clone K and 
clone L share 1 replacement mutation but do not contain the other additional 
mutations, after branching of the clonal tree, indicated in Figure 4.32 which 
indicates that the mutations were formed during different and branch mutational 
lineages.  As shown in Table 4.27 these mutations indicate that negative 
selection was occurring in both the CDR and FW regions but this selection was 
only significant in the framework regions.  
 
 
 
Table 4.27 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO23 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally 
related sequences mutations shared across the sequences are only counted once and p values 
are calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number 
of replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A 
negative sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
 
 
 
 
 
 
 
 
 
VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-33*01 No D gene Assignment 5*02 6 3 0.46759 -0.4743 5 7 0.67394 -0.0086 
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Germline3-33*01      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneA-I             CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneJ               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneK               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneL               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC  
                      
                          CDR1 
Germline3-33*01      TCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT  
CloneA-I             TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneJ               TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneK               TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneL               TCCTGTGTAGCCTCTGGACTCACCTTTAGTAACTATTGGATGAGCTGGGTCCGCCAGGCT  
                     
        CDR2 
Germline3-33*01      CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTAT  
CloneA-I             CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT 
CloneJ               CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
CloneK               CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
CloneL               CCAGGGAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
                      
 
Germline3-33*01      GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneA-I             GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT 
CloneJ               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAGTTCCAAGAACACGCTGTAT  
CloneK               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneL               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
                      
            CDR3 
Germline3-33*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA-I             TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneJ               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneK               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneL               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
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Figure 4.32 Clonal Proliferation in Sample MYO23 
 
A set of sequences was isolated from sample MYO23 which demonstrated somatic hypermutation and clonal 
proliferation.  Figure A - The letters in the circles refer to individual sequences isolated from each B cell clone.  
Numbers indicate the minimum number of mutations required between each sequence with bracketed figures 
representing additional silent mutations.  The dashed circle represents a hypothetical intermediate whose 
sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the clonally 
related sequences were aligned using ClustalW software to highlight the common and independent mutations.  
CDR regions are highlighted in yellow, replacement mutations in blue and silent mutations in purple. 
A 
B 
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4.2.10 Sample MYO24  
Infiltrating B cells were not observed within sample MYO24 but their 
differentiated counter-parts plasma cells were identified within the infiltrating 
population.  These areas of plasma cells were microdissected and the resultant 
DNA was amplified for VH1-6 families (Figure 4.33).  Despite the presence of 
amplification bands for the VH5 family no functional rearrangement sequences 
could be identified from these or subsequent microdissections. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection After Microdissection 
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Figure 4.33 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO24 
 
The region of plasma cell infiltration was microdissected from sample MYO24.  Figure 
4.33A demonstrates the microdissection of the region of cellular infiltration.  Images were 
taken at 200X.  DNA released from these microdissections was amplified using a Nested 
PCR system (Figure 4.33B), as described in Chapter 2.  – indicates negative control PCR 
reactions where DNA was substituted with water while + indicates positive control PCR 
reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual. Results show amplification of VH 5 family genes. 
400 bp 
400 bp 
VH1 VH2 VH3 
VH4 VH5 VH6 
_ 
MYO 
24 + 
_ 
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4.2.11 Sample MYOC 
Aggregates of infiltrating cells in sample MYOC were microdissected and the 
DNA amplified for all 6 VH families (Figure 4.34).  Despite the various areas of 
infiltration within sample MYOC, and the presence of both CD20+ cells and 
plasma cells, only 1 gene rearrangement was isolated from various 
microdissections, Table 4.28A.  This gene used the 3-33*01 VH gene segment 
along with JH2*01 in its functional rearrangement, no DH gene could be 
statistically assigned.  The rearrangement contained a CDR3 length of 13 
amino acids.  This gene rearrangement was isolated for every clone checked 
and from various sections and regions of the sample but was not evident in any 
other samples tested therefore could not be the result of contamination.  The 
sequence isolated from MYOC was highly mutated with a total of 47 mutations 
throughout the VH gene segment.  Examining the distribution of these mutations 
(Table 4.28A), the majority of mutations were located within the CDR2 region.  
Mutational percentages within framework regions of the sequence were similar 
to that of the CDRs.  Analysis of the R and S mutations within this sequence 
demonstrate a significant negative selection in the framework regions of this 
sequence (Table 4.28B).  A positive selection was observed in the CDR but this 
was not significant.  As no DH gene could be assigned to this Ig rearrangement 
the sequence composition, P and N Nucleotides, in the junctional regions of the 
sequence could not be identified. The lack of different gene rearrangements 
and clonally related sequences may indicate that memory cells are infiltrating 
the muscle and are proliferating without mutating.    
 
From the sequence isolated from the inflammatory infiltrate in sample MYOC no 
discrepancies in gene assignment was observed between the JOINSOLVER 
and IMGT/V-QUEST software’s. 
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Before Microdissection After Microdissection 
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Figure 4.34 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYOC 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYOC.  
Figure 4.34A demonstrates the microdissection of the region of cellular infiltration.  Images 
were taken at 200X.  DNA released from these microdissections was amplified using a 
Nested PCR system (Figure 4.34B), as described in Chapter 2.  – indicates negative control 
PCR reactions where DNA was substituted with water while + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual. Results show amplification of all 6 VH families. 
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Mutational Distribution 
 (% of length) 
 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-33*01 No D gene Assignment 2*01 1 47 ARAIHITAWSFDL 13 12.2 13.3 33.3 29 7 
 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
15 5 0.46759 0.85564 16 11 0.67394 -0.0438 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Table 4.28 A&B Sequence Analysis from Sample MYOC 
 
Table 4.28A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYOC myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.28B - The number of replacement and silent mutations and the presence of any positive and negative selection were conducted as per Hershberg et 
al (294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.12 Sample MYOE 
From the microdissections and DNA amplification of infiltrating plasma cells in 
sample MYOE (Figure 4.35), that were previously described in Chapter 3, only 
2 different functional rearrangements were isolated from various 
microdissections within sample MYOE (Table 4.29A).  One of the isolated 
genes used the VH1-f*01 gene along with the DH2-2*01 and JH4*02 while the 
other gene isolated used the 3-09*01 VH gene with an unidentified DH gene 
while JH6*02 completing the functional rearrangement.  The VH1 gene 
rearrangement contained 6 mutations, only 1 of these was within the CDR 
region of the sequence.  Conversely the VH3 gene rearrangement contained a 
total of 36 mutations.  As described in Table 4.29A mutations were distributed 
within all regions of the functional gene, 12.2% of the framework regions of the 
sequence contained mutations while 31.1% of CDR regions of the sequence 
contained mutations.  Analysis of the R and S mutations of these sequences 
demonstrated that negative selection was occurring in both the CDR and FW 
regions of these sequences, but these selections were not deemed significant 
(Table 4.29B).  Both sequences contained similar CDR3 lengths with only 1 
amino acid difference between the two sequences which may be representative 
of a common antigenic epitope.  As no DH gene could be assigned to the VH3-
09*01 gene rearrangement, P and N nucleotides at the VD and DJ regions of 
the junctions as well as exonuclease activity at the VH5’ and JH3’ regions could 
not be assigned.  For the other isolated gene from sample MYOE no P 
nucleotides were identified as either of the VD or DJ junctions while 6 and 11 N 
nucleotides were observed at the VD and DJ respectively.  There appeared to 
be no exonuclease activity at the 5’VH end of the rearrangement but 8, 4 and 5 
nucleotides were removed by exonuclease activity at the 5’DH, 3’DH and 3’JH 
regions of the rearrangement.    
 
No anomalies between the JOINSOLVER and IMGT/V-QUEST algorithms were 
observed. 
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Figure 4.35 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYOE 
 
The region of plasma cell infiltration was microdissected from sample MYOE.  Figure 4.35A 
demonstrates the microdissection of the region of cellular infiltration.  Images were taken at 
200X.  DNA released from these microdissections was amplified using a Nested PCR 
system (Figure 4.35B), as described in Chapter 2.  – indicates negative control PCR 
reactions where DNA was substituted with water while + indicates positive control PCR 
reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual. Results show amplification of VH 3, 4 and 5 families. 
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Mutational Distribution  
(% of length) VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-f*01 2-2*01 4*02 1 6 ATGRVVVPAATASIFDF 17 2.3 6.7 0 44 19 
3-09*01 No D gene Assignment 6*02 1 36 VQDVSRLTDLWRSMDV 16 12.2 20 11.1 38 7 
 
 
VH Gene DH Gene JH Gene R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-f*01 2-2*01 4*02 1 0 0.42032 -0.8133 3 2 0.68787 -0.6761 
3-09*01 No D gene Assignment 6*02 7 2 0.46315 -0.3223 16 11 0.67147 -0.1822 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.29 A&B Sequence Analysis from Sample MYOE 
 
Table 4.29A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYOE 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.29B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
 
A 
B 
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4.2.13 Sample MYO25 (Myositis Control Sample from Healthy Volunteer) 
 
Immunohistochemical studies to identify any infiltrating cell populations within 
control muscle demonstrated that only a few CD68+ cells were present within 
the control muscle sample. To further substantiate this finding DNA was 
released from an entire section of the control sample and the DNA was 
amplified for all 6 VH families by nested PCR (Figure 4.36).  Analysis of these 
PCR products on an agarose gels showed that no amplification products were 
observed from the control muscle sample.  Consequently no further work was 
carried out with this sample. 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36 Amplification of VH-gene rearrangements from Sample MYO25 
 
As no distinct aggregation of infiltrating cells was observed within sample MYO25 and 
infiltrating cells were observed through out the whole section, the whole section was used to 
obtain DNA.  DNA released from the section was amplified using a nested PCR system, as 
previously described in Chapter 2.  – indicates negative control PCR reactions where DNA 
was substituted with water while + indicates positive control PCR reactions using peripheral 
blood mononuclear cells isolated from peripheral blood of a healthy individual. Results show 
no amplification for all 6 VH families. 
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4.2.14 VH Repertoire in Myositis 
In addition to determining the repertoire of infiltrating B cells and plasma cells in 
individual patients the gene usage distribution and mutational patterns were 
also examined collectively for all patients, as well as in the DM and PM myositis 
subsets, to establish if any particular gene family was used preferentially in 
functional gene rearrangements.  As shown in Chapter 2 (Table 2.1) there was 
some discrepancy in the diagnosis of patient MYO17 between PM and IBM in 
the clinical notes, therefore the sequences generated from this sample were not 
included in the PM subset but were for the full collective set of sequences.  
Collective examination of all sequences to establish a common gene selection 
between the different myositis subsets illustrated a selection for VH3 gene 
segments compared to normal control values, which was also observed for the 
sequences identified from DM patients (Figure 4.37A).  A selection for VH2 
gene segments and a selection against VH1 and VH4 gene segments, against 
normal control values, were also observed in sequences from DM patients.  No 
significant positive or negative selections were observed for the sequences 
isolated from PM patients, the repertoire mirrored that of the normal control 
values as well as the germline values.  A comparison of the DM and PM 
repertoires revealed a significant difference for the use of VH5 gene segments 
between the 2 myositis subsets.  Examining the use of individual gene 
segments indicated that in the myositis collective repertoire there was selection 
for the use of various gene segments, VH3-11, 3-15, 3-30, 3-33, 3-66 and 3-7, 
while selection against VH1-2, 3-23 and 4-34 was observed compared to the 
frequency observed for normal control values, although variations in the allele 
use of each gene were observed.  For the DM repertoires a selection for VH2-5, 
3-11, 3-15, 3-30, 3-66, 3-7 and 3-9 and against VH4-34 was observed while in 
the PM repertoire a selection for the use of gene segments VH1-f, 3-30, 3-33, 3-
72 and 5-51 and against the use of VH3-23 was observed compared to normal 
control values.  For DH family genes, genes could be statistically assigned in 
52.7, 59.1 and 41.8% of the sequences from the myositis, DM and PM 
collective sets respectively.  A selection for DH6 gene segments against normal 
control values was observed for both the myositis collective repertoire and the 
DM repertoire, while a decline in the use of DH2 gene segments against normal 
controls was also observed within infiltrating cells for the myositis collective 
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repertoire (Figure 4.37B).  Similarly with the individual VH gene segments, 
selection for the use of DH gene segments was observed.  In the myositis 
collective repertoire a selection for the use of DH3-22 and 6-6 was observed 
while a selection against DH2-2 and 6-19 was also observed.  In the DM 
repertoire the only selection found was a selection for the use of gene segment 
DH6-6 while in the PM repertoire positive selections were observed for the use 
of DH1-7, 3-22, 5-12, 5-24 and 6-19 gene segments.  As previously discussed 
variations in the allele use within these genes were observed.  Selection against 
the use of JH1 gene segments was observed for the myositis and DM collective 
repertoires against normal control values (Figure 4.37C).  These were also 
significant against the germline values for both sets of sequences as well as the 
PM sequence collection.  A selection against the use of JH2 gene segments 
was also observed in the DM sequences which were only significant against 
germline values, conversely a selection for the use of the JH2 as well as JH5, 
gene segments was observed for sequences isolated from the PM patients 
which was significant against normal control values.  A comparison of the DM 
and PM sequence repertoire demonstrated a significant difference in the use of 
JH2, 5 and 6 gene segments.  A significant increase in the use of JH2 and JH5 
gene segments was observed in the PM repertoire compared to the DM 
repertoire while a selection for JH6 gene segments was observed in the DM 
repertoire compared to the PM repertoire.    
 
The numbers of point mutations within the whole collective myositis repertoire 
were found to have a diverse number of mutations and similar distribution in 
each mutational group (Figure 4.38A).  Conversely the sequences in the DM 
repertoire were found to be largely a naïve population of cells with almost 50% 
of sequences containing 0 to 2 mutations in the VH region, although a 
considerable proportion of the sequences from infiltrating cells were highly 
mutated.  Very few naïve cells were found in the PM repertoire, less than 10% 
of the sequences were essentially unmutated with the majority of cells 
containing a large number of mutations.  As expected the majority of these 
mutations were found within the CDRs, for each subset of sequences (Figure 
4.38B).  For the DM repertoire this was greater in CDR1 and was found to be 
almost similar in the PM repertoire between CDR1 and CDR2. 
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Figure 4.37 VH Gene Family Usage in Myositis Patients 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal control values; * represent a significant difference from the germline; ξ represents a 
significant difference between DM and PM myositis subsets (p<0.05).  From all DM, PM and IBM 
patients. 
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A collective summary of the mutational selections (Table 4.30) conducted as 
per Hershberg et al (294) revealed that sequences, with significant selections, 
from all 3 subsets mostly demonstrated negative selection with the FW regions 
in contrast to positive selection in the CDR which would be expected in an 
antigen-driven response.  A small percentage of sequences in the myositis and 
PM collective sets demonstrated positive selection in the CDRs but in the 
myositis collective repertoire negative selection was also found within the 
CDRs.  This negative selection in the CDRs was also observed in some 
sequences of the DM repertoire. 
 
  MYO (n=148) DM (n=93) PM (n=55) 
  CDR FW CDR FW CDR FW 
  # % # % # % # % # % # % 
Positive 
Selection 3 2.0 0 0 0 0 0 0 3 5.5 0 0 
Negative 
Selection 2 1.4 21 14.2 2 2.2 10 10.8 0 0 11 20 
 
Table 4.30 Summary Table of Myositis Sequences with Significant Selection 
 
The total number of sequences with significant selection, positive or negative, in CDR or FW 
regions was calculated (#) and the percentage (%) calculated for each myositis category to 
reveal a higher percentage of sequences contained negative selection in the FW regions 
compared to other selections within the Ig sequences.  From all DM, PM and IBM patients. 
Figure 4.38 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in Myositis Patients 
 
Figure 4.38A - The number of mutations 
within functional rearranged genes were 
analysed collectively from all myositis patients 
as well as in the DM and PM subsets.  Base 
differences within the first 24 bases of 
sequence were disregarded as this part of the 
sequence binds the 5’ VH primer.  Graph 
demonstrates sequences collectively from 
myositis patients show a diverse distribution 
of mutational numbers while sequences from 
DM patients were primarily from a naïve 
populations and sequences from PM patients 
were highly mutated.   
 
Figure 4.38B - The locations of mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.  The numbers of mutations within 
these regions were expressed as a 
percentage of the entire length of the region 
to correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared to 
framework regions for all 3 groups. 
 
 From all DM, PM and IBM patients. 
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In each set of sequences no significant differences in CDR3 length was 
observed and a similar CDR3 length was observed for all functional and non-
functional sequences in each group (Table 4.31).  Analysis of these CDR3 
lengths in correlation with the VH mutational numbers revealed no significant 
differences between the CDR3 length in unmutated and mutated sequences for 
the myositis and DM collective repertoires (Figure 4.39). A significantly shorter 
CDR3 length was observed in the PM collective repertoire for the group of 
sequences containing 21+ mutations in comparison to the sequences with 
between 11 and 20 mutations.  For the additional of P nucleotides there was a 
significant increase observed at the VD junction between functional and non-
functional populations in the myositis and DM sequence sets.  No significant 
differences in N nucleotide additions were observed for any group of sequences 
except the increased addition of N nucleotides in the DJ junction of functional 
sequences in the PM sequence set compared to the VD junction.  A similar 
pattern of exonuclease activity was observed for all 3 groups, an increase in 
exonuclease activity was observed and the 5’DH and 5’JH regions of the junction 
compared to the 3’VH region.  No significant differences were observed, for any 
group of sequences, between the 5’ and 3’DH regions or the 3’DH and 5’JH 
regions of the DJ junction. 
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Figure 4.39 Mean CDR3 Lengths in Relation to VH Mutational Numbers 
 
The mean CDR3 length was calculated for immunoglobulin sequences according the number 
of mutations within the VH segment of the gene rearrangement to establish any relationship 
between mutational number and CDR3 length.  Results are given as Mean amino acid CDR3 
length ± SEM.  Groups within each myositis category were compared for statistical 
significance using the Tukey-Kramer test for multiple comparisons.  *** represents a 
significant difference from 11-20 mutations.  p-values <0.05 were deemed significant.  From 
all DM, PM and IBM patients.  
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Functional 15.7 ± 0.3 MYO Non-Functional 15.8 ± 1.7 
Functional 15.8 ± 0.4 DM Non-Functional 15.8 ± 1.7 
Functional 15.4 ± 0.5 
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VD Junction DJ Junction 
Functional 0.5 ± 0.1 0.4 ± 0.1 MYO Non-Functional 1.4 ± 0.7* 0.4 ± 0.4 
Functional 0.5 ± 0.1 0.5 ± 0.1 DM Non-Functional 1.4 ± 0.7* 0.4 ± 0.4 
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PM Non-Functional N/A N/A 
Functional 7.4 ± 0.5 8.5 ± 0.5 MYO Non-Functional 6.0 ± 0.5 10.2 ± 4.1 
Functional 7.9 ± 0.7 8.1 ± 0.7 DM Non-Functional 6.0 ± 1.5 10.2 ± 4.1 
Functional 6.2 ± 1.0 9.4 ± 0.6** 
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PM Non-Functional N/A N/A 
 
3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.2 ± 0.2 5.0 ± 0.5 θ 3.9 ± 0.4 4.8 ± 0.4 θ MYO Non-Functional 2.0 ± 0.7 2.2 ± 1.2 θ 6.2 ± 2.9 4.6 ± 1.6 θ 
Functional 1.1 ± 0.2 5.2 ± 0.6 θ 4.1 ± 0.4 4.6 ± 0.5 θ DM Non-Functional 2.0 ± 0.7 2.2 ± 1.2 θ 6.2 ± 2.9 4.6 ± 1.6 θ 
Functional 1.2 ± 0.2 4.7 ± 1.3 θ 3.2 ± 0.8 5.3 ± 0.6 θ 
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PM Non-Functional N/A N/A N/A N/A 
 
Table 4.31 CDR3 and Junctional Analysis in Myositis 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all myositis immunoglobulin sequences as 
well as in DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no 
non-functional sequences were identified and values could not be calculated were recorded as 
non applicable (N/A).  * indicates a significant difference between functional and non-functional 
sequences while ** indicates a significant difference between the VD and DJ junctions 
established using an unpaired t-test.   Θ represents a significant difference from 3’VH. 
 
A total of 9 clonally related sets of sequences were found in approximately a 
third of all myositis patients.  Both DM patients, MYO1 and MYO16, contained 
clonally related sets of sequences, 1 from sample MYO1 and 2 from sample 
MYO16, although due to the detection of a deletion in the clonally related 
sequences of sample MYO1 this set of clonally related sequences may not be 
valid depending on the alignment algorithm used.  Sets of clonally related 
sequences were found in 3 of 11 PM patients, MYO3, MYO5 and MYO23, with 
4 different clonal sets in sample MYO5 and 1 each from samples MYO3 and 
MYO23.  In each set of clonal sequences there was no positive selection 
observed within the CDRs, as would have been expected for clonally related 
and antigen-driven sequences.  For 4 of the 9 clones a significant negative 
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selection was observed in the FW regions; remaining clones did not exhibit any 
significant positive or negative selection in either CDR or FW.     
 
Comparison of the different mutations within all sequences identified common 
replacement mutations within a number of sequences.  The replacement 
mutation at amino acid 31 within the CDR1 region, serine to asparagine (S→N), 
was found within all 4 MYO5 clones.  In addition to this mutation within the VH5-
51, VH3-04, VH3-33 and VH3-53 sequences of MYO5, the mutation was also 
observed within the VH1-69 gene in sample MYO3 and the VH3-30 gene in 
sample MYO23.  Other common mutations were also observed within CDR2.  
Silent mutations within amino acids 51 and 59, isoleucine and tyrosine 
respectively, were found in sequences from both MYO3 and MYO5; a 
replacement mutation at amino acid 65 was found in sequences from MYO3, 
MYO5 and MYO7.  At amino acid 65 the glycine amino acid was mutated to an 
aspartic acid amino acid (G→D). Within the same patient these common 
mutations may represent that a common antigenic determinant is driving the 
immune response and hence the mutational patterns of the Ig genes while 
common mutations across different patients suggests mutational hot-spots are 
present within the Ig genes found in these autoimmune disorders.        
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4.3 Discussion 
The role of B cells in myositis is still currently unresolved and it was previously 
thought that myositis was essentially T cell mediated, especially PM and IBM.  
The core aim of this study was to establish if muscle infiltrating B cells were 
being locally stimulated resulting in an antigen-driven response leading to tissue 
pathology.  To address this hypothesis DNA was extracted from microdissected 
B cells from frozen muscle sections and identification of the gene 
rearrangement of Ig sequences from muscle infiltrating B cells was conducted.  
Analysis of these sequences determined if any gene or clonal selection process 
was occurring within the muscle tissue.   At the start of this work no previous 
studies had investigated the gene repertoire or clonal diversification of B cells 
within muscle tissue of myositis patients.   
 
Results from Chapter 3 verified the occurrence of B cells, and their 
differentiated counter-parts plasma cells, within the muscle infiltrating population 
of cells.  The results also established a number of proliferating B cells within the 
inflamed muscle tissue.  This suggested that muscle infiltrating B cells may be 
proliferating, undergoing somatic hypermutation and diversification in an 
antigen-driven response.  Further confirmation of gene selections and 
diversification of the Ig repertoire from normal control values, accumulation of 
mutations and identification of clonally related sequences with common 
mutations would substantiate the hypothesis that muscle infiltrating B cells 
within inflamed muscle were undergoing an antigen-driven response.  The 
results presented in this chapter support these characteristics of antigen-driven 
diversification as well as the hypothesis of a B cell antigen-driven response 
within inflamed muscle of myositis patients. 
 
Gene selections were observed for all 3 segments of the Ig rearrangement, 
these were shown to be both disease specific as well as patient specific.  
Conclusive clonal diversification of these genes was also observed in 4 of 12 
patients, 1 DM patient and 3 PM patients.  Collectively these results indicate 
that an antigen-driven response occurs within the target tissues of these 
patients and that clonal B cells may play a significant role in the pathogenesis of 
these diseases, similar to studies in other disorde
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where ectopic lymphoid tissues have been identified (52;283-285;289;317-325).  
In some instances gene selection and clonal diversification could not be 
assessed in some patients due to the small numbers of rearrangements 
identified from the muscle infiltrating B cell population, a larger number of 
sequences may be required for these samples.  This could be a result of the 
variations in cell phenotypes found to be infiltrating the muscle described in 
Chapter 3.  For patients MYO1, 3, 5 and 16, where gene selections and clonal 
diversification were observed, a significant infiltrating population of B cells was 
observed within frozen muscle sections.  Conversely for other samples, MYO6, 
7, 17, 19, 23, 24, C, E, a larger population of plasma cells were observed within 
muscle sections which could account for the diminished Ig repertoire or lack of 
clonal proliferation within these samples although despite the large plasma cell 
infiltration in sample MYO23 gene selections and clonal diversification of Ig 
genes were observed.  The mutational analysis of some of these sequences 
from these patients would suggest that an antigen-driven response had 
occurred.  It could be postulated that the plasma cells in these samples had 
been recruited to the sites of inflammation in their activated B cell or memory 
state and prior to biopsy had differentiated into plasma cells whereas in the 
previous samples the B cells are expanding and diversifying within the muscle 
and had not yet matured into plasma cells.  The work conducted in this study 
was unable to differentiate between the B cell and plasma cell repertoires; 
further single cell or cell sorting analysis would need to be conducted to 
distinguish the two populations of cells.  A re-stimulation of memory cells may 
also account for the diminished Ig repertoire; chronic stimulation of antigen-
specific memory B cells could account for the large number of replicate 
sequences identified in this study, for all samples, with the same Ig 
rearrangement.  Alternatively memory B cells could have entered a 
differentiation stage of proliferation without further somatic hypermutation 
accounting for the lack of clonal proliferation.  The process used in this study 
could not differentiate between this chronic stimulation and repeated 
amplification of a single amplicon within the PCR reactions unless consecutive 
sections or different regions of the section were analysed in separate PCR 
reactions.  In order to account for this repeated amplification and prevent 
misinterpretation of clonal expansion without mutation these sequences were 
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only counted once within the sample repertoire.  If a chronic stimulation of 
antigen specific memory B cells was to occur within the inflamed muscle tissue 
what remains uncertain is whether these memory cells are recruited to the 
inflamed muscle site in this mature state or whether peripherally activated B 
cells are initially recruited which later mature into memory cells.  It could be that 
the timings of the clinical investigations into the inflamed muscle have missed 
the initial expansion and mutation phase of the B cell antigen driven response.  
The use of a memory B cell marker, CD27, in the previous immunohistological 
studies described in Chapter 3 may have provided additional evidence of the B 
cell role in inflamed muscle of myositis patients. In circumstances where no 
clonally related sets of sequences were identified it may indicate that infiltrating 
B cells are not mutating within the regions of cellular infiltration but are mutating 
and migrating into infected tissue from other locations, presumably the draining 
lymph nodes, in contrast to the proposed hypothesis.  Recent studies have 
demonstrated the expression of AID, the enzyme responsible for SHM and 
CSR, and the functional relationship between AID, CSR and autoantibody 
production within the FDC networks of ectopic GC-like structures in SS and RA 
patients (55;326).  AID expression was not found within target tissues where no 
FDCs or GCs were present except for in interfollicular (IF) large B cells outwith 
these GC compartments where AID has been shown to be functionally active 
(327-329).  Identification and classification of AID expressing cells within 
inflamed muscle would corroborate the findings of this study, SHM and clonal 
diversification, and provide greater insight into antigen-driven responses in 
autoimmune target tissues where no GC structures are present.  The 
participation of ectopic lymphoid tissues in generating antigen specific B cell 
responses has also been recently described by Weinstein et al (330) to further 
substantiate that the target tissue in various autoimmune diseases are sites of 
active antigen-specific response rather than sites of lymphocyte accumulation.      
 
From the results described in Chapter 3 a number of samples contained Ki67+ 
proliferating B cells, MYO1, 17, 19, 24 and E, but evidence of clonal 
diversification was only observed for sample MYO1.  The need for analysis of 
additional muscle sections may be required to fully evaluate the process of 
clonal diversification in these samples. 
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As previously described in Chapter 3 the impact of patient’s therapy on cellular 
infiltration as well as Ig gene repertoire and identification of clonally related 
sequences in this chapter cannot be overlooked.  As previously described in 
Chapter 2 (Table 2.1) and Chapter 3, section 3.3, six patients, MYO5, 19, 23, 
24, C and E, were receiving steroid therapy at the time or just prior to biopsy.  
Additionally patient MYO5 was receiving IVIg therapy while patient MYO19 was 
receiving methotrexate.  These therapies could have distorted the true 
heterogeneity of the B cell response in these patients.  Despite the therapeutic 
interventions gene selections and clonally related sets of sequences in MYO5 
and MYO23 indicate that B cell antigen-driven diversification was still occurring 
within the inflamed muscle tissue.  This is more significant for patient MYO5 
who had been receiving therapy for three years prior to the biopsy while patient 
MYO23 had only received a week of therapy which was stopped two weeks 
prior to the biopsy.  As previously mentioned in Chapter 2 the biopsy for patient 
MYO5 used in this study was conducted approximately 3 years following the 
initial biopsy for clinical investigations for diagnosis.  Examination of this initial 
biopsy would have provided interesting insights into the original Ig gene 
repertoire and clonal diversification sequence sets of B cells within the inflamed 
muscle at the onset of the disease while also revealing the impact of therapy on 
these two factors but unfortunately this biopsy was not available for analysis.    
 
A surprising finding from this study was the lack of significant positive selection 
within CDRs.  The accumulation of mutations and identification of clonally 
related sequences indicate the occurrence of B cell antigen-driven responses 
within the inflamed muscle but are not substantiated with significant positive 
selection in Ig sequences.  Positive CDR selection was observed for a small 
percentage of sequences but the bulk of selection was found to be negative 
selection in the FW regions, although this negative selection was also observed 
in the CDRs (Table 4.30).   Antigen driven responses have traditionally been 
associated with an increase in replacement mutations from expected 
frequencies in CDRs indicating positive selection while decreased levels of 
replacement mutations within FW regions indicated negative selection.  The 
methods previously and currently used to detect selection based on the analysis 
of mutation patterns in Ig sequences are described in section 4.3.3.  Current 
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analysis has indicated that previous methods have misinterpreted positive CDR 
selection with negative selection in the FW regions due to crosstalk which could 
not be differentiated in previous methods.  This may indicate that studies that 
have previously established positive selection above expected frequencies in 
antigen-driven studies may be based on flawed methodology and generate 
false positive selection within the Ig sequences.  Taking into consideration the 
updated parameters of analysis by Hershberg et al (294) which incorporate 
fundamental aspects of sequence variation and diversity into assigning 
selection, provides a more accurate assessment of selection within Ig 
sequences.  The lack of positive selection in CDRs observed in this study may 
relate to findings previously described where selection against amino acid 
replacement in CDRs may occur to prevent the degradation of high affinity 
autoantibodies (331).  Other possibilities may include a lower rate of SHM at 
ectopic sites in comparison to secondary lymph nodes (330) or a defect may 
occur in affinity maturation if there is less competition over lower affinity cells at 
ectopic sites (330) due to an abundance of self antigen or a lack of regulation 
outside GCs (301;332;333).  This could also correspond to the absence of 
FDCs from a large cohort of samples in Chapter 3 and recent studies which 
demonstrated the expression and function of AID in FDC networks (55;326). 
 
Analysis of the CDR3 regions, the addition of P and N nucleotides as well as 
exonuclease activity at the junctional regions in the current study yielded 
different results compared to published studies (238;241;242;251;291).  
Generally previous studies have demonstrated that CDR3 lengths are 
significantly shorter in functional rearrangements.  In the current study no 
significant differences were observed between the CDR3 lengths in functional 
and non-functional populations for individual patients as well as collective 
analysis for the different disease subsets.  In this study very few cells 
expressing non-functional Ig sequences were detected within the infiltrating 
repertoire and in some cases no non-functional sequences were examined in 
individual patients, therefore comparison to the non-functional repertoire could 
not be conducted.  Analysis of a larger population of sequences may be 
required in order to fully determine if selection for smaller CDR3 lengths is 
present within functional sequences in the disease repertoires.  Differences 
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between disease repertoires and the normal control repertoire may also account 
for this change in CDR3 lengths in the functional and non-functional 
populations. One study also demonstrated a significant decrease in CDR3 
length in mutated sequences compared to unmutated sequences (238), 
generally within this study this pattern was not observed with exception for the 
collective PM sequences and sample MYO16 (Figure 4.25) where highly 
mutated sequences contained a significantly shorter CDR3 compared to the 
sequences with fewer mutations.  Again this may indicate a difference in the 
enzymatic mechanisms and gene selections within disease models compared 
to normal control models, although in addition to the CDR3 length the amino 
acid composition of the CDR3 would also have to be considered.  Previous 
studies have also examined the addition of P an N nucleotides as well as the 
exonuclease activity with the junctional regions (251;291;334).  Generally a 
significant increase in P and N nucleotides were found within the VD junction 
compared to the DJ junction, a pattern that was not observed in the current 
study.  The increased addition of N nucleotides at the VD junction is thought to 
relate to the increased TdT expression during the development stage of V-DJ 
joining.  TdT was found to be initially upregulated during the D-J recombination 
in pre-pro-B development stage with a further increase at the V-DJ 
recombination stage observed in pro-B cells, it was then observed that TdT 
expression quickly declines (251).  The results of the current study do not 
correspond to these findings but may relate to selection in the target tissues.  
Previous studies have also reported a significant decrease in exonuclease 
activity at the VH region compared to the 5’DH and JH regions (291;334), a 
similar pattern to that observed in this study.  These variations in exonuclease 
activity at various regions within the CDR3 have been thought to relate to the 
primary sequence of the gene rearrangements.  An increased exonuclease 
activity was observed in DH2, DH3 and JH6 genes compared to other DH and JH 
genes (334).   It had been proposed that the slightly more AT rich region at the 
5’JH region is preferentially targeted by exonuclease activity (291).      
 
One aspect of antigen-driven B cells not examined in this study was the process 
of isotype switching.  Evidence showing the isotype switching of antibodies in 
these responses would further substantiate the antigen driven response in the 
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target tissues of myositis patients.  If these studies were to continue constant 
region primers could be used in PCR reactions to establish the isotype of 
antibody produced from muscle infiltrating B cells alternatively 
immunohistochemical studies could be conducted with antibodies specific to the 
various antibody isotypes.  The occurrence of isotype switching was 
demonstrated in a recent study by Bradshaw et al (90) which also examined the 
incidence of antigen-driven B cell responses in the target tissues of myositis 
patients is discussed fully in section 4.3.1.  Briefly Bradshaw et al identified 
clonal variants of different antibody isotypes (IgG and IgA) in DM patient, 
providing further evidence of antigen-driven diversification of B cells within 
inflamed muscle.  A recent review (335) has suggested that the constant region 
may also influence antibody specificity and affinity.  Another aspect of the B cell 
response not examined in this study was the Ig repertoire and mutations of the 
light chains.  Examination of the light chain sequences from the muscle 
infiltrating B cell population would have given a rounded examination of the full 
B cell response in this study.  Amplification of lambda and kappa light chains 
were conducted for a number of samples in this study with successful 
amplification but due to the extensive nature of the work required for the light 
chain analysis, time constraints and the sufficient use of heavy chain sequences 
to determine antigen-driven clonal diversification this aspect of the response 
was not fully pursued but should be considered in subsequent studies.  
Examination of paired peripheral blood samples, taken at the time of biopsy, 
would also be extremely beneficial in subsequent studies.  Due to the 
constraints of examining archival material and the difficulty in obtaining fresh 
muscle biopsies for this study paired blood analysis was not conducted.  Such 
analysis would allow a comparison of any V, D or J gene selections in the 
peripheral blood to that observed within the muscle as well as identification of 
clonal rearrangements or variants from the muscle infiltrating repertoire in the 
blood.  A study conducted by Voswinkel et al (336) examined and compared the 
B cell repertoires between the synovial tissue and peripheral blood B cell 
repertoire in a patient with RA.  The study detected identically rearranged genes 
within different joints and within the PBL indicating the recirculation of B 
lymphocytes between joint and peripheral blood.  Although affinity maturation 
was observed from the sequences, authors suggested that a primary selection 
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occurred before distribution to the joints and following migration to the joints 
antigen-driven diversification was continued before re-circulating into the 
peripheral blood B cell repertoire. Re-circulation of activated synovial B cells 
has also been demonstrated in another study by Souto-Carneiro et al (337) 
which described the identification of clonally related B cells at different sites of 
synovial inflammation.  The absence of FDCs within these sites suggested to 
the authors that these stimulated B cells from early RA lesions migrate to other 
areas of inflammation and re-enter a cyclic hypermutation process.  This work 
supports previous work (338;339) which demonstrates the cyclic re-entry of 
stimulated B cells.  This could be a plausible situation from the work described 
in the current study where some samples lacked the presence of FDCs as 
previously described in chapter 3.  Conversely Owens et al (340), while 
studying the B cell repertoires in Multiple Sclerosis plaques, found that this 
repertoire was distinct from the repertoire of the PBL.  The results indicated that 
a compartmentalised humoral response was occurring and that there was no 
entry of the CNS sequences into the peripheral blood repertoire.  Comparison of 
the sequences isolated from the muscle and the peripheral blood were 
conducted in the current study from sample MYO5 which demonstrated that no 
sequences with the same rearrangements were found in the two different sites, 
although only a small sample of the total PBL was examined.  Gene selections 
from MYO5 PBL were observed when compared to normal control values as 
well as the MYO5 muscle repertoire.  The peripheral blood sample obtained for 
patient MYO5 was obtained 3 years after the biopsy was conducted and the 
biopsy examined in this study was taken two years after the diagnostic biopsy 
so alterations in the repertoire as a result of treatments and other immune 
responses cannot be overlooked. 
 
4.3.1 Somatic Hypermutation and Clonal Diversification in Myositis 
At the commencement of this study no previous studies addressed if B cell 
antigen driven responses were occurring within the inflamed muscle of myositis 
patients.  Recently Bradshaw et al (90) demonstrated that antigen specific 
responses were occurring in muscle of DM, PM and IBM patients.  This study 
examined the Ig isotype usage, somatic mutations and clonal expansion of B 
cell and plasma cell infiltrates within myositis samples.  Twelve different muscle 
262 
samples (7 IBM, 3 DM and 2 PM) were examined for the presence of B cells 
and plasma cells, in contrast to the results described in Chapter 3 of this study 
very few CD19+ or CD20+ cells were found within the infiltrating population.  The 
majority of B cell derived cells present within these samples were CD138+ 
plasma cells.  The Ig sequences from these 12 patients were examined and 
reveal that the majority of cells infiltrating these muscle biopsies had class 
switched from IgM to either IgG or IgA, indicating a stimulated response as 
naïve cells do not perform class switching until they have encountered antigen.  
Conversely most of the sequences isolated from control blood samples, 2 from 
IBM patients and 2 from normal controls, contained sequences mostly derived 
from B cells producing IgM sequences.  In obtaining the results for this chapter 
the constant regions of Ig were not accounted for but analysis of these regions 
may have provided evidence of class switching occurring within the myositis 
samples used for this study, similar to that observed by Bradshaw et al, to 
suggest a stimulated response within the muscle.  No collective repertoire 
analysis or gene usage percentages were conducted for each patient of 
myositis subset by Bradshaw et al therefore no comparisons of VH, DH and JH 
gene selections could be made.  Mutational numbers within the sequences from 
the twelve patients isolated by Bradshaw et al demonstrated that these 
sequences contained considerably more mutations in comparison to blood 
control samples.  Bradshaw et al demonstrated that mutational numbers within 
inflammatory myopathies were shown to range from between 16 mutations per 
sequence to 27 per sequence; this was in contrast to control sequences which 
contained between 2 and 17 mutations per sequence.  Interestingly it was noted 
by the authors that approximately 50% of the IgM sequences had between 11 
and 30 mutations per sequence and appeared to have undergone affinity 
maturation without class switching.  In the current study a wide range of 
mutational numbers were observed from essentially naïve cells, in contrast to 
Bradshaw et al, to highly mutated cells.  Clonally related sequences were found 
in 10 of the 12 myositis patients with up to four different clonal sets isolated 
from each muscle section and were not observed in any of the blood samples 
used from either the IBM patients or normal control patients.  These clones 
were mostly found to consist of two clonal variants but up to six different clonal 
variants were observed for some clonally related sets of sequences.  Similarly 
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up to four different clonal sets of sequences were found within muscle sections 
in the current study but this was only observed for sample MYO5 where the 
whole section was used instead of microdissected cellular aggregates from the 
muscle sections.  In contrast only a single clonal set of sequences was isolated 
from each microdissected cellular aggregation which contained between 2 and 
8 clonal variants.   Three of the clones from Bradshaw et al, one from each 
myositis subset, were shown to be derived from VH5-51, VH3-23 and VH3-30 
gene rearrangements.  Clonally related sets of sequences containing the VH 
gene segments VH5-51 and VH3-30 were also found within this study which may 
suggest a common selection for these particular genes between different 
patients.  Further mutational analysis of these clones isolated by Bradshaw et al 
demonstrated that a number of identical replacement mutations were found in 
clones of the same patient, indicating that these clonally related sets of 
sequences may be being driven by the same antigen, while other replacement 
mutations were found in many clones from different patients suggests the 
location of mutational hotspots within the Ig sequence as well as indicating that 
a common antigen may be driving the B cell response.  Laser capture 
microdissection (LCM) experiments were used to further assess the degree of 
clonal expansion within inflammatory myopathy tissue.  LCM was used to divide 
tissue sections from each of the 3 inflammatory myopathies into distinct regions 
from which Ig sequences were obtained and analysed.  Using this method, 
further evidence of clonally related sets of sequences were obtained from DM 
and IBM samples demonstrating the presence of clonally related sets of 
sequences within the same and different regions of the same muscle samples 
indicating the expansion of B cells within inflamed muscle tissue.  This could be 
further examined, in both studies, to incorporate additional muscle sections to 
determine if the clonal expansion extends into additional sections.   Results of 
Bradshaw et al, together with the results presented in this chapter indicate that 
antigen driven B cell responses are occurring within muscle rather than in a 
local lymph node as is classically thought.  In contrast a number of patients 
within the current study did not display evidence of an antigen-driven B cell 
response which may also indicate that these infiltrating B cells and plasma cells 
are mutating in other locations and migrating into these areas of infiltration but 
may also be the result of previous immunosuppressive therapy in some patients 
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as previously discussed, although four sets of clonal related sequences were 
isolated from sample MYO5 who had extensive therapy prior to the biopsy used 
in this study. None of the patients in the study by Bradshaw et al had received 
therapy prior to the study.  In comparison to the entire myositis response only a 
small fraction of the response was assessed in several muscle sections which 
may underestimate the true heterogeneity of the B cell response. Clonal 
diversification may be occurring within other areas of muscle which were not 
examined.        
 
4.3.2 Assignment of Ig Genes  
Ig gene assignments in this study were conducted using the JOINSOLVER 
(291) as well as the IMGT/V-QUEST software (292;293).  Numerous 
programmes are available for identification and assignment of germline genes 
in rearranged Ig gene sequences but as JOINSOLVER concentrates on 
characterisation of the CDR3, a region pivotal in identification of clonally related 
Ig genes which addresses the central aim of this study, this programme was 
deemed appropriate for the current study.  To account for any anomalies 
between software algorithms IMGT/V-QUEST was also used in this study.  
Recent updates to the IMGT/V-QUEST software (293), including detection of 
insertions and deletions which is not carried out by the JOINSOLVER software, 
provided a more accurate comparison between the two algorithms.  Following 
completion of the sequence analysis described in this chapter the 
JOINSOLVER algorithm was updated (The Characterization of Mutations in 
Complementarity Determining Region 3 of Human Ig Gene Rearrangements 
using JoinSolver, Nancy S. Longo, Daniel E. Russ, Eric Schloeffler and Peter E. 
Lipsky (manuscript in preparation)) to accommodate mutations within the DH 
and JH gene segments.  This algorithm change creates a greater accuracy of 
gene assignment as well as assignments of P and N nucleotides, in addition to 
those lost by exonuclease activity.  These changes correspond to the manual 
sequence changes conducted within this study but repeat analysis of the 
sequences generated may result in subtle changes to the results described.  
The use of the original JOINSOLVER algorithm and the updated IMGT/V-
QUEST algorithm in this study generated alignments, which for the most part, 
corresponded to each alignment programme.  A difference in gene assignment 
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was observed for approximately 5% of the sequences isolated from muscle 
infiltrating cells while only 2% of sequences contained insertions and deletions. 
Most of these sequences contained deletions in multiples of 3 from the CDR2 
which allowed the reading frame to be maintained and productive translation of 
the Ig. Although rare, the process of insertions and deletions, especially in the 
CDRs, does create further diversification within the Ig repertoire.    
 
The JOINSOLVER software was compared to the DNAPLOT software (Centre 
for Protein Engineering, www.mrc.cpe.cam.ac.uk) (291) using 144 randomly 
selected unmutated and mutated Ig rearrangements.  For 50% of the 
rearrangements both programmes gave comparable D gene assignments but 
JOINSOLVER performed better than DNAPLOT for 22% of rearrangements 
either by finding a higher consecutive match or because DNAPLOT failed to 
identify any D gene for 25% of the rearrangements.  For all sequences 
JOINSOLVER was able to generate some D gene alignment although this was 
not always significant.  New algorithms have recently been described (341;342).  
SoDA (Somatic Diversification Analysis, http://dulci.org/soda/) (342) is a 
dynamic programming alignment algorithm which takes into consideration the 
variation around the recombination sites from nucleotide addition and 
exonuclease activity and allows for insertions and deletions within the gene.  
This algorithm was compared to both JOINSOLVER and IMGT/V-QUEST using 
a set of artificial Ig sequences generated using a simulation programme; all 
programmes use the same libraries from IMGT.  The authors report that SoDA 
identified more rearrangements accurately compared to both JOINSOLVER and 
IMGT/V-QUEST and observed that JOINSOLVER did not perform as well in 
assigning VH gene segments.  It was also observed that IMGT/V-QUEST 
identified fewer DH genes.  All 3 programmes were similar in identifying JH 
genes but at a 15% mutational rate in the artificial sequences both 
JOINSOLVER and IMGT/V-QUEST performed better.  The SoDA algorithm was 
also tested using 30 randomly selected sequences of which some were used in 
the testing of JOINSOLVER (291).  For 18 of these sequences all 3 
programmes agreed in the gene identification and for the remaining 12 SoDA 
never made an identification, for the V and J genes, that was not supported by 
either JOINSOLVER or IMGT/V-QUEST. The iHMMune align 
266 
(www.emi.unsw.edu.au/~ihmmune/) algorithm has recently been described 
(341) and is an alignment application that uses a hidden Markov model (HMM) 
to model the processes involved in Ig gene rearrangement and maturation. This 
algorithm was compared to JOINSOLVER, IMGT/V-QUEST and SoDA using 
both clonally related and randomly selected Ig sequences.  Analysis of clonally 
related sequences demonstrated that all four programmes agreed with the 
assignment of the longer VH and JH genes, although variations in the predicted 
alleles were observed.  Differences were noted within the DH gene assignments 
between the four programmes. Analysis of randomly selected sequences, from 
the same collection as previous studies was also conducted (251;291).  From 
662 sequences total agreement was only observed for 104 of the sequences, 
while agreement in the VH, DH and JH gene assignments was observed for 357, 
291 and 322 sequences respectively.  From this analysis it was observed that 
iHMMune provided a more accurate identification of the rearranged germline 
genes as fewer disagreements were observed with this algorithm compared to 
the other 3 programmes and DH gene alignments were generally longer and 
contained fewer mismatches.  Although iHMMune accounts for modelling Ig 
processes that are not represented by other algorithms it does not account for 
insertions and deletions within germline genes. 
 
Analysis of the sequences from this study with the SoDA and iHMMune 
algorithms may provide a more accurate assignment of gene as well as 
mutational analysis but due to time constraints and timing of publications this 
was not possible for the current study presented.  The difficulties in assigning 
germline genes, especially DH genes, to rearranged Ig genes because of 
germline gene similarities, somatic mutations, exonuclease and TdT activity 
may make it difficult to determine which algorithm would provide the most 
accurate gene assignments.   
 
4.3.3 Detecting Selection of Ig Sequences  
Analysis of selection in this study was conducted by the method proposed by 
Hershberg et al (294) to detect positive antigen-driven selection in the B cell Ig 
genes from the infiltrating B cell population in both the inflamed muscle of 
myositis patients and skin of vasculitis patients.  Many methods and studies 
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have previously been conducted in order to detect selection (343-346), which 
are based on mutation patterns in Ig sequences.  Shlomchik et al (346) used a 
binomial distribution model to study selection which was based on detecting 
positive selection by comparing the fraction of R mutations in the CDR to all 
other mutations while assuming a fixed level of negative selection.  In the study 
by these authors it was expected that half of R mutations within FW regions 
would be eliminated through negative selection, therefore to compensate for 
this fixed level of negative selection the observed number of R mutations in the 
FW was doubled.  The study also assumed that all V-region mutations occurred 
at random which was later accounted for by a revised and extended binomial 
test by Chang and Casali (344).  This test took into consideration that codons 
with a higher susceptibility for R mutations were generally found within CDRs as 
well as removing the fixed level of negative selection from the test by allowing 
for the total number of mutations within the FW.  Following this method Lossos 
et al (345) described a multinomial distribution test which allowed the frequency 
of mutations to be considered in four categories, R and S mutations in CDR 
and/or FW regions of the gene, which the previous binomial methods had failed 
to account for and were based only on two distribution possibilities.  This 
modified method provided a more accurate method of determining antigen 
selection.  This method consisted of a sum of all the binomial probabilities which 
also took into account the inherent susceptibility of the codons of the CDR and 
FW to R mutations.  The results of this multinomial distribution were tested on 
86 VH gene sequences and were compared to that of the binomial test 
described by Chang and Casali.  In the majority of sequences the p values 
obtained using both methods varied in magnitude but not in statistical 
significance, inconsistencies were only found in 8 sequences resulting in 
opposite statistical conclusions, but the authors argue that the proper 
multinomial test should be applied when determining selection even though 
results from each test proved similar.  Despite the increased accuracy of this 
test in comparison to previous methods, the method failed to consider the 
presence of mutational hot-spots within the gene and assumed that mutations in 
the VH genes occurred randomly which can produce the false appearance of 
selection.   Bose and Sinha (343) also examined antigen selection using a 
modified Chang and Cascali / Lossos method which included the effects of hot-
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spot regions in the Ig gene.  While the Chang and Cascali / Lossos method 
assumes that an Ig gene becomes somatically mutated across its length, the 
Bose and Sinha method depends on the length, the codon usage as well as the 
built-in mutability of different regions of the Ig gene.  The results of this study 
identified false positive results and failed to establish the role of antigen-driven 
selection in clonal maturation and concluded that selection can act both for and 
against R mutations in the CDR as well as in the FW regions depending on the 
relative contribution to affinity and structural integrity of the Ig.  Recently 
Hershberg et al (294) have proposed a new focused binomial test for detecting 
selection in Ig V region sequences.  This study demonstrated that the 
multinomial test by Lossos et al, referred to as a global binomial test by 
Hershberg et al, was mathematically equivalent to the previously proposed 
method by Chang and Cascali. The previous method produced a high 
frequency of Type 1 (specificity) false positives and was unable to distinguish 
whether a relatively high frequency of R mutations in CDR was due to positive 
selection in the CDR or negative selection in the FW - crosstalk between 
positive and negative selection.  The authors also concluded that the statistical 
method of Bose and Sinha was also flawed as it was based on these previous 
methods.  The study by Hershberg et al proposed the focused binomial test for 
selection which corrects for the specificity problem exhibited in the global 
binomial test and eliminates crosstalk.  The newly proposed test fully accounts 
for the effects of microsequence specificity, the likelihood of each nucleotide to 
mutate depending on its local sequence, and incorporated the transition over 
transversion bias of somatic hypermutation for the first time in this type of 
analysis.  This method of detecting selection was tested by re-analysis of 
sequences from diffuse large B cell lymphomas (DLBCL) by Lossos et al (347), 
re-analysis of 76 non-functional rearrangements from previously published 
studies and sequences generated in response to the nitrophenyl (NP) antigen in 
conventional Ig heavy chain transgenic mice which do not mutate or isotype 
switch  their heavy chain loci.  In this system positive selection was expected to 
dominate due to a fixed heavy chain which would cause all mutation and 
selection to be focused on the light lambda chain.  Re-examination of 
sequences from DLBCL using the focused binomial test indicated that many 
false positive results were assigned; positive selection was not found in any of 
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the 54 sequences using the focused binomial test compared to 16 out of 54 
sequences using the method proposed by Lossos et al.  It was thought by the 
authors that this false positive selection was a result of crosstalk as negative 
selection was detected in 88% of the 16 sequences with positive selection.  
Studies from the transgenic mice established that positive selection could be 
detected while the analysis of non-functional sequences detected no selection 
and demonstrated that previous positive selection found in these sequences 
was the result of false positive errors.  The results of this study demonstrate that 
the focused binomial test can be used to detect positive and negative selection 
with high specificity and increased sensitivity which can be applied to single 
sequences in addition to independent mutations in clonally related Ig 
sequences.   
 
4.3.4 Summary 
In summary, the work presented in this chapter demonstrates that B cell 
antigen-driven responses are occurring within the target tissues of myositis 
patients, even in PM patients where B cells are traditionally not thought to play 
a significant part in the pathological process.  Ig sequence analysis from 
infiltrating B cells within these myositis samples established positive and 
negative gene selections within individual patients as well as between different 
myositis subsets.  An accumulation of mutations was also observed in these 
sequences with a number of common mutations observed between various sets 
of sequences which share the same Ig gene rearrangements in addition to 
further independent VH mutations, indicating clonal diversification.  Collectively 
these results strongly indicate that B cells present within the inflamed muscle of 
myositis patients are acting in response to an antigen present at the sites of 
inflammation.  In these samples, especially where clonally related sequences 
were not isolated, the mutational features of the sequences indicated the 
occurrence of antigen-driven diversification, possibly at another site or the re-
circulation of antigen specific B cells from other sites of inflammation.  Although 
the work conducted in this chapter demonstrates B cell antigen-driven 
responses in the target tissues of myositis patients and implicates B cells in the 
pathological process of myositis it does not identify the antigen(s) stimulating 
these responses. 
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Chapter 5 - Phenotypic Cellular Characterisation, VH Gene Repertoire and 
Clonal Diversification of Skin Infiltrating B cells in Vasculitis Patients 
5.1 Introduction 
As previously discussed in Chapter 1, vasculitis is another inflammatory 
condition with unknown aetiology.  Vasculitis can act both systemically or locally 
and in both instances vasculitis can manifest within the skin due to the 
abundant vascular supply.  Very few studies have established a role for B cells 
within the vasculitis disorders but the suspected contribution of immune 
complexes and autoantibodies in vascular pathology, in addition to the clinical 
improvements observed using Rituximab B cell depletive therapy in these 
disorders, strongly indicates a pathogenic role for B cells in vasculitis 
conditions.  The previous work in this study supports the hypothesis that 
infiltrating lymphocytes were being stimulated locally to respond to an 
endogenous antigen resulting in tissue damage and has established an antigen-
driven role for B cells in muscle inflammation.  The work of this chapter tests the 
same hypothesis within skin inflammation of vasculitis patients by addressing 
the following key aims: 
 
• Determine the occurrence, organisation and proliferation of skin 
infiltrating B cells and plasma cells along with the additional cell 
phenotypes (T cells (CD3, CD4, and CD8), macrophages (CD68), 
Follicular dendritic cells (FDC), proliferating cells (Ki67) and 
regulatory T cell (FoxP3)) within skin biopsies. 
• Establish the Ig gene repertoire and VH mutational patterns of 
infiltrating B cells and plasma cells to assess sequence 
characteristics from infiltrating B cells and plasma cells which may 
indicate if clonally related B cells are present within the skin 
inflammatory infiltrate undergoing an antigen-driven B cell response 
• Compare the Ig gene repertoire from skin infiltrating cells to the 
paired peripheral blood repertoire to further assess gene selections 
within the vasculitis patients. 
 
The immunohistological data described in this chapter is summarised in Table 
5.1.
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Table 5.1 Immunohistochemistry Summary Table from Vasculitis Samples 
 
Table 5.1 provides a summary overview of the immunohistochemistry profiles observed from each sample for each vasculitis patient.  The table summarises the 
infiltration of each cell phenotype observed throughout the entire biopsy (n=3-7 sections for each cell phenotype depending on tissue availability) and is not 
based solely on the representative images presented in Figures 5.1, 5.3 and 5.5.  Comparisons were made between cell phenotypes in the same patient and not 
between different patients.  For germinal centre formation, – represents the absence of these structures within the skin sections.  The extent of cellular 
aggregation of infiltrating cells was established for each sample and was based on semi quantitative observations; - represents no cellular aggregation with a 
widespread scattering of lymphocytes throughout the skin section; +, ++, +++ represents an increasing degree of aggregation of lymphocytes respectively 
observed within the skin sections.  N/A was applied to samples where no or very little infiltration was present.  Immunohistochemistry summary profiles were 
based on semi-quantitative observations of cellular infiltration; - indicates where cell phenotypes were absent from the infiltrating population while +, ++, +++ 
represent increasing numbers of cell phenotypes respectively within the skin infiltrating population.  Areas highlighted in yellow indicate where proliferating cell 
phenotypes were observed from fluorescent double immunohistochemistry (IF) experiments, these experiments were not included in the semi quantitative 
analysis and were used solely to establish the population of proliferating cells.   
 
 
 
 
 
 
 
 
Sample Germinal Centre 
Formation 
Cellular 
Aggregation CD20 
Plasma 
Cell FDC CD3 CD4 CD8 CD68 FoxP3 Ki67 -IgG1 -IgG2a -IgM 
VAS1 - - - +++ - ++ ++ + ++ + 
-  
(+ IF only) - - - 
VAS6 - + + +++ - ++ ++ + +++ + ++ - - - 
VAS7 - + - +++ - + + + ++ + - - - - 
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5.2 Phenotypic Characterisation of Cellular Infiltrates in Vasculitis 
Patients 
5.2.1 Sample VAS1 
For sample VAS1 no significant regions of aggregation were observed within 
the skin biopsy, infiltrating cells were distributed throughout the entire biopsy 
(Figure 5.1).  No clear association between infiltrating cell populations and 
blood vessels was observed in the sections examined.   No CD20+ (A) cells or 
FDCs (B) were present within the section; small numbers of CD20+ cells were 
later observed in double immunofluorescent experiments (Figure 5.2).  The 
major types of infiltrating cells included plasma cells (C), CD3+ (D), CD4+ (E) 
and CD8+ (F) cells.  As observed within myositis samples the numbers of CD8+ 
cells appears to be reduced in comparison to the CD3 and CD4 cell markers.  
Unlike some of the myositis samples the number of CD4+ cells did not appear to 
be greater than that of the CD3+ cells.  No proliferating cells (G) were observed 
within the VAS1 sections used in these experiments but there was a large 
infiltrate of CD68+ (H) cells.  FoxP3 (I) staining revealed a small number of 
FoxP3+ cells were present within the biopsy.  The use of negative control 
isotype antibodies produced no non-specific staining (J-L). 
 
Analysis of Ki67+ proliferating cells at a greater tissue depth to the sections 
used for the above experiments identified proliferating CD4+ (C) and CD68+ (E) 
cells (Figure 5.2).  Although FoxP3+ cells were identified from initial staining, 
Figure 5.1, no FoxP3 cells were observed during double staining experiments.  
Negative control staining produced no non-specific staining. 
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Figure 5.1 Immunohistochemistry of serial skin sections of Sample VAS1. 
 
A representative example of serial skin sections from sample VAS1 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control (L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the skin section.  Images A – L: 400X 
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Figure 5.2 Double Immunohistochemical staining of serial vasculitis sections of sample 
VAS1  
 
A representative example of serial skin sections from sample VAS1 stained for CD20 (A), CD3 (B), 
CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all sections were stained 
with Ki67 and visualised by Texas Red Avidin D.  This allowed the type of proliferating cells within 
the vasculitis sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  
Arrows identify proliferating cells within the sections. 
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5.2.2 Sample VAS6 
 
A heavy cellular infiltrate was observed within sample VAS6 (Figure 5.3).  
These infiltrating cells formed very loose aggregates of cells in a few areas of 
the section but a large proportion of cells were distributed throughout the whole 
section.  No clear association between infiltrating cell populations and blood 
vessels was observed in the sections examined.  The dominant cell type 
present within sample VAS6 was identified as plasma cells (C). Very few CD20+ 
(A) cells and no FDCs (B) were found within the sample.  CD20+ cells present 
in the sample did appear to form part of the aggregates of cells and were not 
found dispersed throughout the entire section.  CD3+ (D) and CD4+ (E) cells 
were present, both within cellular aggregates as well as the other areas of 
infiltration.  CD8+ (F) cells were also observed but this was reduced in 
comparison to CD3+ and CD4+ cells.  A considerable infiltration of Ki67+ (G) and 
CD68+ (H) cells were also present within sections of sample VAS6 as well as a 
number of FoxP3+ (I) cells.  As with previous staining no non-specific staining 
was observed within the sample (J-L). 
 
In sample VAS6 proliferating cells were identified as CD4+ (C), CD8+ (D), 
CD68+ (E), FoxP3+ (F) cells with a random CD20+ (A) cell also present within 
the infiltrating population (Figure 5.4).  Negative control experiments with the 
antibody isotype controls showed no non-specific staining within sections.   
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Figure 5.3 Immunohistochemistry of serial skin sections of Sample VAS6. 
 
A representative example of serial skin sections from sample VAS6 stained for CD20 
(A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), FoxP3 
(I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control (L) and 
visualised by APAAP and New Fuschin substrate to establish cellular infiltrates within 
the skin section.  Images A – L: 400X 
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Figure 5.4 Double Immunohistochemical staining of serial vasculitis sections of 
sample VAS6  
 
A representative example of serial skin sections from sample VAS6 stained for CD20 (A), 
CD3 (B), CD4 (C), CD8 (D), CD68 (E) FoxP3 (F) and visualised by Fluorescein Avidin D 
before all sections were stained with Ki67 and visualised by Texas Red Avidin D.  This 
allowed the type of proliferating cells within the vasculitis sample to be identified.  Images 
were taken at 630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within 
the sections. 
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5.2.3 Sample VAS7 
 
For sample VAS7 the cellular distribution and phenotypes were similar to that of 
the previous vasculitis sample, VAS6 (Figure 5.5), although a small proportion 
of infiltrating cell populations were shown to associate with blood vessels.  
Predominately plasma cells (C) infiltrated sample VAS7 with very few CD20+ 
(A) cells or FDCs (B).  CD3+ (D), CD4+ (E), CD8+ (F) and CD68+ (H) cells were 
also present within the sample as well as a number of FoxP3+ (I) cells.  VAS6 
and VAS7 cellular populations were similar to each other except for the 
presence of Ki67+ (G) cells.  No Ki67+ cells were present within these sections 
of VAS7 tested for cellular markers.  As with previous samples no non-specific 
staining was observed within sample VAS7 (J-L). 
 
Despite Ki67+ cells being absent from the cellular infiltrate for the initial cell 
characterisation further sections were tested for the presence of Ki67+ cells in 
double staining experiments (Figure 5.6).   No further evidence of proliferating 
cells could be found within sample VAS7.  Negative control staining produced 
no non-specific staining. 
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Figure 5.5 Immunohistochemistry of serial skin sections of Sample VAS7. 
 
A representative example of serial skin sections from sample VAS7 stained for CD20 
(A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3, denoted by circle, (I), IgG1 Negative control (J), IgG2a Negative control (K), 
IgM Negative control (L) and visualised by APAAP and New Fuschin substrate to 
establish cellular infiltrates within the skin section.  Images A – L: 400X 
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Figure 5.6 Double Immunohistochemical staining of serial vasculitis sections of sample VAS7  
 
A representative example of serial skin sections from sample VAS7 stained for CD3(A), CD4 (B), CD8 
(C), CD68 (D), FoxP3 (E) and visualised by Fluorescein Avidin D before all sections were stained with 
Ki67 and visualised by Texas Red Avidin D.  This allowed the type of proliferating cells within the 
vasculitis sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows 
identify proliferating cells within the sections. 
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5.3 VH Repertoire in Vasculitis Patients 
 
5.3.1 Sample VAS1 
As previously described in section 5.2.1 the cellular infiltrate of sample VAS1 
contained limited CD20+ B cells but plasma cells were widely distributed within 
the sample.  Microdissection and DNA amplification was conducted to establish 
the Ig gene rearrangements present within these infiltrating cells (Figure 5.7). 
Three different functional gene rearrangements were isolated from infiltrating 
cells (Table 5.2A).  These sequences utilised the VH1-18*01, VH3-23*01 and 
VH3-33*01 gene segments which were highly mutated, with between 21 and 30 
mutations per sequence.  A DH gene could only be assigned to 1 
rearrangement, VH1-18*01, in all other cases the number of consecutive 
matches was too short to statistically assign a DH gene.  JH5, 4 and 6 gene 
segments were used in the VH1-18*01, VH3-23*01 and 3-33*01 gene segments 
respectively.  The isolated sequences were highly mutated and the percentage 
of mutations present within CDR1 was comparable to that of framework regions 
but an increase in mutational percentages was observed within CDR2 of all of 
the isolated sequences.  Analysis of the R and S mutations revealed that there 
was only significant selection for the VH1-18*01 Ig rearrangement, where there 
was a significant negative selection within the FW regions (Table 5.2B).  CDR3 
lengths were found to range from 13 to 23 amino acids in these sequences.  As 
a DH gene assignment could only be made for the VH1-18*01 rearrangement, 
this was the only Ig rearrangement where analysis of the junctional regions 
could be conducted.  In this Ig rearrangement no P nucleotides were assigned 
at either the VD or DJ junction.  3 and 6 N nucleotides were assigned at the VD 
and DJ junctions respectively while exonuclease activity was found to remove 1, 
5, 7 and 10 nucleotides respectively from the 3’VH, 5’DH, 3’DH and 5’JH gene 
segments of the junction.    For gene rearrangements containing the VH gene 
segments VH3-23 and VH3-33, duplicate copies of the sequence were isolated 
that contained different somatic mutations.  These could not be deemed as 
clonally related sets of genes as there was only one somatic mutation difference 
between each set which could have occurred as a result of PCR error. 
 
No differences in gene assignments between the JOINSOLVER and IMGT/V-
QUEST were observed for any of the Ig rearrangements. 
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Before Microdissection After Microdissection 
A 
B 
Figure 5.7 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS1 
 
The region of plasma cell infiltration was microdissected from sample VAS1.  Figure 5.7A 
demonstrates the microdissection of the region of cellular infiltration.  Images were taken at 
400X.  PCR reactions were conducted for DNA isolated form the muscle sections (Figure 
5.7B) in addition to DNA isolated from PBL (Figure 5.7C), as previously described in 
Chapter 2.  – indicates negative control PCR reactions where DNA was substituted with 
water while + indicates positive control PCR reactions using peripheral blood mononuclear 
cells isolated from peripheral blood of a healthy individual. Results show amplification of all 
VH families.     
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Mutational Distribution  
(% of length) 
 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-18*01 2-2*01 5*02 1 30 ARDDCSGTSCHADL 14 7.7 13.3 20.4 33 16 (+3) 
3-23*01 No D gene Assignment 4*02 2 25, 26 VKTTVINLSYFED 13 7.7, 8.1 6.7, 6.7 13, 13 36 8 
3-33*01 No D gene Assignment 6*03 2 21, 22 ARAKIVAVSASPSMGSYYHYMDV 23 6.3, 6.8 6.7, 6.7 11.1, 11.1 50 9 
 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-18*01 2-2*01 5*02 1 30 10 3 0.47674 -0.9986 9 8 0.68809 -0.0303 
3-23*01 No D gene Assignment 4*02 2 25 7 1 0.45266 0.72724 11 6 0.65 -0.7226 
    26 7 1 0.43496 0.63113 12 6 0.65077 -0.8478 
3-33*01 No D gene Assignment 6*03 2 21 4 3 0.46759 -0.3722 9 5 0.67394 -0.2219 
    22 4 3 0.46759 -0.3722 10 5 0.67394 -0.299 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 A&B Sequence Analysis from Sample VAS1 
 
Table 5.2A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS1 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.2B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al  
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
 
B 
A 
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5.3.1.1 VH Repertoire from VAS1 PBL 
From the paired blood sample obtained at the time of biopsy, 29 functional and 
2 non-functional sequences were identified (Table 5.3).  Using Chi Square 
analysis, a significant selection for the use of VH2 gene segments was observed 
which was significant against normal control values (Figure 5.8A).  A selection 
against VH4 gene segments was also observed, significant against both the 
normal control values and the baseline germline composition.  No other 
selections for the remaining VH families was observed, although selections for 
VH1-3, 1-69, 2-26, 2-5 and 3-21 individual gene segments was observed.  DH 
genes could be statistically assigned in 55.2% of the sequences isolated from 
the blood repertoire, as described using the method in section 2.3.12.3 and the 
V-J lengths and consecutive D match lengths in Table 5.3.  Comparing the 
distribution of these identified DH gene segments against control values 
demonstrated a significant selection for the use of DH3 gene segments in the Ig 
rearrangements, in particular DH3-22 gene segments which was used 
significantly more than normal controls (Figure 5.8B).  DH3 family selection was 
significant against both control values.  No other gene selections were observed 
within the DH repertoire.  Analysis of the JH gene segments revealed a selection 
against JH1 and JH2 gene segments which was only significant to the baseline 
germline complexity (Figure 5.8C).  Negative selection was also observed for 
the use of JH4 and JH5 gene segments, both were significant against normal 
control values but JH5 was also significant against the germline values.  
Conversely a selection for the use of JH3 and JH6 gene segments was observed 
within the VAS1 PBL repertoire, both were significant against the normal control 
values only.  No common gene rearrangements were observed between the 
infiltrating population in the skin and the peripheral blood.    
 
The IMGT/V-QUEST found deletions in the VH3-38*02 DH3-9*01 JH4*02 Ig 
rearrangement.  Using JOINSOLVER this rearrangement was non-functional, 
the same arrangement was observed using IMGT/V-QUEST before the 
detection of deletions.  6 nucleotides were found to have been deleted from the 
CDR2.  Once restored both algorithms identified a functional rearrangement 
consisting of the VH3-23*04 DH3-9*01 JH4*02 gene segments with 23 VH 
mutations.  No other anomalies were detected. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01 No D gene Assignment 4*02 1 30 ARDLPDTGYFDP 27 6 
1-03*01 3-10*01 4*02 1 0 ARVGVVRGDFYFDY 22 12 
1-18*01 No D gene Assignment 3*02 1 3 ARASGDDDAFDI 13 6 
1-46*01 3-22*01 3*02 1 0 ARRGPLAGNYYDSSGYYSGAFDI 51 28 (+3) 
1-69*04 No D gene Assignment 3*02 1 0 ARGRGDAFDI 11 7 
1-69*04 3-22*01 3*02 1 0 ARRGPLAGNYYDSSGYYSGAFDI 51 28 (+3) 
1-69*04 3-22*01 3*02 1 0 ARGSDYYDSSGSNYEAFDI 38 22 (+1) 
1-69*09 No D gene Assignment 6*03 1 1 ARVSESWEVTVAKSVHMDV 39 8 
1-69*09 3-22*01 4*02 1 0 ARETGYYDSSGYWN 32 23 
2-05*09 3-22*01 3*02 1 7 AHRRYSDSSGHGGAFDI 29 17 (+1) 
2-05*10 5-24*01 4*02 1 0 AHTERWLPLDY 23 14 (+1) 
2-05*10 No D gene Assignment 6*03 1 26 VHTPPHYYYIDV 29 6 
2-26*01 No D gene Assignment 6*03 1 35 ARVQKVQLWREAYYYYLDV 43 8 
3-07*01 3-10*02 4*02 1 14 ARILSGNSYDTCDF 38 14 (+2) 
3-21*01 2-2*01 6*03 2 0 ARDGVYCSSTSCYLRNYYYYMDV 38 25 
    1 ARDGVYCSSTSCYLRNYYYYMDV 38 25 
3-21*01 3-3*01 6*03 2 0 ARDRGLYDFWSHTPNYMDV 35 14 
    2 ARDRGLYDFWSHTPNYMDV 35 14 
3-21*01 6-6*01 6*03 1 0 ARDTSSGIAARDYYYMDV 28 13 
3-21*01 No D gene Assignment 6*03 1 0 ARVPTSRGDYYMDV 18 7 
3-21*01 No D gene Assignment 6*03 1 1 ARDPPPLGNQGYYYMDV 24 7 
3-23*01 2-15*01R 3*02 1 18 AKGGVAAGYSFDI 29 12 
3-30*03 3-3*01 4*02 1 12 AKDGAPRTPFGVVIIFGFDY 46 18 
3-38*02 3-9*01 4*02 (1) 37 AKIGNHDLSTAYYNLFDY 43 18 (+2) 
3-48*02 No D gene Assignment 3*01 1 0 ARDSARQDPIL 23 5 
3-66*01 No D gene Assignment 4*02 1 15 ATVSRGALDY 18 6 
4-39*01 No D gene Assignment 6*03 1 0 ARCRYEVPVFYYMDV 24 6 
5-51*01 2-15*01 6*03 1 0 ARLYCSGGSCKTRAPYYYYMDV 38 21 
5-51*01 3-22*01 2*01 (1) 2 ARLVDYYYDSSGYSPAVLRS 40 25 
5-51*01 No D gene Assignment 6*03 1 0 ARHYATVRYYYMDV 16 7 
6-01*01 No D gene Assignment 3*01 1 16 VRGFRSAFDF 27 5 
 
 
 
 
 
Table 5.3 Heavy chain genes identified from the PBL sample of vasculitis patient VAS1 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the VAS1 PBL sample.  The total number of sequences isolated 
is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths and 
consecutive D match lengths (bp) were also identified using the JOINSOLVER software and allowed 
assignment of the DH genes as described in section 2.3.12.3.    
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Figure 5.8 VH Gene Family Usage of VAS1 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
 
 
A 
B 
C 
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5.3.1.2 Mutational Analysis of PBL B Cell Ig Sequences of Sample VAS1 
Analysis of the VH mutations of these sequences demonstrated that 
approximately 65% of the sequences contained 2 or less mutations, an 
essentially naïve population (Figure 5.9A).  The remainder of the sequences 
were highly mutated; approximately 10% of the Ig sequences from the PBL 
repertoire contained over 21 VH mutations.  In Ig rearrangements where 
mutations were observed, a slightly higher percentage of these mutations were 
found within CDRs compared to the FW regions (Figure 5.9B).  Analysis of the 
R and S mutations to assess selection within these Ig rearrangements 
demonstrated that a significant selection was only observed for one Ig 
rearrangement (Table 5.4).  Positive selection within the CDRs was observed 
for the VH3-07*01 DH3-10*02 JH4*02 rearrangement, no other significant 
selection were observed.       
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5.3.1.3 CDR3 Analysis 
Analysis of the VDJ junctional area of these sequences demonstrated that the 
functional Ig rearrangements had a mean CDR3 length of 16.1 ± 0.8 amino 
acids while non-functional rearrangements contained CDR3 lengths of 19 ± 1.0 
amino acids, which were not significantly different (Table 5.5).
A 
B 
Figure 5.9 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in VAS1 PBL 
 
Figure 5.9A - The number of mutations 
within functional rearranged genes were 
analysed in the PBL sample of VAS1.  
Base differences within the first 24 bases 
of sequence were disregarded as this 
part of the sequence binds the 5’ VH 
primer.  Graph demonstrates that PBL Ig 
rearrangements were essentially from a 
naïve population with a small percentage 
of highly mutated rearrangements. 
 
 Figure 5.9B - The locations of mutations 
observed within functional rearranged 
genes were categorised as being within 
FR or CDR regions.  The numbers of 
mutations within these regions were 
expressed as a percentage of the entire 
length of the region to correct for the 
longer lengths observed within the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR regions compared to framework 
regions. 
288 
 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-03*01 No D gene Assignment 4*02 1 30 11 1 0.47328 0.16256 13 5 0.7011 -0.8525 
1-03*01 3-10*01 4*02 1 0 - - - - - - - - 
1-18*01 No D gene Assignment 3*02 1 3 0 1 0.47868 -0.2718 1 1 0.68628 -0.2644 
1-46*01 3-22*01 3*02 1 0 - - - - - - - - 
1-69*04 No D gene Assignment 3*02 1 0 - - - - - - - - 
1-69*04 3-22*01 3*02 1 0 - - - - - - - - 
1-69*04 3-22*01 3*02 1 0 - - - - - - - - 
1-69*09 No D gene Assignment 6*03 1 1 0 0 0.46644 0 1 0 0.67237 0.67237 
2-05*09 3-22*01 3*02 1 7 5 0 0.43955 0.17116 0 2 0.67868 -0.1032 
2-05*10 5-24*01 4*02 1 0 - - - - - - - - 
2-05*10 No D gene Assignment 6*03 1 26 5 4 0.44582 -0.3986 11 6 0.67963 -0.1421 
2-26*01 No D gene Assignment 6*03 1 35 10 4 0.46467 -0.6477 11 10 0.68234 -0.0138 
3-07*01 3-10*02 4*02 1 14 10 0 0.44584 0.02267 1 3 0.668 -0.1221 
3-21*01 2-2*01 6*03 2 0 - - - - - - - - 
    1 0 0 0.49844 0 1 0 0.65896 0.65896 
3-21*01 3-3*01 6*03 2 0 - - - - - - - - 
    2 0 0 0.49844 -0.5016 2 1 0.65896 1.01654 
3-21*01 6-6*01 6*03 1 0 - - - - - - - - 
3-21*01 No D gene Assignment 6*03 1 0 - - - - - - - - 
3-21*01 No D gene Assignment 6*03 1 1 0 0 0.49844 0 1 0 0.65896 
0.65896 
Cont… 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-23*01 2-15*01R 3*02 1 18 8 0 0.45436 0.39523 4 6 0.64769 -0.1247 
3-30*03 3-3*01 4*02 1 12 5 0 0.46794 0.09263 6 1 0.6723 0.33596 
3-38*02 3-9*01 4*02 (1) 37 13 2 0.4377 0.31463 13 9 0.66934 -0.1977 
3-48*02 No D gene Assignment 3*01 1 0 - - - - - - - - 
3-66*01 No D gene Assignment 4*02 1 15 8 1 0.46708 0.18261 3 3 0.66604 -0.2199 
4-39*01 No D gene Assignment 6*03 1 0 - - - - - - - - 
5-51*01 2-15*01 6*03 1 0 - - - - - - - - 
5-51*01 3-22*01 2*01 (1) 2 1 0 0.43336 0.43336 1 0 0.69901 0.69901 
5-51*01 No D gene Assignment 6*03 1 0 - - - - - - - - 
6-01*01 No D gene Assignment 3*01 1 16 6 1 0.47428 0.65021 5 4 0.65306 -0.3332 
 
Table 5.4 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample VAS1 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and 
the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive 
or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene 
sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR respectively.  pCDR represents the probability of 
having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while p-CDR is the p-value of the focused binominal 
test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW represent the 
probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused 
binominal test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a 
negative sign or if the number of mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were 
deemed significant for selection. 
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Analysis of these CDR3 lengths in comparison to the VH mutational numbers did 
not reveal any significant changes to the CDR3 lengths in the different 
mutational groups (Figure 5.10).  Further analysis of the junctional areas 
demonstrated that there were an increased number of P nucleotides at the VD 
junction in functional sequences compared to the DJ junction.  A significant 
increase in exonuclease activity was found at the 3’VH gene portion of the 
junction in non-functional rearrangements compared to the functional 
population.  This reduced exonuclease activity at the 3’VH gene portion of the 
junction was also significantly reduced compared to the 5’DH and 5’JH gene 
portions of the junction.      
Functional 16.1 ± 0.8 CDR3 Length Non-Functional 19 ± 1.0 
 VD Junction DJ Junction 
Functional 0.8 ± 0.2** 0.2 ± 0.1 P Nucleotide Non-Functional 0.5 ± 0.5 0.5 ± 0.5 
Functional 8 ± 1.5 7 ± 0.9 N Nucleotide Non-Functional 13.5 ± 5.5 4.5 ± 1.5 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 0.9 ± 0.3* 4.3 ± 0.8 Θ 6.6 ± 1.3 7.1 ± 1 Θ Exonuclease 
Activity Non-Functional 4 ± 3* 6 ± 5 2.5 ± 2.5 5 ± 0 
 
Table 5.5 CDR3 and Junctional Analysis in VAS1 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all myositis immunoglobulin sequences as well as in 
DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no non-functional 
sequences were identified and values could not be calculated were recorded as non applicable 
(N/A).  * indicates a significant difference between functional and non-functional sequences while ** 
indicates a significant difference between the VD and DJ junctions established using an unpaired t 
test.   Θ represents a significant difference from 3’VH. 
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No clonally related sequences were observed in the PBL repertoire. 
 
Figure 5.10 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated for 
immunoglobulin sequences according the 
number of mutations within the VH segment 
of the gene rearrangement to establish any 
relationship between mutational number 
and CDR3 length.  Results are given as 
Mean amino acid CDR3 length ± SEM.  
Groups were compared for statistical 
significance using the Tukey-Kramer test 
for multiple comparisons.  The graph 
demonstrates that no significant changes in 
CDR3 length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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5.3.2 Sample VAS6 
As shown in Figure 5.3 there was very little evidence of CD20+ cells within 
sample VAS6 but there was a large infiltration of plasma cells.  Nested PCR 
reactions (Figure 5.11) from 2 areas of plasma cells dissected yielded 7 
functional Ig’s with 4 different gene rearrangements, as shown in Table 5.6A.  
These sequences were isolated multiple times from the same vasculitis sample.  
As shown in Table 5.6, the infiltrating cells used VH1, VH3 and VH4 family gene 
segments, DH genes, DH4-17*01 and DH5-12*01, could only be assigned in the 
VH3-30*03 and VH4-59*01 rearrangements respectively.  The remaining 
segments of the gene rearrangements were composed of JH2, 4 and 6 family 
members. The VH1 gene rearrangement and both sets of the VH3 family genes 
were highly mutated with over 16 mutations whilst the VH4 set of genes were 
essentially non-mutated with between 0 and 2 mutations.  Mutational 
distribution within the genes showed a similar pattern to that observed within 
muscle biopsies; a greater percentage of mutations were evident within CDRs 
in comparison to framework regions for each mutated sequence, with a higher 
percentage of mutations within CDR2 in comparison to CDR1.  Despite the 
large number of mutations in most of the Ig rearrangements from sample VAS6 
no significant positive or negative selection was observed in either of the FW or 
CDRs (Table 5.6B).  Similar CDR3 lengths were observed for these sequences 
with a range between 14 and 18 amino acids which may correspond to a similar 
epitope mediating the response within the skin of sample VAS6.  Junctional 
analysis could be conducted on the VH3-30*03 and VH4-59*01 rearrangements 
where DH genes could be assigned.  P nucleotides, 2, were assigned at the VD 
junction of the VH3-30*03 rearrangements, no other P nucleotides were 
identified in any other gene.  For the VH3-30*03 rearrangement 4 and 8 N 
nucleotides were observed at the VD and DJ junctions while 3 and 6 were 
observed in the VH4-59*01 Ig genes.  Exonuclease activity was only observed 
at the 5’JH region of the VH3-30*03 genes where 3 nucleotides were removed.  
For the VH4-59*01 2, 8, 2 and 0 nucleotides were found to be removed at the 
3’VH, 5’DH, 3’DH and 5’JH regions respectively.  The different mutational patterns 
evident within this repertoire were not sufficient evidence for clonal diversity as 
the mutations present were within the PCR error rate.  No differences were 
observed between the two gene assignment algorithms used in this study. 
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Before Microdissection After Microdissection 
A 
B 
C 
Figure 5.11 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS6 
 
Regions of plasma cell infiltration were microdissected from sample VAS6.  Figure 5.11A 
and B demonstrates the microdissection of 2 regions of cellular infiltration.  Images were 
taken at 400X.  PCR reactions were conducted for DNA isolated form the muscle sections 
(Figure 5.11C) in addition to DNA isolated from PBL (Figure 5.11D), as previously 
described in Chapter 2.  – indicates negative control PCR reactions where DNA was 
substituted with water while + indicates positive control PCR reactions using peripheral 
blood mononuclear cells isolated from peripheral blood of a healthy individual.  Results 
show amplification of VH1 to 5 families from muscle tissue but amplification of all 6 families 
from the blood sample. 
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Mutational Distribution (% of 
length) VH 
Gene DH Gene 
JH 
Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-46*02 No D gene Assignment 4*02 1 17 ARDPLDCPNNKCYLYFDH 18 3.2 13.3 14.8 44 7 
3-23*01 No D gene Assignment 6*02 1 25 AKDPILRGSWRGVVAMDV 18 6.3 13.3 16.7 36 8 
3-30*03 4-17*01 2*01 2 16, 17 AKEGHDYGDYFYVWLDH 17 4.5, 5 6.7, 6.7 9.3, 9.3 49 16 
4-59*01 5-12*01 4*02 3 0, 2, 2 ARQSGYDSPNYFDY 14 0, 0.9, 0.5 0, 0, 0 0, 0, 2 22 13 
 
 
 
 
VH Gene 
DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-46*02 No D gene Assignment 4*02 1 17 7 3 0.47666 0.47764 5 2 0.67527 -0.2639 
3-23*01 No D gene Assignment 6*02 1 25 8 3 0.44592 0.50796 10 4 0.65167 -0.584 
3-30*03 4-17*01 2*01 2 16 6 0 0.46606 0.41859 6 4 0.67432 -0.6176 
    17 6 0 0.46606 0.41859 7 4 0.67432 -0.7755 
4-59*01 5-12*01 4*02 3 0 - - - - - - - - 
    2 0 0 0.44001 -0.56 0 2 0.65645 -0.118 
    2 1 0 0.44001 0.44001 1 0 0.65645 0.65645 
 
 
 
 
B 
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Table 5.6 A&B Sequence Analysis from Sample VAS6 
 
Table 5.6A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS6 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.6B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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5.3.2.1 VH Repertoire from VAS6 PBL 
In addition to Ig analysis from the skin infiltrating repertoire of sample VAS6, the 
Ig repertoire of the patient’s peripheral blood was also assessed from a paired 
blood sample at the time of biopsy.  From this sample 36 functional and 9 non-
functional sequences were identified (Table 5.7).  Gene usage analysis of these 
functional rearrangements demonstrated a positive selection for the use of VH2 
gene segments which was significant against both normal control values and 
the baseline germline complexity (Figure 5.12A).  In addition to this positive 
selection, a selection for VH7 gene segments was also observed within the PBL 
repertoire which was significant against normal control values.  A selection 
against VH3 and VH4 gene segments was also observed, these were both 
significant against normal control values while the declined use of VH4 gene 
segments was also significant against the baseline germline complexity.  The 
selection for VH2 and against VH4 gene segments was also observed from the 
PBL sample of patient VAS1 (Figure 5.8A).  Analysis for the use of individual 
gene segments demonstrated a significant selection for the use of the VH1-3, 1-
69 and 2-5 gene segments, these gene selections were also observed within 
the PBL sample of patient VAS1.  In this sample DH genes could be statistically 
assigned in 66.7% of the Ig rearrangements.  From these assignments a 
positive selection was observed for DH3 gene but this was only significant 
against the germline complexity and not against normal control values (Figure 
5.12B).  The use of all other DH gene family segments mirrored the use of the 
normal control values.  Comparing the use of the individual DH gene segments 
to the normal control values, a selection for the use of DH3-9, 5-12 and 6-13 
gene segments was observed.  The repertoire for the use of the JH segments 
also mirrored the normal control repertoire with the exception of the JH2 gene 
segments.  Analysis of this sample demonstrated that there was a significant 
selection for the use of these gene segments.  This selection was significant 
against normal control values but not the baseline germline complexity.  No 
common gene rearrangements were observed between the infiltrating 
population in the skin and the peripheral blood.    
 
No differences in gene assignments from the JOINSOLVER and IMGT/V-
QUEST algorithms were observed for this sample.    
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01 2-2*01 3*02 1 0 ARDRKVVPALDAFDI 21 12 
1-03*01 5-12*01 6*02 1 1 ARVDIVASNSYYYGMDV 23 14 
1-69*01 2-21*02 3*02 1 0 AREALAYCGGDCYSRDAFDI 37 28 
1-69*01 3-10*01 4*02 1 17 ATEIGDMDRGVTRPEF 43 16 (+1) 
1-69*01 6-13*01 6*02 1 2 ARATGYSSRYYYYGMDV 20 14 
1-69*01 6-19*01 3*02 (1) 0 ARGGSHAKYPRIAVAGTPSRGWMLLLI 58 19 
1-69*01 No D gene Assignment 2*01 1 24 ASVRFGESWYFDL 36 8 
1-69*01 No D gene Assignment 5*02 (1) 1 ARDLG*VYQLSHTPEDPTGST 41 9 
1-69*02 3-10*01 3*02 1 0 ARVLDLGYGSGSYYNVFDAFDI 44 24 
2-05*04 3-9*01 5*02 1 20 AHRRNPEYSLTGVNWFDP 41 10 
2-05*04 No D gene Assignment 4*02 1 20 AHRLSISYYFDF 34 7 
2-05*10 1-26*01 5*02 1 13 AHSPSGTYHKQYNWFDP 30 12 (+1) 
2-05*10 3-10*01 1*01 1 0 ARLTPTITMVRGVIITTGEYFQH 49 29 
2-05*10 3-16*02 2*01 1 0 AHWSYDYVWGSYRSPISDWYFDL 48 28 
2-05*10 3-22*01 4*02 1 8 VLLTYYDSSVYPYS 40 21 (+1) 
2-05*10 No D gene Assignment 4*01 1 7 AHRRGAPGYFDY 19 7 
2-05*10 No D gene Assignment 4*02 (1) 1 AHPTELTILARL 27 7 
2-05*10 No D gene Assignment 4*02 1 2 AVAANADYFDY 16 7 
3-11*03 3-22*01 3*02 1 1 ARGVYDSSGYTAFDI 26 18 
3-15*01 No D gene Assignment 4*02 1 10 TTEEYTFGYYIDY 25 7 
3-15*01 No D gene Assignment 4*02 1 9 STVDD 13 7 
3-21*01 5-12*01 4*02 1 0 ARDVEVVATEPDY 24 11 
3-21*01 6-13*01 6*02 1 0 AREGDSSSWGRGGGKYGMDV 37 14 
3-30*03 3-10*01 6*02 1 0 AKRRGSGSYYKLYYYYGMDV 32 20 
3-33*01 No D gene Assignment 2*01 1 12 ARDPPISISVAVSYWYFDL 30 9 
3-49*01 2-15*01 2*01 1 1 AREGPGLLTPYCSGGSCLYWYFDL 53 22 
3-66*01 3-10*01 5*02 (1) 31 SPITMVRGVIITSCLL*FLVRP 54 29 
3-66*01 4-23*01 4*02 1 27 ARVGNSCGIEY 28 10 
4-34*01 3-22*01 1*01 1 1 ARYRLTPNYYDSREGQEDQH 47 16 
4-34*01 3-22*01 6*02 (1) 1 ASRRITMIVVVPQVWT 33 23 
4-34*03 3-22*01 3*02 1 31 ARDAYGEEGYYDSSGYYYSLQDAFDI 63 27 
5-51*01 No D gene Assignment 2*01 1 13 ARGNTGWSEYWYFDL 21 8 
5-51*03 3-10*01 5*02 (1) 0 VNAGRITMVRGVIRPSTTGST 47 27 
5-51*03 4-17*01 2*01 1 0 ARVNDYGDSWYFDL 21 12 
6-01*01 No D gene Assignment 3*02 1 10 VRDSGIGLDAFDI 23 7 
6*01-01 No D gene Assignment 3*02 (1) 0 ARRGS*APMMLLI 23 8 
6-01*01 6-19*01 4*02 (1) 0 ARDLWQWLACTTLT 22 
11 
Cont… 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
6-01*01 6-13*01 6*02 1 1 ARGGAAAGTDYYYYGMDV 21 15 
7-04-1*01 2-2*03 6*02 (1) 0 APLGTWRA**YQLLWGMPTTTTVWT 50 20 
7-04-1*02 No D gene Assignment 1*01 1 14 AREGSIEVTAPGYFQH 27 9 
7-04-1*02 No D gene Assignment 5*02 1 1 ARDEKGFGFDP 14 7 
7-04-1*02 No D gene Assignment 6*02 1 1 AREGGHVYMDV 15 6 
7-04-1*02 3-9*01 4*02 2 1 AREHYDILTGYYEWRGPDYFDY 44 26 
    2 AREHYDILTGYYEWRGPDYFDY 44 26 
7-04-1*02 6-13*01R 3*02 1 0 ARDFRYQLPHDAFDI 21 11 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.2 Mutational Analysis of PBL B Cell Ig Sequences of Sample VAS6  
 
As observed within the PBL sample of VAS1 the majority of cells within the 
blood sample VAS6 were essentially from a naïve population; approximately 
60% of the sequences contained between 0 and 2 mutations within the VH 
region (Figure 5.13A).  The remaining sequences contained from 3 mutations 
per sequence to over 21 mutations per sequence.  Most of these remaining 
sequences, approximately 20%, contained between 11 and 20 mutations.  A 
higher percentage of these mutations were located within the CDRs of the Ig 
rearrangements, with a higher percentage observed in CDR1 compared to 
CDR2 (Figure 5.13B).  Further analysis of these mutations in assessing the 
selection within these genes demonstrated that a significant selection was 
observed in 4 different gene rearrangements within the PBL samples of VAS6 
(Table 5.8).  As shown in Table 5.8 this selection was observed in 3 functional 
genes and 1 non-functional gene.  All Ig rearrangements contained a negative 
selection within the FW regions.  Other positive and negative selections were 
observed in all the sequences in both the FW and CDRs but they were not 
statistically significant.  
 
 
Table 5.7 Heavy chain genes identified from the PBL sample of vasculitis patient VAS6 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the VAS6 PBL sample.  The total number of sequences isolated 
is given in the 4th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino acid sequences were also identified using the JOINSOLVER software; * indicates the 
presence of a stop codon within the CDR3. V-J lengths and consecutive D match lengths (bp) were 
also identified using the JOINSOLVER software and allowed assignment of the DH genes as 
described in section 2.3.12.3.    
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Figure 5.12 VH Gene Family Usage of VAS6 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
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5.3.2.3 CDR3 Analysis 
No significant differences in the mean CDR3 amino acid length were observed 
in these sequences between the functional and non-functional populations 
(Table 5.9).  Despite these results a significant decrease in CDR3 length was 
observed for the sequences containing between 3 and 10 mutations (Figure 
5.14).  This significance was only against sequences containing 2 or less 
mutations and not significant against sequences with more than 10 mutations 
per sequence.  Further analysis of the CDR3 region examined the addition of P 
and N nucleotides at the VD and DJ junctions as well as the exonuclease 
activity at the gene segment ends, 3’VH, 5’DH, 3’DH and 5’JH, within the VDJ 
junction.  Within these sequences no significant differences were observed 
between the VD and DJ junction, or between functional and non-functional 
sequences, for the addition of P and N nucleotides at these regions.  
Conversely a significant difference in exonuclease activity was observed at the 
3’VH gene segment of the junction between the functional and non-functional Ig 
rearrangements, with a significant reduced exonuclease activity in functional 
rearrangements.  This reduced enzyme activity was also significant against the 
5’DH and 5’JH regions in functional rearrangements.      
Figure 5.13 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in VAS6 PBL 
 
Figure 5.13A - The number of mutations 
within functional rearranged genes were 
analysed in the PBL sample of VAS6 
PBL.  Base differences within the first 24 
bases of sequence were disregarded as 
this part of the sequence binds the 5’ VH 
primer.  Graph demonstrates that PBL Ig 
rearrangements were essentially from a 
naïve population with a small percentage 
of highly mutated rearrangements. 
 
 Figure 5.13B - The locations of 
mutations observed within functional 
rearranged genes were categorised as 
being within FR or CDR regions.  The 
numbers of mutations within these 
regions were expressed as a percentage 
of the entire length of the region to 
correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared 
to framework regions. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-03*01 2-2*01 3*02 1 0 - - - - - - - - 
1-03*01 5-12*01 6*02 1 1 0 0 0.47328 0 1 0 0.7011 0.7011 
1-69*01 2-21*01 3*02 1 0 - - - - - - - - 
1-69*01 3-10*01 4*02 1 17 5 1 0.45038 0.5459 8 3 0.66893 -0.9625 
1-69*01 6-13*01 6*02 1 2 1 0 0.45038 0.45038 1 0 0.66893 0.66893 
1-69*01 6-19*01 3*02 1 0 - - - - - - - - 
1-69*01 No D gene Assignment 2*01 1 24 7 1 0.45038 0.53682 11 5 0.66893 -0.8331 
1-69*01 No D gene Assignment 5*02 (1) 1 0 0 0.45038 0 1 0 0.66893 0.69488 
1-69*02 3-10*01 3*02 1 0 - - - - - - - - 
2-05*04 3-9*01 5*02 1 20 5 2 0.44921 -0.5082 6 7 0.67583 -0.0325 
2-05*04 No D gene Assignment 4*02 1 20 4 1 0.44921 -0.2326 6 9 0.67583 -0.0161 
2-05*10 1-26*01 5*02 1 13 6 0 0.44582 0.20661 4 3 0.67963 -0.5535 
2-05*10 3-10*01 1*01 1 0 - - - - - - - - 
2-05*10 3-16*01 2*01 1 0 - - - - - - - - 
2-05*10 3-22*01 4*02 1 8 2 0 0.44582 0.19875 6 0 0.67963 0.09855 
2-05*10 No D gene Assignment 4*01 1 7 1 0 0.44582 -0.4922 3 3 0.67963 -0.3821 
2-05*10 No D gene Assignment 4*02 (1) 1 0 0 0.44582 0 1 0 0.67963 0.67963 
2-05*10 No D gene Assignment 4*02 1 2 1 0 0.44582 0.67963 1 0 0.67963 0.67963 
3-11*03 3-22*01 3*02 1 1 0 0 0.45384 -0.5462 0 1 0.66416 -0.3358 
3-15*01 No D gene Assignment 4*02 1 10 3 2 0.44151 0.78267 4 1 0.65731 -0.6389 
3-15*01 No D gene Assignment 4*02 1 9 2 1 0.44151 -0.633 3 3 0.65731 -0.2389 
3-21*01 5-12*01 4*02 1 0 - - - - - - - - 
Cont… 
301 
VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
3-21*01 6-13*01 6*02 1 0 - - - - - - - - 
3-30*03 3-10*01 6*02 1 0 - - - - - - - - 
3-33*01 No D gene Assignment 2*01 1 12 6 3 0.46949 0.43089 2 1 0.67189 -0.1116 
3-49*01 2-15*01 2*01 1 1 0 0 0.44792 -0.5521 0 1 0.66152 -0.3385 
3-66*01 3-10*01 5*02 (1) 31 13 4 0.46708 0.35578 5 6 0.66604 -0.0105 
3-66*01 4-23*01 4*02 1 27 7 1 0.46166 0.41664 15 4 0.66979 0.46598 
4-34*01 3-22*01 1*01 1 1 0 0 0.42295 -0.5771 0 1 0.65147 -0.3485 
4-34*01 3-22*01 6*02 (1) 1 0 0 0.42295 0 1 0 0.65147 0.65147 
4-34*03 3-22*01 3*02 1 31 9 3 0.42279 0.6563 12 7 0.6487 -0.3217 
5-51*01 No D gene Assignment 2*01 1 13 6 0 0.43336 0.08806 5 2 0.69901 0.97214 
5-51*03 3-10*01 5*02 (1) 0 - - - - - - - - 
5-51*03 4-17*01 2*01 1 0 - - - - - - - - 
6-01*01 No D gene Assignment 3*02 1 10 2 2 0.47428 -0.5285 4 2 0.65306 -0.3897 
6*01-01 No D gene Assignment 3*02 (1) 0 - - - - - - - - 
6-01*01 6-19*01 4*02 (1) 0 - - - - - - - - 
6-01*01 6-13*01 6*02 1 1 0 0 0.47428 0 1 0 0.65306 0.65306 
7-04-1*01 2-2*03 6*02 (1) 0 - - - - - - - - 
7-04-1*02 No D gene Assignment 1*01 1 14 4 0 0.42769 -0.533 2 8 0.66832 -0.0036 
7-04-1*02 No D gene Assignment 5*02 1 1 1 0 0.42587 0.42587 0 0 0.67038 - 
7-04-1*02 No D gene Assignment 6*02 1 1 0 0 0.42587 
-
0.57412 
0 1 0.67038 
-
0.32961 
7-04-1*02 3-9*01 4*02 2 1 0 1 0.42587 -
0.54412 
0 0 0.67038 
-
0.32961 
    2 1 0 0.42769 0.42769 1 0 0.66832 0.66832 
7-04-1*02 6-13*01R 3*02 1 0 - - - - - - - - 
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Table 5.8 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample VAS6 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according as per Hershberg et al (294) 
and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish 
positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known biases within the 
immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR respectively.  pCDR represents 
the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while p-CDR is the p-value of the 
focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value 
of the focused binominal test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be 
preceded by a negative sign or if the number of mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in 
yellow and were deemed significant for selection. 
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Functional 16.5 ± 0.8 CDR3 Length Non-Functional 19 ± 1.8 
 VD Junction DJ Junction 
Functional 0.8 ± 0.2 0.4 ± 0.1 P Nucleotide Non-Functional 1.6 ± 0.7 1 ± 0.8 
Functional 8.8 ± 1.5 7 ± 1.1 N Nucleotide Non-Functional 8.6 ± 3.6 8 ± 3 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1.1 ± 0.3* 4.4 ± 0.7 Θ 4.1 ± 0.7 3.8 ± 0.8 Θ Exonuclease 
Activity Non-Functional 4 ± 1.3* 3.6 ± 1.9 3.4 ± 1.3 5 ± 3.1 
 
Table 5.9 CDR3 and Junctional Analysis in VAS6 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all myositis immunoglobulin sequences as 
well as in DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no 
non-functional sequences were identified and values could not be calculated were recorded as 
non applicable (N/A).  * indicates a significant difference between functional and non-functional 
sequences using an unpaired t test.   Θ represents a significant difference from 3’VH. 
 
 
 
0-2 3-10 11-20 21+
0
5
10
15
20
25
*
Number Of Mutations
M
ea
n
 
CD
R
3 
Le
n
gt
h 
(aa
) ±± ±±
 
SE
M
 
 
 
 
 
 
No clonally related sequences were observed in the repertoire isolated from the 
PBL, but as only a small sample of the whole repertoire was isolated and 
identified clonally related sequences were not expected within the Ig repertoire. 
 
 
 
 
Figure 5.14 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
304 
5.3.3 Sample VAS7 
As previously described in section 5.2.3 very few B cells were present within the 
cellular infiltrates of sample VAS7, but plasma cells were shown to be present 
within cellular aggregates. A similar observation to that observed in the other 
vasculitis samples.  Figure 5.15 demonstrates the microdissection and DNA 
amplification from these cells which was used to establish the gene repertoire 
these infiltrating cells.  Five different functional gene rearrangements were 
amplified from DNA released from the VAS7 microdissection (Table 5.10A).  
Two of the amplified genes contained VH1 gene segments, 1-46*01 and 1-
69*09, while the remaining 3 gene rearrangements contained VH3 gene 
segments, 3-12*01, 3-30*03 and 3-73*01.  DH3-10*01 could only be assigned in 
the VH1-46*01 gene rearrangement.  JH1, 4 and 5 gene segments were also 
assigned.  Mutational numbers were high in the gene rearrangements 
containing the VH1-46*01, 3-21*01 and 3-73*01 gene segments with over 15 
mutations per sequence.  The remaining two sequences isolated from VAS7 
sections contained less than 10 mutations per sequence.  Location analysis of 
these mutations demonstrated that the majority of mutations occurred within the 
CDR compared to framework regions.  Table 5.10A demonstrates that these 
were largely found within CDR1 compared to CDR2.  No significant selection 
could be assigned to any of the gene rearrangements regardless of the large 
number of mutations within the VH region of the sequence (Table 5.10B).  For 
these sequences isolated from the skin infiltrating population, CDR3 lengths 
were found to range from 9 to 17 amino acids.  Junctional analysis in the VH1-
46*01 gene rearrangement where a DH gene could be assigned demonstrated 
that no P nucleotides were present at either the VD or DJ junction.  On the 
contrary 17 and 3 N nucleotides were assigned respectively at the VD and DJ 
regions of the junction.  Analysis of the exonuclease activity demonstrated that 
0, 8, 8 and 6 nucleotides were removed from the respective 3’VH, 5’DH, 3’DH 
and 5’JH gene segments of the junction.  No clonally related sets of sequences 
were found within the infiltrating cells and all gene assignments from the 
JOINSOLVER algorithm corresponded to the gene assignments of IMGT/V-
QUEST.  
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Before Microdissection After Microdissection 
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Figure 5.15 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS7 
 
A region of plasma cell infiltration was microdissected from sample VAS7.  Figure 5.15A 
demonstrates the microdissection of 2 regions of cellular infiltration.  Images were taken at 
400X.  DNA released from these microdissections was amplified using a Nested PCR 
system (Figure 5.15B), as previously described in Chapter 2.  – indicates negative control 
PCR reactions where DNA was substituted with water while + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual.  Results show amplification of all 6 VH families. 
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VH Gene DH Gene JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
1-46*01 3-10*01 4*02 1 16 5 0 0.47813 0.65911 7 4 0.67198 -0.788 
1-69*09 No D gene Assignment 1*01 1 2 0 1 0.46644 -0.2847 0 1 0.67237 -0.1073 
3-21*01 No D gene Assignment 4*02 1 24 6 4 0.51535 -0.3872 9 5 0.65709 -0.1773 
3-30*03 No D gene Assignment 4*02 1 8 5 1 0.46794 0.09263 2 0 0.6723 -0.9479 
3-73*01 No D gene Assignment 5*02 1 21 5 2 0.47451 -0.5352 8 6 0.66316 -0.1863 
 
 
 
Mutational Distribution 
 (% of length) VH Gene DH Gene 
JH 
Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa) Framework CDR1 CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-46*01 3-10*01 4*02 1 16 ARESIIFADGSGSYGDY 17 5 33.3 0 37 17 
1-69*09 No D gene Assignment 1*01 1 2 VIHLIQLST 9 0.5 0 2 25 7 
3-21*01 No D gene Assignment 4*02 1 24 AREHWELLRGNDYYLDY 17 6.3 20 13.7 43 6 
3-30*03 No D gene Assignment 4*02 1 8 ARRGYLNSVDY 11 0.9 20 5.9 20 8 
3-73*01 No D gene Assignment 5*02 1 21 TRREDGSGSFSA 12 6.3 13.3 9.8 28 8 
A 
B 
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Table 5.10 A&B Sequence Analysis from Sample VAS7 
 
Table 5.10A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS7 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.10B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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5.3.4 VH Repertoire in Vasculitis 
As a limited number of Ig sequences were obtained from skin infiltrating cells in 
each individual vasculitis patient, the results from all three patients were pooled 
to establish if a common pattern of gene usage and mutational patterns 
occurred.  The results demonstrated that the collective repertoire of VH gene 
usage mirrored the normal control values as well as the baseline germline 
complexity (Figure 5.16A).  These findings are in contrast to those observed 
within the PBL repertoire of samples VAS1 and VAS6 where a common 
selection for the use of VH2 gene segments and selection against VH4 gene 
segments was observed in both samples.  Despite the lack of selection for the 
different VH gene families as a whole within the skin, selections were observed 
for the use of VH1-46, 3-33, 3-73 and 4-59 individual gene segments.  From the 
Ig repertoire from skin infiltrating cells DH genes could be assigned in 41.2% of 
gene rearrangements.  From this a selection for the use of DH4 and DH5 gene 
segments was observed which was significant against normal control values, in 
particular the DH4-17 and 5-12 gene segments which were significantly selected 
(Figure 5.16B).  Similar to the VH repertoire these selections were in contrast to 
that observed within the two paired blood samples.  The positive selection for 
the use of DH3 gene segments within the PBL was not observed in the Ig 
rearrangements from the cellular infiltrates within the skin.  JH2 gene segments 
were found to be over-represented in the 3 vasculitis patients, which was 
significant against the normal control values but not the baseline germline 
complexity (Figure 5.16C).  This selection was also observed within the 
repertoire from one of the peripheral blood samples, VAS6, but is in contrast to 
the results from the second blood sample, VAS1.        
 
5.3.4.1 Mutational Analysis in Vasculitis 
Analysis of mutational numbers from the 17 functional Ig rearrangements 
isolated demonstrated that approximately a quarter of the sequences isolated 
were essentially non-mutated and from a naïve population (Figure 5.17A).  The 
remaining sequences were highly mutated with over 50% of the sequences 
containing over 11 mutations per sequence.  These mutations were largely 
observed in the CDRs compared to FW regions, with a slightly higher 
percentage within CDR1 compared to CDR2 (Figure 5.17B). 
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Figure 5.16 VH Gene Family Usage of Vasculitis samples 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
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From the collective repertoire of 17 functional sequences, selection was only 
significantly observed in 1 functional Ig rearrangement.  In this Ig rearrangement 
negative selection was observed in the FW region, no other significant selection 
was observed from any other rearrangement. 
 
5.3.4.2 CDR3 Analysis 
 
In the isolated repertoire from the vasculitis samples no non-functional Ig 
rearrangements were identified, therefore significant differences in the 
junctional characteristics between functional and non-functional sequences 
could not be established.  For the functional repertoire the mean amino acid 
CDR3 length was 15.5 ± 0.9 amino acids (Table 5.11) and no significant 
difference in CDR3 length was observed within the various mutational groups of 
sequences (Figure 5.18). The addition of P and N nucleotides at the VD and DJ 
junctions were not found to be significantly different within the functional 
population of sequences.  Examination of the exonuclease activity at the 
various gene segments of the junctional area demonstrated a significant decline 
in the enzymatic activity at the 3’VH region compared to the 5’DH region in the 
VD region of the junction.  No other significant differences were observed.     
 
Figure 5.17 Numbers of Mutations and 
Mutational Distribution of Functional 
Sequences in Vasculitis Patients 
 
Figure 5.17A - The number of mutations 
within functional rearranged genes were 
analysed collectively from all vasculitis 
patients.  Base differences within the first 
24 bases of sequence were disregarded 
as this part of the sequence binds the 5’ 
VH primer.  Graph demonstrates 
sequences within cellular infiltrates show 
a diverse distribution of mutational 
numbers. 
 
 Figure 5.17B - The locations of 
mutations observed within functional 
rearranged genes were categorised as 
being within FR or CDR regions.  The 
numbers of mutations within these 
regions were expressed as a percentage 
of the entire length of the region to 
correct for the longer lengths observed 
within the framework regions.  Graph 
demonstrates a higher percentage of 
mutations within CDR regions compared 
to framework regions. 
A 
B 
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Functional 15.5 ± 0.9 CDR3 Length Non-Functional N/A 
 VD Junction DJ Junction 
Functional 0.8 ± 0.4 0 P Nucleotide Non-Functional N/A N/A 
Functional 5.3 ± 2 6.1 ± 0.6 N Nucleotide Non-Functional N/A N/A 
 3’ VH 5’ DH 3’ DH 5’JH 
Functional 1 ± 0.4 5.3 ± 1.4 Θ 2.7 ± 1.1 3.4 ± 1.5 Exonuclease 
Activity Non-Functional N/A N/A N/A N/A 
 
Table 5.11 CDR3 and Junctional Analysis in Vasculitis 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all vasculitis immunoglobulin sequences 
as well as in DM and PM subsets.  Results are given as the Mean ± SEM, statistical significance 
was established using an unpaired t-test.  Instances where no non-functional sequences were 
identified and values could not be calculated were recorded as non applicable (N/A).  Θ 
represents a significant difference from 3’VH. 
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One common replacement mutation was observed between the VH1-18*01 
gene isolated from sample VAS1 and the VH1-46*01 gene isolated from sample 
VAS6.  At amino acid 69, situated close to CDR2, a replacement mutation 
occurred within both sequences converting the methionine to a valine amino 
acid (M→V).  The serine to asparagine replacement mutation (S→N), amino 
acid 31, which was observed within some of the myositis samples was also 
observed within the VH3-33*01 isolated from sample VAS1. 
 
 
Figure 5.18 Mean CDR3 Lengths in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated 
for immunoglobulin sequences according 
the number of mutations within the VH 
segment of the gene rearrangement to 
establish any relationship between 
mutational number and CDR3 length.  
Results are given as Mean amino acid 
CDR3 length ± SEM.  Groups were 
compared for statistical significance 
using the Tukey-Kramer test for multiple 
comparisons.  The graph demonstrates 
that no significant changes in CDR3 
length were observed at the various 
number of mutations.  p-values <0.05 
would have been deemed significant. 
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5.4 Discussion  
In a similar situation to myositis, the role of B cells in the inflammatory process 
of vasculitis is unknown.  Pathological manifestations within vasculitic disorders 
have been attributed to the activation of T cells but the presence and 
contribution of immune complexes and autoantibodies within these 
inflammatory disorders strongly implicates a pathological role for B cells.  This is 
substantiated by the clinical improvement observed in patients undergoing B 
cell depletive therapy as previously described.  Previous work in this study 
aimed to define a possible role for B cells in muscle inflammation by testing the 
hypothesis that muscle infiltrating B cells were being locally stimulated resulting 
in an antigen-driven response contributing to tissue pathology.  This hypothesis 
was also tested for skin infiltrating lymphocytes in vasculitis patients using the 
same procedures described for muscle infiltrating cells to determine if antigen-
driven Ig sequence characteristics such as gene selection, mutational 
accumulation and clonal diversification were present within the Ig gene 
rearrangements expressed on skin infiltrating B cells. 
 
Initially the identification and organisation of skin infiltrating cells was 
determined.  In contrast to some of the muscle samples very few B cells were 
present within the infiltrating population and the vast majority of infiltrating cells 
were plasma cells.  Skin infiltrating cells were widely distributed throughout the 
entire biopsy with very little aggregation and likewise to the organisation 
observed within myositis samples no ectopic germinal centre type structures 
were observed.  Other cell markers were also identified, CD3, CD4, CD8, CD68 
and FoxP3, while FDCs were entirely absent from the infiltrating population for 
all samples.  Very few Ki67+ proliferating cells were identified, collectively these 
results may indicate that an active antigen-driven response is not occurring 
within the skin and the infiltrating cell population is present as a result of 
inflammatory mediator gradients. 
 
The lack of B cells, FDCs and ectopic germinal centre structures in the samples 
of the current study is in contrast to studies by Voswinkel et al (348;349) in 
Wegener’s granulomatosis (WG), a disease of unknown aetiology characterised 
by necrotising granulomatosus inflammation and systemic vasculitis 
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predominately affecting small vessels.  Voswinkel et al (348) observed different 
lymphocytic phenotypes ranging from diffusely infiltrating cells to cellular 
aggregates of T and/or B cells without FDCs in addition to germinal centre type 
structures containing FDCs. The initial study (348) identified B lymphocyte 
containing infiltrates in endonasal biopsies of all 6 WG patients studied.  
Approximately 30% of the cells within the follicle-like structures were identified 
as CD20+ B cells; plasma cells were also evident but did not appear to be as 
substantial to the infiltrating plasma cell population in the three vasculitis 
patients used within the current study.  The findings of Voswinkel et al are also 
supported by additional studies (350).  The variations in immunohistological 
findings between these studies and the current study may represent different 
disease and B cell mechanisms occurring at various target sites of vasculitis. 
 
To address the hypothesis that skin infiltrating B cells are being stimulated 
locally in an antigen-driven response the sequence characteristics of Ig 
rearrangements expressed on infiltrating cells was assessed.  Within each 
individual patient a limited number of rearrangements were identified.  Due to 
the low numbers a comparison of gene usage could not be conducted on each 
individual patient, therefore a collective analysis was required to determine the 
sequence characteristics of the Ig rearrangements.  The different methods used 
to assign gene segments within the Ig rearrangements which may result in 
alterations in gene assignments, previously discussed in section 4.3.2, are also 
relevant to this part of the study.  From the collective repertoire gene selections 
were observed for DH and JH gene segments and mutations were found in 
approximately 75% of sequences with over 40% of sequences containing 21 or 
more mutations.  These results would indicate that antigen-driven diversification 
of B cells had occurred but the lack of VH selection and clonal related 
sequences from the infiltrating lymphocytes contradicts the proposed 
hypothesis of this study.  Analysis of a larger number of sequences from a 
larger cohort of patients may be required to fully assess B cell antigen driven 
diversification.  Modifications to the Ig repertoire from patient therapies, Table 
2.1, must also be considered.  The sequence results could relate to the 
previous immunohistological studies in these samples.  As previously described 
a large number of plasma cells were found within the infiltrating populations 
314 
along with a limited proliferating population of cells.  Taken together the Ig 
rearrangements identified may correspond to the highest affinity, antigen-
specific and clonally diversified rearrangements from B cells which have 
terminally differentiated into plasma cells and infiltrated into target areas of the 
skin with the secreted antibodies from these cells contributing to the tissue 
pathology. In such a situation it would be expected that the sequences isolated 
would exhibit positive selection based on the R and S mutation within the 
sequence.  Selection in this study was based on the newly proposed method 
described by Hershberg et al (294), which was previously discussed in section 
4.3.3.  Using this method selection was only detected in 1 Ig rearrangement, 
which was found within the FW regions and was significant for negative 
selection.  The lack of positive selection, in a similar situation to myositis Ig 
rearrangements discussed in section 4.3, may be the result of the improved 
parameters used to assign selection which now account for the fundamental 
aspects of sequence variation and diversity.      
 
It could also be postulated that the accumulation of plasma cells observed 
within these samples is simply a consequence of the immune response which, 
as a result of inflammatory mediators, had provided a suitable niche for plasma 
cells within the inflamed skin and that the cells do not bear Ig rearrangements 
which are specific to a vasculitis specific or associated antigen.  Alternatively 
the work of this study may suggest a different B cell mechanism in contrast to 
the proposed hypothesis of this study.  Initiation of inflammation within the skin, 
in response to a vasculitis specific autoantigen, may generate a favourable 
environment for the migration and transition of high affinity pre-plasma cells 
which have the capacity to generate long-lived plasma cells and secrete 
pathogenic autoantibodies.  Identification of the antigen specificity of antibodies 
secreted from plasma cells within the 3 vasculitis samples of this study would 
help clarify the mechanism of these cells in inflamed skin.  This hypothesis may 
result in the limited Ig repertoire observed within this study and substantiates 
the significance of these B cell derived cells in the pathogenesis of vasculitis.  
The importance of modulating production, survival and mechanisms of plasma 
cells in vasculitis disorders is substantiated by previous studies which 
demonstrate the importance of these cells and the antibodies they produce in 
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the pathogenesis of vasculitis (6;171;178;188;202;351-355), reviewed 
(149;157;179;185;356).     
 
As well as analysing the gene segment usage and mutational patterns of Ig 
rearrangements identified from vasculitis biopsies, the different mechanisms at 
the junctional regions of VDJ recombination were examined.  Within this 
repertoire of sequences no non-functional sequences were isolated so 
significant differences between CDR3 lengths in functional and non-functional 
populations could not be examined to support previous findings 
(238;241;242;251;291).  There was also no significant difference between 
CDR3 lengths in different mutational groups in contrast to previous studies 
(238).  The addition of P and N nucleotides between the VD and DJ junctions 
was also found not to be significant between the two regions of the junction, as 
previously observed (251;291;334), while a significant decrease in exonuclease 
activity at the 3’VH region was found compared to the 5’DH region.  These 
results mirror that found within the Ig gene isolated from inflamed muscle and 
may correlate differences within diseased repertoires compared to normal 
control repertoires. 
 
In contrast to the work of Chapter 4, paired blood samples were obtained for 
two of the vasculitis patients.  Both Ig gene repertoires demonstrated both 
positive and negative gene selections when compared to normal control values, 
with common selections observed in both patients.  These selections were not 
observed in the repertoire from Ig expressed on skin infiltrating cells.  From 
these samples identically rearranged genes were not found in both the 
peripheral blood and inflamed skin which may represent a compartmentalisation 
of the immune response within the skin, although analysis from a larger number 
of patients and of a larger number of sequences from both sources may be 
required to fully examine the differences between peripheral blood repertoires 
and the repertoires observed within the target tissues of autoimmune diseases.  
These results are in contrast to previous studies where recirculation of activated 
B cells was observed in the synovial membranes and peripheral blood 
repertoires of RA patients (336).  Patient VAS6 had a past medical history of 
ankylosing spondylitis (AS).  A previous study has demonstrated that antigen-
driven B cell responses occurred within synovial membranes of an AS patient 
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(320), it would be interesting to assess the repertoires from different sites in this 
patient to fully assess the mechanisms involved in gene selection as well as 
recirculation and maturation of activated B cells.  Collectively these results 
would indicate whether clones isolated from the skin have recirculated from the 
synovial membranes and the skin infiltration is non-specific and the vasculitis is 
secondary to the chronic inflammation of the ankylosing spondylitis.   
 
Studies by Voswinkel et al (348;349) have demonstrated the antigen-driven and 
clonal diversification of B cells in WG, a subset of vasculitis.  B lymphocyte 
infiltrates, in various organisations as described above, were observed in all 6 
endonasal biopsies tested from which 184 VH rearrangements were compared 
to healthy VH repertoires (348).  Five samples displayed a VH repertoire with 
prevalence for VH3 and VH4 gene rearrangements with a predominance of VH3-
30, VH3-23, VH4-34 and VH4-59 genes.  A high proportion of mutations within 
sequences were observed compared to healthy repertoires which were found to 
relate to an increased disease activity and clonally related sets of sequences 
were found in 4 of the 6 patients suggesting antigen-driven affinity maturation.  
These results were substantiated by the presence of autoantigen specific PR3+ 
cells within the cellular infiltrate.  Another recent study by this group has 
analysed the Ig rearrangements from single B cells laser dissected from frozen 
sections from endonasal biopsies of WG patients (349).  The results confirm the 
previous study but also allowed characterisation of individual B cell receptors by 
analysing the L chain sequences and pairings from these cells.  Both studies 
conclude the selection and maturation of antigen-specific B cells in an 
autoimmune response of WG, a disease characterised by vasculitis, but a direct 
comparison cannot be made to the study of this chapter as different responses 
may occur at different sites of inflammation and the stimulating antigen may 
also be different at various locations and between different patients.     
 
In summary, these results suggest that antigen-driven B cell responses may 
play a role in the inflamed skin of these vasculitis patients but with very few B 
cells and no clonally related sequences identified, the primary responses may 
be occurring at other sites of inflammation, or secondary lymphoid organs, 
resulting in migration of high affinity antigen-specific cells into inflamed skin.      
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Chapter 6 - Identification of Antigens Driving the Immune Response in 
Myositis Patients 
6.1 Introduction 
Previous results within this study, Chapters 4 & 5, have demonstrated the 
presence of antigen-driven diversified cells at the sites of inflammation within 
the target tissues of myositis and vasculitis.  Gene selections and mutational 
analysis of the Ig gene rearrangements, where no clonally related sequences 
were identified, indicate that cells had undergone an antigen-driven 
diversification and were possibly stimulated by antigen at other locations, 
presumably the draining lymph node, and migrating into the sites of 
inflammation while identification of clonally related sequences suggested that 
infiltrating cells were being stimulated locally by antigens present at these sites 
of inflammation.  Although the results have demonstrated the occurrence of an 
antigen-driven response they do not indicate the identity of the antigen(s) 
stimulating the response.   
 
Autoantibodies were detected in the sera of five myositis patients, Table 2.1.  
To summarise patient MYO3 and MYO23 were Jo-1+ while patient MYO3 also 
tested positive for Sm/RNP antibodies.  Two of the myositis patients, MYO16 & 
MYO19, tested positive for anti-nuclear antigens (ANA).  The nucleolar pattern 
of staining indicated that the antigen may be topoisomerase 1 (Scl70) which is 
normally found within systemic sclerosis patients (113;357).  Anti-DNA 
antibodies were also found in serum samples of patient MYOE, a characteristic 
of SLE patients.  Therefore to identify the stimulating antigens occurring within 
the target tissues of these patients, biotinylated recombinant antigens were 
used to establish the following aims of the chapter: 
• Identify antigen-specific muscle infiltrating lymphocytes. 
• Establish the phenotype of these antigen specific cells as B cells and/or 
plasma cells using double immunohistochemical experiments. 
• Use laser capture microdissection to isolate antigen specific cells and 
determine the Ig gene rearrangements of these cells.  
 
The results described in this chapter were in preliminary stages and were 
intended as provisional for future work in autoantigen identification. 
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6.2 Identification of Antigen-Specific Cells within Cellular Infiltrates in 
Myositis Muscle Biopsies  
6.2.1 Sample MYO3 
Patient MYO3 was positive for both serum Sm/RNP and Jo-1 antibodies.  
Staining with these biotinylated antigens provided two very diverse patterns of 
staining (Figure 6.1).  Staining for Jo-1 (Figure 6.1A-B) demonstrated that Jo-
1+ cells were located sporadically throughout the muscle section.  In some 
cases a small cluster of Jo-1+ cells were found but it also appeared that single 
Jo-1+ cells were also located within the sample.  The use of biotinylated 
Sm/RNP (Figure 6.1C-D) showed extensive staining throughout the whole 
biopsy located between the muscle fibres.  Negative control staining showed no 
non-specific staining as did the use of biotinylated Sm/RNP on tonsil sections 
(data not shown).  Single cells were not able to be identified within the extensive 
staining of Sm/RNP.  Extensive staining with the Sm/RNP antigen may have 
occurred as a result of large numbers of anti-Sm/RNP antibodies secreted by 
infiltrating plasma cells in the inflamed muscle.    
 
Double immunofluorescence experiments with the recombinant antigens 
revealed that the Jo-1 specific cells were mostly CD20+ cells (Figure 6.2A-B) 
while the Sm/RNP+ cells were found to be mostly plasma cells (Figure 6.2C-D).  
The extensive staining of Sm/RNP in areas of plasma cell infiltration made it 
difficult to identify isolated single antigen-specific cells, but a small cluster of 
plasma cells were found within that large area of Sm/RNP staining.       
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Figure 6.1 Immunohistochemical staining using biotinylated antigen in Sample MYO3  
 
Muscle sections from sample MYO3 were stained with biotinylated antigen, Jo-1 (A-B) and Sm/RNP 
(C-D), and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
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Figure 6.2 Double Immunohistochemical staining using biotinylated antigens in 
sample MYO3  
 
Muscle sections from sample MYO3 were stained for Plasma cells (A&C) and CD20 (B&D) 
and biotinylated antigen; Jo-1 (A-B) and Sm/RNP (C-D).  Cell phenotypes were visualised 
by Texas Red Avidin D and antigen-specific cells by Fluorescein Avidin D.  This allowed the 
phenotype of antigen-specific cells within the myositis sample to be identified.  Images were 
taken at 630X; Scale Bar represents 15 µm.  Arrows identify antigen specific cells within the 
sections. 
321 
6.2.2 Sample MYO16 
Patient MYO16 was positive for anti-nuclear antigens (ANA), the nucleolar 
pattern of staining indicated that the antigen may be Scl70 (Topoisomerase 1).  
Recombinant Scl70 used for staining the muscle sections demonstrated the 
occurrence of small clusters of Scl70+ cells within the sample (Figure 
6.3.1A&B).  In comparison to the levels of infiltrating B cells and plasma cells 
within the sample, identified in Chapter 3, it appears that Scl70 may not be the 
only antigen stimulating a response within patient MYO16.  Double staining 
experiments with recombinant Scl70 indicated that the antigen-specific cells 
were plasma cells (Figure 6.3.2A&B), there was no evidence of any antigen 
specific B cells within the sections used for staining.  For B cell staining very few 
infiltrating cells were observed, this is in contrast to the staining experiments 
used in Chapter 3 where a very dense cluster of B cells was observed.  
Although these experiments were conducted on serial sections, these sections 
were at a greater depth of tissue than the sections described in Chapter 3, 
which may explain the absence of B cell infiltration in later sections.  Clonally 
related sets of sequences observed within this patient may be in response to 
Scl70.         
   
6.2.3 Sample MYO19 
For sample MYO19, who also tested positive for ANA with a nucleolar pattern, 
results were similar to that of patient MYO16.  Small clusters of Scl70+ cells 
were observed throughout the sample (Figure 6.4.1 A&B).  In double staining 
experiments both antigen-specific B cells and plasma cells were observed 
(Figure 6.4.2 A&B).  The lack of clonally related sets within patient MYO19 may 
suggest, like the other samples, that B cells are stimulated by the antigen at 
another location which then migrate into inflamed muscle.  As with MYO16 the 
frequency of antigen-specific cells in comparison to the frequency of B cells and 
plasma cells previously found within the sample sections indicates that other 
antigens may be participating in the response.   
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Figure 6.3 Immunohistochemical staining using biotinylated antigen in Sample MYO16 
 
Figure 6.3.1 - Muscle sections from sample MYO16 were stained with biotinylated antigen, Scl70, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.3.2 - Muscle sections from sample MYO16 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Scl70.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
  
323 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Scl 70 Negative 
Scl70 PC Scl70 PC 
 
Scl70 CD20 Scl70 CD20 
 
A 
B 
1 
2 
Figure 6.4 Immunohistochemical staining using biotinylated antigen in Sample MYO19 
 
Figure 6.4.1 - Muscle sections from sample MYO19 were stained with biotinylated antigen, Scl70, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.4.2 - Muscle sections from sample MYO19 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Scl70.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D. This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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6.2.4 Sample MYO23 
Patient MYO23 tested positive for serum Jo-1 autoantibodies.  Staining with 
recombinant Jo-1 identified antigen positive cells within the sample (Figure 
6.5.1A&B).  In contrast to sample MYO3 these mostly appeared to be isolated 
single cells.  Double staining experiments on MYO23 (Figure 6.5.2A&B) 
sections showed the presence of antigen-specific plasma cells within the 
sample.  Antigen-specific B cells were not observed in the samples tested for by 
double immunofluorescence staining using recombinant antigen, but this does 
not exclude their presence in other sections of the sample but as very few B 
cells were identified in the initial cell phenotype staining this suggests that the 
antigen-specific cells may solely be infiltrating plasma cells.  Clonally related 
sets of sequences were observed within this patient, which may be in response 
to Jo-1.       
 
6.2.5 Sample MYOE 
As shown in Table 2.1 patient MYOE tested positive for anti-DNA antibodies.  
Staining MYOE sections with biotinylated ds-DNA identified a small number of 
DNA+ cells within the infiltrating population (Figure 6.6.1A&B).  The occurrence 
of anti-DNA+ cells was reduced in comparison to other types of antigen specific 
cells identified in the other myositis patients, although no direct quantification 
was conducted.  Some of these DNA+ cells appeared to form small aggregated 
clusters.  Double staining experiments established the phenotype of antigen-
specific cells as plasma cells (Figure 6.6.2A&B).  The low frequency of DNA+ 
cells infiltrating the sample and the low numbers of infiltrating B and plasma 
cells identified in Chapter 3 meant very few antigen positive cells could be 
identified.  
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Figure 6.5 Immunohistochemical staining using biotinylated antigen in Sample MYO23 
 
Figure 6.5.1 - Muscle sections from sample MYO23 were stained with biotinylated antigen, Jo-1, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.5.2 - Muscle sections from sample MYO23 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Jo-1.  Cell phenotypes were visualised by Fluorescein Avidin D and antigen specific 
cells by Texas Red Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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Figure 6.6 Immunohistochemical staining using biotinylated antigen in Sample MYOE 
 
Figure 6.6.1 - Muscle sections from sample MYOE were stained with biotinylated antigen, DNA, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.6.2 - Muscle sections from sample MYOE were stained for Plasma cells (A) and CD20 (B) 
and biotinylated DNA.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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6.3 Sequence Identification of Antigen-Specific Cells 
After identification of antigen specific cells within these 5 myositis patients, and 
the confirmation of these cells as B cells or plasma cells by double staining 
immunofluorescence experiments, further nested PCR reactions were 
conducted to identify the immunoglobulin genes of these antigen-specific cells.  
Antigen-specific cells were isolated using laser capture microdissection (Figure 
6.7) and the Ig genes were amplified from the RNA released from these cells 
using the methods described in Chapter 2.  These experiments were only in the 
primary stages and from the microdissections from Figure 6.7 a rearranged 
immunoglobulin sequence was isolated from sample MYO16 for a Scl70+ cell 
which displayed sequence characteristics of an antigen-driven response (Table 
6.1).  This VH5-51 gene rearrangement contained 14 different point mutations 
which were concentrated within the CDR, mostly CDR1; a sequence 
characteristic of a B cell from antigen-driven response or a memory B cell.  
Despite this no significant selection was observed in either the CDR or FW 
regions of the sequence.  This gene rearrangement was not observed in any 
other patients, including MYO16 which could be the result of using tissue 
sections from different depths of the biopsy and also cannot be a result of 
contamination.  Additional isolation and amplification of immunoglobulin genes 
for antigen-specific cells would provide greater insight into the gene 
rearrangements of cells specific for autoantigens.    
 
 
 
 
 
 
 
 
 
  
Before After Cap 
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Figure 6.7 Laser Capture Microscopy for Antigen-Specific Cells in Myositis 
Patients 
 
Laser-capture microscopy for single antigen specific cells identified by APAAP staining 
using biotinylated recombinant antigens.   Arrows denote antigen-specific cells to be 
microdissected.  Images taken after antigen specific cells have been microdissected, 
both in the muscle section (middle column) and on the LCM HS Cap (right-hand 
column).  All images taken at x400.  
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VH Gene DH Gene JH Gene Number of Mutations 
V-J 
Length 
(bp) 
Consecutive D 
Match Length (bp) 
5-51*01 No D Gene Assignment 2*01 14 28 7 
CDR3 Mutational Distribution  (% of length) 
Framework CDR1 CDR2 
ARREDSGPLHWFFDL (15aa) 3.6 20 6 
R-CDR S-CDR pCDR p-CDR R-FW S-FW pFW p-FW 
6 0 0.4336 0.18182 5 3 0.69714 -0.6548 
 
Table 6.1 Sequence Analysis from Scl70 Positive Cell from Patient MYO16 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database using 
JOINSOLVER software.  V-J lengths and consecutive D match lengths (bp) were also identified using the 
JOINSOLVER software to allow assignment of the DH genes as described in section 2.3.12.3.  The 
number of mutations within functional rearranged VH genes were analysed, base differences within the first 
24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.  The locations 
of VH mutations were categorised as being within FR or CDR regions.  The numbers of mutations were 
expressed as a percentage of the entire length of the region to correct for the longer lengths observed 
within the framework regions.  The number of replacement and silent mutations and the presence of any 
positive and negative selection was conducted as per Hershberg et al (294) as previously described.   R-
CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in 
the sequence except R mutations within the FW while pFW represents the probability of having a R 
mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-
CDR/FW represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
6.4 Discussion 
 
Previous results in this study have demonstrated antigen-driven diversification 
of infiltrating cells within the target tissues of myositis and vasculitis patients 
either by the identification of clonally related sequences or antigen-driven 
sequence characteristics such as gene selection and mutational patterns.  
Collectively the results may indicate local antigen stimulation within the target 
tissues and/or stimulation at other sites, presumably the draining lymph nodes, 
resulting in migration of affinity matured lymphocytes into the target tissues of 
these autoinflammatory disorders.  Regardless of the location of antigen 
stimulation, the results presented thus far do not provide information on the 
identity of the stimulating antigen.  In some of the myositis cases, 
autoantibodies were detected in serum samples from the patients therefore the 
presence of antigen positive cells for these autoantibodies within myositis 
samples was tested.  Biotinylated recombinant antigens were used to determine 
if antigen specific cells were part of the infiltrating repertoire of myositis 
samples. 
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The results presented in this chapter demonstrate that autoantigen-specific cells 
were included within the inflammatory infiltrating cell population in myositis 
samples.  Antigen positive cells were identified in each of the five myositis 
cases for all four antigens tested and were identified as a combination of B cells 
and plasma cells.  Most of the antigen specific cells formed small clusters of 
cells or existed as single isolated cells.  Staining for Sm/RNP produced a very 
different pattern of staining, extensive staining was observed throughout the 
entire section between the muscle fibres.  Individual antigen positive cells could 
not be observed amongst the widespread staining which may have occurred 
due to enhanced antibody secretion from infiltrating plasma cells.  Taking the 
frequency of the other antigen-positive cells in comparison to the number of B 
cell or plasma cell infiltration, identified in Chapter 3, results from these 
experiments may indicate that other antigens are also participating in the 
inflammatory response.  In most of the cases described in this chapter there 
was a small number of antigen positive cells in comparison to the number of 
infiltrating B cells or plasma cells observed in Chapter 3.  A wide range of 
additional antigens or modified version of the antigens used in these 
experiments may be responsible for some of the remaining infiltrating cells.  The 
other autoantigens tested for in these five patients have also been observed in 
other disorders and may indicate myositis as a secondary disorder within these 
patients; DNA, in the form of dsDNA, and Sm are specific for SLE, which is also 
associated with RNP autoantibodies and Scl70 antibodies are generally 
observed within systemic sclerosis (scleroderma) patients. 
 
The presence of antigen-specific plasma cells could indicate that B cells were 
stimulated and underwent diversification in other locations and that antigen 
specific plasma cells migrated into areas of muscle inflammation.  It is also 
possible that B cells are being stimulated directly within the muscle and the B 
cells are also undergoing maturation and diversification into plasma cells at the 
sites of inflammation within the muscle.  Following the confirmation of the 
phenotypes of the antigen specific cells, the cells were isolated by laser capture 
microdissection to establish the immunoglobulin gene rearrangements used by 
these antigen-specific cells.  These experiments were only in the primary stages 
and only a few samples were tested prior to completion of this study.  From the 
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samples tested a single gene rearrangement was isolated from Scl70+ cells in 
patient MYO16.  This gene rearrangement or gene family was not observed in 
the original gene repertoire described in Chapter 4 where selection against VH5 
gene segments was also observed.  Variations in the gene rearrangements 
isolated for MYO16 could be attributed to different serial sections being used for 
the different experiments; each section could possibly contain B cells 
expressing alternative gene rearrangements not observed in previous sections.  
Due to the difficulty for successful Ig amplification from a small number of 
antigen specific cells, additional testing of isolated antigen-specific cells would 
establish if this gene rearrangement is specific for Scl70 antigen positive cells or 
if additional gene rearrangements are specific for the Scl70 antigen.  Also, 
additional testing of the other antigen positive cells would allow the gene 
rearrangements specific for the other antigens to be assessed.  Similar studies 
could also be conducted on two of the vasculitis patients as these patients 
tested positive for Ro, La and c-ANCA autoantibodies (Table 2.3); these 
patients were not included in the original study due to a lack of recombinant 
antigen.     
 
Similar studies to those discussed in this chapter have been conducted in other 
autoimmune disorders, SS, MG, WG, Hashimoto’s Thyroiditis (HT) and most 
recently in RA.  Tengnér et al (358) demonstrated the presence of Ro/SSA and 
La/SSB antibody producing cells in salivary gland biopsies from SS patients 
indicating that anti-Ro/SSA and anti-La/SSB autoantibodies were produced and 
present at the sites of inflammation implicating their involvement within the 
disorder.  Biotinylated antigens were used to identify antigen positive cells 
which were thought to exhibit plasma cell morphology.  These antigen-specific 
cells appeared scattered, singularly or in clusters primarily within the 
inflammatory infiltrates, findings similar to that presented in this chapter.  The 
study also established that patients with higher levels of serum autoantibodies 
contained higher numbers of autoantibody producing cells within the salivary 
glands.  Salomonsson et al (359), in a later study into the ectopic germinal 
centre formation in SS, also used biotinylated recombinant antigens (Ro and 
La) as probes and located antigen-specific cells within salivary gland biopsies of 
SS patients.  The frequency of these positive cells was significantly higher in 
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patients with germinal centre formation compared to those without germinal 
centres.  The study demonstrated that these antigen-specific cells were located 
at the periphery of the inflammatory infiltrates and also demonstrated a strong 
correlation between local salivary gland production and serum autoantibodies.  
Although present at the sites of inflammation it has also been shown that some 
autoantibody producing cells for Ro/SSA and La/SSB are present in the 
circulating peripheral blood (360). 
 
Antigen-specific cells have also been identified in the thymus of Myasthenia 
Gravis patients (52;361).  MG is mediated by autoantibodies directed against 
various epitopes of the adult acetylcholine receptor (AchR) at the 
neuromusclular junction, resulting in muscle weakness.  These autoantibodies 
can also bind to the foetal AchR also present in the thymus.  Sims et al (52) 
used complexes containing an antagonist of AchR function, 125I-αBungarotoxin 
(αBuTx), to identify the occurrence of AchR antigen-specific cells within the 
thymus.  Approximately 50% of the germinal centres present within the thymus 
contained antigen positive cells, in a similar pattern to the FDC network.  
Results demonstrated that the germinal centres containing these antigen-
specific cells were undergoing antigen-driven clonal proliferation, somatic 
hypermutation and selection.  In a subsequent study Matthews et al (361) 
demonstrated that autoantibodies directed towards the foetal AchR were 
significantly more common in females sampled after pregnancy than those who 
present before pregnancy suggesting that they may be induced by the foetus.  
Cloning the Fabs of these high affinity antibodies demonstrated that these 
antibodies used the VH3-07, 4-61, 3-23 and 3-21 gene segments.  These 
antibodies were shown to undergo clonal diversification and antigen-driven 
selection.     
 
While analysing the VH gene repertoires of infiltrating B cells from endonasal 
lesions in WG patients Voswinkel et al (348) identified PR3-ANCA positive cells 
in the vicinity of B cell-rich follicle-like structures and plasma cells.  The authors 
suggest that potentially PR3-ANCA producing cells might be selected in PR3+ 
granulomatous lesions starting in localised WG and continuing in generalised 
WG.  Armengol et al (54) demonstrated the presence of antigen-specific cells 
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within active intrathyrodial germinal centres of Hashimoto thyroditis patients, an 
autoimmune thyroid disease.  Antigen specific cells to two thyroid-specific 
antigens were found to be present within GCs, thyroglobulin (Tg) and 
thyroperoxidase (TPO).  The results showed that two types of cells bound the 
thyroid antigens; numerous small cells, which demonstrated a similar 
distribution to B cells, as well as strongly positive cells with a strong cytoplasmic 
staining scattered all over the lymphoid follicles within the thymus, plasma cells.  
Double staining experiments revealed that most of the antigen specific cells 
were also IgG+.  Results of this study suggest that intrathyrodial lymphoid 
follicles were committed to thyroid antigen immune responses.  Recently anti-
citrullinated protein/peptide antibody (ACPA) producing plasma cells were 
identified in the synovial tissue of RA patients using biotinylated citrullinated 
fibrinogen in double immunofluorescence experiments (55).  These antibodies 
are highly specific markers for RA and are potentially pathogenic.                                
 
In summary, the work presented in this chapter demonstrated that antigen-
specific B cells and plasma cells are present within sites of inflammation in 
myositis patients and support previous studies where antigen specific cells were 
found at ectopic sites in autoimmune diseases.  These results in conjunction 
with those of Chapter 4, identifying clonally related sets of genes, indicate that B 
cells may be stimulated at the site of inflammation demonstrating that an 
antigen-driven response occurs within the muscle but it may also be possible 
that cells are also stimulated at other sites and migrate into the sites of 
inflammation within the muscle.  Additional, but extremely preliminary, 
experiments to identify the immunoglobulin genes of these antigen-specific cells 
isolated the gene rearrangements and sequence of a Scl70+ cell.  The 
mutational characteristics of the isolated gene support the occurrence of an 
antigen-driven response, possibly within sites of muscle inflammation but as 
previously mentioned these reactions may also occur at other sites leading to 
migration of antigen specific cells into inflamed muscle.  Further analysis of 
immunoglobulin genes from antigen-specific cells would be required to provide 
further insight into the gene rearrangements, sequence mutations and clonal 
diversification mechanisms occurring within inflamed muscle specific to 
autoantigens.      
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Chapter 7 – General Discussion 
Of paramount importance in the understanding of autoimmune inflammatory 
disorders is whether highly specific B cell antigen-driven adaptive immune 
responses are present within the target tissues of these disorders.  In the 
current study this question was addressed in the target tissues, muscle and 
skin, of myositis and vasculitis patients respectively by examining the Ig 
repertoire and mutational characteristics of tissue infiltrating B  and plasma cells 
and establishing if clonal diversification and affinity maturation mechanisms 
were ongoing within the target tissues.  Collectively the data presented in this 
thesis demonstrated that antigen-driven B cell responses were occurring within 
inflamed muscle of the various myopathy subsets.  Ig gene selections and 
oligoclonal expansion of B cells were observed in these samples signifying that 
muscle infiltrating B cells were being stimulated by antigen(s) within the muscle 
and could contribute to the pathological mechanisms in play at the sites of 
inflammation.  Conversely in inflamed skin, gene selections and oligoclonal 
expansion were not observed from the sequences isolated from skin infiltrating 
cells indicating that there is no antigen driven B cell responses occurring within 
the inflamed skin but infiltrating plasma cells, outwith their normal bone marrow 
residence, may be contributing to the response and the pathology within the 
skin through the secretion of autoantibodies.  Ig sequences isolated from these 
cells contained antigen-driven sequence characteristics. At the commencement 
of this work no other study had established these antigen-driven responses 
within these target tissues and despite the different outcomes of both disorders 
of this study the results presented do suggest the active participation of antigen-
driven responses in the target tissues of autoimmune disorders as well as a role 
for B cells in the pathophysiology of these diseases.              
 
The main objective of this work was to test the hypothesis that B cells play an 
antigen-driven role within these disorders.  In some instances disorders are 
characterised as B cell mediated due to the presence of autoantibodies which 
are implicated in the associated pathology of the disease.  In others, despite the 
presence of autoantibodies, disorders are categorised, or previously have been 
categorised, as T cell mediated disorders and the true involvement of B cells 
within these disorders was not fully recognised until studies, similar to the 
335 
current study, have identified biased gene repertoires and oligoclonal expansion 
of B cells within target tissues.  Such studies support the involvement of B cells 
within the complex immune responses in the target tissues of these disorders 
which could be associated with the pathological mechanisms involved and 
provide a greater understanding into the course of autoimmune disease.  Such 
studies have been conducted in a number of diseases including SLE, RA, MG, 
SS, MS, OS and AS (52;283;284;289;317-325;362).  Despite the different 
methodologies and source tissues involved in all these studies, the results are 
in parallel with those described in this study, particularly in the myositis 
disorders.  In each study a bias in the Ig gene repertoires was found along with 
the identification of gene segments which were clonally expanded in immune 
reactions within the target tissues, providing insights into the usage of preferred 
VH gene families and possible gene dysregulation in response to antigen within 
these autoimmune disorders.  Additional studies could indicate if certain gene 
combinations are prone to mutations which result in high affinity autoantibodies 
or are associated with pathogenicity.  Subsequent to this, work has been 
conducted which has used the sequences generated in such studies to analyse 
the lineage trees generated from the clonally expanded B cells (363-366).  
Lineage trees were constructed from published Ig sequences from ectopic 
germinal centres or affected tissue B cell clones in patients with various 
autoimmune disorders using the IgTree© algorithm (366).  These were then 
compared to lineage trees from normal PBL and germinal centre samples using 
MTree©, a computer aided algorithm for the measurement of graphical shape 
properties of lineage trees.  This method allowed the interplay between somatic 
hypermutation and antigen-driven selection in different lymphoid tissues and 
disease situations to be assessed while alleviating the effects of different 
experimental protocols between research groups.  Comparing lineage trees 
from diseased states with normal controls demonstrated that lineage trees 
generated from autoimmune disorders were larger than in normal controls. 
Analysis of mutational characteristics suggested a more vigorous diversification 
process and accumulation of more mutations within autoimmune disorders 
compared with normal controls; lineage trees from autoimmune disorders 
demonstrated a longer diversification process.  The changes in B cell selection 
were also assessed from clonal trees based on the degree of tree branching 
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and were found to be similar between normal controls and autoimmune 
disorders suggesting a normal selection strength acting on the B cells within 
autoimmune disorders.  However a recent study (367) by this group in 
ulcerative colitis (UC) using these methodologies revealed no significant 
difference in tree shape properties between sequences isolated from UC 
samples and control samples.  In this study normal Ig gene diversification and 
trafficking of clones between the gut and associated lymph nodes was 
observed.  
 
Antigen-driven reactions are typically thought to occur within the confinements 
of GC structures in secondary lymphoid organs but are commonly found in the 
target tissues of several autoimmune diseases.  As previously described, the 
functionality and potential contribution of these GC reactions in disease 
pathogenesis has recently been described in SS and RA patients (55;326).  In 
addition to these GC reactions the enzyme required for SHM and CSR, AID, 
has been observed and found to be functional in a subset of B cells outside 
GCs.  Prior to this, studies have described antigen-driven reactions occurring 
outside GCs.  These reactions were found to occur outside GC structures in 
areas lacking a FDC network in autoimmune murine models (301;332;333).  It 
has been postulated that such reactions give rise to autoreactive B cells which 
are not governed by the protective mechanisms that occur within GCs.  The 
cells participating in these extrafollicular reactions were found to be activated B 
cells as well as plasmablasts, the dominant producer of autoantibodies in these 
models (333;368;369).  These findings have been extended to mice with normal 
backgrounds and collectively implicate that factors such as antigen density, T 
cell help, BCR affinity and TLR signals may regulate the occurrence of 
extrafollicular responses and GC responses (332;370-372).  Another study has 
demonstrated affinity maturation by SHM in a lymphotoxin-α mouse models 
which fails to develop germinal centres (255).  In the current study clonal 
diversification of B cells has been observed within the target tissues of myositis 
patients although no GC structures were observed.  Such studies do not 
exclude the involvement of GC reactions but indicate an alternative pathway for 
the disease mechanisms generating autoantibodies towards self antigens.  
Contrary to this Cantaert et al concluded that synovial lymphoid neogenesis 
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was a process associated with inflammation and was independent to B 
lymphocyte autoimmunity (373).     
  
As well as identification of clonally expanded B cells the outcomes of such 
studies also provide insight into the mechanisms of diversification in play during 
autoimmune reactions.  Mechanisms such as receptor revision and codon 
insertions and deletions can also be examined to establish if defects or 
irregularities in these mechanisms contribute to the repertoire and pathogenicity 
of autoimmune reactions.  Class switching is another mechanism which can be 
analysed from gene repertoire studies, providing that constant region primers 
have been used. As previously described in Chapter 4, section 4.3.1, class 
switching to other isotypes, including IgA, is evident within the infiltrating B and 
plasma cell populations in myositis samples (90) and authors hypothesised that 
the different Ig isotypes may have a broader role in autoimmunity, especially 
IgA which would normally reside on mucosal surfaces. Class switching has 
been identified by various methods in a number of myositis studies by this 
group (89;90) and the presence of isotype switched secreting plasma cells (IgA, 
IgG and IgM) has also been observed in MS (374).  IgA secreting plasma cells, 
as previously described, are also thought to contribute to the pathology 
associated with a subset of vasculitis, KD (171).  The work of Bradshaw et al 
(90) demonstrated that this class switching was occurring within the muscle with 
the identification of clonal variants with different isotypes.  The process of class 
switching in target tissue of autoimmune disorders has recently been 
substantiated by the identification if AID in the target tissues of SS and RA 
patients (326).  The findings of such studies enhance the understanding of 
immune mechanisms within the target tissues of autoimmune disorders and 
indicate that these responses are occurring within the target tissues and not 
solely within the periphery resulting in infiltration into target tissues.  This would 
be especially significant in the two disorders of the current study where no 
classic germinal centre structures, the typical site of class switch recombination, 
were observed.  Identification of Ig gene repertoires and oligoclonal expansion 
of autoreactive B cells can also provide the foundation for examining the 
mechanism of somatic hypermutation and the influence of particular mutations 
on antigen affinity within these sequences.  Studies have been conducted on 
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anti-dsDNA antibodies isolated from SLE patients which demonstrate the 
influence of particular mutations on antigen affinity (375-379). Li et al (375) 
established that the binding activity of a monoclonal anti-DNA antibody, with 11 
somatic mutations, to its target antigen was mediated through Arg105 and 
Arg107.  Conversion of each of these residues, independently, to glycine 
resulted in comparable binding efficiency to ssDNA and to that of the original 
antibody but the binding efficiency to dsDNA was lost, indicating that both 
arginine residues were required for dsDNA binding but either was sufficient for 
ssDNA binding.  More recently (376) a combinational library was constructed 
from splenic lymphocytes of a male patient with active SLE.  Selection against 
dsDNA isolated 15 IgG Fabs where a strong correlation was observed between 
the R:S ratios on the CDRs 1 and 2 and affinities for ssDNA and dsDNA; high 
R:S ratios correlated with increased affinity.  Subsequent studies have also 
linked arginine mutations to DNA antigen affinity but have also gone onto 
demonstrate the relationship between somatic mutations that influence the 
affinity to multiple antigens rather than focussing on one antigen (377-379).  
Specific heavy chain and light chain mutations have been found that can either 
enhance an antibody affinity to DNA or eliminate the affinity.  For the light 
chains involved in these experiments arginine residues at position 94 (CDR3) in 
one light chain abolished DNA binding while somatic mutations resulting in an 
arginine residue at position 92 in two other light chains had the opposite effect.  
The work of this group also observed that a mutation to an arginine residue at 
position 27 within CDR1 played a role in binding to histones, further enhancing 
the affinity for dsDNA and was confirmed by a reduction in binding when the 
residue was altered to serine.  In the heavy chain of these anti-DNA antibodies 
an arginine residue at position 53 (CDR2) was found to contribute to the 
enhanced DNA binding.  Conversion of this residue to 3 other variants by site 
directed mutagenesis and the germline configuration of the gene resulted in 
reduced binding to DNA.  A mutation within the germline at position 53 was also 
found to be insufficient for binding indicating that other mutations or sequence 
characteristics are required.  The mutation at position 53 was also shown to 
enhance the antibody binding to a number of other antigens, α-actinin and 
glycoproteins which are significant in the pathogenesis of antiphospholipid 
syndrome (APS).  Such studies examine the effects of somatic hypermutation 
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on the relationship between sequence, structure and antigen binding and 
highlight the influence of individual somatic mutations in autoantibodies.  
 
As previously described in Chapter 1 the B cell depletive therapy, Rituximab, 
has emerged as an influential therapeutic strategy in the treatment of both 
myositis and vasculitis, in addition to a number of other autoimmune disorders 
where clinical improvements, stabilisation and remission are observed in 
patients (140-145;147;148;150-152;159;202;203;205;206;355;380-384).  This is 
further substantiated by the emergence of alternative B cell depletive therapies 
which are targeting B cells from alternate approaches (385) and fully illustrates 
the importance and contribution of B cells within these disorders.  Although this 
therapy has been found effective in various studies the emergence of B cell 
populations associated with clinical relapses, variations in autoantibody and 
autoantigen levels, which may suggest that some of the underlying disease 
mechanisms are still ongoing, and the wider immunological effects such as 
cellular modulations (386;387) illustrates the complexity of the B cell role within 
autoimmune disorders.  In the context of this study, many studies examining the 
Ig gene repertoire and diversification of B cells within target tissues or 
peripheral blood of autoimmune patients are conducted prior to specifically 
targeted therapeutic interventions and the impact of therapies like Rituximab on 
the repertoire and diversification of B cells within target tissues or peripheral 
blood have not been extensively studied.  Studies have been conducted in RA 
which examined the peripheral blood repertoire following Rituximab therapy 
(388) which illustrated that the use of Rituximab resulted in subtle modulation of 
the RA repertoire. Although the objective of this therapy is removal of CD20+ 
populations of B cells, the influence and modulatory effect of Rituximab on the 
Ig repertoires of the remaining CD20- population of B cells along with the re-
emerging CD20+ populations would be of interest to study.  Such studies would 
aid the understanding of Ig gene profiles associated with clinical remission and 
relapse as well as highlighting those Ig sequences that are of importance within 
the disorders.   
 
The work presented in this thesis has focussed in on the antigen-driven role and 
diversification of B cells within the target tissues of myositis and vasculitis 
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patients but multifunctional roles have been attributed to B cells within immune 
responses, which influence and are influenced by an extensive number of 
parameters of the immune response.  B cells are also capable of acting as 
antigen presenting, regulatory and stimulatory cells.  Antigen-specific B cells are 
capable of taking up, internalising, processing and presenting antigen to T cells 
as well as other cells and may be the primary role of B cells in contributing to 
pathogenesis.  These functions have been implicated in the initiation of immune 
responses, particularly those that are autoimmune.  Antigen presentation by B 
cells could enhance the antibody production and expansion of antigen specific 
B and T cells, thus intensify the immune response to self antigens.    Studies 
have shown that antigen specific B cells can capture soluble antigen and initiate 
a T cell response earlier than DCs and recently the transfer of antigen from B 
cells to other antigen presenting cells, macrophages, has been observed which 
could possibly lead to amplification or editing of antigen specific immune 
responses resulting in chronic autoimmune responses (313;389). The B cell 
receptor (BCR) is proposed to play a significant role in antigen presentation by 
B cells; antigens are internalised by receptor-mediated endocytosis in B cells, a 
mechanism carried out by the BCR.  Two features of antigen processing within 
B cells are not observed within other APCs.  Firstly BCR ligation with antigen 
induces internalisation and directs the BCR–antigen complex through the 
endocytic pathway towards MHC class II rich compartments promoting the 
formation of MHC class II-peptide complexes (390). The signalling resulting 
from BCR ligation upregulates MHC class II expression and stimulates their 
traffic through the same compartments used by the antigen-BCR complexes 
(391).  These methods allow B cells to combine antigen recognition with the 
complexes in charge of its processing, favouring presentation of these 
internalised antigens in comparison to antigens internalised by pinocytosis.  
Secondly, antigen processing within B cells has been shown to induce the 
expression of HLA-DO, a non-classical MHC class II molecule which functions 
to inhibit the actions of HLA-DM, which favours presentation of peptides derived 
from antigen internalised through the BCR (392).  Receptor-mediated 
endocytosis through the BCR also allows the concentration of very small 
quantities of antigen for efficient presentation.  It has been reported that BCR 
affinity is directly proportional to the capacity of the B cell to participate in 
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antigen presentation to CD4+ T cells (393).  The study also demonstrated that 
presentation via the pinocytosis method required a 5000 fold increase in antigen 
concentration.  In SLE, B cells have been shown to act as APCs of the target 
antigen snRNP (394).  Transfer of B cells obtained from mice primed with 
snRNP from a different species lead to autoreactive CD4+ T cell activation.  
Transgenic mice expressing a BCR specific for snRNP was also used in studies 
to demonstrate that high numbers of autoantigen-specific B cells can activate 
CD4+ T cells in an autoimmune background and tolerize them in a wild-type 
background, supporting the role of B cells as pathogenic APCs (395).  Anti-DNA 
B cells in lupus have also been shown to act as APCs (396).   
 
In addition to their possible role as antigen presenting cells, B cells have been 
shown to exert effects through possible regulation of immune responses in 
autoimmune disorders.  A subset of B cells, regulatory B cells, exist that 
suppress the exacerbation of and/or enhance the recovery from acquired 
immune-mediated inflammations by mechanisms that include IL-10 and TGF-β1 
production, secondary antigen presentation and interaction with other immune 
cells either directly or through secreted antibodies (397).  B cells have the ability 
to produce detectable quantities of immunoregulatory cytokines such as IL-2, 
IFN-γ, IL-12 and IL-4 in addition to IL-6, TNF-α and IL-10 which have a long 
term association with B cells (398).  Two populations of effector B cells were 
identified, Be1 and Be2.  Both cell types produced IL-2, IL-6 and IL-10 upon 
restimulation but higher levels were observed within Be2 cell populations, Be2 
cell populations also produced IL-4 while Be1 cells produced IFN-γ; only trace 
amounts of IFN-γ were observed in Be2 cells while IL-4 was completely absent 
from Be1 populations.  The role of these cytokine profiles in regulating T cell 
differentiation was studied by addition of cytokine-blocking antibodies to 
cultures of effector B cells and naïve T cells.  Anti-IFN-γ added to cultures 
containing Be1 cells and T cells severely reduced the IFN-γ production 
produced by the effector T cells, suggesting that IFN-γ produced by Be1 cells 
was sufficient to differentiate T cells into IFN-γ producing effector-cells. Similar 
cultures containing Be2 cells and anti-IL-4 antibodies demonstrated the 
requirement of IL-4 to differentiate T cells to Th2-like cells.  The use of anti-IL-4 
antibodies resulted in no detectable levels of IL-4, IL-5, IL-6 or IL-10, but 
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conversely produced increased levels of IFN-γ indicating that Be2 cells may 
negatively regulate the differentiation of T cells into IFN-γ producing cells.  
Results suggest that like other APCs, effector B cells have the capacity to 
regulate the type of immune response generated in response to antigen. 
 
With a focus on the inflammatory myopathies, widespread studies have been 
conducted examining the various cell phenotypes within myositis, as well as 
other autoimmune disorders, as previously described in Chapter 3.  Such 
studies demonstrate the complex nature of immune responses and are required 
to analyse the B cell response in context with the overall immune mechanisms.  
The influence of cytokines and chemokines on the responses involved in 
autoimmune disorders is also of interest.  In recent studies levels of BAFF/BLys 
(B cell activating factor/B lymphocyte stimulator), which is crucial in B cell 
maturation and survival and is also thought to play a role in autoantibody 
production, have been examined in serum samples of myositis patients (42).  
Serum levels were found to be elevated in myositis patients compared to control 
individuals and it was also noted that patients with DM or anti-Jo-1 
autoantibodies had higher serum levels compared to other myositis subsets or 
other patients without any specific autoantibodies respectively.  BAFF levels 
were also shown to correlate positively with CK levels and negatively with 
glucocorticoid treatment.  This study demonstrates the important role of B cells, 
and BAFF, in myositis patients and provides further insights into the 
mechanisms involved within the muscle but could also relate to mechanisms of 
other disorders such as vasculitis.  Following Rituximab therapy in SS patients, 
the repopulation of B cells has been shown to be modulated by BAFF (399) 
which again demonstrates the importance for further studies on B cells within 
autoimmune disorders.  A marked increase in BAFF levels have also been 
observed in RA and SLE patients following Rituximab therapy which declined 
with the re-emergence of B cells (380;400).  It has been suggested that 
elevated BAFF levels in myositis samples are induced by the type I IFN system 
produced by PDCs (42); levels of type I IFN cytokines in DM and PM have been 
found to correlate with disease activity (305).  As described in Chapter 3 these 
cell phenotypes have been identified within myositis patients and in addition to 
influencing BAFF serum levels these cells and their products have been shown 
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to act in the differentiation of plasma cells as well as antigen presenting cells, all 
of which could contribute to the functions and actions of B cells as well as the 
pathophysiology with inflamed muscle.  Recently IFN-α stimulation has been 
shown to up-regulate Ro52, at both the messenger and protein levels (401); 
autoantibodies to Ro52 are found in correlation with anti-Jo-1 antibodies in 
myositis patients as well as in other autoimmune disorders.  This stimulation 
was also shown to result in translocation of the Ro52 protein into the nuclear 
compartment from the cytoplasm which could contribute to the pathological 
mechanisms observed in myositis and other autoimmune disorders.  A 
correlation, and possible link to disease mechanisms, between IFN-α and 
immune complexes containing anti-Ro52 autoantibodies has also been shown 
be Elorenta et al (123).   Another cytokine, and cell phenotype, that is reported 
to contribute to the development of germinal centre derived autoantibodies and 
play a role in autoimmune disease is IL-17, produced by Th-17 cells which are a 
distinct population of CD4+ T helper effector cell population that differs in 
phenotype and function from classical T helper cells (402-405).  Initially IL-17 
was characterised as a potent proinflammatory cytokine coordinating local 
tissue inflammation but it has also been linked with the induction of 
autoimmunity.  Reduced or eliminated levels of this cytokine have been 
associated with a reduced autoantibody response, the cytokine has been 
associated with the development of RA, MS and inflammatory bowel disease 
and IL-17 had been found to accelerate and stabilise germinal centre reactions 
and autoantibody formation of enhanced somatic hypermutation although the 
exact mechanisms are unresolved.  Continued characterisation of autoimmune 
reactions provides greater insight into the mechanisms involved in these 
diseases and how these may influence the roles and actions of B cells within 
these disorders.                         
 
In addition to the number of factors of the immune system which might regulate 
the immune response within the muscle of the myositis patients described in 
this study the muscle cells themselves are also thought to contribute to the 
responses.  It has been proposed that muscle cells themselves may act as 
antigen presenting cells during inflammatory reactions (406), as well as 
modulating the function of other APCs (407) present within the muscle during 
344 
immune responses.  Antigen presentation capabilities were demonstrated in 
human myoblasts, cultured from muscle which constitutively express MHC class 
I molecules but no detectable amounts of MHC class II.  IFN-γ and TNF-α 
stimulation induced MHC class II expression which was necessary but not 
sufficient for functional antigen presentation to CD4+ T cells.  These functions of 
muscle cells have been shown to be mediated through expression of MHC and 
co-stimulatory molecules such as CD40, ICOSL and B7 ligands (408-415), 
mostly recently B7-H3 which was shown to be expressed on muscle cells from 
different myositis subsets and was found to be a potent inhibitor of immune 
CD8+ mediated lysis of muscle cells (411).  The active participation of muscle 
cells in immune responses is also supported by the variety of cytokines and 
chemokine secreted from muscle cells and the expression of cell adhesion 
molecules, ICAM-1, which results in the interaction between muscle and 
immune cells (406).  As well as antigen presenting functions human skeletal 
muscle derived myoblasts were found to increase the phagocytic capacity of 
macrophages and modulate DC maturation (407).  
 
Nagaraju et al (79) demonstrated that the sustained up-regulation of MHC Class 
I molecules in mice leads to self-sustaining myositis, with similar features to 
human myositis, and the production of MSAs.  Results suggest that 
autoimmune myositis may occur as a consequence of an apparently non-
specific event, like the sustained up-regulation of MHC Class I molecules.  
 
Besides the study of antigen-specific immune responses, non-immune 
mechanisms are also thought to contribute to the pathology associated with 
myopathies.  These mechanisms could also be related to the pathology in other 
target tissues such as the skin (86;416).  One such nonimmune mechanism 
may be the endoplasmic reticulum (ER) stress response.  The ER plays a 
critical role in the synthesis, folding, processing and exporting of newly 
synthesised proteins.  The ER stress response occurs when there is an excess 
accumulation of proteins within the ER, which is greater than the muscle cells 
ability to process.  Ischaemia, hyperhomocysteinemia, viral infections and 
mutations that impair protein processing may also result in the ER stress 
response. Cells have a variety of self-protection responses to ER stress and 
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include the up-regulation of the NF-κB pathway, up-regulation of protein 
assembly associated proteins to prevent further accumulation of proteins within 
the ER, reduction in protein translation to prevent further accumulation and cell 
death.  This ER stress response has recently been proposed to participate in 
the pathological mechanisms associated with myositis.  Nagaraju et al (86) 
demonstrated, using human myositis samples and tissue from class I MHC-
transgenic mice, that ER stress responses are highly activated in both samples 
of myositis.  Data also demonstrated that the NF-κB pathway is highly activated 
in myositis samples in response to ER stress.  Activated NF-κB induces target 
genes including class 1 MHC which in turn further exacerbates the ER stress 
response, thus initiating a self-sustained loop.  This pathway and its role in 
pathogenesis of myositis have also recently been demonstrated by Grundtman 
and Lundberg (416). 
 
The work of this study has established an antigen-driven role for B cells in the 
target tissues of myositis and has demonstrated the potential influence of B cell 
antigen driven mechanisms from other sites on the target tissues of vasculitis 
patients where no direct and active mechanisms were observed.  These 
findings are substantiated and correlate with other studies examining the role of 
B cells in such mechanisms.  Despite this a number of questions still need to be 
explored to fully understand the mechanisms occurring within these 
autoimmune diseases.  From the work of this study identification of the 
stimulating antigen(s), epitopes and sequence characteristics of the responding 
high-affinity antibodies would provide a greater insight into pathological 
mechanisms.  Sequence characteristics of antigen specific cells were very 
transiently explored and examined in this study, Chapter 6, but further 
identification of Ig rearrangements and mutational characteristics of antigen-
specific cells would greatly enhance the understanding of the antibody response 
to autoantigens.  Alternative approaches could include the use of phage-display 
technologies (417-420) or production of recombinant antibody molecules to 
isolate high-affinity antibodies.  Such methods have been used in the 
characterisation of antibodies in Wegener’s granulomatosis to PR3 (421), SLE 
to DNA (422) and in subacute sclerosing panencephalitis (423). Antigen 
specificity, antibody affinity characteristics and the effects of individual 
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mutations on specificity or affinity between different members of the same 
clonally related set of Ig V-gene sequences could then be assessed in these 
antibodies.  Computer modelling techniques could also be used on isolated 
antibodies to establish important characteristics of these antibodies such as 
selected mutations which contribute to autoantibody specificity and affinity.  
Patients with autoimmune disorders could mount immune responses to various 
and some as yet unidentified antigens and produce a wide range of pathogenic 
and non-pathogenic antibodies as a result.  Characterisation of pathogenic 
antibodies and their stimulating antigens could assist the understanding of why 
some protein targets are selected in autoimmune disorders resulting in a loss of 
B cell tolerance and how the pathogenic antibodies mediate their actions which 
result in pathology.  Such studies would also provide a greater insight into the 
initiation of such reactions and determine the compartmentalisation within target 
tissues or widespread actions of these reactions in the periphery.  Wider studies 
could address the promotion and regulation of autoreactive B cells and how 
other cell phenotypes, cytokines and co-stimulatory molecules contribute to the 
development and maintenance of these autoreactive B cells.  Ultimately further 
work is required to fully ascertain the role of B cells and their antibodies within 
the target tissues of autoimmune disorders as greater understanding of these 
roles will facilitate the diagnosis, treatment and management of disorders.                
 
To conclude, the work of this study has examined the antigen-driven B cell 
responses in the target tissues of myositis and vasculitis patients and 
demonstrated that these responses are present and active within inflamed 
muscle of myositis patients but absent from inflamed skin of vasculitis patients.  
Despite this, pathological mechanisms in the skin, secretion of potentially 
pathogenic autoantibodies from infiltrating plasma cells for example, could still 
be influenced by antigen-driven B cell responses occurring at alternative sites, 
presumably in peripheral lymphoid organs or at other ectopic locations.  The 
results of this study highlight the involvement of B cells within the target tissues 
of autoimmune disorders and provide a foundation for future characterisation of 
autoantibodies, autoantigens and the autoimmune reactions of these disorders.    
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Appendix 1 – Ig DNA Sequence Alignments using the JOINSOLVER Software 
 
The JOINSOLVER algorithm (http://joinsolver.niams.nih.gov) (241) was used to 
match the isolated Ig DNA sequences from myositis and vasculitis samples to 
the corresponding germline genes.  The software was used with the default 
parameters.  For illustration purposes only the alignments for the assigned 
genes have been shown, in most instances this was the best matching and 
highest scoring alignment but where alternative, lower scoring, matches have 
been assigned the higher scoring alignments have also been given with the 
assigned gene highlighted in yellow.  Assignment of DH genes and junctional 
analysis was conducted as described in section 2.3.12.3.  Primer regions, the 
first 24 bases at the 5’ VH region, were disregarded; for illustration purposes in 
the sequence alignments below and on the attached CD these regions were 
converted back to germline configurations once the best matching germline 
gene had been assigned to allow mutational numbers to correspond to those 
used in the analysis of these sequences in Chapters 4 and 5.  Junctional 
nucleotides highlighted in yellow illustrate the P and N nucleotides used in the 
analysis of these regions after manual analysis of the D gene assignment and 
junctional regions.   
 
In addition to JOINSOLVER the IMGT/V-QUEST algorithm was also used 
match the isolated Ig DNA sequences to the corresponding germline genes.  
Any anomalies between the two alignment algorithms are given within the 
results section of Chapters 4 and 5.  The IMGT/V-QUEST algorithm has the 
capability of searching the isolated sequence for the presence of insertions and 
deletions of nucleotides, which is not available using the JOINSOLVER 
algorithm.  Where insertions and deletions were detected the corresponding 
alignments from the IMGT/V-QUEST algorithm are provided in addition to the 
subsequent alignments, using both programmes, following restoration of the 
insertions or deletions.  
 
Sequence alignments to gene assignments for all sequences used in this study 
can be found on the attached CD; alignments from one patient from each 
principal disorder of this study are shown below. 
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379 
Sample MYO17 
Sequence – VH3-30*03, DH3-9*01, JH4*02 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGCCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAGTGGCTGGCAATTATTTCATATGATGGAGGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATTTCCAGAGACAATTCCAAGAATACGCT
GTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTATATTGGTGTGCGACAGGCGCGTATTATGATATTTTGAGTGGTGCTCGGCCGTTTGACTACTGGGGCCAGGGAACC
CTGGTCACCGTCTCCTA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWLAIISYDGGNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAED 
TAVYWCATGAYYDILSGARPFDYWGQGTLVTVS 
 
JoinSolver 
Rearrangement is productive: 
 
Highest scoring matches:  
V: IGHV3-30*03  D:IGHD3-9*01  J: IGHJ4*02 
The VH segment has 12 mutations 
CDR3 Length:  51 
 A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   
GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   R   S   L   
 
score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG TCT CTG  
IGHV3-30*03 1317 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ..C ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 R   L   S   C   A   A   S   G   F   T   F   S   T           Y   A   M   
 
AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT ACC --- --- TAT GCC ATG  
IGHV3-30*03 ... ... ... ... ... ... ... ... ... ... ... ... .G. --- --- ... .G. ...  
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___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 H   W   V   R   Q   A   P   G   K   G   L   E   W   L   A   I   I   S   
 
CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG CTG GCA ATT ATT TCA  
IGHV3-30*03 ... ... ... ... ... ... ... ... ... ... ... ... ... G.. ... G.. ..A ...  
   
  
________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 Y           D   G   G   N   K   Y   Y   A   D   S   V   K   G   R   F   
 
TAT --- --- GAT GGA GGT AAT AAA TAC TAT GCA GAC TCC GTG AAG GGC CGA TTC  
IGHV3-30*03 ... --- --- ... ... A.. ... ... ... ... ... ... ... ... ... ... ... ...  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   
 
ACC ATT TCC AGA GAC AAT TCC AAG AAT ACG CTG TAT CTG CAA ATG AAC AGC CTG  
IGHV3-30*03 ... ..C ... ... ... ... ... ... ..C ... ... ... ... ... ... ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   A   E   D   T   A   V   Y   W   C   A   T   G   
 
AGA GCT GAG GAC ACG GCT GTA TAT TGG TGT GCG ACA GGC  
IGHV3-30*03 ... ... ... ... ... ... ..G ... .AC ... ... .G. .A   
   
D Match Results 
  
 A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   W   G   Q   G   T   L   V   T   V   S           
 len|rf GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TA       
IGHD3-
9*01 10|2               . ... ..C ... ... ... .C. ... TA. TAT AAC  
  
   
J Match Results 
  
 A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   W   G   Q   G   T   L   V   T   V   S           
 
score GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TA       
IGHJ4*02 176                                                  AC TAC ... ... ... ... ... ... ... ... ... ... ... ... ... .CA G    
  
   
Junction Analysis 
V Match: IGHV3-30*03  D Match: IGHD3-9*01  J Match: IGHJ4*02 
  V-J Distance: 38 
VD Junction: # of P,N Nucleotides: (0,14)  CAGGCGCGTATTAT 
DJ Junction: # of P,N Nucleotides: (0,14)  GTGGTGCTCGGCCG 
381 
Sequence – VH6-01*01, No D Gene Assignment, JH5*02 
 
Raw Sequence 
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA
GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGCAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGCCGAATAACCATCAACCCAGACACATCCAA
GAACCAGTTCTCCCTGCAGCTGAACTCTGTGATTCCCGAAGACACGGCTGTCTATTACTGTGTAAGATCCCCCCTTAAGCAGTGGCTGGAACCCTGGGGCAAGGGAACCCTGGTCACC
GTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLARTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVI 
PEDTAVYYCVRSPLKQWLEPWGKGTLVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV6-01*01   D:IGHD3-16*02R  J: IGHJ5*02 
The VH segment has 5 mutations 
CDR3 Length:  33 
 V   R   S   P   L   K   Q   W   L   E   P   
GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 Q   V   Q   L   Q   Q   S   G   P   G   L   V   K   P   S   Q   T   L   
 
score CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC  
IGHV6-01*01  1425 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 S   L   T   C   A   I   S   G   D   S   V   S   S   N   S   A   A   W   
 
TCA CTC ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT AGC AAC AGT GCT GCT TGG  
IGHV6-01*01  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
   
  
___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 N   W   I   R   Q   S   P   S   R   G   L   E   W   L   A   R   T   Y   
 
AAC TGG ATC AGG CAG TCC CCA TCG AGA GGC CTT GAG TGG CTG GCA AGG ACA TAC  
IGHV6-01*01  ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ... ...  
382 
 
  
________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 Y   R       S   K   W   Y   N   D   Y   A   V   S   V   K   S   R   I   
 
TAC AGG --- TCC AAG TGG TAT AAT GAT TAT GCA GTA TCT GTG AAA AGC CGA ATA  
IGHV6-01*01  ... ... --- ... ... ... ... ... ... ... ... ... ... ... ... ..T ... ...  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   I   N   P   D   T   S   K   N   Q   F   S   L   Q   L   N   S   V   
 
ACC ATC AAC CCA GAC ACA TCC AAG AAC CAG TTC TCC CTG CAG CTG AAC TCT GTG  
IGHV6-01*01  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 I   P   E   D   T   A   V   Y   Y   C   V   R   S   
 
ATT CCC GAA GAC ACG GCT GTC TAT TAC TGT GTA AGA TCC  
IGHV6-01*01  .C. ... ..G ... ... ... ..G ... ... ... .C. ... GA   
   
D Match Results 
  
 V   R   S   P   L   K   Q   W   L   E   P   W   G   K   G   T   L   V   T   V   S   S       
 len|rf GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC TGG GGC AAG GGA ACC CTG GTC ACC GTC TCC TCA A    
IGHD3-16*02R 6|3 .AT .AC ... ... AAA CGT A.T CAT AAT AC   
  
J Match Results 
  
 V   R   S   P   L   K   Q   W   L   E   P   W   G   K   G   T   L   V   T   V   S   S       
 
score GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC TGG GGC AAG GGA ACC CTG GTC ACC GTC TCC TCA A    
IGHJ5*02 183                      .C A.C ... T.C ..C ... ... ... C.. ... ... ... ... ... ... ... ... G    
  
Junction Analysis 
V Match: IGHV6-01*01   D Match: IGHD3-16*02R  J Match: IGHJ5*02 
  V-J Distance: 29 
VD Junction: # of P,N Nucleotides: (2,3)  TAAga(tc) 
DJ Junction: # of P,N Nucleotides: (0,18)  CTTAAGCAGTGGCTGGAA 
 
 
 
 
 
 
383 
Sample VAS1 
Sequence – VH1-18*01, DH2-2*01, JH5*02 
 
Raw Sequence 
CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTCTCCTGCACGGCCTCTGGTTACACCTTTACCAGCTATGCTGTCAGCTGGGTGCGACAGG
CCCCTGGACAAGGTCTTGAGTGGATGGCGTGGATCAGCACTTACTATGATGATGCAAAATATGCGCCGAAATTCCAGGGCAGACTTTCCGTGACCACGGACACATCCACGAGCACAGC
CTACATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCAGATACTTCTGTGCGAGAGACGATTGTTCTGGTACCAGCTGTCATGCCGACCTCTGGGGCCAGGGAACCCTGGTCACC
AAGCCG 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVQSGAEVKKPGASVTVSCTASGYTFTSYAVSWVRQAPGQGLEWMAWISTYYDDAKYAPKFQGRLSVTTDTSTSTAYMELRSLRSDD 
TARYFCARDDCSGTSCHADLWGQGTLVTK 
 
JoinSolver 
Rearrangement is productive: 
 
Highest scoring matches:  
V: IGHV1-18*01  D:IGHD2-2*01  J: IGHJ5*02 
The VH segment has 30 mutations 
CDR3 Length:  42 
 A   R   D   D   C   S   G   T   S   C   H   A   D   L   
GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 Q   V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   A   S   V   
 
score CAG GTT CAG CTG GTG CAG TCT GGA GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG  
IGHV1-18*01 1155 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
   
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 T   V   S   C   T   A   S   G   Y   T   F   T   S           Y   A   V   
 
ACG GTC TCC TGC ACG GCC TCT GGT TAC ACC TTT ACC AGC --- --- TAT GCT GTC  
IGHV1-18*01 .A. ... ... ... .A. ..T ... ... ... ... ... ... ... --- --- ... .G. A..  
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___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 S   W   V   R   Q   A   P   G   Q   G   L   E   W   M   A   W   I   S   
 
AGC TGG GTG CGA CAG GCC CCT GGA CAA GGT CTT GAG TGG ATG GCG TGG ATC AGC  
IGHV1-18*01 ... ... ... ... ... ... ... ... ... ..G ... ... ... ... .GA ... ... ...  
   
  
________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 T           Y   Y   D   D   A   K   Y   A   P   K   F   Q   G   R   L   
 
ACT --- --- TAC TAT GAT GAT GCA AAA TAT GCG CCG AAA TTC CAG GGC AGA CTT  
IGHV1-18*01 G.. --- --- ... A.. .G. A.C A.. ..C ... ..A .A. ..G C.. ... ... ... G.C  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 S   V   T   T   D   T   S   T   S   T   A   Y   M   E   L   R   S   L   
 
TCC GTG ACC ACG GAC ACA TCC ACG AGC ACA GCC TAC ATG GAA CTG AGG AGC CTG  
IGHV1-18*01 A.. A.. ... ..A ... ... ... ... ... ... ... ... ... ..G ... ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   S   D   D   T   A   R   Y   F   C   A   R   D   
 
AGA TCT GAC GAC ACG GCC AGA TAC TTC TGT GCG AGA GAC  
IGHV1-18*01 ... ... ... ... ... ... GTG ..T .A. ... ... ... ..   
   
D Match Results 
  
 A   R   D   D   C   S   G   T   S   C   H   A   D   L   W   G   Q   G   T   L   V   T   K   P           
 len|rf GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC TGG GGC CAG GGA ACC CTG GTC ACC AAG CCG          
IGHD2-2*01 10|2       . .GA T.. ... AG. A.. ... ... ..C T.. ...  
  
J Match Results 
  
 A   R   D   D   C   S   G   T   S   C   H   A   D   L   W   G   Q   G   T   L   V   T   K   P           
 
score GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC TGG GGC CAG GGA ACC CTG GTC ACC AAG CCG          
IGHJ5*02 100                                  A. AAC TGG TT. ... .C. ... ... ... ... ... ... ... ... GTC T.C TCA G    
  
Junction Analysis 
V Match: IGHV1-18*01  D Match: IGHD2-2*01  J Match: IGHJ5*02 
  V-J Distance: 33 
VD Junction: # of P,N Nucleotides: (0,11)  CGATTGTTCTG 
DJ Junction: # of P,N Nucleotides: (0,12)  TCATGCCGACCT 
 
 
385 
Sequence – VH3-23*01, No D Gene Assignment, JH4*02 (25 Mutations) 
 
Raw Sequence 
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGGTTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGACTCCCCTTTAGAAGCTCTGCCATGAGCTGGGTCCGCCAGG
CTCCAGGGAAGGGGCTGGAGTGGGTCTCAAGTATTAGTAGTAGTGGCAGTACCACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCGTCTCCAGAGACAATTCCAGGAACACTTT
ATTTCTGCAATTGAACAGCCTGAGAGCCGAGGACACGGCCATATACTACTGCGTGAAGACCACGGTTATAAACCTGTCGTACTTTGAAGACTGGGGCCGGGGGACCACGGTCACCGTC
TCCTCAGGAACCCTGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
EVQLLESGGGLVEVGGSLRLSCAASGLPFRSSAMSWVRQAPGKGLEWVSSISSSGSTTYYADSAKGRFTVSRDNSRNTLFLQLNSLRAED 
TAIYYCVKTTVINLSYFEDWGRGTTVTVSSGTLVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-23*01  D:IGHD1-14*01R  J: IGHJ4*02 
The VH segment has 25 mutations 
CDR3 Length:  39 
 V   K   T   T   V   I   N   L   S   Y   F   E   D   
GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 E   V   Q   L   L   E   S   G   G   G   L   V   E   V   G   G   S   L   
 
score GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA GAG GTT GGG GGG TCC CTG  
IGHV3-23*01 1209 ... ... ... ... ... ... ... ... ... ... ... ... C.. CC. ... ... ... ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 R   L   S   C   A   A   S   G   L   P   F   R   S           S   A   M   
 
AGA CTC TCC TGT GCG GCC TCT GGA CTC CCC TTT AGA AGC --- --- TCT GCC ATG  
IGHV3-23*01 ... ... ... ... ..A ... ... ... T.. A.. ... ..C ... --- --- .A. ... ...  
   
  
___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 S   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S   
 
AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA AGT ATT AGT  
IGHV3-23*01 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... GC. ... ...  
 
386 
  
________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 S           S   G   S   T   T   Y   Y   A   D   S   A   K   G   R   F   
 
AGT --- --- AGT GGC AGT ACC ACA TAC TAC GCA GAC TCC GCG AAG GGC CGG TTC  
IGHV3-23*01 G.. --- --- ... ..T G.. .G. ... ... ... ... ... ... .T. ... ... ... ...  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   V   S   R   D   N   S   R   N   T   L   F   L   Q   L   N   S   L   
 
ACC GTC TCC AGA GAC AAT TCC AGG AAC ACT TTA TTT CTG CAA TTG AAC AGC CTG  
IGHV3-23*01 ... A.. ... ... ... ... ... .A. ... ..G C.G .A. ... ... A.. ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   A   E   D   T   A   I   Y   Y   C   V   K   T   
 
AGA GCC GAG GAC ACG GCC ATA TAC TAC TGC GTG AAG ACC  
IGHV3-23*01 ... ... ... ... ... ... G.. ..T ... ..T .C. ..A GA   
   
D Match Results 
  
 V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S   G   T   L   V   T   V   S   S      
 len|rf GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA GGA ACC CTG GTC ACC GTC TCC TCA A   
IGHD1-14*01R 8|1     GT. GTT C.. ... ... CC   
  
J Match Results 
  
 V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S   G   T   L   V   T   V   S   S      
 
scoreGTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA GGA ACC CTG GTC ACC GTC TCC TCA A   
IGHJ4*02 168                                  AC ... ... ..C T.. ... ... .A. ..A ... CT. ... ... ... ... ... .    
  
Junction Analysis 
V Match: IGHV3-23*01  D Match: IGHD1-14*01R  J Match: IGHJ4*02 
  V-J Distance: 36 
VD Junction: # of P,N Nucleotides: (0,9)  TGAAGACCA 
DJ Junction: # of P,N Nucleotides: (0,19)  AACCTGTCGTACTTTGAAG 
 
 
 
 
387 
Sequence – VH3-23*01, No D Gene Assignment, JH4*02 (26 Mutations) 
 
Raw Sequence 
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGGTTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGACTCCCCTTTAGAAGCTCTGCCATGAGCTGGGTCCGCCAGG
CTCCAGGGAAGGGGCTGGAGTGGGTCTCAAGTATTAGTAGTAGTGGCAGTACCACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCGTCTCCAGAGACAATTCCAGGAACACTTC
ATTTCTGCAATTGAACAGCCTGAGAGCCGAGGACACGGCCATATACTACTGCGTGAAGACCACGGTTATAAACCTGTCGTACTTTGAAGACTGGGGCCGGGGGACCACGGTCACCGTC
TCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
EVQLLESGGGLVEVGGSLRLSCAASGLPFRSSAMSWVRQAPGKGLEWVSSISSSGSTTYYADSAKGRFTVSRDNSRNTSFLQLNSLRAED 
TAIYYCVKTTVINLSYFEDWGRGTTVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-23*01  D:IGHD1-14*01R  J: IGHJ4*02 
The VH segment has 26 mutations 
CDR3 Length:  39 
 V   K   T   T   V   I   N   L   S   Y   F   E   D   
GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 E   V   Q   L   L   E   S   G   G   G   L   V   E   V   G   G   S   L   
 
score GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA GAG GTT GGG GGG TCC CTG  
IGHV3-23*01 1200 ... ... ... ... ... ... ... ... ... ... ... ... C.. CC. ... ... ... ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 R   L   S   C   A   A   S   G   L   P   F   R   S           S   A   M   
 
AGA CTC TCC TGT GCG GCC TCT GGA CTC CCC TTT AGA AGC --- --- TCT GCC ATG  
IGHV3-23*01 ... ... ... ... ..A ... ... ... T.. A.. ... ..C ... --- --- .A. ... ...  
   
  
___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 S   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S   
 
AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA AGT ATT AGT  
IGHV3-23*01 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... GC. ... ...  
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________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 S           S   G   S   T   T   Y   Y   A   D   S   A   K   G   R   F   
 
AGT --- --- AGT GGC AGT ACC ACA TAC TAC GCA GAC TCC GCG AAG GGC CGG TTC  
IGHV3-23*01 G.. --- --- ... ..T G.. .G. ... ... ... ... ... ... .T. ... ... ... ...  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   V   S   R   D   N   S   R   N   T   S   F   L   Q   L   N   S   L   
 
ACC GTC TCC AGA GAC AAT TCC AGG AAC ACT TCA TTT CTG CAA TTG AAC AGC CTG  
IGHV3-23*01 ... A.. ... ... ... ... ... .A. ... ..G CTG .A. ... ... A.. ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   A   E   D   T   A   I   Y   Y   C   V   K   T   
 
AGA GCC GAG GAC ACG GCC ATA TAC TAC TGC GTG AAG ACC  
IGHV3-23*01 ... ... ... ... ... ... G.. ..T ... ..T .C. ..A GA   
   
D Match Results 
  
 V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S       
 len|rf GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA A    
IGHD1-14*01R 8|1     GT. GTT C.. ... ... CC   
  
J Match Results 
  
 V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S       
 
score GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA A    
IGHJ4*02 159                                  AC ... ... ..C T.. ... ... .A. ..A ... CT. ... ... ... ... ... G    
  
Junction Analysis 
V Match: IGHV3-23*01  D Match: IGHD1-14*01R  J Match: IGHJ4*02 
  V-J Distance: 36 
VD Junction: # of P,N Nucleotides: (0,9)  TGAAGACCA 
DJ Junction: # of P,N Nucleotides: (0,19)  AACCTGTCGTACTTTGAAG 
 
 
 
 
 
 
 
 
389 
Sequence – VH3-33*01, No D Gene Assignment, JH6*03 (21 Mutations) 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTAAAGGCTCTGGATTCAGTTTCAGCAACTATGGCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAATGGGTGGCAGTTATCTGGTACGATGGAAGTCAGAAAAATTATGCAGACTCCGTGAAGGGCCGAGTCACCATCTCCAGAGAGAATTCCAAGAACACGCT
GTATCTGGAAATGAACAGCCTGAGAGGCGAGGACACGGCTGTATATTACTGTGCGAGGGCGAAAATTGTAGCAGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATCACTACATGGAC
GTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGTSLRLSCKGSGFSFSNYGMHWVRQAPGKGLEWVAVIWYDGSQKNYADSVKGRVTISRENSKNTLYLEMNSLRGED 
TAVYYCARAKIVAVSASPSMGSYYHYMDVWGKGTTVTVSSK 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-33*01  D:IGHD5-24*01R  J: IGHJ6*03 
The VH segment has 21 mutations 
CDR3 Length:  69 
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   
GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   T   S   L   
 
score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG ACG TCC CTG  
IGHV3-33*01 1236 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 R   L   S   C   K   G   S   G   F   S   F   S   N           Y   G   M   
 
AGA CTC TCC TGT AAA GGC TCT GGA TTC AGT TTC AGC AAC --- --- TAT GGC ATG  
IGHV3-33*01 ... ... ... ... GC. .CG ... ... ... .CC ... ..T .G. --- --- ... ... ...  
   
  
___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I   W   
 
CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAA TGG GTG GCA GTT ATC TGG  
IGHV3-33*01 ... ... ... ... ... ... ... ... ... ... ... ..G ... ... ... ... ..A ...  
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________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 Y           D   G   S   Q   K   N   Y   A   D   S   V   K   G   R   V   
 
TAC --- --- GAT GGA AGT CAG AAA AAT TAT GCA GAC TCC GTG AAG GGC CGA GTC  
IGHV3-33*01 ..T --- --- ... ... ... A.T ... T.C ... ... ... ... ... ... ... ... T..  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   I   S   R   E   N   S   K   N   T   L   Y   L   E   M   N   S   L   
 
ACC ATC TCC AGA GAG AAT TCC AAG AAC ACG CTG TAT CTG GAA ATG AAC AGC CTG  
IGHV3-33*01 ... ... ... ... ..C ... ... ... ... ... ... ... ... C.. ... ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   G   E   D   T   A   V   Y   Y   C   A   R   A   
 
AGA GGC GAG GAC ACG GCT GTA TAT TAC TGT GCG AGG GCG  
IGHV3-33*01 ... .C. ... ... ... ... ..G ... ... ... ... ..A .A   
   
D Match Results 
  
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S   K    
 len|rf GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A  
IGHD5-
24*01R 9|1             GT. ... ... ..C A.C ..T A.   
  
   
J Match Results 
  
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S   K    
 
score GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A  
IGHJ6*03 243                                                      AT TA. .A. ... ..C T.. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... G    
  
   
Junction Analysis 
V Match: IGHV3-33*01  D Match: IGHD5-24*01R  J Match: IGHJ6*03 
  V-J Distance: 50 
VD Junction: # of P,N Nucleotides: (0,6)  GGCGAA 
DJ Junction: # of P,N Nucleotides: (0,35)  AGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATC 
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Sequence – VH3-33*01, No D Gene Assignment, JH6*03 (22 Mutations) 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTAAAGGCCCTGGATTCAGTTTCAGCAACTATGGCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAATGGGTGGCAGTTATCTGGTACGATGGAAGTCAGAAAAATTATGCAGACTCCGTGAAGGGCCGAGTCACCATCTCCAGAGAGAATTCCAAGAACACGCT
GTATCTGGAAATGAACAGCCTGAGAGGCGAGGACACGGCTGTATATTACTGTGCGAGGGCGAAAATTGTAGCAGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATCACTACATGGAC
GTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGTSLRLSCKGPGFSFSNYGMHWVRQAPGKGLEWVAVIWYDGSQKNYADSVKGRVTISRENSKNTLYLEMNSLRGED 
TAVYYCARAKIVAVSASPSMGSYYHYMDVWGKGTTVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-33*01  D:IGHD5-24*01R  J: IGHJ6*03 
The VH segment has 22 mutations 
CDR3 Length:  69 
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   
GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC  
V Match Results 
  
----------------------------------------------------------FR1----------- 
  
 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
  
 Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   T   S   L   
 
score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG ACG TCC CTG  
IGHV3-33*01 1227 ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ...  
   
  
----------------------------------------------- ___________CDR1_________ 
  
 19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
  
 R   L   S   C   K   G   P   G   F   S   F   S   N           Y   G   M   
 
AGA CTC TCC TGT AAA GGC CCT GGA TTC AGT TTC AGC AAC --- --- TAT GGC ATG  
IGHV3-33*01 ... ... ... ... GC. .CG T.. ... ... .CC ... ..T .G. --- --- ... ... ...  
   
  
___ --------------------------------FR2-------------------- ____________ 
  
 35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
  
 H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I   W   
 
CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAA TGG GTG GCA GTT ATC TGG  
IGHV3-33*01 ... ... ... ... ... ... ... ... ... ... ... ..G ... ... ... ... ..A ...  
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________________________CDR2___________________________________ -------- 
  
52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
  
 Y           D   G   S   Q   K   N   Y   A   D   S   V   K   G   R   V   
 
TAC --- --- GAT GGA AGT CAG AAA AAT TAT GCA GAC TCC GTG AAG GGC CGA GTC  
IGHV3-33*01 ..T --- --- ... ... ... A.T ... T.C ... ... ... ... ... ... ... ... T..  
   
  
------------------FR3--------------------------------------------------- 
  
 68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
  
 T   I   S   R   E   N   S   K   N   T   L   Y   L   E   M   N   S   L   
 
ACC ATC TCC AGA GAG AAT TCC AAG AAC ACG CTG TAT CTG GAA ATG AAC AGC CTG  
IGHV3-33*01 ... ... ... ... ..C ... ... ... ... ... ... ... ... C.. ... ... ... ...  
   
  
-------------------------------------- ___CDR3_____  
  
 83  84  85  86  87  88  89  90  91  92  93  94  95  
  
 R   G   E   D   T   A   V   Y   Y   C   A   R   A   
 
AGA GGC GAG GAC ACG GCT GTA TAT TAC TGT GCG AGG GCG  
IGHV3-33*01 ... .C. ... ... ... ... ..G ... ... ... ... ..A .A   
   
D Match Results 
  
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S      
 len|rf GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A   
IGHD5-
24*01R 9|1             GT. ... ... ..C A.C ..T A.   
  
J Match Results 
  
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S      
 
score GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A   
IGHJ6*03 243                                                      AT TA. .A. ... ..C T.. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... G   
  
Junction Analysis 
V Match: IGHV3-33*01  D Match: IGHD5-24*01R  J Match: IGHJ6*03 
  V-J Distance: 50 
VD Junction: # of P,N Nucleotides: (0,6)  GGCGAA 
DJ Junction: # of P,N Nucleotides: (0,35)  AGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATC 
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Appendix 2- Statistical Analysis Results  
 
Statistical analysis, as described in section 2.3.13 was conducted using 
GraphPad Prism 4 (GraphPad Software Inc., San Diego CA, USA).  The 
following tables present the p-values obtained from each statistical test 
conducted in the analysis of results presented in this study.  Areas highlighted 
in yellow indicate where a statistically significant difference was observed and 
the p-values obtained were less than 0.05.  ‘N/A’ or ‘–’ illustrate where statistical 
analysis could not be conducted either because a non-productive repertoire was 
not identified within the samples or where numbers were not sufficient to allow 
the respective statistical analysis to be conducted.  
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Table 1a - Results (p-values) from Chi Square Test in the Statistical Analysis of Functional Ig Gene Distributions from Muscle 
Infiltrating B Cells in Individual Myositis Patients Compared with PBL or Germline V-gene Frequencies. 
 
 
 MYO1 MYO3 MYO5 MYO5 PBL MYO16 MYO23 
 PBL Germline PBL Germline PBL Germline MYO5 PBL PBL Germline PBL Germline PBL Germline 
VH1 0.3048 0.2966 <0.0001 0.0021 0.0311 0.0254 0.0016 0.0028 0.0949 0.0603 0.0612 0.1678 0.1456 
VH2 0.0003 0.567 0.5556 0.3064 0.3965 0.8179 0.3506 <0.0001 0.32 0.391 0.1386 0.668 0.4554 
VH3 0.0381 0.1305 0.0645 0.1155 0.7001 0.7 0.9848 0.0801 0.2151 <0.0001 0.0009 0.0097 0.0154 
VH4 0.1418 0.4402 0.5317 0.7291 0.514 0.7424 0.4177 0.0029 0.0179 0.1513 0.3625 0.3611 0.4696 
VH5 0.4842 0.9097 0.3128 0.4072 <0.0001 0.0034 0.0574 0.303 0.2877 0.1419 0.2339 0.4627 0.5457 
VH6 0.2377 0.2882 0.519 0.5608 0.5084 0.5084 0.21 0.0566 0.23 0.348 0.3981 0.6389 0.6718 
VH7 0.4696 0.2882 0.6929 0.5608 0.6532 0.5084 - 0.53 0.3559 0.5655 0.3981 0.7738 0.6718 
 
             
DH1 0.6003 0.7725 0.9148 0.7935 0.4064 0.8079 0.0377 0.1022 0.0528 0.1122 0.0595 
DH2 0.1395 0.8488 0.5723 0.9719 0.0982 0.2207 0.1939 0.5053 0.8667 0.2605 0.7741 
DH3 0.6692 0.1095 0.1867 0.039 0.9886 0.3545 0.4113 0.1403 0.0254 0.3817 0.6883 
DH4 0.4237 0.604 0.4623 0.2783 0.4046 0.2207 0.2987 0.5171 0.7203 0.8377 0.3633 
DH5 0.559 0.1899 0.5237 0.9719 0.1079 0.6056 0.4436 0.6027 0.0723 0.2301 0.096 
DH6 0.3954 0.7024 0.2925 0.2783 0.4554 0.6056 0.4436 0.7525 0.0723 <0.0001 0.0023 
DH7 0.4383 0.2319 0.7394 0.6053 0.706 0.5582 - 0.5937 0.409 0.6042 0.4222 
N/A 
Expected frequency for 
observed values was 
below 5 therefore Chi 
Square Analysis could 
not be conducted. 
 
             
JH1 0.1165 0.0019 0.3913 0.0852 0.3294 0.0512 - 0.1728 0.0068 0.2122 0.0132 0.5328 0.2049 
JH2 0.5385 0.0475 0.5285 0.4202 0.3946 0.0512 0.096 0.0019 0.7243 0.2762 0.0132 <0.0001 0.132 
JH3 0.3074 0.5309 0.1051 0.0852 0.5102 0.9315 0.9668 0.3174 0.9086 0.0117 0.5666 0.2382 0.2049 
JH4 0.6287 0.1729 0.7 0.1897 0.2513 0.0991 0.1817 0.4895 0.332 0.4439 0.3496 0.01 0.2049 
JH5 0.5898 0.8609 0.0238 0.541 0.7013 0.5949 0.1637 0.0195 0.7171 0.0955 0.1391 0.0023 0.2636 
JH6 0.0849 0.3421 0.4781 0.9566 0.4539 0.9315 0.3025 0.017 0.5767 0.2572 0.4136 0.0824 0.2049 
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Table 1b - Results (p-values) from Chi Square Test in the Statistical Analysis of Functional Ig Gene Distributions from Different 
Myositis Subsets Compared with PBL, Germline V-gene Frequencies or Between Myositis Subsets. 
 
 MYO DM PM  
 PBL Germline PBL Germline PBL Germline DM vs PM 
VH1 0.5548 0.2773 0.0491 0.0922 0.621 0.9596 0.0759 
VH2 0.0878 0.5744 0.0227 0.8991 0.9223 0.2726 0.2889 
VH3 <0.0001 0.0348 <0.0001 0.0081 0.3118 0.4324 0.0688 
VH4 0.0071 0.2504 0.0416 0.3236 0.0972 0.3462 0.9331 
VH5 0.8661 0.6687 0.1446 0.5362 0.0942 0.1736 0.0228 
VH6 0.1687 0.4212 0.1315 0.1754 0.2461 0.2968 N/A 
VH7 0.2408 0.0856 0.3557 0.1754 0.4775 0.2968 N/A 
 
       
DH1 0.6589 0.3451 0.6566 0.342 0.9868 0.5987 0.7879 
DH2 0.0126 0.6398 0.0641 0.7944 0.0977 0.5069 0.6113 
DH3 0.7246 0.1011 0.8965 0.1783 0.5722 0.1057 0.5878 
DH4 0.7094 0.1535 0.5817 0.4358 0.1828 0.0543 0.135 
DH5 0.5649 0.1535 0.2495 0.0677 0.3512 0.8572 0.1219 
DH6 <0.0001 0.141 0.0002 0.1166 0.0839 0.3206 0.6702 
DH7 0.2638 0.0857 0.3511 0.151 0.5465 0.3512 N/A 
 
       
JH1 0.0109 <0.0001 0.045 <0.0001 0.1231 0.0023 N/A 
JH2 0.1425 0.243 0.2471 0.0085 <0.0001 0.7861 0.0025 
JH3 0.984 0.8145 0.4417 0.9723 0.3507 0.5541 0.2262 
JH4 0.7873 0.2272 0.923 0.2215 0.716 0.2628 0.8172 
JH5 0.2695 0.8922 0.5417 0.5819 0.0209 0.7698 0.0408 
JH6 0.9515 0.6307 0.1809 0.4533 0.1358 0.9848 0.0461 
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Table 2 - Results (p-values) from Chi Square Test in the Statistical Analysis of Functional Ig Gene Distributions Collectively from Skin 
Infiltrating B cells and Two Paired Peripheral Blood Samples or Germline DNA. 
 
 
 VAS VAS1 PBL VAS6 PBL 
 PBL Germline PBL Germline PBL Germline 
VH1 0.5103 0.7291 0.0551 0.2483 0.7542 0.9849 
VH2 0.5556 0.3064 <0.0001 0.1418 <0.0001 0.0239 
VH3 0.2856 0.3268 0.6258 0.7472 0.0121 0.0555 
VH4 0.5317 0.7291 0.0093 0.0291 0.0092 0.0391 
VH5 0.3128 0.4072 0.7728 0.5573 0.9795 0.72 
VH6 0.519 0.5608 0.7094 0.6821 0.2162 0.3654 
VH7 0.6926 0.5608 0.606 0.4524 <0.0001 0.013 
 
      
DH1 0.308 0.2177 0.1233 0.0616 0.2012 0.1123 
DH2 0.5723 0.9719 0.6663 0.7763 0.2018 0.8105 
DH3 0.2804 0.7935 0.0029 0.001 0.0888 0.0173 
DH4 0.0284 0.3949 0.2665 0.0991 0.8247 0.4733 
DH5 0.0006 0.102 0.8161 0.3747 0.9243 0.4733 
DH6 0.2925 0.2783 0.3881 0.3747 0.6695 0.856 
DH7 0.7394 0.6053 0.615 0.4272 0.5379 0.341 
 
      
JH1 0.7198 0.4202 0.2628 0.0257 0.2098 0.5197 
JH2 0.0452 0.7592 0.3284 0.0257 <0.0001 1 
JH3 0.1051 0.0852 0.0055 0.4782 0.2879 0.8725 
JH4 0.0787 0.1233 0.0466 0.6919 0.1503 0.4857 
JH5 0.4543 0.4202 0.0497 0.0257 0.5278 0.5197 
JH6 0.8803 0.7261 0.0147 0.2 0.2434 1 
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Table 3 - Results (p-values) from Chi Square Test in the Statistical Analysis of 
Individual VH Gene Distributions from both disorders and paired peripheral 
blood samples compared to normal control values of Volpe and Kepler (251). 
 
 
VH Gene MYO DM PM MYO5 PBL VAS 
VAS1 
PBL 
VAS6 
PBL 
1~18*01 0.2268 0.9154 0.1895 0.7867 0.4949 0.8972 0.2885 
1~2*01 0.016 0.0578 0.1445 0.1969 0.4171 0.2893 0.2377 
1~24*01 0.3813 0.4906 0.596 0.6392 0.7682 0.7003 0.668 
1~3*01 0.6717 0.3359 0.0501 0.0166 0.6807 0.0015 0.0063 
1~45*02 0.7338 0.7889 0.8368 0.8555 0.9089 0.8811 0.8677 
1~46*01 0.2187 0.3674 0.3598 0.3582 0.0034 0.5524 0.4005 
1~58*01 0.6304 0.7048 0.7708 0.7967 0.8713 0.8325 0.8137 
1~69*01 0.7845 0.3407 0.0797 0.197 0.9428 0.0057 0.0278 
1~8*01 0.4461 0.2502 0.3765 0.4342 0.6229 0.5208 0.4743 
1~f*01 0.127 0.7048 0.0027 0.7967 0.8713 0.8325 0.8137 
2~26*01 0.4436 0.5487 0.6447 <0.0001 0.7976 0.009 0.7091 
2~5*01 0.1336 0.0076 0.328 0.3454 0.5865 0.0004 <0.0001 
2~70*01 0.4252 0.2424 0.8194 0.4257 0.6164 0.513 0.4661 
3~11*01 0.004 <0.0001 0.7979 0.3099 0.5232 0.4043 0.8632 
3~13*01 0.4652 0.5652 0.6583 0.6958 0.8058 0.7481 0.7205 
3~15*01 0.0468 0.0007 0.264 0.3233 0.5346 0.4173 0.177 
3~19*01 - - - - - - - 
3~20*01 0.3886 0.4973 0.6016 0.6444 0.7716 0.7046 0.6728 
3~21*01 0.1189 0.1044 0.6713 0.9997 0.4328 <0.0001 0.3081 
3~23*01 0.0052 0.0971 0.0175 0.293 0.2389 0.2771 0.0545 
3~30*01 0.0018 0.0374 0.0382 0.6037 0.335 0.4311 0.302 
3~30-3*01 0.06761 0.1493 0.2673 0.3267 0.5375 0.4206 0.3695 
3~33*01 0.0131 0.5004 0.0009 0.2423 0.0393 0.337 0.9162 
3~35*01 0.8326 0.8655 0.8964 0.9083 0.9432 0.9247 0.9161 
3~38*02 0.8792 0.9047 0.9266 0.9351 0.9592 0.9467 0.9406 
3~43*01 0.5069 0.6013 0.6878 0.7198 0.8232 0.7704 0.7451 
3~48*01 0.8864 0.2184 0.1827 0.098 0.4555 0.9212 0.281 
3~49*01 0.826 0.9533 0.6281 0.4813 0.6579 0.563 0.3579 
3~53*01 0.7962 0.3071 0.0776 0.4874 0.6623 0.5684 0.5251 
3~64*01 0.3685 0.4714 0.5797 0.6243 0.7581 0.6575 0.6541 
3~66*01 0.0052 0.0044 0.3201 0.9877 0.7305 0.077 0.136 
3~7*01 <0.0001 <0.0001 0.2511 0.5476 0.3903 0.848 0.2113 
3~72*01 0.0617 0.5569 0.0001 0.6895 0.8017 0.7428 0.7147 
3~73*01 0.7165 0.5111 0.1447 0.0764 0.0012 0.7136 0.6826 
3~74*01 0.2483 0.1697 0.9285 0.3504 0.5571 0.4432 0.3929 
3~9*01 0.0774 0.0195 0.941 0.3543 0.5602 0.4468 0.3967 
4~28*01 0.7923 0.8357 0.8733 0.8879 0.9293 0.9078 0.8973 
4~30-2*01 0.142 0.2476 0.3729 0.4317 0.621 0.5184 0.4719 
4~30-4*01 - - - - - - - 
4~31*01 0.1532 0.1229 0.2354 0.2941 0.5095 0.3889 0.3371 
4~34*01 0.039 0.0402 0.8627 0.4301 0.2271 0.1147 0.6022 
4~39*01 0.1075 0.162 0.429 0.1876 0.4073 0.9038 0.2279 
4~4*01 0.7927 0.9109 0.8031 0.3315 0.5246 0.4059 0.3545 
4~55*01 - - - - - - - 
4~59*01 0.1753 0.0676 0.9386 0.1903 0.0032 0.2821 0.2308 
Cont… 
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VH Gene MYO DM PM MYO5 PBL VAS 
VAS1 
PBL 
VAS6 
PBL 
4~61*01 0.3315 0.6449 0.3302 0.3892 0.5882 0.4785 0.4308 
4~b*01 0.8836 0.4865 0.585 0.6292 0.7614 0.6917 0.6586 
5~51*01 0.8413 0.1238 0.0176 0.1116 0.3804 0.4985 0.7188 
5~a*01 0.4832 0.8241 0.3901 0.4473 0.6328 0.5326 0.4869 
6~1*01 0.1687 0.1315 0.2461 0.0509 0.519 0.7094 0.2162 
7~4-1*01 0.2249 0.3598 0.4813 0.5355 0.6954 0.6091 <0.0001 
7~81*01 0.8792 0.9047 0.9266 0.9351 0.9592 0.9467 0.9406 
 
Table 4 - Results (p-values) from Chi Square Test in the Statistical Analysis of 
Individual DH Gene Distributions from both disorders and paired peripheral 
blood samples compared to normal control values of Volpe and Kepler (251). 
 
 
 MYO DM PM MYO5 PBL VAS 
VAS1 
PBL 
VAS6 
PBL 
0~IR*01 0.3465 0.4364 0.6115 0.6532 0.7793 0.6718 0.6038 
1~1*01 0.2781 0.0721 0.4879 0.5394 0.702 0.5629 0.4786 
1~14*01 0.407 0.493 0.6546 0.6922 0.805 0.709 0.6476 
1~20*01 0.727 0.1728 0.8506 0.8676 0.9172 0.8751 0.8474 
1~26*01 0.8431 0.0721 0.793 0.3011 0.519 0.3296 0.7592 
1~7*01 0.47 0.3604 0.0055 0.5975 0.7419 0.6186 0.5421 
1~IR1*01 0.2813 0.373 0.561 0.607 0.7484 0.6277 0.5526 
1~OR15*1 0.7142 0.7621 0.8434 0.8612 0.9132 0.8691 0.84 
2~15*01 0.2017 0.1273 0.9581 0.3786 0.5829 0.0936 0.9972 
2~2*01 0.0075 0.0511 0.2377 0.3735 0.8862 0.9996 0.2176 
2~21*01 0.0648 0.0721 0.4127 0.488 0.6513 0.4945 0.6951 
2~8*01 0.647 0.9432 0.4946 0.28 0.7063 0.5689 0.4854 
2~IR2*01 0.5252 0.5994 0.7317 0.7617 0.85 0.7749 0.7262 
2~OF15*2 0.2974 0.389 0.5739 0.6189 0.7564 0.6391 0.5657 
3~10*01 0.8907 0.4803 0.4816 0.6612 0.5773 0.5584 0.1477 
3~16*01 0.3435 0.702 0.2804 0.3396 0.5515 0.3679 0.8809 
3~22*01 0.0229 0.7604 <0.0001 0.6429 0.4316 0.0007 0.1267 
3~3*01 0.6988 0.9417 0.5495 0.0008 0.4456 0.0969 0.1579 
3~9*01 0.5596 0.4566 0.3412 0.3997 0.5995 0.4272 0.0263 
3~OR15*3 0.4478 0.5303 0.6821 0.7171 0.8212 0.7326 0.6756 
4~17*01 0.909 0.0721 0.3244 0.6975 0.001 0.4111 0.9774 
4~23*01 0.8925 0.805 0.561 0.607 0.7484 0.6277 0.2675 
4~4*01 0.9586 0.6631 0.5968 0.6398 0.7704 0.6591 0.589 
4~OR15*4 0.5447 0.6165 0.7438 0.7725 0.8569 0.7852 0.7385 
5~12*01 0.0904 0.4619 0.0362 0.3381 <0.0001 0.5468 0.0434 
5~24*01 0.5239 0.2536 0.0465 0.3727 0.681 0.3063 0.4465 
5~5*01 0.1208 0.1995 0.4024 0.4588 0.6441 0.4849 0.3924 
5~OR15*5 0.6393 0.6984 0.8003 0.823 0.889 0.8329 0.7961 
6~13*01 0.4175 0.0091 0.2954 0.3546 0.5637 0.3828 0.0046 
6~19*01 0.0022 0.1783 0.0002 0.435 0.4837 0.2897 0.6376 
6~25*01 0.573 0.6412 0.761 0.7879 0.8667 0.7997 0.756 
6~6*01 0.0012 <0.0001 0.4748 0.5272 0.6934 0.2649 0.4654 
7~27*01 0.2638 0.3556 0.5465 0.5937 0.7394 0.615 0.5379 
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Table 5 – Results (p-values) from Two Tailed Unpaired t-tests in Individual Patients, Paired Peripheral Blood Samples, Collective 
Patients and Disease Subsets of both Myositis and Vasculitic Disorders in Comparison of CDR3 Lengths in the Functional and Non-
Functional Repertoires.   
 
 
 
 
Table 6 – Results (p-values) from Two Tailed Unpaired t-tests in Individual Patients, Paired Peripheral Blood Samples, Collective 
Patients and Disease Subsets of the Myositis Disorders in Comparison of P and N Nucleotide Lengths at Different Regions of the Ig 
Gene Recombination Junction and in the Functional and Non-Functional Repertoires.   
 
 
 
 MYO1 MYO3 MYO5 MYO5 PBL MYO16 MYO23 MYO MYO DM MYO PM 
 
 VD vs DJ VD vs DJ VD vs DJ VD vs DJ VD vs DJ VD vs DJ VD vs DJ VD vs DJ VD vs DJ 
Productive 0.3758 0.3615 0.6239 0.5886 0.5262 N/A 0.6342 0.7839 0.6309 
Non-
Productive 0.2725 N/A N/A N/A N/A N/A 0.2725 0.2725 N/A 
 VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ 
P
 
N
u
c
l
e
o
t
i
d
e
 
P vs NP 0.039 0.9447 N/A N/A N/A N/A 0.2679 N/A N/A N/A N/A N/A 0.0124 0.9314 0.0239 0.7963 N/A N/A 
Productive 0.4064 0.2261 0.3495 0.9787 0.0596 N/A 0.1654 0.8557 0.0073 
Non-
Productive 0.364 N/A N/A 0.2589 N/A N/A 0.364 0.364 N/A 
 VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ VD DJ 
 
N
 
N
u
c
l
e
o
t
i
d
e
 
 
P vs NP 0.2658 0.3928 N/A N/A N/A N/A 0.4129 0.3212 N/A N/A N/A N/A 0.5242 0.4644 0.4043 0.432 N/A N/A 
 
 
 MYO1 MYO5 PBL MYO MYO DM MYO PM VAS VAS1 PBL VAS6 PBL 
CDR3 
Length 
P vs NP 
0.661 0.5017 0.9529 0.9461 N/A 0.0716 0.3613 0.1632 
400 
Table 7 – Results (p-values) from Two Tailed Unpaired t-tests in Collective 
Vasculitis Patients and Paired Peripheral Blood Samples in Comparison of P 
and N Nucleotide Lengths at Different Regions of the Ig Gene Recombination 
Junction and in the Functional and Non-Functional Repertoires.   
 
 
 
 
VAS VAS1 PBL VAS6 PBL 
 
 
VD vs DJ VD vs DJ VD vs DJ 
Productive N/A 0.0343 0.202 
Non-
Productive N/A 1 0.5761 
 VD DJ VD DJ VD DJ P 
Nu
cl
eo
tid
e 
P vs NP N/A N/A 0.721 0.3453 0.13 0.229 
Productive 0.6487 0.5394 0.3282 
Non-
Productive N/A 0.2552 0.9017 
 VD DJ VD DJ VD DJ N 
Nu
cl
eo
tid
e 
P vs NP N/A N/A 0.238 0.3662 0.975 0.715 
401 
Results (p-values) from Two Tailed Unpaired t-tests in Comparison of Exonuclease Activity at Different Regions of the Ig Gene 
Recombination Junction and in the Functional and Non-Functional Repertoires.   
Table 8a 
  MYO1 MYO3 MYO5 MYO5 PBL 
  3' VH 5' DH 3'DH  5' JH 3' VH 5' DH 3'DH  5' JH 3' VH 5' DH 3'DH  5' JH 3' VH 5' DH 3'DH  5' JH 
P vs NP 0.2468 0.1282 0.3957 0.8798 N/A N/A N/A N/A N/A N/A N/A N/A 0.016 0.9219 0.8556 0.2724 
VH vs JH <0.0001 0.0002 0.0008 0.0002 
5'DH vs3'DH 0.3414 0.8507 0.0787 0.6078 
VH vs 5'DH <0.0001 0.0925 0.0472 0.0004 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH 0.8918 0.7814 0.0035 0.4661 
 
Table 8b 
 
 MYO16 MYO23 MYO MYO DM MYO PM 
  3' VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 
P vs NP N/A N/A N/A N/A N/A N/A N/A N/A 0.238 0.2155 0.181 0.9035 0.249 0.1359 0.2073 0.9947 N/A N/A N/A N/A 
VH vs JH 0.0006 N/A <0.0001 <0.0001 <0.0001 
5'DH vs3'DH 0.1346 N/A 0.1058 0.1286 0.3309 
VH vs 5'DH 0.0006 N/A <0.0001 <0.0001 0.0103 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH 0.1917 N/A 0.0923 0.4023 0.0593 
 
Table 9 
  VAS VAS1 PBL VAS6 PBL 
  
3' 
VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 3' VH 5' DH 3'DH 5' JH 
P vs NP N/A N/A N/A N/A 0.027 0.528 0.29 N/A* 0.003 0.6796 0.639 0.5869 
VH vs JH 0.1518 <0.0001 0.0021 
5'DH vs3'DH 0.1758 0.1333 0.7844 
VH vs 5'DH 0.0132 0.0007 0.0001 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH 0.075 0.7324 0.7912 
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Table 10 – Results (p-values) from One-Way Analysis of Variance Test Used In 
Conjunction with the Tukey-Kramer Multiple Comparison Post Test in Individual 
Patients, Paired Peripheral Blood Samples, Collective Patients and Disease 
Subsets of both Myositis and Vasculitic Disorders to Determine Statistical 
Difference Between Mean CDR3 Lengths in Mutated Sequences. 
 
 0-2 vs 3-10 0-2 vs 11-20 0-2 vs 20+ 3-10 vs 11-20 3-10 vs20+ 11-20 vs 20+ 
MYO1 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
MYO3 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
MYO5 N/A N/A N/A >0.05 >0.05 >0.05 
MYO5 PBL >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
MYO16 >0.05 >0.05 <0.0001 >0.05 <0.05 <0.05 
MYO >0.05 >0.05 <0.05 >0.05 >0.05 >0.05 
MYO DM >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
MYO PM >0.05 >0.05 >0.05 >0.05 >0.05 <0.05 
VAS >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
VAS1 PBL >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
VAS6 PBL <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
